BioHealth Innovation, Inc. (BHI) is an innovation intermediary that translates market-relevant research into commercial success by connecting management, funding, and markets.
BHI's vision is to transform the Central Maryland region into a leading global bio-health entrepreneurial and commercialization hub.
What does BHI do? BHI sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It aims to: - Increase the flow of private and public early stage capital; - Develop an active commercialization talent network; - Facilitate accelerated tech transfer and commercialization of relevant innovations; - Market and brand the region as a global biohealth leader; and - Ensure an adequate supply of experienced biohealth entrepreneurs and workers.
Vision: Within five years, BioHealth Innovation (BHI) will be a catalyst to transform Central Maryland into a leading BioHealth entrepreneurial and commercialization Region.
Mission: BioHealth Innovation will connect market relevant research assets to appropriate funding, management and markets to facilitate the development of commercially viable bio health products and companies.
BUGSS (Baltimore Under Ground Science Space) is a Maryland non-profit corporation started in the summer of 2012 to provide a place for people interested in biotechnology to learn, practice and hang-out with others fascinated by the world-changing potential of synthetic biology and biotechnology.
Come check out our space-2700 square feet of wet and dry labs convieniently located in east Baltimore.
BUGSS members enjoy lab access, credits for lab supplies to work on your own projects, participation in group projects, discounts on courses and being part of the coolest science project around.
Shady Grove Innovation Center (SGIC) is the county’s first incubator, in operation since 1999 (formerly the Maryland Technology Development Center). It set the standard of excellence in promoting the growth and success of technology companies. The SGIC is located in the nation’s third largest biotech cluster along the I-270 Technology Corridor, near leading biotech companies such as MedImmune, Human Genome Sciences and Otsuka Pharmaceuticals. It is also adjacent to high level research and academic resources providing critical support for biotech and advanced technology companies. Institutions include the National Institutes of Health, Johns Hopkins University and the University fo Maryland’s Center for Advanced reserach in Biotechnology (CARB I and II).
60,000 square feet to accomodate 40-50 advanced technology and life sciences companies 60 offices 24 wet labs and 3 conference rooms a large multi-purpose room, seating 50-60 people kitchenette and lunch room business and audio-visual equipment laboratory equipment telephone and video conferencing ability offices are voice and data ready a tenant services coordinator Internet providers: Atlantech Online (301-589-3060); Comcast Xfinity (301- 294-7749); Verizon DSL @ 7.1MGB
The BioPark is a biomedical research park on the vibrant academic medical center campus of the University of Maryland, Baltimore (UMB). Its community of life science companies and academic research centers are commercializing new drugs, diagnostics and devices and advancing biomedical research.
Become part of a growing community of science joining other emerging, high-growth life science companies and translational research centers of the University of Maryland (UM). For early-stage to mature bioscience companies, the BioPark offers a sophisticated laboratory and office environment on the University's vibrant academic medical center campus. In 2007, the Association for University Research Parks (AURP) named the BioPark the "Emerging University Research Science Park of the Year."
Founded in 1807, the University of Maryland is a thriving biomedical research institution in downtown Baltimore with professional schools of medicine, dentistry, nursing, pharmacy, law, social work and a multi-disciplinary graduate school. Nearly 1,200 faculty received $529 million in extramural funding in the last fiscal year, more than $2 billion in the last four years, in areas including cancer, genomics, vaccines, neuroscience, vascular biology, HIV/AIDS, and regenerative medicine.
The 12-acre BioPark on the west side of campus will boast 1.8 million square feet of lab and office space in 12 buildings plus garage parking and landscaped parks at final build-out. By 2010, 470,000 square feet in two-multi-tenant buildings, one 638-space parking garage and the State of Maryland's new Forensic Medical Center were completed. Development of a third multi-tenant commercial building is planned and a new clinical facility, the Maryland Proton Treatment Center, is under construction.
BioPark building designs maximize flexibility to accommodate a range of occupancies from small-scale pre-built lab and office space in the BioInnovation Center to full floor users. Infrastructure meets the requirements of the most demanding science environments while permitting optimum internal planning flexibility with minimum intrusions.
Whether your company is locally-rooted or internationally-based, the BioPark provides an ideal location in the midst of a large regional bioscience cluster that is situated at the mid-point of the U.S. East Coast life science corridor and with direct access to the University's talented scientists and outstanding biomedical facilities. The BioPark is also just minutes from major interstates, the airport, rail connections, and Baltimore’s beautiful Inner Harbor.
Join our sponsors, BioHealth Innovation, Inc. (BHI) and the Johns Hopkins University Center for Biotechnology Education, along with many others from our local biotech industry at another exciting BioBuzz event on March 20 from 4:30 - 7 p.m.
As always, the event is always free and we offer free drinks to the first 50 who arrive. People from all around the the region are coming out each month for this unique and welcoming monthly happy hour. It’s a great place to meet up with coworkers past and present, make new connections or just catch up on the latest industry gossip. If you’re new and haven’t yet made it out to an event, then we hope that you’ll join us this month and see what all the Buzz is all about.
The Maryland Biotechnology Center was created in 2009 by Governor Martin O'Malley as one of the first initiatives of BioMaryland 2020 - the State Strategic Plan for Life Sciences delivered by the Maryland Life Sciences Advisory Board. The Center is your portal to programs and resources intended to grow and strengthen the State's bioscience community.
The Center, in collaboration with some of the State’s finest partner programs, will serve to integrate entrepreneurial strategies to stimulate the transformation of scientific discovery and intellectual assets into capital formation and business development.
Our programs are also aimed at encouraging workforce training and development, as well as connecting Maryland’s federal and academic life sciences research centers to our vibrant industry. The Center provides investments in talent, infrastructure and future commercialization opportunities, through its grant programs.
Be sure to register with us to stay current with our activities and programs. We want to hear from you so please email us and give us your feedback on how the Center can better serve your needs and Maryland's bioscience community.
The Maryland Biotechnology Center was created in 2009 by Governor Martin O'Malley as one of the first initiatives of BioMaryland 2020 - the State Strategic Plan for Life Sciences delivered by the Maryland Life Sciences Advisory Board. The Center is your portal to programs and resources intended to grow and strengthen the State's bioscience community.
The Center, in collaboration with some of the State’s finest partner programs, will serve to integrate entrepreneurial strategies to stimulate the transformation of scientific discovery and intellectual assets into capital formation and business development.
Our programs are also aimed at encouraging workforce training and development, as well as connecting Maryland’s federal and academic life sciences research centers to our vibrant industry. The Center provides investments in talent, infrastructure and future commercialization opportunities, through its grant programs.
The Maryland Center for Entrepreneurship (MCE) is an organization developed by the HCEDA under the leadership of its CEO, Laura Neuman and County Executive Ken Ulman. The MCE provides a robust, interactive community of innovators, entrepreneurs, investors and advisors collaborating to successfully ignite innovation and launch high-growth, technology-based companies in an entrepreneurial ecosystem abundant with resources. Centrally located in Columbia, the MCE leverages its position in the heart of the Baltimore-Washington metropolitan corridor to deliver best in class resources and services.
"Getting Shtuff Done" is the tagline gsd@mce indicates. The priorities of the MCE are consistent with that of the HCEDA's goals of starting, growing, and attracting new companies. Specifically, activities revolve around the three categories listed below.
At Mogambo Solutions, our clients count on us to provide high-quality and cost-effective IP research services. Together, we are empowering business and driving innovation.
Every minute of every day, businesses make critical decisions that affect their success. At Mogambo Solutions, our goal is to ensure that success by delivering comprehensive and in-depth information to empower our clients with the knowledge they need to drive their business forward.
From case-by-case prior art searching, to assuming entire patent research functions for our clients, Mogambo Solutions helps the companies we serve to sustain and improve their competitive edge.
In addition to IP law expertise, many of our professionals are former scientists and engineers who have worked with leading companies in the field. This combination of R&D experience, combined with the in-depth knowledge of PTO practice allows Mogambo Solutions to provide unique and highly valuable perspectives for our clients. In addition, our multi-disciplinary approach allows all of our practice groups to utilize specific strengths and expertise of all of our professionals.
Alper Biotech, LLC. is a biotechnology company focused on the identification of novel proprietary cancer biomarker proteins and development of highly-specific monoclonal antibodies to detect these novel protein targets. The company was founded by Ozge Alper.
Alper's monoclonal antibodies uniquely recognize proteins that are modified and differentially expressed in cancer cells. Its pipeline of cancer diagnostic kits will cover many tumor types starting with breast cancer and expanding into other tumors of major concern to Oncologists. The company's monoclonal antibodies are selected to help address high unmet medical needs in managing cancer diagnosis and therapy. Its products include: AB-PCBP1 IgG1 MoAb, AB-HER2 IgG1 MoAb, AB-Actinin-4 IgG2b MoAb, AB-GMF-B IgG1 MoAb etc.
Maryland Technology Development Center, 9700 Great Seneca Highway
Rockville, MD, USA
American Gene Technologies International Inc. (AGTII) is engaged in developing bio-safe, high efficiency lentivirus therapies to treat cancer and other chronic human diseases. It was founded in 2007 by Jeffrey A. Galvin, with a vision to use its technology to enable the one hundred billion dollar genetic drug market.
AGTII has developed an efficient, effective, targeted system for expressing genes in any type of human cell in-vivo. Its ProTarg(TM) is a genetic vector which interrupts the cellular mechanisms of prostate cancer. Its In-vitro tests have shown that this compound results in destruction of prostate cancer cells without any effect on normal, healthy cells. The company's MesoTarg(TM) utilizes its platform to deliver a genetic attack on pancreatic cancer cells.
AGTII's products incorporate a proprietary technology for the clinical application of gene expression technology in cancer therapy, autosomal disorders, stem cell treatment, and cosmetic applications. Its products include: AG-1101 for the treatment of prostate cancer, AG-1102 for the treatment of pancreatic cancer, and AG-1103 for the treatment of liver cancer.
Amplimmune, Inc. is engaged in the development of immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. It was founded in 2007, with a vision to develop drugs active in the treatment of cancer and infectious diseases involves selectively activating T cell populations to eradicate tumor or infection via either increasing T cell co-stimulation agonists and/or blocking immune checkpoints.
Amplimmune's co-stimulation/immune checkpoint inhibition portfolio provides unprecedented flexibility and versatility in modulating immune responses. The portfolio encompasses many of the B7 family members and patents covering their use as agonists to enhance co-stimulation or the application of antagonists to block members that induce inhibition.
Amplimmune's products include: AMP-110 for the treatment of autoimmune diseases; and AMP-224, a fusion protein that blocks the interaction between PD-1 and B7-H1, for treatment of cancer and chronic infections.
Amplimmune has collaborations with GlaxoSmithKline plc, National Institutes of Health, The National Cancer Institute, The U.S. Department of Health and Human Services, Fast Forward, LLC and The National Multiple Sclerosis Society. Its investors include: InterWest Partners and The Wellcome Trust.
Anjin Group, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted therapies to treat a variety of cancers and immune disorders using a class of drugs known as fusion protein toxins or targeted toxins.
Anjin's research and development center has expertise in the design and development of targeted toxins. These proteins are created by using genetic engineering to splice two genes, each encoding a separate protein, together to create a fusion gene. The fusion gene encodes a new protein which is highly effective at recognizing, binding to and causing the death of the targeted cells. The company has employed a modified diphtheria toxin ("DT") as a platform to develop its targeted toxins. It is also involved in improving the side effect profile of therapies. The company's different targeting and dosing regimens, combined with more complete molecular characterization of tumors in cancer patients, allows for specific tailoring of therapy using multiple targeted toxins to put a disease in remission.
Anjin has partnership with The Leukemia & Lymphoma Society.
BioFactura Inc is a biopharmaceutical development offers companies developing monoclonal antibody-based drugs shorter time-to-market, reduced costs, and high potency/fidelity drug candidates through the application of its proprietary Rapid Human Antibody Generation or RHAGe System. The company utilizes its expertise in bio-manufacturing to develop technologies that adds value to therapeutics as they progress from discovery through clinical trials and into the market.
BioFactura's Rapid Human Antibody Generation or RHAGe is an end-to-end system for the discovery and commercialization of fully-human monoclonal antibody (mAb) drug candidates. Its VeriCyte Discovery Platform isolates fully human therapeutic mAbs from human B lymphocytes. The Company's StableFast Biomanufacturing Platform, which utilizes the FDA-approved NS0 cell line, and allows the rapid development and production of lead mAb candidates. Its RHAGe drug development system offers companies developing monoclonal antibody-based drugs shorter time-to-market, reduced costs, and high potency and fidelity drug candidates. It also offers contract services such as: Stable Cell Lines - StableFast-NS0 Cell Line, CHO DG44 Cell Line; Bioprocess Development; and Biologics Manufacturing.
BioFactura is committed to identifying and fulfilling unmet national biodefense and biomedical needs. The company is focused on bringing a drug for the treatment of smallpox and adverse smallpox vaccination events in collaboration with the U.S. Army and Department of Defense.
BioFactura's partners include: University of Maryland, USAMRIID, Sequella, Inc, Capital Genomix Inc, BioAssay, etc.
Biosynexus Incorporated is a biopharmaceutical company focused on the development of monoclonal antibody. The company's mission is to bring products to the market for the prevention and treatment of bacterial infections with emphasis on the prevention of staphylococcal infections in VLBW infants. It is a wholly owned subsidiary of QVT Fund LP.
Biosynexus' product portfolio includes: Pagibaximab, a monoclonal antibody indicated for the treatment of staphylococcal bloodstream infections in very low-birth weight infants; Lysostaphin, a recombinant bacterial derived enzyme indicated for the treatment of life threatening staphylococcal infections; and Nisin, a topical antibiotic indicated for the treatment of staphylococcal skin infections.
Biosynexus has collaborations with GlaxoSmithKline plc, Avecia Biologics Limited, Nutrition 21 Inc, Fujifilm Diosynth Biotechnologies (formerly MSD Biologics (UK) Ltd) etc.
Celek Pharmaceuticals LLC addresses the need for new medicines to help patients suffering from cancers that lack effective treatment options. The company was founded in the year 2009.
Celek focuses on the development of targeted therapies for bladder cancer, a prevalent yet underserved disease in need of safer and more effective treatments. Bladder cancer is the non-muscle invasive disease (NMIBC) which involves transurethral resection of the tumor, often followed by intravesical (i.e., transurethrally instilled) cytotoxic chemotherapy or immunotherapy with Bacillus Calmette-Guerin (BCG).
Celek's lead oncology product CEL-031, targets cGMP phosphodiesterases in cancer cells to induce selective programmed cell death. It has obtained exclusive rights to its lead anti-cancer compound, CEL-031, from OSI Pharmaceuticals which is a member of the Astellas group of companies.
Clarassance, Inc. is specialized in the development of biopharmaceutical products based on the unique family of proteins called secretoglobins. Secretoglobins are small, hardy proteins that are conserved at an evolutionary level. The company was founded by Aprile L. Pilon.
Clarassance's biopharmaceutical product candidate is a recombinant human CC10 protein (CC10), which has several clinical applications in inflammatory, fibrotic, and autoimmune diseases, particularly respiratory diseases. It develops CC10 for respiratory indications including indications in persistent sinusitis, severe influenza-like illness (ILI), and neonatal bronchopulmonary dysplasia. The company's CC10 reduces viral titers for influenza and respiratory syncytial virus.
Clarassance's CC10 is also known as secretoglobin 1A1, CCSP, CC16, uteroglobin, urine protein-1, PCB-binding protein, and blastokinin. Transgenic knockout mice suffer from a number of conditions brought on by a lack of sufficient CC10, including systemic inflammation, poor growth, kidney disease, greater susceptibility to infection, and highly exacerbated responses to respiratory insults such as allergens and ozone.
Cortica Neurosciences Inc is a biopharmaceutical company focused on the development and commercialization of disease-altering therapies to prevent cellular degeneration of the brain. It was established in 2006 by J. Kelly Ganjei & Luciano D'Adamio.
Cortica Neurosciences' technology is dependent on a pivotal role of BR12 in the processing of Amyloid precursor protein. It has novel proprietary models of AD that have been used in the development of peptide drugs.
Cortica Neurosciences has developed suite of therapeutic product candidates for neurodegenerative disease. The company's product pipeline includes: RGX-100 (Intranasal peptide) for the treatment of Alzheimer's disease; RGX-200 (R&D Stage Small molecule) for the treatment of Alzheimer's disease and dementia; and RGX-Tgx: Transgenic animal models of Alzheimer's disease and cognitive decline.
Functional Genetics Inc. (FGI) is a biotechnology company focused on the development of antiviral drugs that can prevent or treat a broad spectrum of different viral diseases. The company has started its operations from 2001 to capitalize on a new technology for target discovery, Random Homozygous Gene Perturbation (RHGP). It was co-founded by Stanley N. Cohen.
FGI's core discovery technology, Random Homozygous Gene Perturbation (RHGP), combines molecular biology and functional understanding of cell behaviour to find elegant solutions to complex biological problems. RHGP can efficiently interrogate every gene in a cell, both for gain or loss of target function, and efficiently focus upon those targets that directly cause the desired experimental outcome. RHGP centers upon the use of a novel genetic element, known as a Gene Search Vector (GSV), which can probe the entire genome to up- or down-regulate each target in a cell. The company utilizes RHGP to identify novel targets with applications to cancer (targets that cause chemotherapy resistance or metastasis), infectious disease (targets for broad-spectrum antivirals and antibiotics), Alzheimer's disease (targets that cause amyloid plaques), manufacturing of biologics (pathways that increase the efficiency of monoclonal antibody production), and other indications.
FGI has developed a portfolio of broad-spectrum antiviral products and discovery technologies. Its product pipeline includes small molecule therapeutics and monoclonal antibodies. Its commercial product focus has targeted three broad areas: Respiratory viruses (Respiratory Syncytial Virus (RSV), Influenza), Hepatitis viruses (HBV, HCV) and Sexually-transmitted viruses (HIV, Herpes). The company's government product focus is on the hemorrhagic fever viruses (Ebola, Marburg, Lassa).
FGI's products include: FGI-101-1A6, a fully human monoclonal antibody that targets a host protein, TSG101, which is uniquely exposed on the surface of virus-infected cells; FGI-102-100, a small molecule therapeutic that selectively binds TSG101, a host protein that is 'hijacked' to support the dissemination of enveloped viruses from infected cells; FGI-103-723, a small molecule therapeutic that has demonstrated impressive abilities to prevent or treat infections caused by a broad spectrum of different viral pathogens, including respiratory syncytial virus (RSV) and other paramyxoviruses; FGI-110 program, which is developing fully human antibodies for the treatment or prevention of respiratory infections; and FGI-111 program, which is developing fully human antibodies for the treatment or prevention of sexually transmitted diseases. Its core discovery engine, RHGP, identified Robo1 as a target for a broad spectrum medicine to treat or prevent infection by sexually-transmitted viruses.
FGI has collaborations with Elanco Animal Health, ProBioGen AG, U.S. Department of Defense, etc.
Genox Corp is a biotechnological company that involves in the development and application of oxidative stress biomarkers for the advancement of basic and applied research related to oxidative stress and aging. The company was founded in 1991 by a small group of investors, along with Dr. Richard G. Cutler, with a mission to provide service to the scientific community by developing fast, accurate and useful oxidative stress related products so that the basic and applied research in this field can progress in a faster pace. It is a subsidiary of Nikken Seil Co Ltd.
Genox's Analytical Testing Services includes 1) oxidative damage assays - DNA Damage, Lipid Damage and Protein Damage; 2) ORAC assays - This assay measures the Oxygen Radical Absorption Capacity (ORAC) of the sample being tested. This service is offered to measure the whole ORAC values of Serum, Plasma, Tissue Homogenates, Plant Extracts, Natural Products, and Dietary/Nutrition Supplements; 3) lipid soluble antioxidants; and 4) Antioxidant Panels.
Genox's products include 1) ELISA Kits - 'New 8-OHdG Check' ELISA Kit, 'High Sensitive 8-OHdG Check' ELISA Kit, Hexanoyl - Lysine ELISA and Potential Antioxidant Test kit; 2) Monoclonal Antibody Products - Anti - 8 - Hydroxy - 2' - Deoxy Guanosine Monoclonal Antibody, Anti Thymidine Glycol (TG) Monoclonal Antibody, Anti - Hexanoyl - Lysine Monoclonal Antibody, Anti - 4 - Hydroxy - 2 - Nonenal Monoclonal Antibody, Anti - Acrolein Monoclonal Antibody, Anti - Malondialdehyde Monoclonal Antibody, Anti - 4 - Hydroxy - 2 - Hexenal Monoclonal Antibody, Anti - Crotonaldehyde Monoclonal Antibody, Anti - Methylglyoxal Monoclonal Antibody etc.
Gliknik Inc. is a biotech company focused on discovery, development and marketing of novel therapies for treating for patients with cancer and autoimmune or inflammatory diseases.
Gliknik has expertise in immune modulation. Its research platforms are: Immunomodulator platform - includes peptide drugs that generate immune responses against targeted cancer epitopes with the goal of turning a cancer patient's immune system against his or her tumor; Stradomer(TM) platform - includes recombinant drugs for a wide range of inflammatory and autoimmune diseases; Stradomer(TM) coated device platform - includes a drug coating to prevent the body's normal reaction to implanted devices; and Stradobody(TM) platform - includes biologics similar to monoclonal antibodies with increased tumor cell killing.
Gliknik's product pipeline includes: GL-2045, a recombinant version of intravenous immunoglobulin (IVIG) indicated for the treatment of autoimmune diseases; GN-4001, a nano-engineered stradomer indicated for the treatment of local inflammatory diseases; Stradobody(TM), represents antibody mimetics indicated for the treatment of cancer; GL-0810, a vaccine indicated for the treatment of head and neck squamous cell carcinoma(HNSCC); and GL-0817, a vaccine indicated for the treatment of head and neck squamous cell carcinoma (HNSCC) and myeloma.
Gliknik has agreements with The University of Maryland and Mayo Clinic. Its investors are LifeTech Development Partners and the MHCPDC investment fund.
Innovative Biologics, Inc. is focused on the development of new anti-microbial drugs targeting bacterial toxins. It was established in December 2003.
Innovative Biologics' research is based on the premise that simultaneous blocking of bacterial growth by antibiotics and inhibition of anthrax toxin action would be beneficial for the treatment of anthrax. The two anthrax toxins are formed by three different proteins: protective antigen (PA), which either combines with lethal factor (LF) to form lethal toxin (LeTx), or with edema factor (EF) to form edema toxin (EdTx). LF and EF are enzymes targeting substrates within the cytosol and PA facilitates their transport across the cell membrane forming a heptameric pore.
Intracel Corp is a manufacturer of custom made cardiovascular disease research products and provides overnight handling on a wide range of lipoproteins and media supplements.
Intracel's products categories include: cardiovascular disease products and lipoprotein isolation schedule. Its cardiovascular disease products include: Human Lipoprotein HDL, Human Lipoprotein Custom Order, Human Lipoprotein Bulk Isolated LDL, Modified Human Lipoprotein Acetylated LDL, Modified Human Lipoprotein Oxidized LDL, Lipoprotein Probe DiI-labeled Acetylated LDL, Lipoprotein Probe Biotinylated HDL, Lipoprotein Probe Biotinylated Oxidized LDL, Fetal Bovine Lipoprotein-Deficient Serum, etc. Its lipoproteins (VLDL, LDL, HDL) are derived from fresh human plasma that has tested negative for Hepatitis C, HIV-1 and -2 antibodies as well as Hepatitis B surface antigen and HIV-1 antigen. The company's human lipoprotein deficient serum (LPDS) is derived from normal healthy male AB serum that has tested negative for HBsAG, HIV 1 / 2, HIV-1 AG or HIV-1 NAT, HCV and Syphilis.
INTRACEL has collaborations with Vaccinogen, Inc., Johnson & Johnson, Mentor Corporation, Merck & Co., Inc. (formerly Schering-Plough Corporation), Organon BioSciences N.V., Organon Teknika, etc.
Intralytix, Inc. is a biotechnology company focused on the production and marketing of products using bacteriophages to control bacterial pathogens in environmental, food processing, and medical settings. It was founded in 1998 to address growing problems in the control and treatment of disease-causing bacteria.
Intralytix uses core bacteriophage technology to develop safe and effective products based on naturally-occurring bacteriophages, for use in food production and processing, environmental cleanliness, veterinary applications, sanitation, consumer products, and problems of antibiotic resistance in human therapy. Its phage technology is based on the philosophy that naturally-occurring bacteriophages provide one of the safest and most environmentally-friendly, targeted approaches for dealing with bacterial infections in a variety of settings.
Intralytix' product portfolio includes: Food safety products- ListShield(TM), EcoShield(TM), SalmShield(TM); Probiotic/Nutraceutical Products- ShigActive(TM); Animal Health Products- INT-401(TM), PLSV-1(TM); and Human Health Products- SAP-100(TM).
Intralytix has alliances withÂ Procter & Gamble,Â US Army and SurModics.
LeukoSight Inc. is a biotechnology company focused on the development of therapeutics that can be used to treat autoimmune and inflammatory diseases. The company was founded by David Mosser.
LeukoSight's technology offers a convenient, safe and more effective treatment option for autoimmune and inflammatory diseases.
LeukoSight has developed a line of proprietary recombinant polypeptides that "reprogram" white blood cells (leukocytes) to produce immunoregulatory molecules. Its therapeutic platform is directed at treating the most prominent of autoimmune and inflammatory diseases, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease.
Maxim Biotech Inc is a biotechnology research and development company. Its principle objective is to employ biological processes to develop quality and innovative products for health care and life science. It was founded in July 1992.
Maxim's core technology competency in developing multiplex amplification assay systems affords researchers the opportunity to significantly increase their assay through-put while reducing the time consuming and laborious nature that is typical of many of today's amplification assay systems. Its diverse lines of kits and services are designed to address the limitations and make molecular biology research techniques faster, easier, more cost- effective, and more accessible to researchers working in a broad range of disciplines.
Micromet Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. It was founded in 1993, with a goal to discover, develop and commercialize breakthrough therapies with the potential to deliver meaningful clinical benefit to oncology patients. Its vision is to develop a new class of drugs that mobilize T cells, the body's most potent killer cells, enabling them to detect and destroy normally unrecognizable cancer cells.
Micromet advances a robust pipeline of therapeutics based on its proprietary BiTEÂ® technology. Its product candidate blinatumomab (MT103) has demonstrated single-agent activity in both adult and pediatric patients with acute lymphoblastic leukemia. The company's products include: Blinatumomab (MT103), a Bispecific T cell Engager (BiTEÂ®) antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express CD19; MT110 and MT111 (also known as MEDI-565), a Bispecific T cell Engager (BiTE)Â® antibody for the treatment of solid tumors; MT203 for the treatment of acute and chronic inflammatory and autoimmune diseases including rheumatoid arthritis, asthma and multiple sclerosis; and MT228 for the treatment of metastatic melanoma.
Micromet has partnerships with Boehringer Ingelheim GmbH, Lonza Group Ltd, Sanofi-aventis, Bayer Ag, Bayer Schering Pharma AG, Nycomed SICAR S.C.A., Affitech A/S, etc.
NeuroNascent, Inc. is focused on discovering and developing therapies for depression, Alzheimer's, Parkinson's, and other neurodegenerative diseases based on the science of neurogenesis that: reduce the loss of neurons, restore and replace damaged neurons, promote the formation of new neurons and reverse cognitive loss. It was founded in 2004 by Judith Kelleher-Andersson.
NeuroNascent's technology platform is based on neurogenesis and hibernation. It aims to enhance neurogenesis to promote greater numbers of mature neurons that will subsequently promote cognitive improvements in patients with Alzheimer's disease, depression, or Parkinson's disease.
NeuroNascent's unique drug discovery platform is used to identify active compounds that promote increased numbers of mature neurons from neuronal progenitor cells in a cell culture system. These compounds will be developed into small-molecule therapeutics for patients with: Alzheimer's disease (AD), Depression, Parkinson's disease, Down syndrome, and Ischemia.
NeuroNascent has partnerships with ChemRar Pharma, ChemDiv, Inc., University of Maryland, The University of Maryland, Baltimore (UMB), Lifeline Cell Technology and International Stem Cell Corporation.
Prolias is a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease.
Prolias' technology platform is based on ProSpectrum Ligands(TM) which employ chemically synthesized sets of peptide ligands on microscopic chromatography resins. The ligands also utilize a robust technology that allows binding to specifically targeted protein domains, purifying proteins and physiological protein complexes from complex sources. These ligands are used to prepare samples for proteomic investigations from a broad range of complex biological materials that are compatible with ProSpectrum Ligands(TM), including anti-coagulated whole blood, serum, bacterial extracts, tissue homogenates, and cell culture media.
Prolias products include: High-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), Cardiac Troponin I (cTnI), Hemoglobin, Fibrinogen, Alpha-1-antitrypsin etc. The company's services include: Ligand Identification by Bead Blot(TM) technology; Sample Preparation using ProSpectrum Library (TM) (PSL-2) and Drug discovery by Functional Identification of Novel Activities (FIoNA(TM)) technology.
Rexahn Pharmaceuticals Inc is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments for cancer, central nervous system disorders and other unmet medical needs. The company was founded in 2001 by Chang H. Ahn with a mission to impact the health and wellness of patients with life-threatening and life-debilitating diseases.
Rexahn's discovery platform features small signaling molecule discovery (TIMES), computational predictive modeling (3D-GOLD) and nanoscale drug targeting and delivery. These technologies enable to screen, select and optimize large numbers of compounds while retaining stringent selection criteria. It's proprietary TIMES small molecule signaling technology has enabled it to discover more than a dozen targets involved in cancer proliferation. The company's 3D-GOLD is an integrated computational modeling tool of 3D-finger printing / pharmacophore, 3D-QSAR/proprietary QCID, 3D-ligand constructs, and 3D-dockings, that helps to predict the structural activity relationship of molecules using 3-dimensional models. The company is developing cutting-edge drug delivery systems based on nano-liposome and polymer encapsulation of existing medicines that could increase bio-availability while minimizing adverse reactions.
Rexahn's portfolio presents unique compounds for a wide variety of conditions from cancer to brain disorders and promises to improve the standards of care for multiple diseases. Its development pipeline includes - 1) Cancer: ArchexinÂ®, an inhibitor of the Akt-1 protein kinase in cancer cells. It is being developed for the treatment of renal cell carcinoma (RCC) and pancreatic cancer, glioblastoma, and cancers of ovary and stomach. The company's other pipeline products include: RX-0047-N, RX-5902, RX-3117, RX-1792, RX-8243, RX-0201-N, etc; and 2) CNS disorders: SerdaxinÂ® for the treatment of major depressive disorder (MDD) and Parkinson's disease; and Zoraxelâ„¢ is a CNS-based sexual dysfunction drug that is being developed to treat erectile dysfunction.
Rexahn has collaborations with United States Department of The Treasury, TheraTarget, Inc., Korea Research Institute of Chemical Technology (KRICT), Teva Pharmaceutical Industries, Ltd., University of Maryland, Amarex Clinical Research, Inc., UPM Pharmaceuticals, Inc., Revaax Pharmaceuticals LLC, etc.
Royer Biomedical, Inc. (RBI) is a mid-stage biotechnology enterprise targeting novel drug delivery systems. RBI has developed proprietary bioabsorbable polymer hydrogel technology for topical and internal controlled release of a wide variety of pharmaceuticals including antibiotics, chemotherapeutic agents, and local anesthetics. The various polymer and calcium-based matrix formulations have extensive patent protection in the US, Europe, Asia, Australia and Mexico. Royer Biomedical is focusing on novel polymer hydrogel based drug delivery systems to provide next generation therapies for diabetes, cancer, and localized infection.
Royer Animal Health LLC is engaged in development of distinct drug delivery matrices for veterinary medicine. The company is a wholly owned subsidiary of Royer Biomedical Inc.
Royer Animal Health offers veterinary practitioners with therapeutic treatments for cancer, infections and general wound management. The company's Matrix IIIâ„¢ technology is based on an inorganic-biopolymer composite. The nature and proportions of the inorganic components and polymers, determine the release profile and the desired erosion rate. The therapeutic advantages based on attributes of the unparalleled Matrix IIIâ„¢ bead technology include: Resorbed by the mechanism of dissolution; Product stability; Unique micro environment; etc.
Royer Animal Health's products include: Matrix IIIâ„¢ cisplatin beads that are effective in the treatment of cancer; and R-Gelâ„¢ antibiotic wound dressing that is proven effective against numerous localized infection. The R-Gelâ„¢ antibiotic wound dressing contains a proprietary formulation of oxidized dextran solution with an adipic dihydrazide cross-linking agent.
Royer Animal Health has partnerships with MWI Veterinary Supply, Inc and Marion duPont Scott Equine Medical Center, Johns Hopkins NIH and Ohio State University.
Sequella Inc. is a biopharmaceutical company focused on commercializing improved treatments for serious infectious diseases. It was founded in 1997 by Carol A. Nacy and Leo Einck with a mission to develop and commercialize new, more effective therapeutics for serious or life-threatening infectious diseases.
Sequella develops novel small molecule and natural product-based therapeutics for infectious diseases, starting with TB. Its initial research programs identify new scaffolds with antibacterial and antifungal activity and several compound libraries were prepared using focused combinatorial chemistry and modern synthetic techniques. It has developed and validated several high-throughput screening assays that are used to analyze the libraries for target pathogen activity and identify the most promising compounds for clinical development. Its drug candidates have broad market potential with applications in Tuberculosis, Peptic Ulcer Disease and Gastric Cancer, Fungal Diseases, Crohn's Disease, Bacterial Pneumonia, and a number of other infectious diseases.
Sequella's pipeline includes: SQ109, SQ609 and SQ641 for the treatment of TB; SQ109 - for the treatment of tuberculosis, duodenal ulcers, gastric carcinoma and Candida glabrata infection.
Sequella has partnerships with The University of Maryland, Baltimore (UMB), PATH (Program for Appropriate Technology in Health), Chembio Diagnostic Systems, Inc., BioFactura, Inc., Tibotec Pharmaceuticals Limited, Johnson & Johnson, National Institutes of Health, Daiichi Sankyo Company, Limited, Sankyo Co., Ltd. etc.
Spherix Incorporated is developing biopharmaceutical products and providing technical and regulatory consulting services to food, consumer products and pharmaceutical companies. It was launched in 1967 by Gilbert V. Levin, with a mission to create and grow shareholders value through innovations that benefit its clients and the human condition. The company's subsidiaries include: Biospherics, develops and commercializes proprietary health, drug, and medical products and processesl and Spherix Consulting provides the necessary strategic, regulatory, and scientific support to its clients for the purpose of securing their successful market position by assuring the safety, regulatory compliance/approval and benefit of their products.
Spherix's Biospherics is specialized in the application of chiral carbohydrate chemistry and has developed an extensive pipeline of candidates across a broad range of therapeutic indications. Its clinical candidate, D-Tagatose is a naturally occurring simple sugar being developed as an oral treatment for glycemic control in patients with Type 2 diabetes and other indications. Biospherics pipeline products include: SPX 7233801 for the treatment of atherosclerosis, SPX-8522876 for the treatment of Dyslipidemia, SPX 10624258 - Metabolic syndrome, SPX 8818309- Obesity and SPX 8818440 - Diabetes.
Spherix' Spherix Consulting provides expert support throughout the lifecycle of its clients' products. It provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.
Spherix has collaborations with Inalco S.P.A, Anaclim, LLC, Gleneagles CRC Pte Ltd, Yeshiva University, and United States Department of Agriculture (USDA).
Stealth Peptides is a biopharmaceutical company developing novel mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal, ophthalmologic, neurologic and metabolic conditions. The company was founded in 2006.
Stealth's has a rich and promising pipeline of preclinical and clinical compounds from a unique class of short peptides that target mitochondria. Its first clinical candidate, Bendavia(TM), targets the mitochondria to treat ischemia reperfusion injury.
Trophogen, Inc is a biotechnology company focused on the development of high affinity glycoprotein hormone and related growth factor analogs for human and animal infertility as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers. It was founded in 2001, with a mission to develop superactive hormones and growth factors for a wide array of therapeutic applications.
Trophogen technology represents the first successful design of super active analogs of glycoprotein hormones that shows major increases in bioactivity and far exceeds results shown for other protein ligands. Its platform technology of substituting amino acids in protein sequences based on electrostatic interactions has implications in a variety of therapeutic fields from infertility to cancer.
Trophogen product portfolio includes: FSH and LH superagonist for the treatment of human and animal infertility; Labeled TSH superagonist imaging agent for thyroid cancer; TSH superagonist- radionuclide or -toxin for the targeted therapy of thyroid cancer; LH and FSH superagonist- radionuclide or toxin for the targeted therapy of ovarian cancer; LH superagonist- radionuclide or toxin for the targeted therapy of breast and prostate cancer; etc.
Trophogen has established partnership with Bioniche Life Sciences Inc.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
United Therapeutics' has Five Strategic Objectives: develop the best medicines possible from our intellectual property; conduct the most insightful clinical trials of our medicines; achieve superior communication and awareness of its products among physicians; grow its business to be in the top quintile of its peers; achieve its goals by doing the right thing and using the highest ethical standards.
United Therapeutics' pipeline include: Oral Treprostinil for Pulmonary Arterial Hypertension (PAH); Beraprost-MR for PAH; ch14.18 for Neuroblastoma; 3F8 MAb for Neuroblastoma; Oral Trepostinil for PVD; Aviptadil for PAH; 8H9 MAb for Metastatic Brain Cancer; IW001 for IPF and PGD; and Glycobiology Antiviral Agents.
United Therapeutics' products include: Remodulin, a medication used to treat pulmonary arterial hypertension (PAH); Adcirca, the only once-daily phosophodiesterase-5 (PDE-5) inhibitor for Pulmonary Arterial Hypertension (PAH); TYVASO, an inhaled medicine used to treat PAH; CardioPALÂ®, technologically advanced portable heart monitor etc.
United Therapeutics has collaborations with Eli Lilly & Co, Lee's Pharmaceutical Holdings Ltd, BIOWEST THERAPEUTICS Inc., Memorial Sloan-Kettering Cancer Center, Aradigm Corp, Mochida Pharmaceutical Co., Ltd., etc.
Zyngenia Inc is a biotherapeutics company focused on the development of next-generation of antibody-derived drugs called Zybodies(TM). It was founded in 2008 and was engaged in the research and development of creating therapies for patients who have unmet medical needs in cancer and autoimmune diseases.
Zyngenia uses proprietary technology to enable the development of single molecular entities that address two or more targets, by combining the activity of two or more biologic therapies into one protein (known as a Zybody(TM)). In addition, the technology will also be applied to drug targets that have not been reachable through the use of traditional, single specificity, monoclonal antibodies. Since the technology is based on intact antibodies, the company believes that the molecules generated will possess desirable effector and pharmacokinetic properties that are mediated through the Fc regions.
Zyngenia's investor is New Enterprise Associates, Inc. It has partnership with Selexis SA and Antitope Ltd.
Angimmune LLC is a new small biotech company founded by Dr. David Neville and two former members of his previous lab at the National Institutes of Health (NIH), Dr. Yuan-Yi Liu and Dr. Jung-Hee Woo. While at NIH these founders developed a unique immunotoxin technology. Angimmune has now licensed this technology from NIH.
Cerecor's principals and advisors have > 200 years of biotechnology discovery, development, finance and commercialization experience. Indeed, members of our Board of Directors have delivered > $35 Billion in new enterprise value creation. We have a very strong track record in successfully forming companies and investing in new biotechnologies that were at early stages of development, had no prior investment, and generated a significant, rapid inflection in asset values. We have worked with and have relationships with many leading healthcare investment banks, venture capital firms and major multinational pharmaceutical corporations. Our people, partners, lead candidate and product strategy, when combined with our intellectual property portfolio, will allow for rapid commercialization and the establishment of a very favorable market position.
EdgeBio is an established research reagents and sequencing services company. Our products and services help simplify the complex task of discovery, and make it affordable and fun. In a high-pressure field with so many unknowns, Edge offers our customers both peace of mind and a competitive edge.
Fina Biosolutions LLC is a private, research and development stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for prevention of life-threatening diseases. Fina has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. The technology is currently licensed by leading vaccine manufacturers in both Europe and Asia, including GlaxoSmithKline for marketed vaccines Synflorix™ Menitorix™, Nimenrix™, The Serum Institute of India Ltd., and others.
RAFAGEN’s primary focus is on the development and commercialization of next generation gene expression systems, with applications in solving the most challenging problems in molecular therapeutics. RAFAGEN will leverage its core technology to build up a strategic framework for revenue generation in licensing deals and service contracts, and eventually, for its own development of highly effective molecular therapy drugs.
Founded in 2001, with offices in Rockville, Maryland, Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".
Synthetic Biologics is a biotechnology company focused on the development of synthetic biologics and innovative medicines for serious infections and diseases. Synthetic Biologics is developing a biologic for the prevention of C. diff infection, and a series of monoclonal antibodies (mAbs) for the treatment of serious infectious diseases, including pertussis and Acinetobacter. The Company is also develoing a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension (PAH).
In addition, Synthetic Biologics is developing a product candidate to treat relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS; designing a clinical development pathway for the treatment of amyotrophic lateral sclerosis (ALS); and, has partnered the development of a treatment for fibromyalgia. The Company is also evaluating additional in-licensing opportunities.
Teva Biopharmaceuticals USA (TBU) is committed to the discovery and development of improved, next generation and novel biopharmaceuticals for the treatment of disease and serious medical conditions. Using proprietary albumin fusion technology, TBU can improve and expand the use of established and novel biopharmaceuticals by developing drug candidates with reduced dosing frequency and increased safety.
The TBU development team has a significant track record in translating early drug opportunities into clinically-proven drug candidates. TBU’s research and manufacturing facility based in Rockville, Md., is fully equipped and capable of supporting both GLP development and cGMP manufacture of biologics. TBU has capitalized on the depth of our pipeline and the breadth of our technology to develop drug candidates that will address a broad spectrum of unmet medical needs including chemotherapy supportive care, autoimmune disorders, metabolic disorders, cardiovascular disease, and enzyme replacement therapy.
Aeras has collaborations with Advanced BioScience Laboratories, Inc., Omnia Biologics, Inc., ACE BioSciences A/S, University of California, Statens Serum Institut (SSI), etc. Its partners include: Crucell, Emergent BioSolutions, GlaxoSmithKline Biologicals, Immune Solutions, ImmunoBiology, Intercell, Sanofi Pasteur, Serum Institute, Statens Serum Institut, Thymed, Wuhan Institute of Biological Products, etc. Its investors include: National Institute of Allergy and Infectious Diseases, The Research Council of Norway, Bill & Melinda Gates Foundation, etc.
AuRx, Inc. is a biotechnology company that specializes in the treatment of long lasting and recurrent viral diseases.
AuRx's epidemiological studies have demonstrated that herpes viruses infect high proportions of population groups around the world. The company believes in the clinical data gained in the therapy of genital herpes will allow the company to effectively and efficiently design therapeutic vaccines for the relief of other long lasting viral diseases including HIV, Human Papilloma Virus, Epstein Barr Virus and Cytomegalovirus. Its AuRx herpes therapy works via cell-mediated immunity (CMI) and is based on facts that recurrent disease is associated with a preponderance of immune regulatory T cells [helper type 2 (Th2)] that function to downregulate the ability of the virus specific CMI to control virus replication. The AuRx therapy also reduces the production of the soluble mediator IL-10 which stimulates production of Th2 cells. It uses its recombinant technology to develop a rapid serological assay for HSV-2 which is based on the protein kinase of the large subunit of HSV-2 ribonucleotide reductase.
AuRx has alliance with Landsteiner Scientific, S.A. de C.V.
Biological Mimetics, Inc. (BMI) is a biotechnology company that commercializes the pharmaceutical products which improves the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. It was founded in 1996 by Peter L. Nara and George Lin. The company's mission is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer.
Biological Mimetics' technologies include: Deceptive Imprinting and Immune Dampening and Refocusing. Its Deceptive Imprinting is a common strategy by which many disease pathogens and cancer cells evade conventional vaccine strategies as well as host immune responses. The company's proprietary, platform technology of Immune Dampening and Refocusing is a method that defeats antigenic variation and deceptive imprinting. Its technology has the potential to generate vaccines against pathogens for which no effective vaccine exists, improve on the limited protection of previously tried human and veterinary vaccines, and develop therapeutic vaccines that can be given after the onset of disease to supplement the natural response of the immune system. The company's technology is able to alter the natural antigenicity and immunogenicity of targeted protein antigens for vaccine purposes. The identification of novel therapeutic antibodies using Immune Dampening and Refocusing can be done in infectious disease and oncology applications.
Biological Mimetics' research and development is focused on the development of vaccines for Human Applications- Influenza Virus, Rhinovirus, Non-typeable Haemophilus Influenza, etc; and Veterinary Applications- Foot and Mouth Disease Virus, Infectious Pancreatic Necrosis Virus, and Porcine Reproductive and Respiratory Syndrome Virus.
Biologics Resources LLC is a vaccine and a biopharma company engaged in developing new medical countermeasures to protect human life against bioterrorism. The company's mission is to develop biodefense vaccines, biodefense antibodies and non-biodefense vaccines and therapeutics for children and adults.
Biologics Resources has expertise in vaccine & antibodies development and manufacturing, protein chemistry, organic chemistry (synthesis), molecular biology, immunology, quality, and regulatory affairs.
Biologics Resources has secured license for the development of conjugate anthrax vaccine to induce dual antibodies having immunity against both, capsule which is responsible for initiation of infection by evading the host immune system and toxins that are responsible for toxemia and death. It is also in the process of securing license for the development and production of humanized monoclonal antibodies against Bacillus anthracis capsule and toxins induced by the conjugate vaccine for pre-exposure and post-exposure prophylaxis.
Biologics Resources has partnership with National Institute of Health (NIH), National Institute for Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), University of Massachusetts and UTMB, Galvaston.
ChemGen Corp. is a biotechnology company specializing in developing products through the use of microbial fermentation technology. Its mission is to discover and commercialize novel feed enzymes. The company pioneered the development of post-pelleting application techniques for the addition of small-volume liquid ingredients to animal feed. It was founded in 1985. The aim of the company is to explore the industrial and applications of biotechnology.
ChemGen provides the industry with an assay service to ensure that the recommended amount of enzyme product is applied to feed. Meat and egg producers already use feed enzymes to help the environment by reducing the phosphorous content of feed and ease the growth of animals by improving livability and reducing disease conditions.
ChemGen developed proprietary and patented bioprocesses for its contract research clients. The company has international distributors that includes: Behn Meyer Europe GmbH, Nutribase, Kannar Incorporated, etc.
Classen Immunotherapies, Inc. is a biopharmaceutical company involved in the discovery of the safer uses of vaccines, drugs, devices, chemicals and related products. The company is dedicated in understanding the chronic effects of vaccines and developing safer immunization methods for those who choose to be immunized.
Classen Immunotherapies has developed and patented methods which create financial incentives for finding and disclosing adverse event information. These methods pertain to patenting the disclosure of adverse events. The methods are expected to lower the cost of drugs and other products through lowering the frequency of costly adverse events.
Integrated BioTherapeutics Inc (IBT)Â is a research-based biotechnology company engaged in the development of vaccines and discovery of small molecules targeting emerging infectious agents. Its focus is on the development of vaccines and immunotherapeutics for complications resulting from Staphylococcal and Streptococcal infections.
Integrated BioTherapeutics uses its proprietary technology to develop a multivalent panfilovirus vaccine for prevention of the deadly hemorrhagic fevers caused by different strains of Ebola and Marburg viruses. Its technology is based on virus-like particles, hollow particles that mimic the ebola- or marburgvirus, but are devoid of the viral genetic information. The company's technology VLP system is not vector-based and does not require another viral system for propagation and efficiency.
Integrated BioTherapeutics develops vaccines and therapeutics for two groups of infectious diseases: infections and septic shock caused by staphylococcal and streptococcal infections and viral hemorrhagic fevers. Its vaccines rely on a structure-based design and are designed to induce antibodies for neutralization of superantigens. The company is also developing a set of recombinant vaccines for streptococcal pyrogenic exotoxins.
Integrated BioTherapeutics targets various toxins produced by bacteria that aid them to evade the immune response and establish persistent or acute infections using a portfolio of proprietary recombinant mutant vaccines and vaccine candidates. The company's product pipeline includes: FiloVax, STEBVax, Multivalent Staph Vaccine, SEB-HIG and TSS-HIG. Its services include antiviral testing, antibiotic testing, custom testing etc.
Integrated BioTherapeutics has alliances with National Institute of Health, NCI-Frederick, Omrix biopharmaceuticals, BD (Becton, Dickinson and Company), Functional Genetics, Inc and so on.
MedImmune, LLC. (formerly Molecular Vaccines, Inc.) is a biotechnology company, focused on the areas of infectious disease, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. It was established in 1988 as Molecular Vaccines, Inc. It is a wholly owned subsidiary of AstraZeneca plc.
MedImmune aims to deliver several promising new biologics to the market through cutting-edge technology by accelerating the development of novel antibody or antibody-like therapeutic and preventive medicines. The company is looking to engineer novel properties, such as effector function improvement, into antibodies to enhance their potency; exploring the possibility of generating long-lasting antibody therapy so that dosing frequency can be reduced; developing bi-specific antibodies, polyspecific antibodies, or polyclonal antibodies to target multiple disease mediators to increase drug efficacy while maintaining an appropriate safety profile. The company uses technologies such as antibody engineering, cell culture production, live viral vaccines, reverse genetics, and virus-like particle technology.
MedImmune's pipeline include: Anti-Ang2 for oncology, MEDI-570 for systemic lupus erythematosus, PIV3 vaccine for lower respiratory tract disease caused by PIV3, Motavizumab nti-RSV humanized IgG1 MAb, MEDI-578 for the treatment of pain, anti-CD19 MAb or MEDI-551 for the treatment of Systemic sclerosis(scleroderma), MEDI-575 for the treatment of advanced solid tumors, etc. It's SynagisÂ® (palivizumab) is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by RSV disease.
MedImmune has research and development collaborations with Amgen Inc, Immune Design Co., DeveloGen AG, Medarex, Inc., Abbott, BioWa, Inc, Catalyst Biosciences, Human Genome Sciences (HGSI), SBI Biotech, and Trellis Biosciences.
Nabi Biopharmaceuticals is focused on developing and marketing products that address unmet medical needs and offer commercial opportunities in its core business areas: Gram-positive bacterial infections and nicotine addiction. The company's mission is to develop and deliver high-value biopharmaceutical products utilizing its innovative conjugate vaccine antibody technologies.
Nabi Biopharmaceuticals' product pipeline includes: NicVAXÂ® (Nicotine Conjugate Vaccine), an investigational vaccine designed as an aid to smoking cessation, as well as an aid to prevent relapses of a treated smoker; and EnteroVAX(TM) (Enterococcus faecalis Conjugate Vaccine).
Nabi Biopharmaceuticals has alliances with Diosynth RTP, Inc., GlaxoSmithKline plc, Glaxosmithkline Biologicals, U.S. Department of Defense, Uniformed Services University, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Sanaria Inc is a biotech company engaged in the production of a vaccine protective against malaria. Its mission isÂ to develop and commercialize a metabolically active, non-replicating malaria sporozoite vaccine against Plasmodium falciparum.
Sanaria is focused on development of whole-parasite malaria vaccines that confer high-level, long-lasting protection against malaria caused by Plasmodium falciparum and P. vivax. The company's products include: SanariaÂ® Plasmodium falciparum Sporozoite Reagents, SanariaÂ® PfSPZ Challenge Mosquitoes, SanariaÂ® Plasmodium Reagents and SanariaÂ® Plasmodium Reagent Slides. It also offers assay services and custom services.
Sanaria has collaborations with Naval Medical Research Center, Protein Potential LLC, Center for Disease Control, University of Maryland Biotechnology Institute, National Institute of Standards & Technology (NIST), The PATH Malaria Vaccine Initiative (MVI), National Institutes of Health - The National Institute of Allergy and Infectious Diseases (NIAID) and The US Department of Health and Human Services.
The PATH Malaria Vaccine Initiative (MVI) is a non-profit organization whose mission is to accelerate the development of malaria vaccines and to ensure their availability and accessibility in the developing world. It was established in 1999 through a grant from the Bill & Melinda Gates Foundation.
The PATH Malaria Vaccine Initiative's activities include: evaluating and managing intellectual property issues to overcome or avoid commercial barriers to vaccine development; developing clinical trial sites and conducting malaria vaccine clinical trials; assessing the demand for malaria vaccines; supporting countries to strengthen decision-making processes in preparation for a new vaccine; etc. Its research and development (R&D) strategy supports the long-term goal of eradicating malaria. It is also engaged in the process of defining acceptable vaccine product characteristics by developing target product profiles for each vaccine candidate and for potential candidates.
The PATH Malaria Vaccine Initiative is accelerating the development of malaria vaccines by testing multiple candidates simultaneously. It identifies potentially promising malaria vaccine candidates that target the most dangerous malaria parasite, Plasmodium falciparum.
The PATH Malaria Vaccine Initiative's partners include: GlaxoSmithKline Biologicals, Infectious Disease Research Institute, International Centre for Genetic Engineering and Biotechnology, Crucell, Sanaria Inc., Seattle Biomedical Research Institute and Walter Reed Army Institute of Research.
Vaccinogen, Inc. is a biotechnology company that develops and commercializes cancer vaccines and other immunotherapeutic products. It focuses on discovering, developing and manufacturing fully human monoclonal antibodies for human clinical use. It was formed in 2007 by Michael G. Hanna.
Vaccinogen's lead product, OncoVAXÂ® vaccine is indicated for the treatment of stage II colon cancer. It is an active specific immunotherapy (ASI) that uses the patient's own cancer cells to block the return of colon cancer following surgery. This patient-specific vaccine comprises sterile, metabolically active, irradiated, non-tumorigenic autologous tumor cells, with or without fresh frozen Bacillus Calmette-Guerin ('BCG') bacterial as an adjuvant.
Vaccinogen develops other programs in both active specific immunotherapy (vaccines) and passive specific immunotherapy (fully human monoclonal antibodies). Its HumaSPECT antibody was widely approved for any clinical use worldwide. The company develops other products based on pioneering work in colon carcinoma, renal carcinoma and melanoma.
Vaccinogen's partners include: Clinipace, Inc., Pro Concepta Zug Ag and INTRACEL Corp.
Sanofi Pasteur, the vaccines division of Sanofi, is the largest company in the world devoted entirely to human vaccines. Our driving goal is to protect people from infectious diseases by creating safe and effective vaccines.
Our company offers the broadest range of vaccines in the world, providing protection against 20 bacterial and viral diseases. We distribute more than 1 billion doses of vaccine each year, making it possible to vaccinate more than 500 million people across the globe.
SynAm Vaccine's mission is to eradicate pneumococcal diseases — pneumonia, middle ear infections, and meningitis — with the world's first universal vaccine. Pneumococcal diseases are the leading cause of serious illness in children and adults throughout the world and account for more deaths than all other vaccine-preventable bacterial diseases combined.
SynAm Vaccine's lead universal vaccine candidate addresses the critical unmet medical need in the marketplace by providing universal coverage against all 91 bacteria serotypes, while current marketed vaccines cover only a fraction of the serotypes.
BioManufacturing; Research Services & Supplies; Suppliers (CRO)
A&G Precision Antibody is focused on providing customized, high-affinity monoclonal and polyclonal antibodies to pharmaceutical and biotechnology companies as well as to academic, government, and nonprofit research institutions. It is a wholly owned service division of A&G Pharmaceutical, Inc. The company was established in 2000.
A&G has developed more than 1000 novel customized antibodies. Its products and services are based on a proprietary antibody discovery and development platform technology that enables rapid development of target-specific, high-affinity antibodies. The company's portfolio of optimized research antibodies include: Anti-GST, Anti-HIS, Anti-MYC, Anti-C19ORF5, Anti-LRP-5/6 and Anti-AR-V7.
A&G offers a wide range of custom antibody development services that include: monoclonal development, polyclonal development, antibody production, conversion of polyclonal to monoclonal, biacore analysis, cell banking, etc. The company is a one-stop solution for antibody production and purification services. Its manufacturing facility is capable of small-scale as well as bulk production of any antibody clone both in vitro and in ascites. It also offers other services such as characterization of purified antibodies including isotype determination, affinity determination by BIACore, cryopreservation of clones, and conjugation of antibodies.
A&G's partners include: SAIC-Frederick, Inc and U.S. Environmental Protection Agency.
Advanced Bioscience Laboratories Inc (ABL) is a biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. It was established in 1961 as Bionetics Research Laboratories (BRL), in 1968 BRL was acquired by Litton Industries and became Litton Bionetics, Inc (LBI) and later it was renamed as Advanced BioScience Laboratories, Inc (ABL). The company's mission is to combine the scientific expertise of its highly trained and experienced staff with that of other outstanding scientists within government, academia and the private sector for the sole purpose of developing solutions and treatments that will prevent the spread of HIV and other infectious diseases and ultimately improve the quality of life and benefit all mankind.
Advanced BioScience's research reagents and kits include: ELISA Kits, viral antigens and proteins, virus stocks, antibodies and hyper immune serum (high titer, monospecific). It offers a broad range of services ranging from process development, scale-up, master and working cell banks, fermentation, downstream purification and stability testing of the final product. The company has manufactured products for clinical trials which include: Viral glycoproteins, Monoclonal antibodies, Immunotoxins and Other proteins.
Advanced BioScience offers a wide range of lab services which include: vaccine and product development, immunomonitoring of animal studies, GLP studies, virus expansion, recombinant protein production and purification. Its core resources expertise include: Quality, Scientific, cGMP Manufacturing, Regulatory Affairs, Validation and Project Management. The company produces a number of specialized products (antibodies, research reagents, viral stocks, etc.) and kits (antigen capture) for HIV, SIV, and virologic research. Its testing services include: vet screen, reticulocyte count, macaque antibody profile (SRV, STLV, SIV, Herpes and Measles), complete blood chemistry, platelet count and cell phenotype.
Advanced BioScience has agreements with Life Technologies Corporation, Hawaii Biotech, Inc., NovaDigm Therapeutics, Inc., National Institutes of Health, National Institute of Allergy and Infectious Diseases, The U.S. Department of Health and Human Services, Aeras Global TB Vaccine Foundation, Sanaria, Inc., etc.
Advanced Biotechnologies Inc (ABI) is engaged in producing and supplying innovative virology products and services to researchers and manufacturers worldwide. It was founded in 1982.
ABI offers a wide range of standard and custom products and services. Its product areas include: Blood Products, Concentrated Infectious Virus, Purified Inactivated Virus, Purified Infectious Virus, Virus Infected Cell Extracts, Viral Proteins, ELISA/IFA Test Kits, Immunoassay Stabilizer, Antiviral Antibodies, Quantitated DNA PCR Controls, etc. The company's services include: Cell Banks, Custom Designed Projects, Electron Microscopy, Virus Inactivation and Virus Production.
B/R Instrument is a manufacturer of solvent recyclers for high purity solvent recycling, and is a manufacturer & distributor of distillation equipment. The company's mission is to be a leading manufacturer and distributor of distillation equipment throughout the world.The company was established in 1966 by Roger Roark and Harry Brown.
B/R Instrument's Solvent recyclers are used in histology labs to recycle xylene, alcohol, formalin and xylene substitutes. The company's HPLC solvent recycling and GPC solvent recycling have also become more popular due to the high cost of the solvents. Crude oil distillation and petroleum distillation are also common applications of company's fractional distillation equipment. The company's Spinning band distillation is a technique which uses a rotating helical band to create a high number of theoretical plates.
B/R Instrument products include: 9700 ProCycler Solvent Recycler, MiniProCycler Solvent Recycler, PureForm 2100 Formalin Recycler, 9600 High Efficiency Distillation System, B/R Instrument 36-100 High Efficiency Distillation System, Automaxx 9100 Crude Oil Distillation System, B/R Instrument 800 - High Efficiency Micro Distillation, 9400 CODS for Crude Oil Distillation, VAC-1000 Vacuum Regulation System and ASTM D1160 Vacuum Distillation Apparatus.
Bell-More Laboratories, Inc. is a contract pharmaceutical manufacturer with particular emphasis on custom lyophilization of small volume parenteral drugs. The company was founded in 1973.
Bell-More utilizes state of the art equipment from stokes freeze dryers to metromatic vial washing machines. Its products are carefully formulated to specifications and then 0.2 micron sterile filtered. The company's customers include prestigious leaders in the pharmaceutical industry. It also provides custom freeze drying services.
BIOCON Inc is a contract research organization specialized in offering preclinical research services to government, military, bio-pharmaceutical, medical device, chemical and consumer products clients. The company was founded in 1978.
BIOCON has expertise in animal holding and breeding, small-animal model development, acute, subacute and subchronic toxicity testing, vaccine development, product safety testing and animal disease diagnostic services. The company offers a comprehensive range of non-GLP and GLP-compliant in vivo preclinical services designed to meet all of client's small-animal research, housing and breeding needs. It has extensive experience in breeding and maintaining numerous mouse strains, including congenic and transgenic mice. The company also provides quality housing, breeding, technical manipulation and colony management of small research animals. It is specialized in providing a wide range of support services that include: cryopreservation, embryo re-derivation, veterinary pathology, routine histology, quarantine, and animal health-screening services. The company designs and performs both discovery and preclinical phase safety studies to determine whether biologic materials intended for human use produce either unexpected or unacceptable levels of reactivity in test animals. It is AAALAC-accredited, OLAW approved and USDA compliant company.
BioLogics, Inc is engaged in the manufacture of laboratory instrumentation for the life sciences. The company offers novel systems that dramatically enhance microbiology applications such as automating antibiotic potency testing (zones of inhibition) and bacterial automated colony counter. It was founded in 1996 with a commitment to improve life science instrumentation.
BioLogics manufactures the OMNICONÂ® image analysis system with specific applications for zones of inhibition and tumor colony analysis. It also manufacturers automated colony counters and ultrasonic homogenizers that can disintegrate most cells, bacteria, spores or tissue. The company's OMNICON tumor colony analyzer is a powerful combination of the advanced image analyzer, automatic stage and software dedicated to count soft agar assays. Its OMNICON zone reader integrates image analysis, comparison and reporting to provide accurate results in record time. It's OMNICON large plate zone reader automates the measurement of zones of inhibition performed during the testing of antibiotics to determine potency during the manufacturing process.
BioLogics' products have evolved from the integration of several image analysis companies which include: Artek Systems Corporation, Bausch and Lomb, Dynatech and Imaging Products Group Inc.
BioSTAR Inc is a biomedical consulting and program management company specialized in the development of first responder, far forward and military relevant medical project development. It is a member of the BioSTAR Group of companies.
BioSTAR Inc delivers multi-faceted medical and research support for program development, funding opportunities and collaborative R&D programs between universities, government, and industries. It has expertise in program management, basic biomedical R&D, medical product development, and funding resource development.
BridgePath Scientific (BPS) offers a wide variety of laboratory equipment, preventative maintenance, and repair services as well as contract research and reagents & kits to the scientific community.
BPS offers following product categories: Laboratory Equipment - Balances, Benchtop Centrifuge, Freezers/Fridges, Incubators, Microscopes, Microtoms, PCR/Thermal Cyclers, Spectrophotometers, Vacuum Pumps/System, Warehouse Clearance Items, etc; and Research Products - Cell Culture Products, Probiotics, Protein Expression Products, Protein Stains, Reagents and Kits, and Western Blotting.
BPS scientific services include: Recombinant Protein Production, Genetic Services and BioPharmaceutical Services. The company has expertise and experience in producing, purifying, and characterizing recombinant proteins using: Bacterial systems, Insect cell culture systems and Mammalian cell culture systems. Its genetic services include: de novo gene synthesis, cloning and subcloning, Mutagenesis, cDNA library construction, Plasmid preparation, and expression vector generation for mammalian, insect, and bacterial systems. The company's biopharmaceutical services include: Cell banking, Antisera production, Fill and finish, Vaccine manufacturing, Cell line characterization, Methods development, Process validation, Stability testing, Protein & analytical chemistry, etc.
BPS has an agreement with Izon Science and APE-BridgePath Scientific.
Cadista Pharmaceuticals Inc. is specialized in pharmaceutical research and development, manufacturing and industry support services. It is the global generics business unit of Jubilant Organosys Limited. The company is dedicated to provide cost-effective healthcare solutions to its customers.
Cadista utilizes vertical integration from base chemicals to final distribution. It focuses on relevant extended and immediate release oral solid products to deliver high value to the global marketplace. The company manufactures anti-hypertensive, diuretic, and andrenocortical steroid tablets and capsules.
Cadista's products include: Cyclobenzaprine HCl, Hydrochlorothiazide, Hydrochlorothiazide, Lamotrigine, Methylprednisolone, Meclizine, Oxcarbazepine, Prednisone, Prochlorperazine Maleate, and Terazosin HCl. It specializes in the formulation and /or process development of generic prescription medications in both tablet and capsule form. The company's development capabilities and expertise ranges from sustained release pellets and capsules to immediate release tablets and capsules.
Cangene bioPharma (formerly Chesapeake Biological Laboratories, Inc.) is a contract manufacturer that provides fill/finish services to pharmaceutical and biotechnology companies. It was founded in 1980 as Chesapeake Biological Laboratories (CBL) and later was renamed as Cangene bioPharma inÂ DecemberÂ 2009. The company is a subsidiary of Cangene Corporation.
Cangene bioPharma aseptically fills liquid and lyophilized products into vials and syringes. It offers a wide range of services which include: clinical manufacturing, commercial manufacturing, lyophilization and product testing/product stability. The company performs clinical manufacturing for all regulatory phases. Its analytical services department (QC) performs the following tests: HPLC, UV, TOC, RI, IR, GC, etc and the microbiology department performs the following tests: enhancement and inhibition, endotoxin, bioburden method qualification, etc.
Cangene bioPharma has collaborations with Questcor Pharmaceuticals, National Institute of Allergy and Infectious Diseases, National Institute of Standards and Technology, etc.
Capital Biosciences, Inc is engaged in assisting pharmaceutical and biotechnology industries in their pursuit of broadcasting their products and services. Its goal is to become the premier service provider of innovative technologies, products, unique tools and services for biotechnology and pharmaceutical companies.
Capital Biosciences offers a variety of biological products including Cell Immortalization Products, Clinically Defined Human Tissue, cDNA ORF Clones, Premade Adenoviruses, Purified Proteins, Viral Expression Systems, Viable Human Tissue, Frozen and FFPE Human Tissue, Tissue Specific RNA, Tissue Specific Proteins, Optimized Laboratory Technologies, etc. The company's services include: Custom Recombinant Lentivirus Production, Custom Recombinant Adenovirus Production, Primary Cell Immortalization Service, Stable Cell Line Production, Multiplexed Protein Assay, HLA testing, Protein Production Services, etc.
Chemical Biosciences has a distribution agreement with BioCision, LLC.
Cardiocore is a cardiac core lab that delivers superior global services, expert scientific consulting and state-of-the-art data and information management. It was founded by Lawrence Satin.
Cardiocore's centralized services include: electrocardiography (ECG) - Consulting, Project Management, Digital ECG Equipment, Paper ECG Processing, ECG Analysis, Expert Reporting etc; Holter Services - Digital Holter Equipment, Digital Holter Data Transfer, Holter Analysis, Extraction of ECGs etc; ECHO/MUGA Services - ECHO Analysis, Global Logisitics etc; and Consulting Services - Protocol Development (ECG, Holter, and ECHO/MUGA), Cardiac Safety Reports, Statistical Analysis Plans and Reports, Regulatory Guidance and Support, and Strategic Planning for Cardiac Safety Assessment.
Cardiocore's therapeutic areas include: Addiction, Allergy, Cardiovascular, Central Nervous System, Endocrinology, Gastroenterology, Hematology, Immunology, Infectious Disease, Metabolic Disease, Musculoskeletal, Oncology, Ophthalmology, Pulmonary/Respiratory, Rheumatology, Urology and Virus/Vaccines. The company provides the CardioPortal(TM) system, a web-based data delivery portal and the HolterGateway(TM) data transfer system, a unique advancement in Holter data management.
Cardiocore has partnerships with Metrics Champion Consortium, Mortara Certified Partner and Cardiac Safety Research Consortium.
Cellogenetics, Inc provides gene discovery tools and molecular and cell biology laboratory services to academic and governmental research institutions to improve human condition.
Cellogenetics' Gene discovery services include: Design & construction of retrovirus based shRNA gene silencing vectors; Full length cDNA construction and subcloning in selected expression vectors; cDNA mutagenesis and creation of constitutively active or dominant negative cDNA mutants; and Mouse targeting vector design & construction.
Cellogenetics' Gene Discovery Tools include: cDNA clones and mutants, shRNA vectors, Luciferease transcription reporters and RT-PCR primer sets. It offers luciferase transcription reporters for assaying gene pathway activity.
CellPoint Scientific is a developer and manufacturer of laboratory equipment used in life science research.
CellPoint Scientific's products are designed and manufactured in-house and its products include germinator 500, the popular table top glass bead sterilizer, micro drills, infusion pumps and accessories, wound closure systems, rodent brain and heart matrices, slides, dyes, stains, and cauterizers.
Chantilly BioPharma LLC. is a development, manufacturing, commercialization, licensing and marketing specialty product pharmaceutical company. The mission of the company is to establish a portfolio of value-added oral drug delivery systems, innovative multiple advanced technologies with a broad range of product applications in different therapeutic categories, develop product profiles which exhibit improved compliance and easier administration, controlled blood levels of drugs, improved efficacy, reduced side effects and expanded indications, increase shareholder value, solid revenue base from development, manufacturing, licensing, marketing and product sales with good profit margins and sustainable growth, develop human capital for continuous innovation, manufacturing quality products that meet FDA cGMP and other U.S and International regulatory requirements.
Chantilly BioPharma's facility includes state-of-the-art cGMP development; Quality Control & Analytical; and manufacturing capabilities. The company's business development services include out-licensing of pipeline products, in-licensing of new product opportunities, partnered product development and pharmaceutical contract services. The company's capabilities include: Specialty drug development for prescription products, Clinical and contract manufacturing, Analytical, stability and packaging services, Proprietary technology application for Modified Release, Orally Disintegrating Tablets and Taste masking and Bioenhancement. CBL has developed products in numerous therapeutic categories include: Cardiovascular, Gastro-Intestinal Tract, Central Nervous Systems, Pain Management and Metabolic. Its analytical and stability services include: 1) Raw Materials for physical characterization; differential scanning calorimetry; release testing and compatibility testing, 2) Drug Substance Analysis for impurity characterization; degradation characterization; particle size characterization and organic volatile impurities, 3) Drug Product Analysis for dissolution; impurity analysis; laser diffraction PSA and residual solvent analysis, 4) Microscopic/Spectral Evaluation for scanning electron microscopy; elemental analysis; particle size image analysis; micro-FT-IR; FT- Raman module and hot stage analysis for melt processing and 5) Stability Chambers - 3 walk-in (ICH conditions); 1 reach-in and photostability. Its formulation and clinical manufacturing services include: Granulation, Compression, Ceform Microsphere Process, etc.
Chantilly BioPharma is involved in the commercialization of products incorporating its Ceform(TM), Smart Coat(TM), KORTABS(TM), Beads, Matrix, Layered, Flash Dose(TM) and Shearform(TM), technologies for use in microsphere processing, modified release drug delivery, orally disintegrating tablets and drug solubility/bioenhancement. Its products therapeutics categories include: Cardiovascular (Calcium Channel, blockers etc.), Gastro-Intestinal products (Ulcerative Colitis, etc.), Pain Management (Opiates, NSAIDS, etc.), CNS (Antidepressants, Anti-anxiety, etc.) and Metabolic (Anti-diabetics). The Company is registered with FDA, DEA and other appropriate regulatory authorities.
Chesapeake Perl, Inc. (C-Pearl) is a custom protein production (expression and recovery) service provider. Its primary focus is to supply proteins to biotechnology communities from its production platform called the PERLXpress System. It was founded in 2000.
Chesapeake Perl's PERLXpress system is a unique, powerful protein expression platform that combines well-established recombinant baculovirus technology with mass oral infection of synchronous Trichoplusia ni larvae. The system is efficient and reproducible which results in high levels of expression of target proteins. In addition, PERLXpress is highly scalable, providing the opportunity for production of pilot and commercial quantities of functional proteins. The company's PERLXpress system offers greater speed, scalability and flexibility than traditional eukaryotic protein production systems. It employs baculovirus expression vector system (BEVS) to produce recombinant proteins. The company's technologies include: Vector development, Protein expression, Protein production, Protein recovery, etc.
Chesapeake Perl's services include: Baculovirus Preparation, Baculovirus Screening for Optimal Expression, Protein Production in Insects and Protein Purification. It provides high quality, difficult-to-produce recombinant proteins from microgram quantities for physical or functional analysis through scaled production.
ChiRhoClin, Inc. is a research and development oriented pharmaceutical company focused on the development of peptide and protein-based drug products. It was founded in 1991 by Edward D. Purich. Its mission is to provide high-quality peptide and protein-based drug products for the GI community and to develop orphan drug products that will aid, treat, and diagnose Gastrointestinal diseases.
ChiRhoClin's two diagnostic drugs include: Synthetic Porcine Secretin and Synthetic Human Secretin (ChiRhoStim(TM)).
ChiRhoClin also provides contract services to the pharmaceutical industry including FDA regulatory support, statistical analysis, protocol development, clinical and laboratory study management, medical monitor services, safety surveillance, NDA and IND submissions, drug master files, CMC & analytical validations, population pharmacokinetic and pharmacodynamic analysis.
Cognate BioServices, Inc. provides support to companies and institutions engaged in the development of cell-based products and therapies. The company was formed in 2002 to provide a broad range of preclinical, development and clinical phase services to biotechnology companies.
Cognate has extensive experience in development of cell-based therapeutics using human bone marrow stromal cells (BMSCs) to augment the body's innate capacity for repair and regeneration of damaged or diseased tissues. The company's services include: cGMP manufacturing - provides full development and cGMP manufacturing services to companies and institutions engaged in development of cell-based products; stem cell services; preclinical services - provides a broad range of preclinical, development and clinical phase services to institutions, biotechnology companies and large health care companies; assay development services - offers a broad range of analytical test methods, development and testing services for cell-based products; regulatory services; and process development services.
Cognate has collaborations with MaxCyte, Inc, Northwest Biotherapeutics Inc and TiGenix N.V.
Express Genomics, Inc provides services for life science research. The company was founded by former employees of Life Technologies.
Express Genomics will construct cDNA libraries from customer supplied tissue, cells or RNA. The company's products include standard cDNA libraries, PCR and RT-PCR services, 454-Ready cDNA, large insert cDNA, microquantity cDNA libraries, nanoquantity cDNA libraries, subtracted cDNA libraries, normalized cDNA libraries etc.
Fisher BioServices is provider of specialized biological material management services to pharmaceutical and biotech companies, national, state and institutional organizations. It is a business unit of Thermo Fisher Scientific (TFS).
Fisher provides sample processing, including aliquoting, DNA/RNA extraction and amplification, sample storage, distribution, and clinical trial support. It also offers transport and storage of active pharmaceutical ingredient (API and bio-API), including cryogenic. Its core areas of focus include: clinical trial services and collection kit production, biological storage and distribution, sample laboratory processing and analytical testing, clinical agent packaging, and biopharmaceutical agent storage and distribution.
Fisher's clinical trial support services include: Design and Set-Up, including creating the study manual and presenting at Investigator's meetings; IVRS/IWRS Services; HIPAA Compliance; Collection Kits to standardize specimen collection and transport; Randomization and Blinding of study products; Laboratory Processing, including DNA/RNA extraction and amplification; Labeling and Distribution of Drug Products and Clinical Agents, including biopharmaceutical agents (in cryogenic shippers) and vaccines (in validated shippers with on-board temperature monitors) around the world; Storage and Handling of Clinical Agents, in compliance with 21 CFR 211.142 and Pharmacy Regulations for the State of Maryland; and Financial Flexibility, through monthly billing.
General Research Laboratory, Inc. (GRL) is a biopharmaceutical company focused on developing technologies to serve the pharmaceutical industry and the discovery of novel therapeutics to treat diseases and conditions related to battlefield medicine and military personnel. The company was established in 2005.
GRL holds proprietary technologies on the use of an Epoxy Encapsulated Magnetic Nanoparticle (EEMNP) system for drug delivery in oncology. The company has active programs in Whole-Genome siRNA Library (WGSL)-based high throughput screening for identification of novel drug targets and for re-invigoration of failed drugs in late stages of clinical testing. It has used the platform technologies in the identification of RNAi therapeutic candidates for treatment of prostate cancer and the improvement of wound healing. The company is actively engaged in the identification of optimal combination therapeutic regimens, including use of botanical drug candidates.
GRL is in the process of screening more than 10,000 botanical and plant extracts identified in Classic Chinese Medicine (CCM) and Ayurvedic medicine as potential botanical drug products (BDPs) for use in the treatment of diseases that are of specific importance in military medicine (battle-field Medicine) and oncology. It has active research programs in wound/bone healing, infectious diseases as well as various forms of cancer. The company plans to develop these novel therapeutic moieties for a variety of human conditions and diseases. In addition to its therapeutic formulas and molecules, the company is developing a platform for its drug discovery process that includes the application of micro-array technology to investigate the effect of BDPs on targeted disease processes.
GRL also offers services like high-throughput drug screening services and protein array services to support the drug discovery efforts of pharmaceutical and biotechnology companies.
H.R. Simon and Company Inc is a producer of x-ray chemicals. The company was founded in 1955.Â
H.R. Simon and Company's product portfolio includes: 1) Automatic Medical Solutions - Chemblend Three Part Developer, Chemblend Fixer, and CB2 Two Part Developer; 2) Mammography Chemistry - UHC AGFA Approved Developer, CKE Kodak Clone Developer, & SEF2 Developer; and 3) Special Solutions - Simon Blue - Medical Surface Cleaner, Clinic Pack Developer & Fixer, and Simon Screen.
H.R. Simon and Company has distribution contracts with Kendro Laboratory Products LP, NEN Life Science Products, MCI/OPTOMIX and Bar Ray Products.
IM Systems (Individual Monitoring Systems Inc) is a medical instrument company engaged in the business of research, product design and development, clinical testing, manufacturing and sales of miniature ambulatory monitoring devices principally related to sleep disorders such as sleep apnea and insomnia for use in the home, clinic and sleep laboratory. It was established in 1988, with a mission to develop and market highly personal monitoring devices for use in the clinical setting as well as the home environment.
IM Systems has developed a completely new, very low-cost, full featured physical activity monitor referred as an actigraphy monitor device that provides an impressive array of operational functions and, with breakthrough pricing, has set new standards for ambulatory motor recording. It has gained considerable expertise in designing micro-powered ambulatory devices.
IM Systems' product line includes: SleepCheck, DigiTrac, ActiTrac, BedMate, BioTrainer-II, and the BioTrainer-PRO. Its other products include movement disorder monitoring for Parkinson's tremor and recording physical activity using actigraphy utilizing various types of accelerometer-based devices and activity monitors.
Imgen Technologies is a sales and support company for molecular biology and life science product manufacturers. It is a manufacturer representative group for laboratory equipment, reagents, kits and custom services.
Imgen Technologies has equipment that includes: BMG LABTECH Microplate Readers, NanoDrop Spectrophotometers, Nexcelom Automated Cell Counters and Syngene Gel Documentation. The company has software like syngene 2D gel imaging analysis. The company's services/kits/reagents include: Primm Custom Antibodies, Peptides, Protein Analysis, and Gene Synthesis. BMG Labtech PHERAstar is used for SNP Genotyping chemistry development and high throughput production genotyping.
Imgen Technologies markets and sells products serving the life science and medical research community. Its marketing includes cold calling, local product shows, mail box stuffing, emails, and telephone campaigns. The company's product portfolio includes manufacturers like: BMG Labtech, Nexcelom BioScience, Syngene and PrimmBiotech, Inc.
ImQuest BioSciences is a contract research organization for the biotechnology and pharmaceutical industries. Its mission is to be the leading provider of services ranging from the discovery of anti - infective and anti - cancer drugs and vaccines through complete preclinical and clinical therapeutic development. The company was founded by Daniel R. Caffoe and Robert W. Buckheit in 2004.
ImQuest's range of programs and services include: anti-infectives, anti cancer, topical microbicides, formulation and development, technical services and professional services. It offers formulation work specializing in semi-solid and solid drug delivery formulation in the microbicide field. Its formulation capabilities include: oral dosage formulations, intravenous formulations, semi-solid formulation, film formulation and nanoparticle formulations. The company has the capabilities to develop and evaluated biodegradable nanoparticles for drug delivery. Its capabilities in nanoparticle formulation include: manufacturing of nanoparticles, drug encapsulation and characterization, in vitro dissolution and release of drug from nanoparticles, microscopy targeting of nanoparticles in vitro and ex vivo, and nanoparticle toxicity.
ImQuest's technical services include: microbiology and virology services, molecular biology services, tissue culture services, biochemistry services, enzymology services and immunology services. The company's microbicide development program utilizes a wide range of microbiological, biochemical and molecular technologies to assess the activity of agents against HIV, define the precise mechanism of action of potential microbicides using assays that closely mimics the microbicide environment, and analyze the potential toxicity of an inhibitor. It also provides professional services that include: grant and contract proposals, consulting support, R&D and therapeutic consulting services, IND preparation and submission, and regulatory compliance support.
ImQuest has agreements with National Institutes of Health, The U.S. Department of Health and Human Services, Aethlon Medical Inc, Arisyn Therapeutics, Inc., Samjin Pharmaceutical Co. Ltd.
Inotech Biosystems International Inc sells biomedical research equipment and reagents developed and produced by the parent company. It is the U.S. sister company to Connectorate AG (formally, Inotech AG).
Inotech Biosystems's Encapsulator the first commercially available instrument for the polymer microencapsulation of metazoan cells, microbes, and other biologicals. Promising research incorporating microencapsulation is underway, including the first clinical trial of an engineered, encapsulated cell being used in the treatment of pancreatic cancer.
Inotech Biosystems's product catalog includes Encapsulators, Cell Harvester, VacuSafe Pumping Station, Disc-to-Vial Distributor, Vacuset and Vacubottle, Steriguard Hot Glass Bead Instrument Sterilizer, Western Membrane Strip Cutter, Hesisitating Rocker and Heparin Adsorbant, etc.
KAI Research, Inc. is a contract research organization (CRO) that focuses on providing innovative, cost-effective, and practical support to the pharmaceutical, biotech and academic institutions and the National Institutes of Health (NIH). It was founded in 1986 with a mission to exceed client expectations through cutting-edge technological tools in clinical research. The company is a wholly owned subsidiary of Altarum Institute.
KAI provides comprehensive CRO services for phase I - IV clinical trials and epidemiological studies in a wide variety of therapeutic areas in both adult and pediatric populations. The company's therapeutic areas include: CNS, dermatology, endocrinology, infectious disease, pain, psychiatric disorders, rheumatology, substance abuse and vaccines.
KAI offers various services including clinical studies support, clinical data management, pharmacovigilance and safety reporting, medical communication, data warehousing, statistical analysis and quality assurance. Its clinical support services include: protocol development through regulatory submission, electronic CRF (eCRF) clinical data capture and data management, study assistance services, clinical monitoring, clinical study report preparation and IVRS - randomization and patient diary.
KAI has agreements with Henry Jackson Foundation and Italian pharmaceutical company.
Kempbio, Inc. is a CRO company focused on protein expression. It was founded in January 2009, with an expertise in baculoviral and mammalian expression systems with exceptional customer service to provide its customers with the best possible outsourcing experience.
Kempbio has developed a robust system for the transient expression of recombinant proteins using the human cell line, HEK-293. This system provides a mechanism for the rapid expression of milligram to gram quantities of recombinant proteins with authentic human post-translational processing. Its optimized serum-free media, cell line and transfection reagent combine to provide the highest quality and quantity of protein expression available. The company provides protein purification services for both affinity-tagged and untagged proteins.
Kempbio's baculovirus expression service offers a complete line of services related to the expression of recombinant proteins using the baculovirus expression system. Its baculovirus expression service include: production, purification and characterization of recombinant baculovirus clones in addition to scale-up for protein expression. The company also provides GLP cell banking services. It has experience in producing cell banks for non-recombinant and recombinant mammalian and insect cell lines. Each bank is tested for mycoplasma contamination, sterility and viability on thaw.
Kempbio's mammalian cell culture offers expanded services for the optimization, scale-up and production of cell culture derived materials. Its services include: the production of secreted and non-secreted proteins, protein purification and the isolation of cellular sub-fractions (i.e. membranes and nuclei) from recombinant and non-recombinant cell lines. The company has worked with Human Monocytic Leukemia, 293 (Recombinant), Human Colon Adenocarcinoma, CHO (Recombinant), Hybridoma (Murine), EBV Transformed Cells, Heterohybridoma (Mouse-Human), rMyeloma, Myeloma (Recombinant), Neuroblastoma, Primary Mouse Embryo Fibroblasts, etc.
Kempbio has signed a license agreement with Polyplus-transfection SA for the transfection of cells used for the production of recombinant proteins.
Kensington Bio is an Independent Manufacturer's Representative for several premiere Biotechnology Equipment Manufacturers and Product Service Companies. It is specialized in providing proteomics, genomics, and molecular biology sample preparation products and services used throughout the laboratory community.
Kensington offers following products used in laboratory sample preparation: Electrophoresis Gels and Gel Boxes, Gel Documentation Systems, Bio-Fermenters and Cell Culture Systems, HPLC Systems, Benchtop Constant Temperature and Motion Laboratory Equipment, Disposable Laboratory products, Sample Preparation, Liquid Handling Systems, Sample Identification systems, Thermoblocks, etc.
Kensington represents following manufacturers: Digilab, Aurogene, AR Brown, it4ip Membranes, Cleaver Scientific, Major Scientific, UVITech, Bionexus, Taitec, Nissin, Azer Scientific, etc.
KOL Bio Medical Instruments is a healthcare support organization focused on maintaining long term contracts with select manufacturers for the exclusive distribution of high technology and unique medical devices. It was founded in 1971with a mission to fulfill its purpose by regularly meeting or exceeding the goals of its manufacturer clients, providing growth opportunities for people.
KOL Bio Medical Instruments business model is to seek out and partner with the most ethical and innovative client manufacturers who have a strong desire to enhance the healthcare value chain by improving patient health and/or dramatically reducing costs in the system. The company's products are focused in the areas including: Surgery/Operating Room, Blood, Critical Care, Women and Interventional Radiology/Cardiac laboratories.
KOL Bio Medical Instruments represents the following companies: Ameritus Medical Products, Angio Systems, Becton Dickenson, Charter Medical, Clinical Innovations, Corpak MedSystems, Fresenius Kabi, LLC, MediPurposeâ„¢, Megadyne, Prodimed, Scion Cardio-Vascular, Inc., and Worldwide Innovations & Technologies, Inc. The company has agreements with MediPurpose Pte., Ltd. and LiDCO Group Plc.
LifeTech Research, Inc., (LTR) is an independent consulting firm that provides clients with proprietary and highly customized analyses of emerging biomedical technologies, companies, and markets. The company was founded by Joel B. Braunstein and Ilana Fogelman in 2003, with a mission to distill data, information, and trends into clear, specific, and actionable insights. Its vision is to provide the best due-diligence research in the biomedical community.
LifeTech Research has extensive expertise in the design, analysis, and interrogation of clinical trials, including pharmaceutical, biologics, and device registration trials. It is committed in providing client-tailored research of a depth, quality and focus not found elsewhere. The company analyses encompass all phases of the product life cycle, from the conception of an idea, to preclinical and clinical testing, through reimbursement and global marketplace positioning. Its Report Store(TM) is a repository of research reports that are available for online purchase. Each provides an in-depth analysis of a single product or class of products in development within the pharmaceutical, biotechnology, device or diagnostics industries. The company's product Rx Vigilance(TM) consists of unique statistical, epidemiological, and clinical analyses of spontaneous adverse event data reported to the FDA and the World Health Organization (WHO) for marketed products.
LifeTech Research's services enable institutions to benefit from the expertise of a select team of industry authorities and their exclusive clinical, regulatory, and policy insights. Its customized due-diligence services evaluate: 1) Basic medical and scientific merits of novel products, 2) Quality of publicly reported preclinical and clinical trial data, 3) Outcome scenarios and probabilistic estimates of upcoming key events, 4) Clinical trial methodology and statistical analyses, 5) Regulatory strategy and risk 6) Competition, 7) Policies affecting third-party payer coverage and market demand, 8) Macroeconomic and political factors, and 9) Product safety in the context of overall cost-effectiveness.
Lupin Pharmaceuticals Inc is a pharmaceutical company that develops products for healthcare professionals to improve the health and well being of individuals. The company's mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets. It is a wholly owned subsidiary of Lupin Limited.
Lupin Pharmaceuticals provides the advanced manufacturing capabilities and processes that create quality specialty and generic products. Its technology is focused on the following: 1) Generics - includes drug master files (DMFs) for APIs and formulation development, and abbreviated new drug applications (ANDAs) for finished products; 2) New Drug Delivery Systems (NDDS) - includes oral controlled release systems (OCRS), advanced drug delivery systems (ADDS), and taste masking system; and 3) New Chemical Entities (NCE) - includes proprietary molecules with potential as anti-migraine, anti-TB, anti-psoriasis agents, and investigating herbal and synthetic routes.
Lupin Pharmaceuticals' product portfolio includes: Generics - Amlodipine Besylate, Benazepril Hydrochloride, Cefadroxil, Cefdinir, Cefprozil, Ceftriaxone Sodium, Divalproex Sodium, Imipramine HCl, Levetiracetam, Lisinopril, Lovastatin, Ramipril, Sertraline HCl, Simvastatin, Trandolapril, etc; Specialty pharmaceuticals - SupraxÂ®, an anti-infective product in pediatric and other physician practices; and Active Pharmaceutical Ingredients (API's) - Cephalosporin active pharmaceutical ingredients in oral and injectable dosage forms.
Lupin Pharmaceuticals has agreements with Forest Laboratories, Inc, Sunovion Pharmaceuticals, Inc. (formerly Sepracor, Inc.), inVentiv Health Inc, etc.
Mediatech, Inc. is a leading Life Science company providing products, services and solutions to support customer's research, development and production. The company manufactures and supplies cell culture and molecular biology reagents to biopharmaceutical, academic and government research facilities, as well as biotechnology companies. It focuses on the development of products related to tissue and cell culture applications.
Mediatech manufactures and sells a range of cell culture media and reagents. The company's product portfolio includes: Classical Media, Cell Culture Reagents, Buffered Salt Solutions, Insect Media and Reagents, Microbiology and Molecular Biology, Serum, Serum-Free Media and Supplements, Water, Flexible Packaging, Custom Production, Current Promotions and Islet Product Information. Its products include L-Alanyl-L-Glutamine (Dipeptide L-glutamine), Liquid, 25-015-CI, MEM Nonessential Amino Acids, 25-025-CI, cellgro COMPLETE(TM) Serum-Free/Low-Protein Medium, Dulbecco's Phosphate-Buffered Saline, 10X, 20-030-CV, Dulbecco's Phosphate-Buffered Saline, Powder, 55-031, Insectagro DS2(TM) Serum-Free/Protein-Free Medium, 1X, 13-402-CV, Dulbecco's Modification of Eagle's Medium/Ham's F-12 50/50 Mix, 15-090-CV-SPECIAL etc.
Mediatech has collaborations with ArunA Biomedical, Inc., DiaKine Therapeutics and GlobalStem, Inc. and GlobalStem, Inc.
Microbiology International is specialized in providing laboratory equipment. The company was established in 1997, with a mission to supply systems that increase laboratory productivity, save money and improve the quality and consistency of data generated.
Microbiology International's product categories include: Air Samplers, Anaerobic Hypoxic Systems, Autoclaves, Barcoding/Labeling System, Chromogenic Media, Colony Counters, Gravimetric Diluters, Impedance Systems, Media Preparation, Pathogen Identification Kits, Peristaltic/Vacuum Pumps, PCR Equipment and Consumables, Sample Preparation Units, Spiral Plating, Sterility Testing, Surface Swabbing, Tube and Bottle Fillers, and Used/Demo Equipment, etc. It also provides laboratories with the most innovative automation equipment as well as the highest quality rapid detection kits and consumable products for pathogen detection.
Microbiology International has distribution partnership with Idaho Technology Inc. The company's partners include: Bio-Systems International, Cherney Microbiological Services, Deibel Laboratories, Synbiosis, Systec, Don Whitley Scientific, Sartorius and so on.
Minkon Biotechnology Inc is a nutraceutical and pharmaceutical company focused on the development of innovative food and health products for obesity prevention and treatment. It was founded by James P. Xu, with a mission to develop and market safe and effective food and health products to improve the lives of overweight and obese people.
Minkon Biotechnology proposes to deliver reliable and efficient weight management products to a market suffering from a shortfall of options. The company's key technology is based on the modulation of body fat metabolism and utilization by directly regulating a key enzyme involved in a metabolic pathway. It has also developed various trade secrets for its nutraceutical and pharmaceutical product development. The company is also developing dietary supplements, food based bioactive ingredients, and pharmaceuticals for the prevention of body fat accumulation.
Minkon Biotechnology's product pipeline includes- pharmaceuticals for obesity, type II diabetes and infertility and nutraceuticals for obesity and cancer prevention. Its nutra-therapeutical products are developed to focus on cancer providing needed bioactive nutrients to speed patient recovery.
MPR Associates was founded by three top engineers I. Harry Mandil, Robert Panoff, and Theodore Rockwell, who led the U.S. Navy nuclear power program in the year 1964. Its vision is to create a client-driven, excellence-oriented, "First Principles" based firm is still at the core of organization.
MPR provides technical, consulting, engineering and project management services for development, financing, design, construction, operation, and maintenance for energy industry facilities and equipment. Its clients are involved in the following energy sector business areas: renewable and conventional power generation, fuels, refining and petrochemical, equipment and technology development and financing and investment. Its specific services include the following: conceptual design, FEED, technology selection, specification development, etc.
MPR's product development group specializes in the development of new life sciences technologies spanning the medical landscape including integrated medical devices, diagnostic systems, combination devices, implants, and disposables, in addition to the design of commercial and consumer products. It also provide consulting services to the industry, focusing on the areas of medical device and diagnostics operations, pharmaceutical process development, due diligence, and productivity improvement for both development and manufacturing organizations.
MPR's partners include: CH IV International and Basler Electric. It provides consulting services to the Liquefied Natural Gas (LNG) industry through CH IV International.
Neuro Probe, Inc. is engaged in design, manufacture and sale of cell activity assay instruments which include quality reusable instruments, Boyden chambers, and a line of disposable instruments, the ChemoTx system. It focuses on the development and manufacture of chronic stereotactic equipment.
Neuro Probe's product portfolio includes: Chemotaxis Chambers- Single-well chamber, 96-well microplate chamber, Zigmond cell orientation chamber, 10-well chemotaxis chamber, 96-well disposable ChemoTxÂ® System, etc; Protein Crystallography- 96-well hanging drop crystallography system; Cell Settling Chamber and Accessories- 8-well cell settling chamber, Centrifuge accessory pack, Wicking media, Replacement gasket, etc. Its other Chemotaxis accessories include: Filters, Multiwell Accessories, Blindwell & Boyden Chamber Accessories, Spacers and Low Volume Inserts for the MB-series and other consumables.
Next Breath LLC is a contract services provider for pharmaceutical, biotech and medical device companies that bring new inhalation and nasal products to market. The company provides an array of in-vitro services, from pre-clinical formulation development to analytical testing in support of submissions to regulatory agencies. It was founded by Julie D. Suman, with a mission to serve as an effective liaison between innovators of promising drug molecules, pulmonary and nasal drug delivery devices.
Next Breath's services include: method development and validation CMC studies, in vitro bioequivalence studies, batch release and stability studies. The company's testing capabilities include: DPIs, MDIs, inhalation solutions, nebulizers and spacers - shot weight, plume geometry, microbial limits, impaction force, electrostatics, etc; chemistry â€“ assay, impurities, degradation products; nasal sprays, nasal dry powders and topical sprays - particle/droplet sizing by laser diffraction, spray content uniformity, spray pattern, osmolality, viscosity, etc.
Next Breath has partnerships with Chemimage, Innove Systems Inc., Proveris Scientific(TM), Malvern, Copley Scientific, Jeiven Pharmaceutical Consulting, Chemic, Lancaster Laboratories, Inc and University of Maryland School of Pharmacy.
Noble Life Sciences was founded by five veteran biotech industry leaders to meet the R&D needs of clients in the biotech and pharmaceutical industries as well as academia. Its mission is to assist its clients in conducting exceptional-quality research to advance human health, particularly through the facilitation of personalized medicine.
Noble's specialized expertise in personalized medicine and biomarker research and preclinical drug development offers a depth and breadth of services under one roof. The company enables the development of personalized medicines by providing a range of services including a proven fit-for-purpose biomarker selection and validation process for patient stratification, preclinical drug testing services, cellular- and animal-based disease models and vivarium.
Noble's biomarker services include: discovery of biomarkers that track disease or drug activity, pairing of drug candidates with predictive biomarkers, pharmacodynamic modeling of response biomarkers for candidate selection, etc. Its preclinical vaccine and drug development services include: anatomical pathology, pharmacodynamics, PK/PD modeling, acute, sub-chronic and chronic toxicology, drug metabolism, etc. The company offers a variety of options for drug administration including: oral gavage, capsule, dietary admixture, dermal, intravenous and so on.
Noble's partners include: IBT BIOSERVICES and Innovive Inc.
Nutravail Technologies specializes in the development of delivery systems for the nutraceutical and pharmaceutical industries. The company also serves as a contract manufacturer for various soft chew and medicated chewing gum products. It began as Fuisz Technologies and after being acquired by Biovail Corp. in 1999, the Company's name was changed to Nutravail Technologies.
Nutravail's patented delivery system, uncooked soft chews gives a unique ability to deliver high loads of functional ingredients in a great tasting, candy-like format. The company also manufactures several soft chew products, including soft chews containing Omega-3 fatty acids, Multi-vitamins, Fiber, Glucosamine-Chondroitin, Vitamin D, Vitamin C, Calcium, Probiotics, Caffeine, Resveratrol, Acai and other Super Fruits, and the flavonoid Quercetin. Its spun matrix flakes are also used in a unique manufacturing process for Sodium Diacetate and are manufactured using its unique spinning heads (known as Jefferson Spin Heads). Its flash shear beads are made with a patented process that protects active ingredients and releases them over time. It also specializes in the development of various medicated gums including nicotine-based smoking cessation gums.
Omnia Biologics offers translational medicine services in the areas of process development, assay development, GMP manufacture, and fill-finish for preclinical and clinical programs for therapeutics. These include vaccines, autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company has established relationships with both biopharmaceutical companies and academic investigators. Its mission is to address the process development (PD) and manufacturing needs of individual investigators and organizations requiring flexible, pre-clinical and Phase I/II GMP manufacturing services for novel biologics. Its focus is on Viral based products and cell therapeutics.
Omnia's technical focus include: Adenovirus, Lentivirus, Retrovirus, AAV, VLP and Other viral platforms. It provides a full array of services for early stage therapeutics. Its services include: Manufacturing, Process Development, Cell and Virus Banking and Aseptic Filling.
Omnia produces preclinical and GMP Phase I/II clinical materials used in vaccine and gene therapy applications. Its process development (PD) goals include: Maximizing the production capacity of a therapeutic platform, Reducing manufacturing costs, etc. Its aseptic filling services include: GMP aseptic filling of viral and infectious materials, Documented to meet FDA requirements for Phase I/II clinical manufacture and Pricing is based on small runs for a small, not large and facility. Its Cell and Virus banks include: Mammalian cell banks and viral seed stocks.
Omnia Biologics has agreement with Biotech Experts, Inc., Aparna Biosciences Corp., Potentia Pharmaceuticals, Aeras Global TB Vaccine Foundation, AFG Biosolutions, Prolong Pharmaceuticals, Lentigen Corporation, Intradigm Corporation, University of Maryland and AT-GC BioPharm.
UMB BioPark- Bldg II, 801 W Baltimore St, Suite 401
Baltimore, MD, USA
Paragon Bioservices Inc offers contract services for accelerating the development and manufacturing of biologics. It was founded in 1990 by Marco A. Chacon.
Paragon's process development bridges the distance between the research bench and GMP manufacturing for clinical trials. Its assays services include: Gel electrophoresis (Native, SDS-PAGE, agarose), HPLC assays (SEC/RP/IEX), Immunoassays (Western Blot, ELISA), Odyssey(TM) IR immunoassays, CRL EndoSafe-PTS endotoxin assay, Spectrophotometric assays, Bioassays / bioassay development services and Enzyme assays. The company's preclinical research services include: recombinant protein expression & purification, recombinant virus expression & purification, production & purification of bacteriophages, functional studies - target validation assays, GLP compliance, and histology / immunohistochemistry and electron microscopy.
Paragon has commercial alliances with NextGen Sciences, Inc. and NextGen Group Plc.
Pharmaceutics International, Inc. (PII) is a contract formulation development, clinical trial materials and commercial manufacturing company. The company was founded in 1994.
Pharmaceutics International's services include: Pre-formulation, Formulation, Clinical Trial Materials, Commercial Manufacturing, Dosage Forms, Project Management, etc. Its pre-formulation services include: Characterization of the drug substance, Salt selection, Polymorph screening, Co-Crystal formation, Solubility Screening, Solubility Optimization Studies, etc. Its clinical trial materials manufacturing and packaging services include: Phase I studies, Phase II studies, Phase III studies and Phase IV studies.
Pharmaceutics International has agreements with Apricus Biosciences, Inc, Bio-Images Research Ltd, Breckenridge Pharmaceutical, Inc., Penwest Pharmaceuticals Co, Penn Pharmaceutical Services Ltd, Adolor Corp, etc.
ProteinOne LLC is a biotechnology company that aims to deliver purified, biologically active proteins to research labs, medical institutions and pharmaceutical companies via a Universal Protein Array (UPA) to help companies with their drug discovery program. The company was incorporated in October 2000.
ProteinOne has developed Active Protein Array (APA) platforms for the multiplex detection and interaction assessment of multiple human activated regulatory whole proteins with DNA, RNA and ligands of interest. Its Active Protein Array system is fast and easy.
ProteinOne's products include: Transcription Factors and Kits, nuclear receptors, cancer proteins, cell extract proteins, splicing factor proteins, GST-tagged proteins, antibodies and modified enzymes. The company provides custom protein purification services which offer all aspects of protein expression, production, purification and development from gene to protein.
ProteinOne has partnerships with Clayton, Dubilier & Rice, Inc, OriGene Technologies, Inc and VWR International, LLC.
RINTECH, Inc. is engaged in research and development of active pharmaceutical ingredients (APIs), unnatural amino acid derivatives, special/rare chemicals and biotech products to serve the pharmaceutical, biotechnology and chemical industries. The company was founded in 1997.
RINTECH focuses on custom organic synthesis, manufacturing and outsourcing, drug discovery and herbal medicines, rapid delivery and products of the highest purity. The company's products include: Amino Acids and Derivatives, Amino Alcohol Derivatives, Aromatics, Benzocycles, Benzodiazepins, Biphenyls, Catechol Derivatives, Dihydroisoquinolines, Diphenylethers, Heterocycles(5 member-rings), Heterocycles, Indoline Derivatives, Other Chemicals, Phenylethylamines, Prolines, Quinolines and Tetrahydroisoquinolines.
RINTECH has partnership with Jiwa Bio-Pharm Holdings Limited.
RRD International, LLC is a product development company dedicated to support the global regulatory, preclinical, and clinical needs of biotechnology, pharmaceutical, and medical device companies. The company was founded in 2002, with a mission to leverage its strategic and operational expertise to help clients' better plan and manage product development.
RRD's service areas include: nonclinical planning, regulatory planning, clinical planning, CMC planning etc. It offers a full suite of development services ranging from C-level strategic planning to individual components of operational program management. The company delivers strategy-driven product development support. Its adaptable model is based on a comprehensive, regulatory-driven approach focused on quantifying and enhancing product value, aligning with each company's fundamental goals.
RRD has partnership with Symphony Capital. It also has agreements with EPIX Pharmaceuticals Inc, Genzyme Corporation, etc.
Sarfez Pharmaceutical, Inc. is a pharmaceutical company that uses innovation to re-purpose inventions, and thereby maximizes value for customers and investors. Its mission is to discover, develop, and manufacture the highest quality of drugs and make them available at affordable prices.
Sarfez is focused on the manufacture of high quality active pharmaceutical ingredients (API) and finished drug products. It has developed novel compounds for Alzheimer's disease and is conducting preclinical studies to determine their toxicity profile and efficacy in animal models. The company specializes in the development of unique combinatorial drug products with areas of research and development in: hypertension, heart failure, migraine and Alzheimer's disease.
Sarfez's product pipeline includes: S90101 indicated for the treatment of hypertension, S90121 indicated for the treatment of heart failure, S90333 indicated for the treatment of Alzheimer's disease, and S90212 indicated for the treatment of migraine.
Sarfez has collaboration with Semler Research Center Pvt. Ltd.
Seraphim provides life sciences companies and investors with a new approach to consulting and due diligence. It has expertise in biologics, gene & cell therapies, pharmaceuticals, medical devices & in vitro diagnostics, contract research & manufacturing, and genomics, proteomics, research tools, & bioinformatics.
Seraphim's ConceptraSM service provides drug development and commercialization as well as services, especially for the reproductive health, family planning and well being of disadvantaged women. This service is committed to assuring the creation and access to providing safe, effective and affordable contraceptives for all women. Its services include: Business Development services: new opportunity assessment, product & partner strategy, blind & pre-qualified introductions, business, technology, market plan, preparation & review, and presentation & pitch development; Due Diligence, Valuation and Monitoring services: target assessments for investment, mergers, acquisitions & alliances, IP licensing & planning, strategic partnering, outsourcing & contracting, board & management support, and start-up & interim management.
Seraphim's services also include: Regulatory Consulting services: product development & regulatory strategies, regulatory submissions & meetings, pre-clinical & clinical testing, operations & QA /QC support, US resident agent services, compliance audits & training, crisis intervention & resolution, and on-site professional staffing; Legal & Accounting Support services: expert witnesses provision, preparation & support, case analysis & preparation, discovery & investigations, mediation & arbitration, and contracts, transaction & counseling support; and Operations & Outsourcing Management services: manufacturing & supply chain development, CRO/CMO outsourcing strategy, vendor selection, qualification & management, contract development & review, and project management.
Spectrum BioScience, Inc. specializes in providing contract compound management services to the life science industry. The company is a member of the national association of scientific material managers and the international society for biological and environmental repositories.
Spectrum BioScience provides processes and facilities with experienced personnel to provide customers with complete compound management solutions including: creating and storing barcoded product inventories, analyzing and plating individual compounds for assay, etc. Its business model dramatically improves customer efficiency by automating manual processes and integrating sample management solutions involved in discovery, allowing the client's research scientists to dedicate greater focus on research and development activities. The company's total compound management solutions free to its customers to focus on their core business; discovering and bringing new drugs to market.
Spectrum BioScience's services include: Laboratory management - Material Handling and Inventory Management; Chemical Management - Procurement support, Chemical Receiving and Hazardous Waste management; Support Services - Glassware washing and management, Media preparation services, Drinking water service, Office supply management, etc; and Compound Management services - Weighing compounds to standardized vials and tubes, Bar code application and tare vials and bottles, etc.
Sterilex Corp develops antimicrobial, anti-biofilm and decontamination products for infection control, biofilm removal, biodecontamination and chemical decontamination. Its mission is to be a leader in developing and marketing innovative, safe and cost-effective anti-biofilm, antimicrobial, cleaning and decontamination products to maximize health, safety and productivity.
Sterilex Corp's patented platform technology is based upon PerQuat(TM) technology alkaline peroxygen phase-transfer chemistry which has the unique ability to penetrate and remove biofilms, kill microorganisms in biofilms, and remove organic contaminants. This chemistry is also effective in decontaminating chemical contaminants including nerve agents, organophosphorus pesticides and carbamates.
Sterilex Corp provides solutions for food and beverage protection, dental water protection, water treatment, animal health and environmental remediation. Its products includes: SterilexÂ® Ultra disinfectant cleaner (liquid), Ultra-Kleen CW502 Powder Biocide, SterilexÂ® Ultra-Kleen solution I & II (liquid biocide), etc.
Sterilex Corp has collaborations with Ivesco, LLC.
Technology Catalysts International (TCI) was founded in 1979 to provide consulting services that satisfy the technology transfer and business research needs of industry. It is specialized in technology licensing, technology assessment, and technology portfolio management.
Technology Catalysts International has conducted specialized consulting for various industries such as: pharmaceuticals, chemicals, advanced materials, biotechnology, consumer care, and biomedical devices. The company has expertise in the various facets of drug delivery: implant and parenteral drug delivery, transdermal and transmucosal drug delivery, oral drug delivery systems and materials, novel delivery systems for proteins and peptides, and novel delivery of poorly soluble and/or permeable drugs.
Technology Catalysts International's services include: Biopharmaceuticals Information Consulting Services (BICS), Drug Delivery Information Services (DDIS), Late-Stage Product Acquisition Service (LSPAS), Licensing Locator (LL), Merger and Acquisition Support Services (MASS), Out-Licensing Services (OLS) and Custom Consulting.
Technology Catalysts International's affiliates are Qualia S.A., Inventia s.r.o., Technology Catalysts International, TCI India, Global Damon Pharma, Technology Catalysts International UK, etc.
Trevigen, Inc. is a biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Its division Trevigen Cell Assays, (TCA) was established in 2008 to conduct contract research work for the pharmaceutical, biotechnology, government and academic segments of the research market.
Trevigen's products range include: Angiogenesis/Cell Differentiation, Antibodies, Apoptosis, Basement Membrane Proteins, CometAssayÂ®, DNA Damage, Molecular Biology, Oxidative Damage, PARP, Stem Cell Assays and 96 Well Format Kits. Its apoptosis products include: Annexin V Kits, TACSÂ® Annexin V-FITC Kit, TACSÂ® Annexin V-Biotin Kit, MitoShift(TM) Mitochondrial Potential Assay, TACS XLÂ® Kits, etc. Its molecular biology product line offers DNA for Hybridization Solutions, DNA Isolation, Electrophoresis Products and DNA Labeling products.
Trevigen's Cell Differentiation/Angiogenesis product line consists of: Basement Membrane Extract, Cell Invasion/Migration Assay Kits, 3D Culture Assays, Specialized Proteins, Antibodies to Basement Membrane Proteins, Cell Viability/Proliferation Assays and Cell Culture Reagents. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.
UPM Pharmaceuticals Inc is a drug development and contract manufacturing company that serves pharmaceutical and biotechnology industries.
UPM provides high quality pharmaceutical drug development services including formulation development, cGMP manufacturing, analytical methods development and stability testing. Its pharmaceutical supports include Formulation development, cGMP manufacturing, Tableting/Film coating/Capsule filling, Fluid bed technology, Granulation/Milling/Roller compaction, Stabilty testing, Scale-up and technology transfer, Blinding of clinical supplies etc. The company is focused on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets. Its services include: Formulation Evaluation, Analytical Services, Clinical Manufacturing, Regulatory Support, Commercial Manufacturing, drug development process, drug development services etc.
UPM Pharmaceuticals has collaborations with Rexahn Pharmaceuticals Inc and SCOLR Pharma Inc.
Veracity Biotechnology, LLC is a biotechnology company. The company was founded in 2005.
Veracity Biotechnology's products include: HIV-1 Integrase Assay Kit, EZ-1700, HIV-1 Integrase Protein, EZ-1794, TeloExpress Quantitative Telomerase Detection Kit, XT-100 and 96-Well RNA Purification Kits and 96-Well DNA Purification Kits. The company's drug discovery is focused on Fibrosis, Idiopathic Pulmonary Fibrosis, and Small Molecule Drugs to Treat Fibrosis.
Veracity Biotechnology's contract research services include: HIV-1 integrase assay services, Telomerase activity determinations, Bovine viral diarrhea virus antiviral evaluation assays, Buccal swab DNA isolation, Molecular cloning, TaqMan real-time (RT-)PCR, Drug lead in vitro cytotoxicity testing and Drug lead in vitro cytotoxicity testing.
Veritas is a scientific R & D company that offers services and consulting in the area of biomedical research and biotechnology.
Veritas has expertise in molecular biological, immunological and biochemical procedures. The company offers a variety of standard research services, which includes: molecular biological services - automated DNA sequencing, PCR product purification, cDNA PCR amplification and purification, synthetic gene construction; recombinant protein expression and engineering (mutation) - bacterial and baculoviral expression and fermentation; antibody production, characterization and purification - peptide synthesis and conjugation, and antibody characterization and purification services; protein and enzyme purification from natural sources - protein modification services, and assay development and optimization services.
Veritas has partnerships with National Institute of Allergy and Infectious Diseases, National Institutes of Health and The US Department of Health and Human Services.
Washington Biotechnology, Inc. is a contract research organization for drug development services including a wide variety of disease model studies as well as PK and toxicity services. It was founded in 1988 by Sean O'Neill.
Washington Biotechnology has developed economically priced in vivo and in vitro test information and custom products of the highest quality. Its major services areas include: preclinical in vivo efficacy testing of compounds in many disease models including inflammatory diseases, cancer and bacterial infection; vaccine testing services including vaccine efficacy testing in disease model studies such as arthritis, bacterial efficacy studies in mice and rats to determine antibiotic efficacy; and pharmacokinetics and related in vivo tests.
Washington Biotechnology's services include: drug & vaccine studies, support services, and custom antibody services, etc. It offers various services for efficacy assessment that include: Pharmacokinetics, Non-GLP Toxicity (MTD, acute and chronic), Compound or Vaccine Efficacy assessed by Disease-Specific In Vivo Models Cell Culture Assays for In Vitro compound screening and Immunogenicity Studies. The company offers support services for: tissue culture, bacterial culture, metabolism studies, viral culture and virus preparations, organ, tissue collection and preservation (flash-frozen, formalin), ELISA, western blot, cytokine analysis, necropsy, clinical chemistry, cell counts and differentials, and necroscopy, etc. Its pharmacokinetic (PK) services include: quality PK testing in mice, rats, guinea pigs, hamsters and rabbits. The company's necropsy services include removal, weights, preservation and collection of designated organs for histology or shipment.
YalePharma is a pharmaceutical company that focused on the development, manufacture and market of pharmaceutical and health care products worldwide. Its mission is to provide society with superior products and services by developing innovations and solutions that help heal, cure disease and improve the quality of life.
YalePharma develops a broad array of brand and generic pharmaceutical products. Its product categories include: Allergy, Colds & Flu, Baby Care, Cardiology, Dental Care, Diabetes Care, Family Planning, Feminine Hygiene, First Aid, Gastrointestinal, Medical Devices & Diagnostics, Nutritionals, Oncology, Orthopedics, Pain Relievers/Analgesics, Prescription Drugs, Skin and Hair Care, Vision Care, Women's Health and Wound Care.
YalePharma provides pharmaceutical related research, including drug screening, target identification and validation, clinical trial studies, and consulting services etc. The company researches, develops, produces, markets, and sells chemical or biological substances for medical or veterinary use, including prescription, generic, and OTC drugs; vitamins and nutritional supplements; diagnostic substances; and drug delivery systems.
Z-BioMed Inc. is a biotech company engaged in conducting innovative research in the areas of cancer and infectious diseases such as influenza. The company provides high quality products, responsive and outstanding biotechnology services to customers from government agents, research universities and pharmaceutical companies.
Z-BioMed's products include: Direct-LoadÂ® Colony PCR Screening Kits, PCR Buffer, Z-PCR Master Mixes, Z-PCR Mix GC-Rich, Direct-LoadÂ® PCR Mixes, Primer Sets for Human Genes, DNA Marker and Gel Loading Dye. The company provides the following high quality and cost-effective custom Molecular biology services like: Mutagenesis, Custom cloning and sub cloning, Mouse Genotyping, Western Blot Analysis, Plasmid Preparations, PCR Amplification for difficult templates, Protein Purification & Antibody Preparation, Extraction of Genomic DNA from: - Paraffin embedded tissues/sections and Micro dissected cells.
Lonza's Walkersville facility is located in northern Maryland approximately 50 miles north and west of Washington, DC. This manufacturing site is a cGMP/GTP compliant clinical cell processing facility, engineered with exceptional quality in mind and designed specifically to meet the needs of our cell therapy clients. Our state-of-the-art manufacturing suites currently include ISO Class 7 (Class 10,000) which are designed to meet US regulatory requirements as well as ISO Class 5 (Class B) suites designed for European regulatory needs. Ranging in size from 275 to 1,000 square feet, each suite is designed with complete flexibility in order to allow us to configure the suites to meet our customer's unique needs.
Unidirectional flow design for materials and personnel Dedicated QC suite Redundant power systems Independent air handling systems Validated and remotely alarmed equipment Excellent technical and support staffs Adequate space for expansion into commercial production scale.
The Walkersville facility is an established FDA Registered Tissue Bank, and is ISO 9001:2000 Registered and ISO 13485 - Medical Devices Registered.
DynPort Vaccine Company LLC (DVC) manages product development programs for U.S. and international government agencies, and provides consulting services to biotechnology and pharmaceutical companies. It's a wholly owned subsidiary of CSC Company.
DynPort's product portfolio includes: vaccines and therapeutics to protect against emerging infectious diseases, including biological and chemical warfare threat agents and seasonal and pandemic influenza. The company has comprehensive experience in the advanced development of biodefense biologics including biological and chemical defense, biological therapeutics, emerging infectious diseases, live attenuated vaccines, recombinant vaccines, therapeutic polyclonal antibodies and alternative vaccine delivery systems. Its area of expertise includes: biological defense, chemical defense, clinical trial management, biologics manufacturing and testing, manufacturing, testing and analytical services, product technical support, storage and maintenance, technology transfer, etc.
DynPort has agreements with ImmuneRegen BioSciences, Inc., National Institutes of Health, Commonwealth Biotechnologies, Inc, and so on.
Emergent BioSolutions Inc is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease.
Emergent's technologies include: spi-VEC(TM), an oral delivery platform technology based on a live attenuated Salmonella enterica serovar typhi bacterium designed to deliver a wide range of antigens to prevent or treat numerous diseases, including bacterial and viral infections & cancer; MVAtor(TM), designed to share the beneficial properties of an MVA strain formerly used as a smallpox pre-vaccine designed to avoid any potential risk of Bovine Spongiform Encephalitis (BSE); TRU-ADhanCe(TM) technology, enhances the antibody-dependent cellular cytotoxicity (ADCC) potency of immunopharmaceutical product candidates by greater than an order of magnitude; Scorpion(TM) therapeutics, a novel platform for the development of multi-specific protein therapeutics; etc. Its MVAtor(TM) is a tool for gene expression and vaccine development.
Emergent's product pipeline includes: BioThraxÂ® indicated for the active immunization for the prevention of disease caused by Bacillus anthracis; Anthrax Immune Globulin (AIG) indicated as a therapeutic vaccine for anthrax; Typhella, a live attenuated strain of Salmonella typhi vaccine; TRU-016 (Anti-CD37), a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia; SBI-087 indicated for the treatment of rheumatoid arthritis; Recombinant Anthrax Vaccine (rPA); etc.
Emergent has agreements with Biomedical Advanced Research and Development Authority (BARDA), Temasek Life Sciences Ventures Pte., Ltd., Oxford University, Pfizer Inc, Biological E. Ltd., etc.
PharmAthene, Inc. is a biodefense company developing and commercializing medical products to counter biological and chemical weapons. It was founded in March 2001, with mission to become the premier company worldwide specializing in the development and rapid commercialization of best-in-class medical countermeasures for the biodefense industry. The company's subsidiary is PharmAthene Canada Inc.
PharmAthene's products include: SparVax(TM), is a novel second generation recombinant protective (rPA) anthrax vaccine for the protection against inhalation anthrax; ValortimÂ® is a fully human monoclonal antibody antitoxin for the treatment of anthrax infection, including inhalation anthrax; ProtexiaÂ® is a recombinant human butyrylcholinesterase for the prevention and treatment of Nerve Agent Toxicity; and rPA anthrax vaccine, etc.
PharmAthene has collaborations with Medison Pharma Ltd., GTC Biotherapeutics Inc, Nexia Biotechnologies Inc., Medarex Inc, etc. It has acquired Avecia Biodefense Vaccines Business Unit in March 2008.
A&G Pharmaceutical, Inc. discovers, develops and commercializes personalized medicinal products that improve screening, monitoring and targeted treatment of cancer. It was founded in 2000.
A&G Pharmaceutical's drug or test products target breast cancer and are based on a unique biomarker known as GP88, or progranulin (GP88/PGRN). The company is focused on development and commercialization of two GP88-based breast cancer diagnostic test kits to improve early detection, diagnosis and treatment of breast cancer. Its product pipeline includes: OncoStain 88(TM), Onco 88(TM), and GP88/PGRN-Neutralizing Antibody, indicated for the treatment of breast and lung cancer.
A&G Pharmaceutical's investors include: ASM Resources, Celltrion, Inc., Crocker Capital, Emerge Capital, Maryland Venture Fund, MedImmune Ventures, Nexus Medical Partners and Olympus, Inc. The company's partners include: AstraZeneca Plc, Celltrion, Inc., MedImmune, Inc. (formerly known as Cambridge Antibody Technology), The National Cancer Institute, and ORChem Co., Ltd.
Asklepion Pharmaceuticals, LLC is a pharmaceutical company focused on liver-based diseases. It was founded in 2006. Â Asklepion has entered into relationships with various universities and hospitals to develop drugs for both very large patient populations as well as for small subsets of patients.
BioMetrx LLC is a drug discovery company engaged in improving clinical outcomes for advanced prostate, colorectal, and breast cancer patients. The company's mission is to develop innovative, affordable medicines for the world. It was founded in 2010 by Milton L. Brown, James H. Mitchell and H. John Wells.
BioMetrx designed rasstoreâ„¢, a novel small molecule in the field of epigenetic therapies. Its product rasstoreâ„¢ can be used as a therapeutic and as a diagnostic which allows it to be used as a tool to locate areas in the body that have concentrated amounts of the therapeutic inside of tumor cells.
Cary Pharmaceuticals Inc. is a pharmaceutical development company that identifies and develops pharmaceutical products and transitions them from basic research through Phase II clinical trials.
Cary Pharmaceuticals' products include: 1) Tempol, an antihypertensive drug which acts by reducing oxidative stress by mimicking the function of superoxide dismutase (SOD) indicated for the treatment of chronic hypertension and 2) QuitPakÂ®, an oral, non-nicotine product specifically designed for smoking cessation. It's QuitPakÂ® utilizes two components that have distinctly different mechanisms of action. The first component is mecamylamine a nicotine antagonist that acts at the site of addiction by blocking the nicotine receptors in the brain and the second components is bupropion.
Cary Pharmaceuticals has an agreement with IntelGenx Corp to jointly develop and commercialize its oral antidepressant ("CPI-300" or the "Product") using IntelGenx's proprietary oral delivery technology.
Cellona Therapeutics is a pharmaceutical company engaged in developing and commercializing targeted cancer drugs designed to inhibit signaling proteins that are critically involved in the growth and survival of human cancers.Â Its mission is to develop and commercialize targeted therapeutics to improve survival paradigms in cancer patients. The company was founded by Beth Lowenthal and Wendy Tsai.
Cellona Therapeutics' lead oncology compounds target novel signaling pathways, and have potential indications in very large therapeutic markets with considerable unmet needs. Its strategy focuses on inhibition of the RAS signaling pathways and family of onco-proteins in cancer cells. The company's oncology compounds offer potent and selective inhibition of onco-proteins that control signaling pathways that regulate cancer growth. Its lead compound CT-10 is a new class of small molecule GGTase inhibitor designed to inhibit RAS and attenuate function and signaling of the RAP1 and RHO A/C cancer proteins and blocks cross-prenylation.
Cellona Therapeutics has an agreement with Duke University.
Chase Pharmaceuticals is a specialty pharmaceutical company. The Company was founded by Thomas N. Chase in 2007. It focuses on the identification and initial clinical development of medications for the treatment of neurologic and psychiatric disease.
Chase Pharmaceuticals provides drugs for intractable brain disorders as Alzheimer's and Parkinson's disease, depression, epilepsy and neuropathic pain. Their lead drug is CPC-001 for the treatment of Alzheimer's disease and other dementias.
EntreMed Inc is a pharmaceutical company focused on the development of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. The company was founded in 1991, with a goal to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammation processes.
Exponential Biotherapies, Inc. is a drug discovery and development company with a growing pipeline of novel small molecule drugs to treat a wide range of severe inflammatory disorders such as septic shock, kidney injury, radiation sickness and avian influenza infections.
Exponential Biotherapies has licensed a family of chemically synthesized biomolecules (the "compounds") that regulate the immune response. These biomolecules can either increase or decrease the activity of the immune system by affecting the activity of one or more of its component parts. Its compounds thus represent a new class of therapeutic agents and can be described as having modulating or controlling functions over the immune response - a capability that makes them clinically relevant for many important disease states that involve the immune system.
Exponential Biotherapies' product folio includes: EA-230, a tetrapeptide which has exerted renal protective effects in small animal studies. The company's drug pipeline addresses seven major clinical areas which include: SIRS/Sepsis, Radiation Sickness, Renal Failure - cardiovascular surgery, Renal Failure - transplantation, Renal Failure - septic shock, Anthrax and Avian Flu.
Exponential Biotherapies has partnerships with Hannover Medical School / Phenos GmbH, Albert Einstein College of Medicine, Biotempt BV, EpiStem Plc and CatchMabs BV.
GlycoMimetics, Inc. is a biopharmaceutical company, engaged in developing small molecule drugs targeting areas of unmet clinical needs with a focus on rare diseases.
GlycoMimetics' pipeline is focused on applying specialized platform technology to the development of drugs to treat rare or orphan diseases. The drug candidates are first-in-class proprietary small molecules. It has designed and synthesized a novel class of patented anti-inflammatory compounds that are selectin antagonists.
GlycoMimetics uses rational design of small molecule drugs that mimic the functions of bioactive carbohydrates to develop new drug candidates. The company has designed and synthesized a family of compounds that are antagonists of both E-selectin and CXCR4. Its GMI-1070 is a synthetic glycomimetic molecule, which was rationally designed to inhibit all three selectin types (a pan-selectin inhibitor). The company has also developed a proprietary, small molecular weight compound known as GMI-1051 for the treatment or prevention of infections caused by Pseudomonas aeruginosa.
GlycoMimetics' investors include: New Enterprise Associates, Genzyme Ventures, Alliance Technology Ventures, Anthem Capital Management, The Novartis Venture Fund, PTV Sciences, L.P and Maryland Department of Business and Economic Development. The company's partners include: National Institutes of Health, The National Heart, Lung, and Blood Institute and The U.S. Department of Health and Human Services.
ImQuest Life Sciences is a drug discovery and development company focused on the strategy of developing a proprietary portfolio of therapeutic agents to target infectious disease and cancer.
ImQuest Life Sciences' pipeline includes: exclusive licenses to highly potent compounds for the treatment of Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C Virus (HBV, HCV), Influenza, including Drug- and Antibiotic-Resistant Microorganisms, and Cancer. The company focuses on the following drug development programs: therapies for the treatment of HIV; topical microbicides for the prevention of transmission of HIV and other sexually transmitted infections; therapies for the treatment of HBV and HCV; and therapies for the treatment of cancer. Its product pipeline includes: infectious disease- HBV lead discovery and IQP-0410 for HIV; anti-cancer agents- IQP-0303 for leukemia and IQP-0304 for prostate cancer; and topical microbicides- IQP-0528, IQP-0831, and IQP-1187.
ImQuest Life Sciences has a drug development alliance with Samjin Pharmaceutical Co. Ltd. The company also forms strategic drug development alliances with individuals, academic institutions, biotechnology companies and pharmaceutical companies which possess novel drug development strategies and technology. It has collaborations with Arisyn Therapeutics, Inc., Aethlon Medical, Inc., International Partnership for Microbicides, Inc., Isis Pharmaceuticals Inc, etc.
Lung Rx, LLC is a biotechnology company focused on unmet medical needs in pulmonary medicine and pulmonary delivery of therapeutic products. It was founded by Rothblatt. The company is a wholly owned subsidiary of United Therapeutics Corporation.
Lung Rx is focused on the treatment of pulmonary arterial hypertension (PAH). Its Adcirca (tadalafil) Tablet is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
MacroGenics Inc., is engaged in the discovery, development and delivery of the novel biologics for the treatment of autoimmune disorders, cancer and infectious diseases. The company was founded in 2000 with a mission to deliver life-changing medicines to patients.
MacroGenics' novel product candidates leverage its fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Dual-Affinity Re-Targeting (DART) platform enables to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy; and Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells.
MacroGenics has a diverse portfolio of product candidates focused in three therapeutic areas: autoimmune disorders, oncology and infectious diseases. Its product folio includes: DART mAb for Inflammation; MGAH22 (HER2) for Breast, other Solid Tumors; DART mAb for Multiple Solid Tumors; MGAWN1 for West Nile Virus etc.
MacroGenics has collaborations with Green Cross Corporation, National Institutes of Health, Eli Lilly & Co, Juvenile Diabetes Research Foundation International, OriGene Technologies, Inc., Neose Technologies Inc, Genzyme Corporation, Tufts University, etc. Its investors include: TPG Ventures, Alta Partners, InterWest, MPM Capital, CDP Ventures West, OrbiMed, etc.
Psyadon Pharmaceuticals Inc is a pharmaceutical company engaged in the discovery and development of new treatments for the serious psychiatric and neurological diseases. The company was originally founded in 2004 under the name Ruxton Pharmaceuticals and later changed name to Psyadon Pharmaceuticals Inc
Psyadon's first lead candidate Ecopipam is a selective dopamine D1 receptor antagonist that selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain. Its product Ecopipam helps people who previously had no other therapeutic options. The company is studying this drug for its ability to ameliorate multiple central nervous system diseases.
ReProtect Inc. develops products to reduce unwanted pregnancies and sexually transmitted diseases (STDs), including HIV/AIDS to protect the reproductive health of women and men throughout the world. It was founded in 1993 by Richard A. Cone, Thomas R. Moench and Kevin J. Whaley, with a goal to provide safe, reliable and effective contraceptive microbicides.
ReProtect is focused on the development of vaginal microbicide that works by maintaining the natural environment of the female reproductive tract. Its product portfolio includes: BufferGelÂ®, a vaginal product indicated to prevent both unwanted pregnancy and STDs by enhancing a natural protective function of the vagina; Duet(TM), a novel cervical barrier and applicator that serves as a platform technology to enhance the effectiveness of microbicides, spermicides, and vaginal therapeutics.
Sigma-Tau Pharmaceuticals, Inc. is a research-based pharmaceutical company focused on the discovery of molecules and therapies to help improve the lives of people who suffer from rare diseases. The company is a wholly owned subsidiary of Sigma-Tau S.p.A. It was founded by Claudio Cavazza.
Sigma-Tau Pharmaceuticals' research is focused on the area of rare diseases. The company's product pipeline includes: Cystaran(TM) indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis, Nuartez(TM) (artesunate) indicated for the treatment of severe and complicated falciparum malaria, orBecÂ® (oral beclomethasone dipropionate) indicated for the treatment of acute graft versus-host disease; XenbiloxÂ® indicated for the treatment of cerebrotendinous xanthomatosis (CTX), etc.
Sigma-Tau Pharmaceuticals is engaged in the development of the following categories of products that include: prescription products and consumer products. Its prescription product portfolio includes: CarnitorÂ® (levocarnitine), MatulaneÂ® (procarbazine hydrochloride), OncasparÂ® (pegaspargase), AdagenÂ® (pegademase bovine), DepoCytÂ® (Cytarabine Liposome Injection), etc. The company's consumer products are- ProXeedÂ® Plus and VSL#3Â®.
Sigma-Tau Pharmaceuticals has collaborations with Enzon Pharmaceuticals Inc , Danisco BioActives, Medicines for Malaria Venture (MMV), Walter Reed Army Institute of Research, U.S. Department of Defense, United States Army Medical Materiel Development Activity, etc.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines based on prostones. The company was founded by Ryuji Ueno and Sachiko Kuno in 1996. It has two wholly owned subsidiaries that include: Sucampo Pharma Europe, Ltd and Sucampo Pharma, Ltd.
Sucampo leverages its prostone technology to develop and commercialize novel pharmaceutical products to treat unmet medical needs, particularly those diseases affecting an aging population. The company uses proprietary technologies to develop treatments for a variety of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders. Its products are based on prostones which are a class of compounds derived from functional fatty acids that occur naturally in the human body.
Sucampo's product portfolio includes: AMITIZAÂ® indicated for the treatment of chronic idiopathic constipation, irritable bowel syndrome and opioid induced bowel dysfunction; Rescula indicated for the treatment of glaucoma and dry age-related macular degeneration (dry AMD); Cobiprostone indicated for the treatment of chronic obstructive pulmonary disease (COPD), oral mucositis, and prevention of non-steroidal anti-inflammatory drug (NSAID) induced ulcers; SPI-3608 indicated for the treatment of spinal stenosis; etc.
Sucampo has collaborations with R-Tech Ueno, Ltd., ABBOTT Japan Co., Ltd., Takeda Pharmaceutical Company Limited, PHT Corporation, Medidata Solutions etc.
Symphony Evolution, Inc is a biopharmaceutical company focused on the development of therapeutics for treating cancer and diabetic neuropathy. The company was founded in 2002 by Harri V. Taranto.
Symphony Evolution's product portfolio includes: XL647, a potent inhibitor of RTKs (receptor tyrosine kinases) implicated in driving tumor proliferation and vascularization; XL999, a potent inhibitor of Flt3 indicated as an important driver of cell proliferation in many patients with acute myelogenous leukemia (AML); and XL784, a potent inhibitor of the ADAM-10 metalloprotease (MP) enzyme indicated for the treatment of renal disease.
Symphony Evolution has aÂ collaboration with Exelixis, Inc. The company's lead investor is Symphony Capital Partners, L.P.
Valens Therapeutics, Inc. is a pharmaceutical company involved in the development of the next generation of novel therapeutics to address important unmet medical needs. The company includes therapeutics to treat diseases caused by abnormal angiogenesis and infectious pathogens. The company's proprietary molecules target human proteins involved in abnormal vascular growth, pathological conditions of the eye, cancer, tumor growth, metastasis and other disease conditions and proteins from infectious pathogens including viruses and bacteria.
Valens Therapeutics's technology platform comprises class of compounds with physicochemical properties, highly stable, resistant to degradation by enzymes and stable folding structures that could be developed into drug candidates against several target areas including ophthalmology, oncology, neurology, inflammation and infectious diseases and also molecules capable of modifying disease state cell characteristics. The technology consists of conjugating several different proprietary molecules to a non-toxic, water soluble, safe, non-immunogenic and biocompatible polymer to create novel next generation multi-targeted therapeutics for the treatment of a variety of human diseases, for which there are no effective treatment drugs.
Valens in the area of ophthalmology, develops a product with characteristics not observed in the available ocular therapies for the treatment of ocular pathologies. Neovascularization in the eye causes a variety of diseases including macular degeneration, choroidal neovascularization, diabetic retinopathy and other eye pathologies. In the area of oncology it develops multi-targeted therapeutic for the treatment of pancreatic cancer. The company develops the next generation multi-targeted anti-HIV therapeutic vaccine for the treatment and prevention of HIV/AIDS in the area of infectious diseases.
Wellstat Biologics Corporation discovers, develops and commercializes biological agents for the treatment of cancer. It was founded in 1994 by Samuel J. Wohlstadter with a goal to develop oncolytic viruses for the treatment of cancer, especially via systemic administration. It is a part of the Wellstat Group of Companies.
Wellstat Biologics' product pipeline includes: PV701, replication-competent oncolytic virus for the treatment of solid tumors; PV327, an oncolytic virus for the systemic treatment of leukemia and solid tumors; and PV921, an oncolytic virus possessing a number of unique properties.
Wellstat Biologics has partnership with Horizon Discovery Ltd.
Amarex Clinical Research is a contract research organization that provides clinical regulatory strategy and product development services for drug, medical device and diagnostic kit approvals in the U.S. and other countries.
Amarex's service areas include: regulatory, clinical trial conduct, biometrics and medical writing. Its regulatory services include: clinical site, manufacturer site and laboratory audits - GCP, GMP, GLP, chemistry & Manufacturing Controls (CMC) consultation for FDA compliance, regulatory strategy creation for clinical product development, FDA meetings and presentations, and U.S. agent to FDA for non-USA companies - annual IND reports, drug master file updates, etc. Its clinical trial conduct services include: trial planning and project management, protocol development, investigator meetings, IRB assistance, clinical monitoring, etc. The company's biometrics services include: ICH E9 compliance, CRF design (EDC or paper), database design and creation, data entry & cleaning, statistical analysis plan, analysis tables, listings, graphs, etc.
Amarex offers services in the following product categories: biologics, botanicals, combinatorial biotech products, diagnostics, medical devices and pharmaceuticals (small molecules / new chemical entities). The company has expertise in the areas of: cardiovascular, central nervous system (CNS), dermatology, gastrointestinal, infectious disease, metabolic, oncology, pain management, pulmonary, urology and wound healing. It's WebView(SM) clinical trial management system offers patient enrollment and randomization, CRF, DCF and regulatory document viewing, trial status reporting, tables & listings review, SAE processing, drug re-supply, study bulletin board, etc.
Amarex has collaborations with OmniComm Systems Inc, Vedic Lifesciences Pvt. Ltd and Rexahn Pharmaceuticals Inc.
BioFortis Inc is a software company engaged in creating software solutions that empower average users by making relevant data more easily accessible to them. The company was formed in 2002 with a mission to unleash the creative force of knowledge workers by breaking down all technical barriers to data access and exploration.
BioFortis' flagship product, Labmatrixâ„¢ is a web-based software application used for information management and integration of patient clinical, specimen, genetic and molecular assay data. The company's Qiagram is a software product that empowers its users to easily access, manage, explore, and retrieve relevant information in data-intensive environments.
BioFortis' core capabilities include: Data Exploration, Biospecimen Management, Clinical Research Management and Research Collaboration Management. It provides solutions for the following application areas: Biomarker discovery, Translation research and Genetic research.
BioFortis has agreements with National Institutes of Health, The National Cancer Institute, The National Eye Institute (NEI) and The US Department of Health and Human Services.
Consent Solutions Inc is specialized in providing web-based electronic informed consent software for clinical research trials and investigational procedures. It was founded in 2005 with a mission to use its domain expertise in patient education to reduce the cost and time required to bring new drugs and medical therapies to market and to minimize the long-term expense caused by ineffective pre-procedure consent delivery.
Consent Solutions provides innovative approaches to improving the consent process through the use of electronic media. The company designs multimedia platforms for educating potential research participants and assuring their understanding of trials, and works with sponsors and trial staff to assure optimum presentation of trial information. Its SecureConsentâ„¢ is an affordable customizable web-based informed consent and clinical trial management tool that should be included in all clinical trial quality and compliance programs. The company's SecureConsentâ„¢ effectively delivers IRB approved consent information, minimizes consent related disputes, and helps sponsors & CRO's monitor recruitment efforts across multiple sites. Its interactive multimedia presentation combines audio, visual graphics, and interactive formats to effectively deliver the clearest information about participating in clinical trials and/or investigative procedures.
Consent Solutions has partnership with TransPerfect Trial Interactive.
DP Clinical, Inc. is a contract research organization (CRO) that serves pharmaceutical and biotechnology clients by providing Project Management, Monitoring, Data Management, Biostatistics and data analysis, and Medical Writing services for Phase I - IV clinical trials. It was established in 1994, with a goal to provide the highest quality of clinical and data management services to the life sciences industry and to satisfy its clients.
DP Clinical is focused on the following therapeutic areas that include: neurological disorders, pediatric trials, cardiology, infectious diseases, ophthalmology, HIV/AIDS, respiratory, oncology, rheumatology, blood disorders, etc. It offers a wide range of clinical trial services that include: project management, site selection and feasibility questionnaire, safety monitoring, preparation of study specific SOPs, monitoring, etc. The company provides an extensive array of clinical data management services that include: design of case report form or eCRF, preparation of CRF or RDC guidelines, data coding using MedDRA and WHO Drug, preparation of data management plan, design database, query management, etc. Its biostatistics services are - clinical trial design, development of statistical analysis plan, statistical programming and validation, interim , exploratory, and meta analysis, data transfers from vendors, validation and documentation, etc.
DP Clinical provides a wide range of medical writing services. The company's medical documents that it normally works on includes: standard operating procedures (SOPs), summary of clinical safety/ISS, integrated summary of efficacy (ISE) reports, serious adverse events (SAE) narratives, etc. Its range of regulatory services include: preparation of recruitment and subject information materials, preparation of informed consent form, review and maintenance of documentation and records, review of advertising and promotional materials, technical writing including clinical study reports and investigator's brochures, etc. The company is also engaged in offering quality assurance and pharmacovigilance services.
DrugLogic is specialized in developing analytical tools for managing risks related to drug safety issues. It develops, designs and delivers products that provide state-of-the-art-solutions in support of pharmacovigilance and drug safety practices for both pharmaceutical and biotech companies.
DrugLogic's product portfolio includes: Qscan-Lifecycle - encompasses the drug safety world with its three part system - Qscan Clinical, Qscan Postmarket, and Qscan Medical, is a multi-source, multi-database, multi-statistic approach to risk management and mitigation strategy; Qscan Clinical - Optimize trials for the best safety position; Qscan Postmarket - Monitor drugs across a multi-database system; Qscan Medical - Allows for "active" surveillance and Quick accessibility to individual medical records.
DrugLogic's services include: Risk Management and Trending Analysis, Safety Surveillance Reporting and Risk Management and Pharmacovigilance Consulting.
DrugLogic has partnerships with BioPharm systems, CSS Informatics, Oracle, Center for Drug Safety, United BioSource Corporation, etc.
Global Research Services, LLC is a contract research organization specialized in cardiovascular and metabolic pharmaceuticals, biotechnologies and medical devices. It is a division of GRSworldwide LLC. The company was founded by Bruce N. Garrett, Sandra S. Garrett, and Julie Garrett, with a mission to utilize rigorous scientific and research methodologies that ensure the protection of human subjects and comply with international regulations in order to achieve high-quality results. Its vision is to provide clinical research and development services that produce new drugs, medical devices, and treatments, primarily in the cardiovascular, renal and metabolic arenas, which improve health, quality of life, and may ultimately save lives.
Global Research Services offer services such as: Development Plans / Commercialization Solutions, Protocol Development / Case Report Design, Study Start-Up, Project Management, Site Management, Data Management/ Private Label Reserve, Drug Safety, Biostatistics, Medical Writing, Quality Assurance, and Regulatory Affairs.
Global Research Services has alliances with CORRONA, Inc. and CardioDynamics International Corporation.
M Squared Associates, Inc. is engaged in providing the full range of clinical and regulatory services that medical device companies need to bring new products to market. The company was founded in 2001 with a mission to provide to clients with unmeasured excellence in service operating as the most highly regarded company in the medical technology consulting business.
M Squared Associates provides the full range of services required throughout the FDA approval/clearance process, including: regulatory strategy and project planning, preclinical study planning, clinical study design, investigational device exemptions (IDE's), premarket approval applications (PMA's), investigational site qualification and study initiation, clinical study management, including monitoring and audits, data analysis and presentation, etc.
M Squared Associates has partnership with Imaging Diagnostic Systems Inc.
Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA) is a neuro-musculoskeletal / orthopedic consulting company assisting established and emerging companies in the development and commercialization of their technologies. It was founded in 2004, with a mission to use the most experienced musculoskeletal strategic advisory team to guide orthopedic products through the regulatory, clinical, intellectual property, and reimbursement process quickly and successfully, thereby creating maximum value for investors.
MCRA's services include: US FDA Regulatory, Global health economics, reimbursement & public policy, Quality assurance & international regulatory, Clinical, Intellectual property, and Surgeon ethics & compliance. Its reimbursement services guide orthopedic technologies throughout the multiple healthcare economic pathways: from technology development, to commercialization and beyond.
RxTrials Inc offers distinct level of service to the medical research community. The company was established in 1994 by Christine Pierre.
RxTrials provides support services to hospitals, health care systems, and private medical practices in connection with the marketing, implementation and management of clinical research sites. Its investigators conducted clinical trials for the following indications: crohn's disease, deep vein thrombosis (DVT), depression, erosive esophagitis (EE), fibromyalgia, functional dyspepsia, flu vaccines, gastro esophageal reflux disease (GERD), heartburn, high cholesterol, hypertension, irritable bowel syndrome (IBS), male and female, low back pain, osteoarthritis, osteoarthritis of the knee, prostate cancer, pulmonary embolism (PE), restless legs syndrome, rheumatoid arthritis, stress urinary incontinence (UI), type II diabetes and ulcerative colitis.
RxTrials offers services which include: investigative site evaluation, human resource support, site marketing evaluation, business development, financial evaluation, budget and contract negotiation, clinical research education and compliance program.
RxTrials's investigative partners include: Integra Clinical Research LLC, Amherst Family Practice, Capital Gastroenterology Consultants, Cardiac Vascular & Thoracic Surgery Associates, Centennial Medical Group, Katzen Eye Group, Tampa Bay Clinical Research Center and Vascular Surgical Associates, P.C.
SciLucent is committed to promote streamlined product development, regulatory approval and project management.
SciLucent's core strengths include: preclinical and clinical development and implementation; regulatory strategy, documentation, and implementation; portfolio expansion and due diligence; chemistry, manufacturing, and controls strategy, documentation, and implementation; optimization of product development processes; quality system design and compliance; and marketed product support. Its services include: business and product development, regulatory strategy/regulatory affairs support, nonclinical, biocompatibility and clinical studies, quality systems and compliance, medical writing and literature reviews and safety surveillance programs.
Summit Drug Development Services LLC is a drug development services company that offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. The company was founded in 2004 and is a wholly owned subsidiary of Cornucopia Pharmaceuticals Inc.
Summit's drug development services include: strategic planning; chemistry, manufacturing and controls (CMC); preclinical studies; clinical trial design and analysis, regulatory submissions; and FDA liaison and project management. Its regulatory services include: FDA regulatory submission preparation and review, risk management, product development plans and timelines, electronic submissions in CTD format (eCTD), FDA meeting support & material preparation, Pre-IND/IND, IND maintenance, etc. The company's clinical services include: protocol design and drafting, CRO identification, clinical Study report writing, interpretation of study results.
Technical Resources International, Inc. (TRI) is a full-service contract research organization that provides a unique range of support services to private industry, government agencies, and associations. It was founded in 1979 by Anthony Lee.
Technical Resources' three service units include: Communications, Health, and Information Technology. The company's Health services include: Bio-Pharmaceutical Development Support, Health Information Services, and Health & Environmental Assessment. Its areas of expertise include: clinical research support, regulatory affairs, quality assurance, and safety & pharmacovigilance. The company's information technology's services include: Web Services, Application Services and Network Services.
Technical Resources provides health information services such as: Scientific and Medical Database Development, Maintenance, and Enhancement; Evaluation of Pharmacological and Toxicological Data (non-clinical and clinical); Scientific, Technical, and Medical Writing & Editing; etc. Its health & environmental assessment's services include: the acquisition, evaluation, and interpretation of toxicological data; exposure assessments involving industry & consumers, and toxicological database development & management.
Technical Resources has agreements with National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases and ICON Clinical Research.
The EMMES Corporation is a contract research organization that is dedicated to providing statistical & epidemiological expertise, computer systems development, data management, study monitoring, regulatory guidance, and overall operational support to clients in clinical and biomedical research. It was founded in 1977.
The EMMES operates, and maintains a powerful, state-of-the-art system of servers and client computers. It has created standardized, shared, and reusable software components and productivity-enhancing tools for internal project personnel and the customers it serve. This approach minimizes the risks associated with new product development. The company's portfolio includes the design and coordination of multi-center, multi-protocol clinical trials networks for Phase I - IV studies and disease registries.
The EMMES specializes in providing support for complex clinical projects. The company has designed and deployed a secure Internet-based Participant Eligibility, Enrollment and Randomization System. It offers a complete information technology solution in support of all phases of medical research and clinical trials to pharmaceutical and biotechnology companies; academic and medical research institutions, non-profit organizations and government. Its solutions are EMMES AdvantageEDCS(SM), is an effective tool that helps sponsors safely conduct clinical studies while meeting the time and business commitments required to bring products to market and EMMES GlobalTrace(SM), a premier materials management capability tracks specimens in real-time, from the time of collection at a clinical site to the arrival at a central laboratory or repository which is essential for many research projects and clinical trials.
United BioSource Corporation (UBC) is a scientific and medical affairs organization that partners with life science companies to develop and commercialize their products. It was founded in 2003 by Ethan Leder and Mark Clein. The company is a subsidiary of Medco Health Solutions, Inc.
UBC's initiatives revolve around safety and risk management, as well as health economics and outcomes research, and have included large prospective safety studies, risk, evaluation and mitigation studies (REMS), cost-benefit and cost-effectiveness evaluations, budget-impact modeling, and epidemiologic studies among the broad suite of services that it brings to its clients. Its Clinical technologies include: Interactive Voice and Web Response Services (IVRS / IWRS), Screening and Randomization, Electronic Data Capture (EDC) and etc. Its services include: Adaptive Trial Solutions, CME & CE, Investigator Services, Site Training Services, Safety & Risk Management and etc.
United BioSource Corporation has collaborations with CogState Ltd, National Community Pharmacists Association, IQ Consultancy Group, CRF Health (formerly CRF Inc.), etc.
Westat, Inc. is a provider of research services to agencies of the U.S. Government, as well as businesses, foundations, and state and local governments.
Westat performs research studies in a wide range of programs and subject areas: health, social services, housing, energy, education, transportation, the environment, human services, military human resources, and the burgeoning science and technology sector. It is also specialized in designing and administering customer satisfaction surveys and providing consulting services and marketing research to meet client requirements. The company has the technical expertise in survey and analytical methods, computer systems technology, biomedical science, and clinical trials to sustain a leadership position in all research endeavors.
Westat has conducted studies on a diverse range of topics: health conditions and expenditures; academic achievement and literacy; medical treatments and outcomes; exposure assessments; program participation; employment and earnings; and respondent knowledge, attitudes, and behaviors. It combines the relevant program area expertise with the capabilities to perform major survey research projects: study design and analysis, methodology, survey data collection, information technology, and web evaluation and design. The company supports two software packages, including: WesVarÂ® and The BlaiseÂ® Family of Software.
Westat's Clinical Trial Services include: Trial design and protocol development, Clinical trials management, Regulatory and safety management, Site management and monitoring, Data management, Training and infrastructure support, WesTraxÂ® (interactive voice response [IVR] and interactive web response [IWR] system), Biostatistical design and analysis, Support for late-phase studies, etc.
Over the past 30 years, PAREXEL has developed significant expertise to assist clients in the worldwide pharmaceutical, biotechnology and medical device industries with the development and launch of their products in order to bring safe and effective treatments to the global marketplace for the patients who need them. Headquartered near Boston, Massachusetts, PAREXEL operates over 70 locations throughout more than 50 countries around the world, and has over 11,000 employees.
We are a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.
In the highly competitive biopharmaceutical marketplace, the need to diversify, innovate, and globalize is greater than ever. To help you make that transformation, PAREXEL Consulting is right where you need us with consulting services including: pharmaceutical consulting, biotech consulting and medical device consulting across a full range of product development stages and therapeutic areas. Drawing on our unique fusion of scientific, regulatory, and business expertise, PAREXEL Consulting provides flexible, strategic solutions designed to fit your specific products, stage of development, and company size and goals. Our integrated product development consulting and commercialization services help biopharmaceutical and medical device companies shorten time to market, manage risk, access new global markets to maximize portfolio value, and maintain regulatory compliance.
With more than 30 years of experience, PAREXEL is a global leader in consulting services focused exclusively on the biopharmaceutical and medical device industries. Our 450+ pharmaceutical consultants include many physicians, scientists, former regulators, and industry professionals with an extraordinary depth of knowledge about the issues that can impact the development of biopharmaceutical products, such as safety, pricing, reimbursement, and compliance. Equally important, our resources include local expertise in every region of the world, so our partners can take advantage of the vast opportunities available in rapidly emerging global markets, such as the Asia/Pacific region.
PAREXEL Consulting experience PAREXEL Consulting provides superior program management, flexible solutions, proactive risk management, and innovative partnering models. We utilize performance metrics to drive results, and design and execute our projects based on your goals. Our ultimate mission is to help our strategic partners safely and effectively advance their products for the benefit of patients worldwide.
Ambu Inc. develops, produces and markets diagnostic and life-supporting devices for hospitals and rescue services. Its mission is to provide its customers with innovative solutions that optimize workflow, reduce cost and improve patient care. The company's vision is to save lives and improve patient care. It is a subsidiary of Ambu A/S.
Ambu has three business areas: Airway Management, Patient Monitoring & Diagnostics and Emergency Care. The primary products are Masks for artificial ventilation and scopes for intubation, Single-use electrodes and sensors for measuring heart rate and diagnosing diseases in nerves and muscles, and Resuscitators, collars and manikins for first aid training. Some of its other products include: AmbuÂ® Disposable Face Masks, AmbuÂ® UltraSeal disposable face mask with check valve, AmbuÂ® Aura-i(TM) Disposable Laryngeal Mask, AmbuÂ® Blue Sensor NEO X, AmbuÂ® Blue Sensor VL ECG Electrode, AmbuÂ® Neuroline Cup, AmbuÂ® Disposable Corkscrew Electrode, AmbuÂ® Mark IV - Reusable Resuscitator, AmbuÂ® Endotracheal Tube Holders, AmbuÂ® Oxygen Regulators and so on.
Ambu's distributors include: BoundTree Medical, Emergency Medical Products, Inc., mooremedical, Progressive Medical International, etc.
AutoMedx Inc. is engaged to improve the survival rate of individuals suffering acute respiratory failure by providing unparalleled access to mechanical ventilation during the first critical minutes of respiratory distress. It was founded in 2004.
AutoMedx has developed Simplified Automated Ventilator device (SAVe), designed to be quickly deployed in a pre-hospital environment by a BLS or ALS provider, the device addresses the dangers associated with bagging patients and frees up a responder to address other injuries, perform compressions, attend to other patients or further assist in transporting the patient. Its SAVe mitigates the potential for injury, reduces operator error, complies with guidelines and improves a medical responder's ability to perform other critical task. The company also provides SAVe accessories like patient breathing circuit, debris filter, patient mask, oxygen tubing, EtCO2 detector, etc.
AutoMedx has partnership with Hemcon Medical Technologies, Inc.
BrainScope Company, Inc. is a medical neurotechnology company developing a new generation of portable, simple-to-use, non-invasive instruments to rapidly, and objectively assess brain function at the initial point of care. Its goal is to provide medical professionals with new, rapid, effective analysis tools to assist in the assessment of brain function.
BrainScope has focused on optimizing analysis of brain electrical signals to enhance detection and assessment of changes in brain function. The company's initial focus is the development of a device for military use, to aid in detection and assessment of Traumatic Brain Injury using an objective scale. Its technology in development is based on the premise that the brain is an organ with function exhibited primarily by electrical activity. All of the brain's activity, whether reflexive, automatic, unconscious or conscious, is electro-chemical in nature, and has mathematically predictable electrical correlates.
BrainScope complies with ISO 13485 medical device standards. Its investors include: Revolution LLC, Alafi Capital, Portage Venture Partners, The Brain Trust Accelerator Fund and Draper Fisher Jurvetson ("DFJ"), etc. The company has major partnerships for ongoing development of its technology & products with New York University's Brain Research Laboratories (BRL) and and Raytheon BBN Technologies.
Dynasplint Systems, Inc. is engaged in the development and marketing of aids that restores physical function and more importantly, quality of life to patients with joint stiffness and limited range of motion caused by injury, trauma, surgery or disease. Its mission is to achieve excellence by incorporating low-load, prolonged duration stretch (LLPS) technology into rehabilitative medicine.
Dynasplint's DynasplintÂ® Systems are bilateral spring loaded tensioning devices that help to increase joint range of motion (ROM) for patients experiencing ROM deficits due to shortened connective tissue while decreasing range of motion rehabilitation time and cost.
Dynasplint offers a wide range of human and veterinary products for the following categories: Orthopedic, Neurological, Ankle & Foot, Trismus, Carpal Tunnel, and Pediatric. Its product portfolio includes: Pronation DynasplintÂ® System, Wrist Flexion DynasplintÂ® System, Ankle Plantar Flexion DynasplintÂ® System, Infant Neurological Ankle Dorsiflexion DynasplintÂ® System, Equine Digital Dorsiflexion, Equine Fetlock Varus Valgus, Canine Hock Flexion, etc.
Eckert & Ziegler Radiopharma Inc provides solutions to radiopharmaceutical production processes which are used for diagnostic imaging and therapeutic area like neuroendocrine tumors and also offers different radiochemicals that are useful for research activities. It develops PET radiomarkers for oncology, cardiology, neurology and pharmacokinetics. The company is a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG.
Eckert & Ziegler's product lines include: bioscan analytical instruments & bioscan radiochemistry which are used in nuclear medicine and radiopharmacy laboratories. Its products include: AR-2000 radio-TLC imaging scanner, mini-scan TLC imaging scanner, hot-cell radiochemistry, etc. The company's radiopharmaceutical products include: yttriga and FDG. Its radiochemicals include: Y-90 chloride solution, Lu-177 chloride solution, etc.
Euclid Systems Corporation is an eye care company that provides customized acuity by developing and implementing a system of vision correction, examination, design, and manufacturing technologies.
Euclid's Emerald(TM) lenses are unique rigid gas permeable contact lenses that temporarily correct myopia by gently reshaping the cornea while sleeping. A customized 4 zone lens design employs base curves calculated to be flatter than the flat cornea curvature, reverse zones of steeper radii, and alignment zones that provide improved lens positioning.
Euclid has partnership with Catalent Pharma Solutions, Inc.
Exmovere Holdings Inc is a biomedical engineering company focused on government and consumer applications for healthcare, security and mobility. Its mission is to develop systems and technologies that make machines more intuitive, help families take care of each other and give hope to the disabled.
Exmovere Holdings is focused on the development of proprietary new technologies. Its product portfolio includes: Telepath wristwatch, Exmogate turnstile and the Chariot wearable vehicle. The company's Bluetooth biosensor Telepath wristwatch uses infrared sensors to detect heart rate without a chest strap, 3-d accelerometers to model human movement, and a variety of metallic sensors to detect skin temperature and skin conductance. Its Exmogate turnstile is a wirelessly controlled secured portal. The company's product Exmogate turnstile incorporates embedded GSR, skin temperature, pressure and auto-diagnostic sensors, as well as a video camera. Its Chariot wearable vehicle is an upright mobility device that surrounds the user's thighs, hips and legs in a kind of cocoon. The company's product Chariot wearable vehicle serves as a unique platform for integrating vital sign, emotion monitoring and environmental sensors for hospitals, military and hazardous materials workers.
EyeTel Imaging Inc is a provider of diagnostics through state-of-the-art telemedicine. It was founded in 1996 by Kevin T. Quinn and began its operations when it has signed a licensing agreement with Johns Hopkins University to develop and commercialize a new technology for retinal imaging.
EyeTel Imaging has developed DigiScope, a semi-automated fundus camera which is easily operated by a technician and produces high quality images allowing screening for and detecting age-related macular degeneration (AMD), diabetic retinopathy and optic disc abnormalities such as Glaucoma. Its Retinal Imaging System was developed as a viable alternative for detecting diabetic retinopathy in the primary care setting.
EyeTel Imaging has collaborations with Johns Hopkins University, Wilmer Eye Institute, Eli Lilly & Co, etc. The company's DigiScope assets have been acquired by NeuroMetrix in 2007 and in 2008 Advanced Diagnostics, LLC has acquired all assets related to sales of DigiScopes and DigiScope related services from NeuroMetrix.
Flexible Medical Systems LLC is engaged in developing technology to extract interstitial fluid (ISF) for analysis without penetrating the skin. This transdermal approach eliminates the pain, needles, and blood associated with typical blood assays.
Flexmed has developed micro technology for membrane permeabilization to access interstitial fluid (ISF) transdermally (thus eliminating) pain, blood or puncture of the skin. Its proprietary microchip technology temporarily disrupts the continuity of the lipid bilayer with tiny electrical signals, rather like shaking oil and water, allowing fluids to flow through the open channel created across the stratum corneum. Its initial transdermal sensing products are being developed for glucose monitoring of diabetes, where it can quickly help the greatest number of people.
FMD, LLC was founded in 1999. The mission of the company is to develop safe medical devices.
FMD team used ESWL technology and developed and tested on the TWINHEADSÂ® lithotripter, which uses the "Synchronous Twin Pulse Technique", with two sources of energy instead of one and was led by the combination of urologists and biomedical engineers. The TwinheadsÂ® technology is based on the discovery that the collapse of cavitation bubbles can be controlled by the timing and direction of additional shock waves. The generation of another shock wave propagates at a certain angle from the original shock wave which increases the treatment effect of shock waves and abolishes or minimize the tissue damage effect outside the focal area.
K2M, Inc. is an innovative spinal device company that develops simplified solutions for the treatment of complex spinal pathologies and procedures. It was founded in 2004 with a mission to develop quality products for physicians and enhance the well-being of patients with spinal disorders. The company has been acquired by Welsh, Carson, Anderson & Stowe on August 19, 2010.
Medispec LTD is focused on development of state of the art medical systems based on shock wave technology and high performance. It was founded in 1992, with a mission to produce most efficient and minimally-invasive medical treatments to patients. The company's vision is to improve the quality of patient care by making affordable, high-tech medical equipment.
Medispec's medical systems enable physicians and hospitals to offer highly efficient treatments to patients suffering from conditions like Urinary stones, BPH, prostatitis, various orthopedic conditions such as fracture non-union, plantar fasciitis and tendonitis, as well as cellulite and body firming aesthetic treatments. The company's innovative shockwave therapy for revascularization of Ischemic heart (ESMR) as well as a breakthrough treatment for erectile dysfunction (EDSWT) using shockwaves. It continuously improves and design medical systems for new applications delivering solutions for the fields of urology, cardiology, orthopedics, physiotherapy, aesthetics and veterinary.
Medispec's products include: E3000, an electrohydraulic extracorporeal shock wave lithotripter that treats urinary calculus and it is for the fragmentation of kidney and ureteral stones; Lithospec, an electromechanical intracorporeal lithotripter for the treatment of urinary calculi; Urospec, an uroflowmeter for diagnosing various diseases caused by urinary tract obstructions; Orthospec ESWT system for chronic heel pain; radial wave therapy system for orthopedics, physiotherapy, sports medicine, chiropractic and traumatologic applications; Cardiospec for optimal cardiac revascularization system and Vetspec Treatment for equine orthopedic disorders.
MiTiHeart Corporation is a research and development company dedicated to develop and market a unique blood pump for patients suffering from congestive heart failure. The company's mission is to prolong life and improve the quality of life of congestive heart failure patients by providing advanced state-of-the-art rotary blood pumps with superior performance. It was founded in February 2003 as a wholly owned subsidiary of Mohawk Innovative Technology, Inc. (MiTi).
MiTiHeart's technology has developed MiTiHeart(TM) Left Ventricular Assist Device (LVAD) that uses magnetic levitation system to eliminate the need for any mechanical contact bearings or contamination from lubricants.
MiTiHeart has developed collaborations with Hershey Medical Center, Argonne National Laboratory, and other leading organizations. The company has approval for MiTiHeart(TM) LVAD by the Food and Drug Administration (FDA).
NovaSom, Inc. (formerly Sleep Solutions, Inc.), is a diagnostic service provider for home testing and evaluation of sleep-disordered breathing, which includes the diagnosis of obstructive Sleep Apnea (OSA). It offers physicians and their patients a fast, cost-effective, accurate and comfortable alternative to in-laboratory sleep studies.
NovaSom has developed NovaSomÂ® QSGÂ® that allows patients to undergo testing for Obstructive Sleep Apnea in the comfort and privacy of their own home. The system can be used for up to three nights to collect sleep data, including respiratory events (apneas and hypopneas), snoring intensity, blood oxygen saturation, pulse rate and respiratory effort. It offers NovaSomÂ® PulseOxÂ®, an easy solution for qualifying oxygen patients by delivering a simple but clinically-accurate overnight pulse oximetry device to the patient's home and instructing the patient on its use. The company has also developed MediTrackÂ® a comprehensive program for cost-efficient, direct-to-patient delivery of testing services and medical products. Its Study Viewer(TM) is an electronic data analysis system that utilizes proprietary algorithms for automated scoring and generation of a comprehensive diagnostic report.
NovaSom provides a comprehensive, ambulatory diagnostic service for sleep-disordered breathing including Obstructive Sleep Apnea (OSA). Its ambulatory testing services benefits include: provides data for respiratory events (apneas, hypopneas, A+H index), snoring intensity, blood oxygen saturation, pulse rate and respiratory effort, requires no staff, training or equipment purchase, provides secure, patient-reported health information and outcomes tracking services to aid therapeutic decisions and disease state management etc.
NovaSom has partnerships with State University of New York at Buffalo (SUNY/UB) and Department of Veterans Affairs.
Novoste Corporation is a medical device company engaged in development of advanced medical treatments for coronary and vascular diseases.
Novoste focuses on vascular brachytherapy - radiation therapy delivered inside a blood vessel to prevent its reclosure (restenosis) following balloon angioplasty and other catheter-based interventional procedures. The company's products include: Novoste(TM) Beta-Cath(TM) 3.5F system, a vascular brachytherapy catheter developed to maximize lesion access and minimize flow restriction; Novoste(TM) Beta-Cath(TM) 5F system, to treat patients suffering from in-stent restenosis, a condition in which coronary stents become blocked with new tissue growth; etc. It has participated in clinical trials for development of START Trial, START 40 Trial, Beta-CathT system trial, etc. The company's Medical services department provides information regarding vascular brachytherapy and use of Novoste products.
Novoste has distribution agreement with Orbus Medical Technologies.
Noxilizer Inc is engaged in development and commercialization of sterilization technologies designed to revolutionize two major sterilization markets, life science manufacturing and hospital reprocessing. The company was founded in 2004.
Noxilizer has developed a sterilization process based on nitrogen dioxide that has application in life science manufacturing and hospital reprocessing. The company provides contract sterilization services to companies that are developing and marketing the next generation products. It has also developed a method that may result in a commercial product that can rapidly, reliably and safely sterilize reusable medical devices in the hospital central sterilization department.
Noxilizer provides contract sterilization services. The company specializes in medical devices, drug-device combination products (for example, prefilled syringes), bioresorbable implants and collagen scaffolds in development and marketed products in smaller volumes. Its other services include: labeling, final packaging, etc.
Noxilizer has partnership with Sterilization Technology Group Inc. The company is an ISO 13485: 2003 certified company.
Orthotic Prosthetic Center Inc provides state-of-the-art orthotics and prosthetics (orthopedic braces and artificial limbs) and patient care to clients in the national capital region. It was founded in the year 1980 by Joan Weintrob. It is a wholly owned subsidiary of Hanger Orthopedic Group Inc.
Orthotic Prosthetic Center provides prosthetics which is the profession of providing artificial limbs (prostheses) for people who have a limb loss or deficiency of an upper or lower extremity and prosthesis may be needed to accommodate a birth deficiency, traumatic injury, or the complications of an illness such as cancer or diabetes. It also provides orthotics which is the art and science of designing, fabricating, and fitting orthopedic braces or orthoses that may be needed because of birth deficiencies (such as spina bifida, cerebral palsy, or brittle-bone disease), as a result of accidents that have impaired function (such as spinal cord injuries, cartilage or ligament tears, head trauma), or when age or disease has taken its toll (such as stroke, poliomyelitis, arthritis).
Orthotic Prosthetic Center provides custom-made prosthetic devices such as lower extremity prostheses, upper extremity prostheses, myoelectric prostheses, hydraulic knees, energy-storing feet, etc. Its orthotic devices include: ankle foot orthoses, knee-ankle foot orthoses, knee braces, spinal braces, thermoplastic and conventional orthoses, etc.
Sensatex is a life science technology company focused on the development of Smart Textile Systems. It is focused on developing its Smart Textile platform in a manner that will allow utilization of the technology in multiple applications useful for the healthcare, life sciences, and government industry. The company was founded in 2000 with a goal not only to develop multiple means for collecting information from the body, but developing the systems to permit the capture, monitoring and interpretation of the information.
Sensatex's first product SmartShirt is a patented wearable Smart Textile unisex T-shirt designed to acquire physiological information and movement data from the human body. The System collects analog signals through conductive fiber sensors and passes them through a conductive fiber grid knitted in the T-Shirt. A textile connector passes the analog signals to a small personal controller held in a pocket on the shirt. The personal controller digitizes the signal and transmits the signal to a Bluetooth or Zigbee receiver connected to a base station where the information is collected, displayed and/or stored. Heart rate, respiration, and body temperature are all calibrated and relayed in real time for analysis.
Vapotherm is engaged in the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs and improve quality of life for patients.
Vapotherm's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification. The company uses its patented membrane transfer technology to saturate a stream of air and/or oxygen, the Vapotherm(TM) system is able to generate a high flow of warm vapor. This warm humid gas is administered to the patient via nasal cannula, resulting in the delivery of the maximum amount of humidity deep into the patient's airway with minimal condensation or dilution with room air. These attributes - high flow, vapor humidity and warmth permits potential treatment applications in a broad range of chronic lung diseases and airway inflammations as well as other, non-respiratory indications.
Vapotherm's products include: Vapotherm 2000i, a respiratory therapy device that allows high flow of breathing gases to be delivered by a narrow tube such as a nasal cannula or other patient interfaces, using patented membrane technology to warm and saturate the gas stream; Precision Flow(TM), a high flow heat and humidification device for the non-invasive delivery of inspired gas flows from 1 to 40 liters per minute; FlowrestÂ®, high flow therapy device designed specifically for homecare and other low acuity environments; and Insolare(TM), next step in developing precision delivery of High Flow Therapy.
Vapotherm has collaborations with Acuity Medical, Inc., Universal Hospital Services, Inc., Bemes, Inc., Northeast Ventilator, Inc and O.E. Meyer Co.
With the emergence of portable electronics and universal connectivity, Audio·Dontics was founded with the belief that the age of ubiquitous "wireless" computing has arrived. Since its inception, Audio·Dontics (formally ES Comms) has been researching and developing new innovative technologies that make the vision of wireless computing and communications a reality.
Audiodontics was founded with the belief that through the use of miniature electronics, a paradigm shift can occur which will allow novel electronic devices to be worn in the mouth. These devices can be developed to provide diagnostic and therapeutic solutions to vexing medical problems. Alternatively they can provide a means wireless voice communication and ubiquitous computing. Audiodontics envisions that through miniature electronic products, a new combination of the dental and medical fields will evolve which will result in new drug delivery methods and treatments for disorders as varied as hearing loss, speech pathology, and sleep apnea.
BOSS Medical LLC was founded in 2011 by biomedical engineers in the Johns Hopkins University Center for Bioengineering Innovation and Design as well as leading spinal surgeons from the Johns Hopkins Medical Institute. This strong team brings together the technical and clinical skills and experiences necessary to develop our technology. Furthermore, BOSS Medical LLC is working with seasoned lawyers, entrepreneurs, business experts and physicians through its vast network, which is key to the company’s ability to bring the product to market.
BOSS Medical LLC was established with the mission of developing new orthopaedic technologies that improve clinical outcomes while decreasing healthcare costs compared to current procedures and devices. Currently, the company is developing a novel surgical device that will enable surgeons to use gold standard autologous bone graft material. Current bone graft solutions are suboptimal in terms of efficacy, safety, and cost. BOSS Medical aims to provide the optimal bone grafting solution in order to improve the lives of our patients worldwide.
Infinite Biomedical Technologies, LLC (IBT) is a medical device company dedicated to creating innovative and useful solutions in prosthetic technology. Our vision is to solve important prosthetic problems through first-hand feedback and by translating our research discoveries into prosthetic products through commercialization. Our mission is to become the leader in pushing the boundaries of new technologies for upper and lower limb prosthetics.
Best Medical International, Inc. is engaged in serving the medical community with the highest quality products. It encompasses a family of trusted companies and organizations with a proven track record of quality and service in external beam radiation therapy, brachytherapy and vascular brachytherapy. The company was founded in 1977 by Krishnan Suthanthiran, with a mission to uphold its reputation for excellence in the healthcare field by developing, manufacturing and delivering cost-effective, high quality products to benefit patients around the world. Its companies include: Best Vascular Inc., Best Medical Belgium, Best Theratronics Ltd., Best Nomos, Arplay Medical, etc.
Best Medical's products has application in the fields of cardiology, neurology, urology, gynecology, radiology, adult/pediatric, radiation therapy/branchytherapy and medical & health physics. The company's products categories include: GYN Applicators & Accessories, HDR Catheters & Accessories, Patient Markers, Radioactive Seeds & Sources, Seed Implant Accessories & Needles, and Steppers & Stabilizers.
Best Medical has agreements with BSD Medical Corp and Nordion Inc. (formerly MDS Inc.).
Biaera Technologies, LLC is a provider of aerobiology-related equipment and program building services. The company was founded in 2003 by Justin M. Hartings.
Biaera's services include: Budgeting & planning for program development, Complete integration of hardware components, Operational readiness checklist for building an aerobiology program, Aerosol technique training, Equipment calibration, SOP development for aerosol procedures, SOP development for decontamination & maintenance of chambers, gloveboxes, etc, Biosafety program development for aerosol studies and Facility design.
Biaera's products include: Aerosol generators and samplers, Aerosol challenge chambers (head only, nose only, and whole body), AeroMP - USAMRIID patented aerosol control system and Turnkey aerosol systems for aerobiology.
BioElectronics Corporation is a medical device developer and manufacturer of advanced medical devices. Its vision is to provide highly effective and safe technological solutions to people and make their lives pain-free.
BioElectronics' technology is a miniaturized medical device that delivers continuous electromagnetic therapy to restore damaged cells. Applied post-surgically or to an injury, its technology quickly relieves edema, inflammation and pain, providing comfort to a patient while reducing bruising and speeding up the onset of natural healing. Its technology stabilizes the leaking cell membrane by recharging the membrane. Its products include: ActiPatchÂ® to relieve from Musculoskeletal Pain; RecoveryRx(TM) for the treatment of Post Surgery Pain and Edema; and Allay(TM) to relieve from Menstrual Pain. The company's HealFast(TM) is a drug-free therapy for horses, cats and dogs that reduces swelling and pain while it speeds healing of muscle and tendon injuries, sores and incisions.
BioElectronics has partnerships with Lemmy's Global Markets Nig., Ltd., Unior Bionic d.o.o., OMEC B.V., YesDTC Holdings, Inc. (formerly PR Complete Holdings, Inc.), Piramal Healthcare Limited (formerly Nicholas Piramal India Limited), eMarkets Group, Vitalmedic, S. A., Ream Surgical Ltd, etc.
Bioscan is a developer of advanced instrumentation for the detection, synthesis and imaging of radiolabeled compounds used in life science research, molecular imaging, pharmaceutical development and nuclear medicine. It was founded in 1980 by Seth Shulman as a supplier of innovative products for radioisotope detection and analysis in life science, pharmaceutical and nuclear medicine research applications. Its mission is to facilitate early disease diagnosis and accelerate drug discovery by providing innovative technologies for bio-tracer chemistry and preclinical imaging.
Bioscan's patented technology improves screening of drug pipeline candidates over classic in vitro methods by providing more relevant biological data, more consistency, as well as reduced cost and complexity. This unique imaging acuity also makes it possible to translate research results from mouse models of human diseases to human clinical trials - driving increased speed to market for drugs. It provides SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography) imaging systems for preclinical applications. Its tools enable researchers, pharmaceutical and biotech organizations to improve their drug development research using in vivo animal models. br> Bioscan services include: Molecular Imaging, PET/Nuclear Medicine and Life sciences. In the field of molecular imaging, in-vivo preclinical imaging has become increasingly important to academic researchers and especially to those involved in the drug development process. Its Molecular Imaging Products Include: NanoSPECT/CT, HiSPECT, NanoPET/CT, Minerve, Imaging Blog; etc.
Bioscan's life science products include: BioChrom radio-chromatography Software, Iatrobeads, Flow count radio-HPLC Detector, AR-200 radio-TLC Imaging Scanner and Mini-Scan radio-TLC Srrip Scanner. Its pet chemistry synthesizers include: FDG-Plus Synthesizer, F18-Plus Nucleophilic Fluorination System, AutoLoop (Carbon-11, Fluorine-18), MeI-Plus (C-11 methyl-iodide/methyl-triflate) and ReFORM-Plus (Product Reformulation).
BioScan has alliances with Definiens AG, Philips Medical Systems and Imaging Diagnostic Systems.
BioWarn, LLC is a biotechnological research and product development company that brings biological substance detection and pathogen surveillance to the healthcare, pharmaceuticals manufacturing, food-processing, and bio-defense fields. The company intends to provide the technology that power a new generation of infection control products and services.
BioWarn's SmartSense is an affinity-based system capable of directly detecting the binding of ligands and their counterparts as molecular complexes are formed. BioWarn conducts its research and development using both polyclonal and monoclonal antibodies with affinities for specific antigens. Future plans include the use of aptamers, small molecules, and other ligands. Its research areas include Avian Influenza and Nosocomial Infections. Its services include Business Strategy and Prototype Development.
BioWarn's SmartSense product "roadmap" includes the development of increasingly miniaturized configurations over time. Its products include SmartBox(TM) Field, SmartScreen(TM) Hand-Held, SmartSand(TM) iniaturized etc.
Brimrose Corporation of America is the manufacturer of Electro-Optic solutions for the Optical Communication industry, Pharmaceutical and Chemical process-control fields. The company's mission to be the leader in the switching arena by providing high quality solutions to the multitude of switching requirements demanded by today's fiber-optic systems.
Brimrose's new generation of solid-state AOTF-NIR Miniature stainless steel Analyzer is built to be placed directly into the production line. The company offers a broad product line of several high quality acousto-optic components and modules for research, other manufacture industries. Its spectrometers include: Luminar 7030 Miniature Stainless Steel FreeSpace NIR Analyzer, Luminar 6000 Miniature Laboratory NIR Analyzer, Luminar 5030 Miniature "Hand-held" NIR Analyzer, Luminar 4030 Miniature Free Space(TM) Process NIR Analyzer, Luminar 4020 Miniature Thin Film NIR Analyzer, Luminar 3077 Tablets NIR Analyzer, Luminar 3076 "Seed Meister" NIR Analyzer, Luminar 3070 Bench Top Laboratory NIR Analyzer, Luminar 3060 Process NIR Analyzer with Built-in Multiplexer, Luminar 3030 Free Space(TM)NIR Analyzer, Laboratory Luminar 3030 Free Space(TM) NIR Analyzer, Luminar 3010 Process NIR Analyzer, etc.
Bunton Instrument Co Inc is specialized in supplying, servicing and repairing microscopes and microscope accessories.
Bunton Instrument's product portfolio includes: Led Transmitted Light Fluorescence microscopes - ideal systems for clinical fluorescence microscopy or retro-fitting existing microscope for fluorescence; Microinjection devices for DNA / Transgenics and ESC procedures; Peltier-Cooled Ccd Digital Camera; Digital Photomicroscopy Sans PC; 3.0MP Color CMOS Camera; XGA True Color RGB Camera; 9MP Color CMOS Digital Camera;SXGA CMOS Color Cameras; etc.
CHEMetrics, Inc is a supplier of water analysis instruments and kits that provides faster, simpler, safer solutions to water analysis needs.
CHEMetrics' platform technologies include: Visual Colorimetric Analysis, High Range Visual Colorimetric Analysis, Instrumental Colorimetric Analysis and Titrimetric Analysis. The company's products include: V-2000 Multi-Analyte Photometer, Photometer Model V-2000 is an advanced portable microprocessor-based LED colorimeter that automatically tests pre-programmed analytes using CHEMetrics Vacu-vialsÂ® self-filling, pre-measured ampoules; SAM Single Analyte Meters, Single Analyte Meters provide unprecedented economy, simplicity, and accuracy for dedicated photometers; and Dedicated Instruments - pH Meter (with Double Junction), Conductivity Meter, TDS Meter (Total Dissolved Solids) and Turbidity Meter.
CSA Medical, Inc. is a medical technology company engaged in advancing the proven science of cryotherapy.
CSA Medical's CryoSpray Ablation system uses a patented technology to deliver liquid nitrogen through a catheter in a standard endoscope. This system of repetitive freeze-thaw cycles destroys unwanted tissue, allowing new tissue to regenerate in its place. Its CryoSpray Ablation procedure is a simple outpatient procedure that requires minimal time (20-30 minutes) to complete.
CSA Medical's CryoSpray Ablation system removes diseased tissue by rapidly freezing and thus destroying the unwanted tissue. Following treatment, the frozen tissue dies and sloughs (falls) off allowing new tissue to regenerate in its place. Its CryoSpray Ablation therapy is unique in its ability to treat tissue of many shapes and sizes and has been used to effectively treat skin, breast, liver, cervical, prostate and lung tissue.
Cytonix, LLC engaged in the manufacture of hydrophobic and oleophobic coating and additive products for life sciences, electronics, aerospace and communications. It was founded in 1985 by Elaine Lanza, Bruce Golden, Richard Schneider, Randal Armant and James Brown as CytoFluidics, Inc.
Cytonix's coating products include: FluoroPel(TM)- for hydrophobic, oleophobic and superhydrophobic suspensions and inks are based on polyperfluoroalkyl and perfluoropolyether polymers, having applications in health care, electronics, information, defense and aerospace; FluoroTac(TM) Perfluoro-Polyether (PFPE) adhesives- resistant to organic solvents and adhere to any surface, including polyolefins and PTFE over a broad temperature range; Fluorothane(TM)- for hydrophobic and super-hydrophobic fluorourethane coatings that have been proven to effectively reduce rain attenuation in aircraft, marine and ground radar and microwave communication systems; and FluoroSyl(TM) Perfluoro-Polyether (PFPE) and perfluoro-alkyl fluorosilanes- provide lubricity, water and oil repellency and fluoropolymer adhesion to metal and oxide surfaces. Its products FluoroPel, FluoroSyl, Fluorothane and FluorN are manufactured using telomer and perfluoropolyether chemistry. Its devices include: Fluid Transistor(TM)- For digital micro-manipulation of chemical & biological fluids; â€˜-Cytometer(TM)- Disposable, precision capillary hemacytometers for counting particles and cells and for viewing emulsions; MetaCell(TM)- Resealable chamber and slide with hydrophobic mask for cell culture and diagnostics; â€˜-Tools(TM)- Super-hydrophobic mask on films, slides, cover-slips, large-format plates and devices; â€˜-Plates(TM)- Super-hydrophobic mask on films, slides, cover-slips, large-format plates and devices; NanoArrays(TM)- Micro, nano and pico-scale devices and arrays.
Cytonix formed the subsidiary Genomic Nanosystems to develop, license and commercialize IP in digital genomics in 2006. Genomic Nanosystems has agreement with Sequenom for digital PCR technologies and methods patents. It also has an agreement with National Institutes of Health (NIH).
Danaher Corp. designs, manufactures and markets products and services to professional, medical, industrial and commercial customers. It was founded by Steven M. Rales and Mitchell P. Rales.
Danaher's business segments include: professional instrumentation segment that encompasses two strategic platforms: test & measurement and environmental; industrial technologies segment that encompasses two strategic platforms: motion and product identification; tools & components segment that encompasses one strategic platform- mechanics hand tools and four focused niche businesses including Jacobs chuck, delta consolidated industries, Hennessy industries and Jacobs vehicle systems and medical technologies segment that encompasses three key businesses: dental equipment and consumables, life sciences and acute care diagnostics.
Danaher's strategic platforms include: environmental, motion, product identification, test & measurement, medical technologies and mechanics' hand tools. The company's medical technology platform encompasses technologies that are contributing to a revolution in dentistry and providing frontline support for critical care in hospitals. Its medical technology's key brands include: Gendex, Imaging Sciences International, Invetech, KaVo, Kerr, Leica Microsystems, Ormco, Pelton & Crane, Radiometer, SybronEndo and Vision BioSystems (now Leica Microsystems).
Danaher has agreements with Leica Microsystems GmbH, KaVo Dental Corporation, Abbott Laboratories, Max Planck SocietyMax Planck Innovation, Align Technology Inc, Menarini Group, A. Menarini Diagnostics S.r.l, Promega Corporation, GeneData AG, Ventana Medical Systems Inc, etc.
Dynex Technologies is specialized in microplate analysis. It was founded in 1952 as Cooke Engineering, later in 1968 was renamed as Dynatech Laboratories and ultimately as Dynex Technologies in 1996. The company is a wholly owned subsidiary of Magellan Biosciences, Inc. Its sister companies are ESA Biosciences and TREK Diagnostic Systems.
Dynex designs and manufactures a full range of automated workstations, laboratory instruments, and associated consumables that enable scientists and clinicians to make breakthrough discoveries, earlier, more-accurate diagnoses - innovations to improve health outcomes and enhance life.
Dynex's product portfolio includes: DSX four-plate system; DS2 two-plate system; Agility: Fully automated 12-plate, 16-assay system; Chromalux microplate; Fluorolux HB microplate; and Immulux microplate. DSX four-plate system's advanced automation and precise liquid-handling capability eliminates variations that occur with manual processes. Its DS2 two-plate system is ideal for clinical, research, and industrial labs that enhance their processes through automation. The company's services include: After-sales service & technical support; Design & engineering services; and Product Registration. Â Dynex's partners include: Vircell S.L., Technogenetics srl, Rayal Ltd, Clindia Benelux BV, Corgenix, Inc., Biosna S.A., etc. It is an ISO 13485: 2003 certified.
Filamatic is a division of National Instrument, LLC that provides solutions for liquid filling applications. It serves the pharmaceutical, biotech, healthcare, cosmetic, specialty chemical, personal care, contract packaging and food/beverage industry. It was founded by Sidney Rosen in 1950.
Filamatic's provides customizable solutions for: pharmaceutical / medical, diagnostic / biotech, cosmetic / personal care, food / beverage, household products, chemical specialties and contract packagers. Its product line ranges from semi-automatic Benchtop fillers to fully automated integrated packaging systems that fill liquids of all viscosities into containers of every shape and size. The company's products include: benchtop filling solutions, synchromat filling machine, H automatic horizontal series, V automatic vertical series, spare parts, metering systems (pumps & nozzles), mini-monobloc fill/finish system, filamaticÂ® model UNC automatic unscrambler, etc.
Fusion UV Systems Inc is a manufacturer of industrial UV curing systems. The company was founded in 1971. It is a member of Spectris plc.
Fusion UV Systems has revolutionized UV curing with electrode less lamp systems that last much longer (as much as 8 times longer) and maintain stable output - significant advantages over conventional arc lamps. The company offers a wide selection of remanufactured equipment such as power supplies, irradiators, blowers, lightshields, curing chambers and conveyors. Its products include: Curing Systems - F300S, Light HammerÂ® 6, F450, VPS/I250, F600S, VPS/I600 and Light HammerÂ® 10; Conveyors - Floor Standing Conveyor - DRS-10/12, and Benchtop Conveyors and Accessories; Other Add-ons - Dichroic Reflectors and Power Supply Tower. Its custom products group provides engineering, design, manufacturing, installation and support of custom UV curing equipment for a wide range of applications and lamp technologies.
Fusion UV Systems has partnerships with Elsicon Inc and DVUV HOLDINGS LLC.
GEA Process Engineering Inc. (formerly Niro Inc.) is a full-service company offering engineering, systems, and solutions for powder and liquid processing. It was established in 1974. The company is a division of the GEA Group.
GEA Process Engineering is recognized in the following technologies: liquid processing, concentration, drying, powder processing and handling, emission control, solid dosage forms & sterile products.
GEA Process Engineering is known for innovative processing systems for drying, granulation, agglomeration, coating, evaporation, distillation, crystallization, filtration, liquid processing, filling and aseptic filling, bottling, bottle and PET conveying systems, powder handling and packaging, tableting, mixing, containment, cleaning (CIP) and fermentation.
GEA Process Engineering's products include Spray Dryers, Fluid Bed Processors, Swirl Fluidizer(TM) - agitated flash dryers, Freeze Dryers (Lyophilizers), Mixers & One Pot Processors, Tablet Presses, Membrane Filtration Systems, Fermentors and Bioreactors, Filling & Bottling, Docking Systems & Valves, Powder Handling and Packaging Systems, etc.
Hunter Associates Laboratory, Inc. provides instruments and services available for the identification, measurement and control of the products that appears to the human eye. The company was founded in 1952 by Richard Hunter.
HunterLab's product portfolio includes Benchtop color measurement systems like spectrophotometer and colorimeter systems; On-line instruments like SpectraProbe XE, ColorTrend HT & ColorQuest OL; Portable systems like MiniScan EZ and software like EasyMatch QC, EasyGroup, EasyMatch Coatings, etc . The company's spectrometers include UltraScanÂ® PRO, UltraScan VIS, LabScanÂ® XE, ColorQuestÂ® XE, ColorQuestÂ® XT and ColorFlexÂ®. It's UltraScanÂ® VIS is a visible-range high-performance color measurement spectrophotometer that measures the full range of human color perception.
HunterLab's on-line instruments provide continuous, real-time measurement of the product on a process line. The company's EasyMatch QC software gives flexibility to process, display, analyze and report color measurement results.
HunterLab has accredited with ISO 9001:2008 certification.
Innovative Biosensors, Inc. develops and manufactures rapid testing systems for the detection of pathogens.
IBI's biosensor technology allows for rapid identification of analytes at previously unseen levels of sensitivity and specificity. Its technology is built upon a foundation of a genetically engineered biosensor that allows for extremely rapid testing of analytes, providing high levels of sensitivity and specificity. In addition, the biosensors can be engineered to detect one target or several targets of interest simultaneously and used to perform a wide variety of bioassays.
IBI's technology has been commercialized as BioFlashÂ® for the environmental detection of biothreat pathogens. Additionally, it is developing the biosensor technology in a clinical instrument format beginning with the detection of infectious diseases. Its BioFlash(TM) system is based on the CANARY(TM) (Cellular Analysis and Notification of Antigen Risks and Yields) technology- a diagnostic technology.
IBI has collaborations with American Type Culture Collection, Universal Detection Technology, BioVigilant Systems, Inc, Cambrex Corporation, National Institutes of Health, US Army and Massachusetts Institute of Technology.
Meso Scale Discovery (MSD) develops and markets solutions for multiplex biological assays, including assays for biomarkers, cytokines and phosphoproteins. It is a division of Meso Scale Diagnostics, LLC.
MSD's platform is based on Multi-ArrayÂ® technology, a proprietary combination of patterned arrays and electrochemiluminescence detection, enabling large numbers of measurements with exceptional sensitivity, wide dynamic range and convenience. The company's Multi-Spot plates offer arrays within the well for increased throughput and assay multiplexing. Its Discovery WorkbenchÂ® software provides real-time data visualization for multiplex assays and allow users to create data files for easy export.
MSD's products have been engineered to enable rapid, sensitive, and convenient biological assays for pharmaceutical drug discovery. The company's products include: Assays and Kits - Cell Signaling, Cytokines, Cardiac, Metabolic, Vascular, Fertility, Alzheimer's Disease, Hypoxia, Bone, Assay Development, etc; Instruments - SECTORÂ® Imager 6000, SECTOR Imager 2400, SECTOR PR 400 and SECTOR PR 100; Reagents - Reagent Kits, Read Buffers, Labeled Reporters, Labeling, Reagents and Whole Cell Lysates; and Plates - Imager 6000 Plates, Imager 2400 Plates, PR 400 Plates and PR 100 Plates.
O.R. Solutions, Inc. provides Automated Surgical Slush Systems and Intra-operative Irrigation Solution Warming Systems.
O.R. Solutions systems address the critical needs of the surgical team by allowing them to know the temperature of irrigation fluids at the time they are administered to the patient. The company's products include: ORS-1075 Hush SlushÂ® System, ORS-2000 Series Irrigation Solution Warming System and ORS-6000 Scope Cradle(TM).
Quality Biological, Inc. is engaged in providing products for the molecular biology laboratory (including buffers, and RNA and DNA reagents) and for the cell biology laboratory (including traditional cell culture media the QBSFÂ® range of serum-free media, and products for stem cell culture research and hematopoiesis research). The company was founded in 1983.
Quality Biological's products are categorized into: Amresco Chemicals, Mallinckrodt Baker, Chemicals Sales, Product Promotions, Bacteriological Plates, Bioservices, Bulk Solutions, Cell Culture Media, Custom Manufacture, Fetal Bovine Serum, Gloves, Labware & Equipment, Glassware, Molecular Biology, Non Fat Dry Milk, Special Productions, Stem Cell Media, etc. Its Molecular Biology Products include: Bacteriological Media & Additives, Buffers, Concentrated Stock Solutions, Reagents for Electrophoresis, Salts, minerals and sugars, Solutions for Nucleic Acid Blotting & Hybridization and Protein Blotting and Microarray buffers.
Quality Biological has agreements with JPT Peptide Technologies GmbH and TheraCode GmbH.
Sensors for Medicine and Science Inc (SMSI) is engaged in developing enabling chemical sensing technologies based on fluorescence sensing. It is focused on developing and commercializing transformative glucose monitoring products that enable people with diabetes to confidently live their lives with ease.
Sensor's patented technologies permit highly sensitive detection and measurement of molecules of significant commercial interest to the medical, industrial and environmental communities. Its technology platform enables performance that surpasses that of existing sensor technologies, and permits the development of new sensor applications. The technology is potentially applicable to a wide range of molecules to be measured (analytes), medically relevant analytes, for example, include glucose, oxygen, carbon dioxide, pH, nitric oxide, lactate, and anesthetic gases. The company's fluorescence chemical sensing systems are divided into two key technologies which include: fluorescent indicator chemistry and electro-optical hardware package. It has also developed two distinct hardware platforms that enable a broad range of uses which include: wired design, used in the SMSI Oxygen Sensor is a platform designed to have a direct electrical connection to supporting electronics; and wireless design, used in SMSI Glucose Sensor is a platform designed to draw power and report its measurements via a proprietary telemetry technology.
Sensor's product portfolio includes: SMSIÂ® Oxygen Sensor, a miniature solid-state transducer that uses fluorescence to measure oxygen partial pressure and SMSIÂ® Glucose Sensor, designed to automatically measure interstitial glucose every few minutes, without any user intervention and communicates wirelessly with a small external reader. The company's novel sensor technology may be used to detect other chemical species besides oxygen and glucose.
Sensors's investors include: New Enterprise Associates, HealthCare Ventures, Rho Capital Partners, Anthem Capital, Abingworth Management Limited, Greenspring Associates, and Delphi Ventures.
Shimadzu Scientific Instruments is engaged in providing analytical solutions to a wide range of laboratories. The company is a subsidiary of Shimadzu Corporation.
Shimadzu Scientific offers high-quality products ranging from absorption spectrophotometers to chromatographs. Its product categories include: Laboratory Instruments, Testing & Inspection Machines, Balances & Scales, and Life Science Lab Instruments. Its products include: FTIR Spectrophotometers, Liquid Chromatographs, Spectrofluorophotometer, TOC Analyzers, UV-Vis Spectrophotometers, Hardness Testers, Powders & Particle Size Analyzers, Analytical Balances, Dual-range Semi-micro Balances, Top-loading Balances, Mass Spectrometer Systems, Protein Sequencers, etc. The company's products are used in a wide range of markets including Agriculture, Biofuels, Biotech, Drug Discovery, Environmental, Food and Beverage, Forensics, Homeland Security, Metals, Nutraceuticals, Petrochemical, Pharmaceutical, etc.
Shimadzu Scientific Instruments is engaged in providing analytical solutions to a wide range of laboratories. The company is a subsidiary of Shimadzu Corporation.
Shimadzu Scientific offers high-quality products ranging from absorption spectrophotometers to chromatographs. Its product categories include: Laboratory Instruments, Testing & Inspection Machines, Balances & Scales, and Life Science Lab Instruments. Its products include: FTIR Spectrophotometers, Liquid Chromatographs, Spectrofluorophotometer, TOC Analyzers, UV-Vis Spectrophotometers, Hardness Testers, Powders & Particle Size Analyzers, Analytical Balances, Dual-range Semi-micro Balances, Top-loading Balances, Mass Spectrometer Systems, Protein Sequencers, etc. The company's products are used in a wide range of markets including Agriculture, Biofuels, Biotech, Drug Discovery, Environmental, Food and Beverage, Forensics, Homeland Security, Metals, Nutraceuticals, Petrochemical, Pharmaceutical, etc.
Sonix Inc is a designer, developer, and manufacturer of scanning acoustic microscopes (SAM), for use in FA/QA laboratories, R&D and as part of the production process. The company was founded in the year 1986. It is a wholly owned subsidiary of the Danaher Corp.
Sonix's systems are used for the non-destructive inspection of a variety of materials including semiconductor packages, automotive parts and other advanced components. Its customers come from a variety of industries including semiconductor packaging, component manufacturing, automotive, aerospace, and traditional non-destructive testing industries.
Sonix manufactures and markets 2 primary product lines - Scanning Acoustic Microscopes (SAM), and Non-destructive Imaging Systems (NDT). The scanning acoustic microscope offers semiconductor manufacturers a state of the art, nondestructive imaging tool. The company's ultrasonic imaging systems perform a variety of material analysis including volumetric analysis of voids, inclusions and in-homogeneity, as well as thickness, density, velocity mapping and acoustic impedance measurements.
Taylor Technologies, Inc. is committed to develop, manufacture, market and support quality test kits and reagents used for water testing. It was founded in 1930 as W. A. Taylor & Company by William Taylor, Fred McCrumb and George Miller and later in 1967 it was incorporated as Taylor Chemicals. The company was sold to Paul F. Wooden in 1980 and was renamed as Taylor Technologies, Inc.
Taylor Technologies offers products for the following markets that include: boiling and cooling systems, water conditioning, industrial processing, food processing, waste water, potable water, environmental monitoring, agri/aquaculture, testing laboratories, industrial cleaning etc. The company's product portfolio includes: Phenol Red-2000 Series, Acid Demand Reagent (ADR-2000 Series), Thiosulfate N/10, Calcium Indicator Liquid, Cyanuric Acid Reagent, Orthotolidine, Molybdate Reagent, Thiocarbamate Reagent, Phosphonate Titrating Solution, Cyanuric Acid Standard 50 ppm, Buret Titration Pack, Combination Boiler/Cooling System, Aerobic Bacteria Test Tubes, Color Card Comparator, ETC. It also offers replacement parts that include: Beaker, Stirring Rod, Dipper, Pipet, Calibrated, Lamp, Hose, Case Divider, etc.
Taylor Technologies is an ISO 9001:2008 certified company.
5 Prime, Inc., is a life science company focused on high quality molecular biology products. It was founded in 2006 with a mission to become a leading source for high quality molecular biology products.
5 PRIME is focusing on the key areas of molecular biology, offering a broad portfolio of more than 250 high quality products that can provide a full solution for all steps from genes to pure proteins: nucleic acid purification (DNA, RNA, plasmids), PCR and real-time PCR, cloning and transfection, recombinant protein expression and purification and molecular biology reagents.
5 Prime's products include: 5 PRIME HotMasterMix, 5 x TaqMaster PCR Enhancer, AntioHis Antibody Selector Kit, ArchivePure DNA Blood Kit, ArchivePure DNA Plant Kit, ArchivePure DNA Yeast & Gram-+ Start Kit, Deoxynucleotide Set, Exact Polymerase, PerfectPrep BAC 96 kit, Masterscript Kit, PCR Extender System, Ready PCR DNA Plate kits, SafeXtractor, Taq DNA Polymerase, TetraoHis Antibody, BSA free, X-Gal, Water, Mol Bio grade etc.
Avanti NanoSciences is a bionanotechnology company developing multiplexed, quantitative biomarker detection and monitoring assays and instrument systems for use in drug development and clinical research through human diagnostics. It is focused on the life science market segments that consistently demand new technologies to further research, development and clinical capabilities. It was founded as a spun-out from AT-GC in late 2006.
Avanti's Smart Detection Technology platform offers a unique approach to miniaturizing and integrating life science applications. Its NanoSciences' technology delivers cost-effective, fast, accurate and reproducible results using less sample and no reagents and with minimal user intervention. The company's Life Sciences at Speed of Light (LSSL) technology is built on proven, time tested technology - fluorescent compounds, acousto-optics, nanocomposites, digital signal processing and traditional biochemistry - that have been integrated in a unique way. By using its proprietary NanoBindi technology platform, many steps of conventional applications are eliminated &/or streamlined into single, nanoliter scale procedures. Its BindiÂ® technology is ideally suited to a wide range of applications throughout the life Science research domains, biopharmaceutical product development, molecular diagnostics, clinical trials end point monitoring of biomarkers, microbial detection and monitoring, bioagent detection and monitoring as well as basic research.
Avanti develops a diverse portfolio of products including proprietary instrument systems, domain as well as process specific nanoarray kits to support both research and diagnostic applications, and data analysis software. The company's biopharmaceutical product portfolio is designed to provide solutions to improve drug development life-cycle by improving R&D efficiency, reduce time to market at a reduce cost. Its products include: EndoSense(TM), EndoStripT(TM), and EndoMon(TM) for Endotoxin Management; Rapid Microbial and Viral Detection Tests, Microbial limit Tests, PathAlert: Pathogen screens, Products for clinical end point monitoring of disease and biomarkers. The company's microbial tests are designed to estimate the number of viable organisms present in pharmaceutical components and raw materials.
Bio-Molecular Technology Inc (BMT) provides technical services to investigators at the NIH, industry and academia in areas encompassing immunology, virology, cell/tissue culture, protein chemistry and molecular biology. It was incorporated in 1986 with a goal to provide investigators with quality services tailored to meet their needs.
BMT's services in the area of cell culture/virology include: production of recombinant gene products using culture flasks, roller bottles, bioreactor or spinner flasks, as appropriate; Preparation of recombinant fowlpox or vaccinia virus in mammalian or chick embryo cell cultures, etc. Its additional services include: ELISA, Western Blot Analysis, immunoprecipitation, immunoglobulin purification, affinity chromatography, etc.
BMT's protein chemistry services include: protein purification and quality control by HPLC and other chromatographic methods, electrophoretic analysis including SDS-PAGE, native gel, IEF and 2-D electrophoresis, etc and its molecular biology services include: isolation of RNA, isolation of genomic and plasmid DNA, amplification by PCR, nested PCR and RT-PCR, etc.
BioAssay Works, L.L.C is focused on antibody-based and antigen-based detection technologies, and on their application in lateral-flow immunoassay for both instrumented and visually-read tests. The company was founded by Stephen Mefferd, Leslie Kirkegaard, and Glen Ford.
BioAssay brings laboratory-based, ELISA-like sensitivity to rapid-format, lateral-flow assays, while maintaining field-use product durability and simplicity. The company offers extensive experience in the development of rapid, point-of-care, lateral-flow-format diagnostic assays. The combination of its proprietary concentrated gold sols and its patented C-FLATÂ® (Counter Flow Amplified Test) assay platform contributes to significant savings in development time and money, and speeds time-to-market.
BioAssay's services include: Custom-conjugation services, hybridoma development, and antibody engineering; Assay development; and C-FLATÂ® Counter-Flow Lateral Amplified Test. Its assay development services include: contract assay development, contract manufacturing, antibody development, lateral-flow component optimization, and reagent supply.
BioAssay's products portfolio includes: Human & Rat KIM-1: biomarker assay for acute kidney damage; Hand-held Assay readers for quantifiable lateral-flow assays; Research Assay Kits: rapid tests for detection of E. coli, Salmonella, H. pylori, equine and animal Sarcocystis neurona, and Vaccinia antibody; Dressed GoldÂ®; Naked GoldÂ®; Iso-Gold(TM) Rapid Mouse-Monoclonal Isotyping Kit; Gold-in-a-Box(TM), an easy-to-use kit for preparing highly reactive gold conjugates; Latex-in-a-Box, an easy-to-use kit for preparing latex conjugates; Tell-Tale GoldÂ®, gold-sol impregnated ribbon; and C-FLATÂ® Lateral-Flow Platform, a patented lateral-flow immunodiagnostic device.
BioAssay has been awarded a grant by Maryland Technology Development Corporation (TEDCO) under its Fort Detrick Technology Transfer Initiative (FDTTI).
Biogenova, Corp. is a biotechnology company specialized in particular technologies. Its goal is to provide its years of experience to the public and enable people to not only conduct R&D more effectively, efficiently and at exceptionally low cost, but with rapid turnaround time.
Biogenova's product categories include: Lentivirus, LV-miRNA, Lv-shRNA, Multi-I, Multi- Control, U-Mix and UBEI-41. It offers full ranges of Lentivirus microRNA (miRNA) vectors carrying identified and updated miRNAs, and produces high titer and ready to use Lenti-miRNA with either GFP/RFP tracker or Puromycin, Hygromycin or Neomycin selection. The custom Lentivirus microRNA (miRNA) services can also generate multiple (chain) miRNA cluster in one lentivirus vectors.
Biogenova has developed a unique in-house technology to produce highly purified and concentrated Lentiviral supernatant carrying markers, gene or siRNA of interest. It is ready-to-use for transduce almost all types of cells, dividing or non-dividing, and obtain stable cell lines in about 3 days.
BioServe provides human biomaterial, preclinical molecular services, and research tools to accelerate breakthroughs in genetics, drug discovery, biomarker research, and molecular diagnostics. It was founded in 1989 by Bob Skurla and Ramakrishna V. Modali.
BioServe offers molecular biology reagents, kits and readymade sample plates. Its products include: DNAQuik(TM), ControlMATCH, SNPlates(TM), OncoRNA; etc.
BioServe's services includes: Global BioRepository which offers: Detailed demographic information, including family history for three generations, gold standard clinical diagnostic information, complete drug history, including adverse events, full pathology report, including H& E slides and complete phenotypic data; and Preclinical molecular services like Sequencing Services, Genotyping, DNA and RNA Extraction, Sequencing, DNA Synthesis etc. The company is maintaining Global RepositoryÂ® a comprehensive library of 600,000 DNA, RNA, human tissue samples and human serum samples.
BioServe has partnerships with Fox Chase cancer center, DNA Genotek Phalanx Biotech Group, Baylor College of Medicine, Celera Diagnostics, Celera Group, Celestar Lexico-Sciences, Inc etc.
Cell Trends is a contract research laboratory providing contract laboratory services for the research community. The company was established in 1991.
Cell Trends offers services in the areas of Cell Culture, Protein Expression, Viral Clearance, Molecular Biology and Custom Services. The company's customized services include: Cell proliferation, Cytotoxicity testing of chemicals and growth factors, Media evaluation and development, Custom product production, ELISA assays, and Customized services per protocols.
Cell Trends offers a broad range of contract laboratory services, utilizing tissue culture and virology-based techniques. Its line of products and services include: Viral clearance & process validation studies, Hollow Fiber Bioreactor Systems, HeLa Cell Pellets, etc.
Frederick Innovative Technology Center, 401 Rosemont Avenue
Frederick, MD, 21701 USA
ChromoTrax, Inc is a biomedical research and development company dedicated to developing innovative technologies and products to improve diagnosis and treatment of patients suffering from genetic-based diseases including cancers.
ChromoTrax possesses two proprietary technologies: Repeat Sequence Deplete DNA probes (ReSeD), and Hybridization in Suspension (informally called Cyto-Flo). The functions of it technologies involves detecting chromosome aberrations through use of colors.
Cybrdi Inc is a biotech company and a provider of tissue array products. The company collects various normal and diseased human tissues to manufacture hundreds of tissue microarrays. It enables to identify, verify and validate molecules of diagnostic and therapeutic importance.
Cybrdi produces some types of special TMAs to meet various research needs, which includes normal tissue screen, tumor screen, biopsy specimen, tumor progression, IHC controls, bone marrow plus prognostic TMAs with survival data and other clinical information. It also collects and reposits various fresh frozen and snap frozen specimens in a broad range from normal to different diseased donors. Most of tissues are collected within 30 minutes to ensure the highest and consistent quality.
Cybrdi services include: histo-pathology services, immunohistochemistry, special staining, antibody EC50/IC50 determination, CDC/ADCC assays, custom TMA development and primary cell establishment .
Cybrdi has alliances with BioServe and Genomics Collaborative, Inc. It is IRB compliance and OHRP registered.
CynerGene LLC is a GLP compliant lab that provides laboratory services for scientific researchers from academic, government and industrial communities. The company was founded in 2006 with a mission to generate high quality data using latest technology at low cost. It is a subsidiary of BioReliance Corporation.
CynerGene's team experience and expertise, both scientific and technical, enhance every stage of the process, from experimental design to data generation and analysis. It provides laboratory services for researchers, pharmaceuticals and biotech companies and focused on bringing fine mapping solutions for molecular genomics related projects to the clients. The company's services include: SNP Genotyping Analysis, DNA Methylation Analysis, Gene Expression Analysis, Microsatellite or Minisatellites Analysis, Pharmacogenomic Analysis Services, Nucleic Acid Isolation and Multiplex Cytokine Assay. It extracts and purifies DNA & RNA from a broad range of biological matrices.
DNA Technologies, Inc. (DTI) provides quality products and services to its fellow researchers from pharmaceutical, biotechnology and biomedical research institutions. Its mission is to develop products and services that expedite and enhance scientific research and collaboration in genomics and proteomics.
DNA Technologies' products include: Cloning Kits and Reagents, Electrophoresis Kits and Reagents, Microarray Related Kits, DNA/ RNA Isolation Kits, cDNA Synthesis Kits, DNA Amplification Kits, Tissue ReadyLysates, Pre-Made Western Blots, Immuno Detection Kits, Enzymes, Pure Reagents, etc.
DNA Technologies' services include: Plasmid DNA Manufacturing, DNA/ RNA Isolation, cDNA Library Construction, Genomic Library Construction, DNA Sequencing Oligo Synthesis, Real Time PCR, Gene Cloning, Expression, and Recombinant Protein Purification.
DNA Technologies has an agreement with ZyGEM Corporation Limited. Its affiliate is DNA Technologies Pvt. Ltd.
Frontier Biosciences, Inc. is a provider of full spectrum of drug discovery and development resources to biotechnology and pharmaceutical industries. The company's mission is to become a full-service global partner in all drug development needs.
Frontier BioSciences offer a comprehensive range of toxicology studies to support clinical trials and marketing approvals of pharmaceuticals, biotechnology, and traditional Chinese medicine products. The company offers services like In vivo PK/ADME, In vitro ADME, Bioavailability, Bioequivalence, Biodistribution, Bioanalytical services etc. Its other services include: Method development & validation, Protein binding & tissue distribution, Pre-drug, drug, & metabolites, Small molecules & biologics, and Bio-equivalence in biological matrices.
Frontier Biosciences provides services with accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International and GLP-compliant data management system by PDS Pathology Data System Ltd. The company partners with WestChina-Frontier Pharmatech Co.
Glen Research Corp is engaged in the development and supply of products and techniques for use in DNA and RNA research.
Glen Research offers phosphoramidites and solid supports for the chemical synthesis, modification, labeling, and purification of DNA and RNA oligonucleotides. The company has contributed to the development of a multitude of research techniques, including diagnostic probes after labeling with haptens or enzymes, attachment of oligos to solid supports for affinity chromatography or dot blot assays, and DNA sequencing. It also supports a variety of simple synthetic schemes, which include: preparation of phosphorothioates during routine synthesis using a sulfurization step in place of the routine oxidation step, use of H-phosphonate monomers to prepare phosphoramidate or phosphotriester linkages, and the production of methyl phosphonate linkages using methyl phosphonamidite monomers.
Glen Research produces biotin, fluorescein, psoralen, cholesterol, and DNP phosphoramidites. Its product categories include: Sterling, Other monomers, Minor bases, Modification, Labeling, RNA, Reagents, etc. Its products include: Sterling CE Phosphoramidites, Expediteâ„¢ Instruments, PolyPlex Instruments, Ultramild CE Phosphoramidites, HT RNA Phosphoramidites, LC RNA Phosphoramidites, Biotin Labeling, Fluorescein Labeling, DyLightâ„¢ Dyes, Terminus Modifiers, Fluoro-Pakâ„¢ Purification, etc.
Glen Research has partnership with TriLink BioTechnologies Inc.
GlycoTech is focused on the biological functions and medical applications of glycoconjugates. The company was founded in 1991 with a mission to discover and develop a new class of pharmaceutical compounds based on the biological functions of the interactions between glycoconjugates and their receptors.
GlycoTech's product areas include 1) complex carbohydrates; 2) Synthetic carbohydrate probes - multivalent biotinylated polymers, univalent biotinylated probes, multivalent fluoresceinated polymers, multivalent polymers and sets, sets of carbohydrate polymers; 3) Carbohydrate analogs and reagents - glycoamino acids, sialic acid derivatives, muramyl peptides, acetylated saccharides; 4) Antibodies - anti-carbohydrate, anti-E-selectin; 5) Apparatus - parallel plate flow chambers, wash chamber for static cell adhesion, chamber for cell adhesion on TLC plates; and 6) Supporting Product - Polyisobutylmethacrylate beads.
HeMemics Biotechnologies, Inc. (HBI) is a product development and manufacturing company that provides in-vitro reagents to the health care and pharma industries.
HeMemics' HBI HeMeDri(TM) technology can provide desiccated proteins, cells and thin tissues (biologics), in dried or semi-dried format, for ease of transportation and storage. The biologics are maintained and preserved in the desiccated state and functions return upon reconstitution.
HeMemics offers the following products and services: Desiccated cells available for research and evaluation purposes, Desiccated red blood cells for research and Desiccated red blood cells for standards and quality control; Product and Process development using HeMeDri(TM) technology platform to stabilize temperature sensitive biologics - Needs analysis, Specification development, Customized products and processes to stabilize temperature sensitive products for transportation and distribution, and Process optimization. The company's products include: HeMeDri(TM) H-RBC, HeMeDri(TM) P-RBC, HeMeDri(TM) B-RBC and HeMeDri(TM) 96 well plates with CHO cells.
K D Medical Inc. is engaged in manufacturing and supplying molecular biology products. It was founded in 1996.
K D Medical's products include: agar, amino acids, antibiotic, carbohydrate, drop outs, luria bertani, super broth, terrific broth, biological buffer, buffered saline, super broth, drosophila media, gel running buffers, nematode growth, buffers and reagents, cal tech media, etc.
K D Medical has agreement with LifeStem International, Inc. (formerly CalbaTech, Inc.).
Kalen Biomedical, LLC is a biotechnology company focused on the production of essential products for cardiovascular research. Â Kalen supplies lipoprotein depleted serum media supplement for specialized cell cultures. Its lipoprotein product line includes: native human lipoproteins and oxidized and acetylated low density lipoproteins (LDL). The company's lipoprotein probes offer the convenience of fluorescence or biotin labeled LDL. Its Human Lipoprotein products include: Human Very Low Density Lipoprotein, Human Low Density Lipoprotein, Human High Density Lipoprotein, Oxidized Human Low Density Lipoprotein, Human MultiPoint Ox LDL Kit, Acetylated Human Low Density Lipoprotein, etc.
Kalen has agreements with Nueva Empressa Europea De Distribucion S.L., MingRui Biotech Co., Ltd. Cosmo Bio Co., Ltd., and Precision Technologies Pte Ltd.
KamTek, Inc provides genomic, proteomic and glycomic solutions for systems-biology at molecular, cellular, organism and population levels. The company's mission is to convert newly evolved concepts of basic biological research and resulting technologies in to widely used applications and marketable biotech products.
KamTek's services include custom microarrays (biochip), cell cultures and bio-repository facilities.
KPL, Inc. is engaged in the development, manufacture and marketing of high quality immunochemicals for life science and in vitro diagnostics. It is focused on commercialization of affinity purified secondary antibodies, a valuable tool for biological research and in vitro diagnostic testing. The company was founded in 1979, with a mission to provide protein detection technologies, reagents, and systems with expert support services to life science researchers and commercial partners worldwide.
KPL's products and services include: affinity purified antibodies and conjugates, western blotting kits and reagents, recombinant protein detection and analysis, Elisa kits and reagents immunohistology kits and reagents, sample preparation and protein purification, protein labeling kits and reagents, custom and bulk services, nucleic acid labeling and detection kits, etc. The company's other products include: BacTrace Shigella Species Positive Control, BacTrace Anti-Vibrio Species Antibody, BacTrace Anti-Yersinia Species Antibody, BacTrace Legionella pneumophila Positive Control, BacTrace Anti-Vibrio cholerae antibody, etc.
KPL supplies antibodies and a full line of immunoassay reagents to in vitro diagnostic, biopharmaceutical, biotech and food pathogen test manufacturers around the world. Its reagents are integral components of commercially available human and animal in vitro diagnostic kits, in-process testing protocols, and high-throughput screening applications.
KPL is an ISO 9001:2008 certified company. Its Partners include: Capital Genomix, Inc, Evident Technologies, Inc, Expression Pathology, Inc, LabVelocity Inc. (formerly Biowire.com), Life Technologies Corporation, Martek Biosciences Corporation, New England Biolabs, Inc, QIAGEN GmbH, Qiagen N.V, Syngene, Thermo Fisher Scientific Inc, University of Maryland and VWR International, LLC.
MoleculA is a biotechnology company focused on providing high quality antisense oligonucleotides to researchers. The company was founded in 1993. It is a subsidiary of CalbaTech.
MoleculA develops and sells numerous research reagents for cell transfection, DNA and RNA purification, protein expression, microarray analysis and other fundamental products. The company is focused on gene function solutions using RNAi technology. It has developed new products like Maxfect(TM), Genfect(TM) and Ifect(TM) transfection reagents as well as The Inducer(TM), a IPTG replacement for increased soluble protein production. The company's product categories are - Custom Oligonucleotides, Cationic Lipid Transfection Reagents, Molecular Reagents, RNAi Oligos, etc. Its product portfolio includes: pDsiPHER(TM) shRNA Vector Kit, pDsiPHER(TM)-GFP shRNA Vector Kit, Rally(TM) Genomic DNA Spin Kit, Ifect(TM) - siRNA transfection reagent, etc. The company also offers technical services for antisense, general oligonucleotide storage and handling, and peptide storage and handling.
Otsuka Maryland Medicinal Laboratories, Inc. (OMML) is dedicated to develop innovative healthcare products that address unmet medical needs in various therapeutic areas. The company was established as Maryland Research Laboratories (MRL) and later became Otsuka Maryland Medicinal Laboratories, LLC in 2003 and was incorporated as a separate entity in January 2007.
OMML is the research center for investigating pharmacological actions of Otsuka's compounds. The company conducts basic research to support global clinical studies and engaged in drug discovery in conjunction with Otsuka Pharmaceutical Co., Ltd. in Japan. Its research and development areas include: Cardiology, Cell Therapy, Molecular Research and Technology, Neuroscience, Phosphodiesterase (PDE) and Thrombosis. The company applies cutting-edge molecular biology technologies such as lentivirus-based RNA interference in the discovery of novel therapeutic entities. This includes new technology development, functional gene discovery and drug target identification, high throughput screening assay development, and novel mechanism of action exploration of pipeline compounds, for the treatment and prevention of cardiovascular and thrombotic disorders.
OMML's cardiology research is involved in developing novel pharmaceuticals to treat cardiovascular diseases. Its cell therapy research is involved in exploratory research projects investigating the use of neurostem cell technology in the area of neurodegenerative diseases. The company performs non-clinical experiments in neuroscience to discover and develop novel central nervous system therapeutic treatments for neuropsychiatric diseases including schizophrenia and depression. It develops anti-thrombotic molecules as potential therapeutic drugs for coronary artery diseases. The company also performs functional studies to develop monoclonal antibodies and small molecules which could inhibit the interaction of platelets with the vessel wall to prevent occlusion of the coronary artery.
OMML is a subsidiary of Otsuka America, Inc. (OAI), which is a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd.
Protein Potential LLC provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified recombinant proteins and DNA plasmids for research and development. It also provides process development, documentation, and technological know-how to transition therapeutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.
Protein Potential's services include: Gene cloning and vector construction, clone screening and selection, strain development and expression optimization, strain improvement and expression enhancement, cell bank preparation and characterization, bioreactor fermentation production and optimization, purification process development, analytical assay development, etc. The company's services are: custom-tailored to meet the needs of industry, academic and government researchers. Each project is uniquely designed depending on the client's needs, resources and ability to collaborate.
Protein Potential's competitive advantage is its experience and capabilities to rapidly and efficiently take newly discovered molecules through all of the steps required to initiate a clinical trial. These include initial protein expression, enhanced protein expression, process development for cGMP manufacture, development of analytical assays, transition to a cGMP site, and other processes for investigational new drug (IND) enabling studies. It manufactures, develops and conducts validated assays required to release vaccines for clinical use and assess their immunogenicity in humans (Protein Potential service packages).
Protein Potential has established a research and development program to produce intellectual property and DNA and protein products. It has initiated a program to produce vaccines for SARS, dengue fever, tularemia, Plasmodium falciparum malaria and Plasmodium vivax malaria.
Protein Potential has partnerships with National Institute of Allergy and Infectious Diseases, National Institutes of Health and The U.S. Department of Health and Human Services.
Quanta BioSciences, Inc is engaged in providing best-in-class qPCR reagents enabling sophisticated applications in life science and drug discovery laboratories. It was founded in June 2001 by Ayoub Rashtchian.
Quanta BioSciences' real time PCR and cDNA synthesis reagents define the standard for the reproducibility, specificity and sensitivity needed by researchers using these techniques. It has developed a comprehensive line of qPCR reagents for TaqManÂ® probe detection and SYBRÂ® green detection as well as cDNA, qRT-PCR and PCR reagents for use in applications such as: gene expression profiling, knock-down confirmation, SNP genotyping, biomarker discovery/validation, and array validation. The company is focused on fast cycling, genotyping and gene expression. Â
Quanta BioSciences' product portfolio includes: qPCR - TaqMan Probe Detection and SYBR Green I Detection; qRT-PCR - TaqMan Probe Detection and SYBR Green I Detection; HRM Analysis â€“AccuMelt(TM)HRM SuperMix; microRNA Profiling â€“ qScript(TM) microRNA System, microRNA cDNA Kits and microRNA PCR Assays; cDNA Synthesis â€“ qScript(TM) cDNA Synthesis; and PCR â€“ AccuStart(TM) PCR.
SABiosciences Corporation is a biotechnology company focused on a new and systematic approach to biological research in the post-genomic era. The company was founded in 1998. It is a part of QIAGEN N.V.
SABiosciences' product and services include: Quantitative RT-PCR & PCR Array, MicroRNA, RNA Interface, ELISArray Kits, Chromatin IP, DNA Methylation, Reporter Assays, Biology-On-Array, Transcriptome PCR Array, iPSC Stem Cell, Somatic Mutation PCR Arrays, etc. Its RTy qPCR Products for gene expression analysis include: PCR Arrays (cataloged), qPCR Primer Assays, MicroRNA PCR Arrays, Biomarker Custom PCR Arrays, Genomic DNA Control Assays, MicroRNA PCR Arrays, etc. The company's qBiomarker iPSC PCR Array System is a complete experimental solution that enables quick and accurate reprogramming and validation of different cell fates from induced pluripotent stem cells (iPS Cells or iPSCs).
SABiosciences provides a complete service for genomic and expression analysis that delivers robust and reproducible results. The service core accepts and processes a variety of biological samples and then leverages cutting-edge tools for either pathway-focused or genome-wide analysis yielding superior results for scientists in academic, government and industrial settings.
SABioscience has agreements with Fluidigm Corporation, Promega Corporation, SuperArray Bioscience Corporation, etc.
Virion Systems, Inc. (VSI) is a biotechnology company focused on the prevention and treatment of infectious diseases, particularly those involving infants and children.
VSI's core technology is the use of the cotton rat as an animal model of human infectious diseases. It develops an array of cotton rat-specific reagents that will eventually include: both RNA and antibody-based reagents for the detection and quantitation of cytokines, chemokines, immunoglobulins and cell-surface markers. It performs contract research for academic and commercial groups, centered on the use of the cotton rat. In addition to research on prevention and treatment of infectious diseases, it also undertake contract research involving the use of adenoviruses as vectors for genetic therapy, as the cotton rat is the only small animal permissive for human denoviruses.
Virusys Corporation is involved in custom antibody development from patient's antigen. It can even use an amino acid sequence from patient's protein to synthesize an epitope and develop an antibody to it. It offers rabbit, chicken, goat, sheep and llama in addition to murine monoclonals. It develops antibodies for cytomegalovirus, Epstein - Barr virus, herpes simplex 1, 2, herpes virus 8, influenza and Varicella zoster.
Virusys offers custom services which are laboratory services performed for custom applications such as a recombinant protein required and monoclonal antibody produced and purified or maybe as simple as getting some of the experimental product lyophilized. It services include: antibody development and production, antibody purification and conjugation, protein purification, protein expression, peptide synthesis, lyophilization, ELISA development and western blot strips.
Virusys has developed a highly sensitive and specific enzyme immunoassay for the detection of Influenza B nucleoprotein antigen in complex sample matrices. The assay can be completed in less than 1.5 hr. and contains only one wash step. Influenza B virus is predominantly a human pathogen, although it has been found to infect seals. The limited host range of influenza B and a slower rate of mutation than influenza A appears to preclude development of influenza B pandemics, but influenza B is a significant human pathogen and on an individual basis, infection may result in death.
Maryland Tech. Dev. Ctr.
9700 Great Seneca Highway
Rockville, MD, USA
AlphaGenics Inc. commercializes genomics science with scientifically-based products aimed at the consumer lifestyle market. Its vision is that people will buy gene-based products that let them feel better about themselves and make them happier.
AlphaGenics leverages the technological advances taking place in biotechnology, computers and telecommunications that enable businesses to develop and deliver focused, personalized products wrapped around a person's normal genes. These technologies include high density microarrays that measure thousands of genes, powerful computer processing with mass storage capabilities that permits the capture, storage and real-time processing of massive amounts of relevant lifestyle and health data about each person, and wireless-cellular technologies that permit virtually instantaneous information exchange anywhere, anytime.
AlphaGenics' JeneJuice(TM) is a personalized beverage, where the ingredient selection and amounts are based upon a person's specific genetic chemistry and adjusted to match the customer's lifestyle goals and consuming purpose. Its MyGene DaVinci(TM) is the first DNA test that exclusively identifies genetic map for normal functions such as dance, creativity, how food tastes, athletics, personality and weight control and provides valuable information about a person's genetic tendencies and strengths. The company's product development uses systems integration approaches where the data is about a person's genes, and the integrated technologies include methods to simultaneously identify and measure thousands of genes in a person, microelectronics, computer processing and storage, and telecommunications.
AlphaGenics has partnerships with: Grant Life Sciences and Ariadne Genomics.
Brassica Protection Products LLC develops and markets scientifically-proven, highly-effective, cancer-protective foods, functional foods, nutraceuticals and pharmaceuticals. It was founded in 1997 with a mission to provide scientifically-sound, cancer-preventive products to the public as functional foods, food ingredients, supplements and pharmaceuticals.
Brassica's product line offers BroccoSproutsÂ® which are the only products that guarantee a consistent level of sulforaphane GS, a natural compound found in broccoli and other cruciferous plants that support the body's own antioxidant function;, SGS(TM) activates the body's own natural antioxidant defense system, including Phase 2 Detoxification enzymes. Its teas are available in four Chinese Sencha green tea flavors, and two Chinese black tea flavors.
Brassica's partners include: Caudill Seed Company and Xymogen.
Martek Biosciences Corporation is engaged in the research and development of nutritional products derived from microalgae and fermentation technology. The company was founded in 1985 and is committed to the discovery and commercialization of life-science based products that promote health and well-being throughout life. It was acquired by Royal DSM N.V. on 21 December 2010.
Martek Biosciences' research and development is focused on identifying and creating new and valuable commercially viable products for the nutraceutical, pharmaceutical and functional food markets. The company is also investigating nutrients and bioactive compounds that provide benefits in the area of inflammation, cognitive function and cardiovascular health. Its Clinical Research group is studying additional potential health benefits of DHA, with a focus on the possible roles of DHA in promoting optimal brain development and cognitive function beyond infancy into childhood, improving cognitive function, and reducing the risk of certain types of neurodegenerative diseases, including Alzheimer's.
Martek Biosciences has developed two fermentable strains of microalgae which produce oils rich in docosahexaenoic acid and a fungus that produces an oil rich in arachidonic acid (ARA). The company's life'sDHA(TM) is a vegetarian source of docosahexaenoic acid and life's ARA(TM) is a source of arachidonic acid.
Martek Biosciences supplies life'sDHA(TM) and life'sARA(TM) for products in following categories - 1) Infant Nutrition: infant formula; 2) Prenatal Nutrition: Prescription prenatal supplements co-packaged with DHA capsules and Over-the-counter (OTC) DHA capsules; 3) Child & Adult Nutrition: life'sDHA(TM) is used in numerous food categories such as dairy products, beverages, bakery confectionary, extrusion products, spreads, dressings and processed meats; and 4) Animal Nutrition: DHA GOLDÂ®S17-B, DHA GOLDÂ® Original and DHA GOLDÂ® C15-P are a source of DHA omega-3 for companion animals, equine, livestock and aquaculture.
Martek Biosciences has partnerships with China Mengniu Dairy Company Limited, BP p.l.c., General Mills, Inc., Fonterra Co-operative Group Limited, The E.T. Horn Company, Milk Powder Solutions Pty., Ltd., Hero AG, Puleva Food, S.L., Lactalis Nutrition Sante, Ragasa Industrias S.A. de C.V. etc.
IGENE Biotechnology Inc is focused on the development, production and marketing of natural astaxanthin for human and animal nutrition. It was founded in 1981 by Robert Austin Milch and William T. Hall. The company's vision is to focus on high growth markets and seek high growth rate in terms of turnover and shareholder value.
IGENE's natural astaxanthin is used primarily as a source of pigment in fish feed for salmonids, but is also used in applications for feed to shrimp, poultry and coloring of egg yolk. It has a focused R&D program with the goal of developing new ground breaking ingredients within feed and nutraceuticals field. Through the use of state-of-the-art fermentation technology, physical and chemical separation technology, and related chemical and biochemical engineering technologies, the company has developed proprietary processes to convert selected agricultural raw materials into commercially useful, cost effective, and environmentally friendly natural alternatives to synthetic products.
IGENE provides research and development services for microbial strain improvement and fermentation process development and scale up from shake flask, to pilot plant, to commercial sized fermentors. The company also provides analytical chemistry services for identification and quantization of carotenoids in foods, feeds, and animal tissues, including verification of wild versus farm raised salmonids.
IGENE has formed joint venture with Archer Daniels Midland.
Imagilin Technology is a biotechnology company specializing in products and technology development for human and animal health and nutrition. The company was founded in 2003.
Imagilin's products include NutriLotsT - nutraceutical supplement for humans, MitoMaxÂ® - probiotic product for dogs, cats, and small animals, MitoHorseT - probiotic product for horses and ponies, MitoFishT - probiotic and prebiotic product for fresh and saltwater fish, MitoSwineT - probiotic product for swine etc.
Imagilin has established collaborative research projects with the Walter Reed Army Institute of Research, the United States Department of Agriculture (USDA), ARS, Beltsville, the University of Maryland, and Hood College.
IRAZU Biodiscovery, LLC (IB) discovers and develops nutraceuticals and pharmaceuticals that mimic the age-decelerating effects of caloric restriction (CR). The company was founded in 2000.
IRAZU has discovered biochemical trigger mechanism that involved searching for an upstream metabolic trigger, a biochemical "switch" that would turn on events at the molecular, cellular, tissue, and organ levels to induce CR-protective benefits. Caloric restriction (CR) is defined as the practice of undernutrition without malnutrition. It is recognized as the only paradigm that has been demonstrated through experimentation not only to extend life span in a variety of species, but to decelerate the onset of age-associated diseases. CR has been shown in repeated experiments to extend mean and maximum life span, decelerate the rate of aging, and inhibit the onset of a number of life-shortening diseases in laboratory animals. The biological mechanism involved in CR protection will provide the means of retarding chronic disease and extending maximum life span in humans.
IRAZU's discovery led to the economic impact on health care and its commercial value would be substantial, with its applications in geriatric medicine, preventive medicine, sports medicine, surgery, and national defense.
Konsyl Pharmaceuticals, Inc. is engaged in providing psyllium products to the consumers. The company is acquired by Pharmaceutical Formulations, Inc. on May 16, 2003.
Konsyl Pharmaceuticals' products are based on natural psyllium fiber supplement. Psyllium fiber is indicated for treating conditions such as constipation, diarrhea, hemorrhoids, diverticular disease, Irritable Bowel Syndrome (IBS), high cholesterol and Type 2 Diabetes. Its product portfolio includes: Konsyl Original Formula 300g, Cholestwin, Konsyl Bladder Control, Nouristor - Step 1- Purify, Nouristor - Step 3 - Restore, On-The-Go Pack (psyllium caps, 30's packets and shaker cup), Konsyl Shaker Cup 6-Pack, Konsyl Easy Mix 300g, etc. Its Konsyl Original and Konsyl Easy Mix psyllium fiber products are all natural, gluten-free and contain no sugar or sugar substitutes.
Medifast Inc is engaged in the production, distribution and sale of weight management and health management consumable products. It was founded in 1980. The company's operations are primarily conducted through its five wholly owned subsidiaries which include: Jason Pharmaceuticals; Jason Properties; Jason Enterprises; Seven Crondall; and Take Shape for Life, Inc.
Medifast markets its product under brand names including Medifast, Take Shape for Life, Hi-Energy Weight Control Centers, and Woman's Wellbeing. The company sells its products and programs via four unique distribution channels which include: 1) the web and national call centers, 2) the Take Shape for Life personal coaching division, 3) medically supervised Medifast Weight Control Centers, and 4) a national network of physicians.
Medifast has collaboration with Hi Tech Pharmacal Co. Inc.
Nutricia North America (formerly SHS North America) is a specialized medical nutrition company. It was established in 1983. The company is part of the Medical Nutrition Division of Groupe Danone, Paris.
Nutricia's products include Hypoallergenic/Gastrointestinal - Neocate Nutra. E028 Splash; Metabolics - XMet Maxamaid, Milupa HOM 2; Neurology - KetoCal 4:1Â®, KetoCal 3:1Â®; Low Protein Foods - Loprofin, Milupa etc.
Nuvilex, Inc. is engaged in the development of nutritional green products. The company was initially established on October 28, 1996 as DJH International, Inc. later changed its name to eFoodSafety.com, Inc. following its October 16, 2000 acquisition of Global Procurement Systems, Inc. It was finally named as Nuvilex, Inc. on March 18, 2009, with a mission to manufacture and market products that are good for people and planet.
Nuvilex' product portfolio includes: Cinnechol(TM), a natural nutritional supplement that helps body to normalize cholesterol and triglyceride levels; Cinnergen(TM), a liquid whole food nutritional supplement that enhances diet by providing the vital nutrients; Cinnsational(TM), a liquid whole food nutritional supplement that proactively eases the hangover symptoms; Reme-Flu(TM), a unique two part homeopathic medicine for preventing and treating symptoms of flu including fever, aches and pains, chills, runny nose and cough; Oraphyte(TM), an all-natural nematocide that is highly effective in combating bacteria harmful to grass and plant growth; Talsyn(TM), a lipid-peptide compound used for the management of keliods, hypertrophic scars, erythema and surgical incisions; etc. Its line of nutritional supplements is formulated to naturally improve cardiovascular, metabolism and daily health.
Nuvilex has agreements with Legacy Biotechnologies, Inc., GGS Holdings, Inc., University of Minnesota, E. I. du Pont de Nemours and Company, etc.
Sigma-tau HealthScience USA is the manufacturer of two key aminocarnitineÂ® ingredients such as arginocarnÂ® (brand of acetyl-L-Carnitine alginate dihydrochloride) and glycocarnÂ® (brand of glycine propionyl-L-carnitine hydrochloride). The company is a wholly owned subsidiary of the pharmaceutical group Sigma-tau Industries SpA.
Sigma-tau HealthScience has expertise in the therapeutic areas such as cardiovascular, cognitive, cellular metabolism and mitochondrial functions. The company has created a number of proprietary molecules and they are used in health supplements.
Sigma-tau HealthScience provides Carnitine products that are nonprescription medicines and dietary supplements involved for supporting the normal functions of the body. The company's L-Carnitine products include: glycocarnÂ® for sport, glycocarnÂ® for cardio, arginocarnÂ®, L-tauroÂ®, lysurgeâ„¢, carnishieldâ„¢, duracarnâ„¢ and livingtonicsÂ®. Its products are available in number of delivery systems and aminocarnitineÂ® is found in a number of products designed to deliver specific amino acids in one breakthrough formula that enhances the benefits of L-Carnitine and can be delivered in a number of formulations including: capsules, tablets, powders, softgels, etc.
Sigma-tau HealthScience's clients include: GlycoCarn, CarniShield, L-tauro, DuraCarn, LySurge, etc.
Vitaflo USA is specialized in developing unique and innovative clinical nutrition products for the treatment of rare, inherited metabolic disorders and disease related malnutrition.
Vitaflo is dedicated to serve the metabolic community through specialized formulas for disease related malnutrition and rare metabolic disorders, including Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Tyrosinaemia (TYR), and Homocystinuria (HCU). The company understands the importance of dietary therapy for the treatment of amino acid metabolism disorders and has developed a new generation of protein substitutes for such conditions.
Vitaflo's product categories include: PKU Products - PKU express and PKU cooler10; MSUD Products - MSUD gel and MSUD express cooler; HCU Products - HCU express and HCU cooler; TYR Products - TYR express and TYR cooler; MMA/PA Products - MMA/PA express; GA Products - GA Gel; Amino Acid Supplements - Arginine Amino Acid Supplement and Citrulline 1000 Amino Acid Supplement; EAA Supplement; FlavorPac; VitaBite; Pediatric Renal - Renastart; PRO-CAL; Pro-Cal; Vitapro; Vitajoule; etc.
American College of Gastroenterology (ACG) is a college engaged in serving the clinically oriented digestive disease specialist through its emphasis on scholarly practice, teaching and research. The college was founded in 1932 with a mission is to serve the evolving needs of physicians in the delivery of high quality, scientifically sound, humanistic, ethical and cost effective healthcare to gastroenterology patients.
ACG's goals include: To provide continuing medical education to clinicians through scientific publications, meetings and multimedia & web-based offerings; To represent the clinician in national and local health care policy issues to ensure that the best interests of patient care and clinical medicine are served; To promote and provide assistance in education to clinical gastroenterologists and fellows-in-training in cost-effective, efficient, and high quality practice management; To promote, encourage and support clinical research in gastroenterologic disorders through the ACG Institute for Clinical Research; and To be a source of educational information for patients with gastrointestinal disorders and their families and to provide liaison with patient advocacy organizations for those with gastrointestinal and hepatic disorders. The college provides conceptual and financial support for clinically relevant investigative studies.
ACG's ACG Institute for Clinical Research & Education serves as a forum in which to build on the goals of the college. The Institute promotes research in clinical gastroenterology, educates physicians and the public and provides resources to support the future needs of clinical gastroenterology, GI patients, as well as young clinical investigators who as they develop careers in academic gastroenterology, enrich knowledge and treatments in digestive diseases.
Georgetown University is an international research university that embodies its founding principles in the diversity of students, faculty, and staff. It was founded in 1789.
Georgetown consists of several national research centers, including: the Center for Applied Research in the Apostolate (CARA), the Center for the Study of Learning, the Prince Alwaleed bin Talal Center for Muslim-Christian Understanding, Lombardi Comprehensive Cancer Center, the Joseph P. and Rose F. Kennedy Institute of Ethics (KIE), and the Center for Trauma and the Community. The University provides opportunities for students to participate in research and scholarly endeavors, through programs including the Georgetown Undergraduate Research Opportunities, Carroll Fellows Initiative, and Hughes Scholars.
Georgetown's research programs include: Alzheimer's disease (Memory Disorders Program), Advanced Research Computing, Advanced Vehicle Development Program (Fuel Cell Bus Program), Aging (Center on an Aging Society), American culture (Center for Electronic Projects in American Culture Studies), Apostolate (Center for Applied Research in the Apostolate), Biomedical research (National Biomedical Research Foundation), etc; Its Memory Disorders Program is dedicated to provide state-of-the-art clinical services for individuals affected by Alzheimer's disease and related disorders and to conducting research aimed at improving treatment options for Alzheimer's disease. Its oncology department is engaged in discovering cancer risk factors, designing effective prevention strategies, and learning how to detect cancers earlier. The university's Institute for Reproductive Health (IRH) is focused on critical needs in reproductive health, and its research-to-practice strategy that includes working with partners to build capacity for sustainable services.
Georgetown's partners include: Samaritan Pharmaceuticals Inc, MedImmune, Inc. (formerly Cambridge Antibody Technology), AstraZeneca Plc, Cypress Bioscience Incorporated, NeoPharm Inc, etc.
The University of Maryland, Baltimore (UMB) is an academic health and law university devoted to professional and graduate education, research, patient care, and public service. It was founded in 1807 and is a part of the University System of Maryland.
The University of Maryland uses its state-of-the-art technological support to educate leaders in health care delivery, biomedical science, social services and law. It conducts internationally recognized research to cure diseases, improve the health, social functioning, and treatment of the people it serves. The University is committed to ensure that the knowledge it generates provides maximum benefit to society directly enhancing the community. It has seven professional and graduate schools that train the majority of the state's physicians, nurses, dentists, lawyers, social workers, and pharmacists. The University's Office of Research and Development directs its research administration and technology commercialization efforts. Its CITS is the central information technology organization which develops and maintains mission-critical information systems and technologies.
The University of Maryland has collaborations with Amicus Therapeutics, Inc., Inc., Horizon Discovery Ltd, Vironova AB, Countervail Corporation, Gliknik Inc., NeuroNascent, Inc. and etc.
Mission: To create an interactive community of educators, students, researchers, corporations and government representatives where collaborative thinking and scientific discovery advance academic and economic development.
Location: Located minutes outside of Washington D.C., the Johns Hopkins University Montgomery County Campus boasts an ideal setting for academics and for research and corporate endeavors. The Campus is close to I-270, the Shady Grove Metro Station on the Red Line and a Metro bus route.
History: The Montgomery County Campus was established in 1988 as a cooperative venture with the County to provide integrated teaching, research and business opportunities.
The campus is experiencing significant growth, with plans to expand from its current 215,000 square feet to 2.7 million square feet of academic, research and corporate space during the next decade.
The Johns Hopkins University Zanvyl Krieger School of Arts and Sciences created the Center for Biotechnology Education to engage diverse audiences in the world of biotechnology and to prepare the leaders of today, tomorrow, and the next generation for the challenges of the 21st century. By expanding the scope of biotechnology education, the Center for Biotechnology Education is building a pipeline of students and professionals prepared to achieve success in K-12 education, graduate school, and the work environment in the fields of biotechnology, bioinformatics, bioscience regulatory affairs, and bioscience business and leadership.
The Center’s mission is to expand the reach of biotechnology education through three channels:
Graduate Education - Our graduate programs are designed for working professionals – delivering the rigorous and practical curriculum they need to advance their careers or academic ambitions. Johns Hopkins' Advanced Biotechnology Studies (ABS) Program is rooted in the multidisciplinary skills of basic research, drug discovery technologies, bioinformatics, regulatory affairs, and product commercialization. The program offers four master's degrees, graduate fellowships, and certificates. Professional Development – Orchestrating partnerships with industry and government organizations to provide community outreach, professional development, educational opportunities, workshops, research symposia, and lecture series for academia, industry, and the general public. Youth Programs – Inspiring the next generation to explore the world of biotechnology is an important objective of the Center. We developed several hands-on programs for children in elementary, middle and high school that introduce them to this exciting field. Our goals are to increase public awareness and understanding of biotechnology, to inform educators of the resources and programs available locally and nationally, to become a resource center for biotechnology information, to coordinate training workshops for students and professionals, and to support biotechnology training and education locally, nationally, and internationally.
National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for research, training, and education programs to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.
NHLBI stimulates basic discoveries about the causes of disease, enables the translation of basic discoveries into clinical practice, fosters training and mentoring of emerging scientists and physicians, and communicates research advances to the public. It creates and supports a robust, collaborative research infrastructure in partnership with private and public organizations, including academic institutions, industry, and other government agencies.
NHLBI collaborates with patients, families, health care professionals, scientists, professional societies, patient advocacy groups, community organizations, and the media to promote the application of research results and leverage resources to address public health needs. The NHLBI also collaborates with international organizations to help reduce the burden of heart, lung, and blood diseases worldwide.
Walter Reed Army Institute of Research is diverse biomedical research laboratory in the department of defense. The mission of the company is to conduct biomedical research that is responsive to DOD and U.S. Army requirements and delivers life saving products including knowledge, technology, and medical materiel that sustain the combat effectiveness of the war fighter. Its vision is to be the premier DOD biomedical research organization, constantly relevant, integrating basic research and advanced technology that protects, projects, and sustains the war fighter today, invents global medical solutions for the future, and keeps the war fighter on point for the Nation.
WRAIR's core capabilities include: antigen discovery and vaccine development for militarily relevant pathogens, drug discovery to address military needs, pilot production of quality biologicals that conform to good manufacturing practices, testing of candidate vaccines, drugs, and devices in endemic areas to counter infectious diseases, etc.
WRAIR develops and field tested antimalarial drugs, such as mefloquine, halofantrine, and tafenoquine, which provide treatment alternatives for drug-resistant strains. It also works on advanced molecular, genetic, and biomedical technologies to produce candidate malaria vaccines. It launched the Multidrug-resistant Organism Repository and Surveillance Network (MRSN) in response to the recent epidemic of Gram-negative multidrug-resistant organism (MDRO) nosocomial and wound infections in the U.S.
SAIC-Frederick, Inc. develops and applies advanced technologies to accelerate the delivery of new treatments to patients with cancer and AIDS. The company is a wholly owned subsidiary of Science Applications International Corporation and operates exclusively under a single, long-term contract to the Frederick National Laboratory for Cancer Research, part of the U.S. National Institutes of Health. SAIC-Frederick's staff of scientific, technical, and support professionals conducts basic and applied research in cancer and AIDS, and maintains a full suite of advanced technologies in areas such as nanotechnology, genomics, and biomedical imaging.
Advanced BioNutrition Corp (ABN) is a biotech company providing customers and partners with environmentally sustainable, science-based solutions for nutrition, health, and industrial applications. The company was founded in 2001 by David J. Kyle.
ABN has developed a unique expertise in delivery technologies that enables its customers and partners to enhance or improve their product development, processing, or performance. The company's delivery technology: MicroMatrix(TM) Targeted Delivery Systems is used to resolve specific product issues and formulation or processing challenges that improve, enhance, or create new and innovative products and ingredients. Its MicroMatrix(TM) system has applications in industrial, human and animal health, and its areas of application include: Probiotics (bacteria), Oral Vaccines (proteins), and Small Molecules (organic and inorganic chemicals).
ABN's investors include: Arancia Industrial SA de CV, BASF and Emerald Technology Ventures. It has collaboration agreements with Martek Biosciences Corp, University of Hull Wageningen University and Research Centre, The National Science Foundation, MdBio, Inc, etc.
Amulet Pharmaceuticals Inc is a biotechnology company that focuses on developing safer and more effective high-value drugs by engineering nitric oxide release into well-established, commercially successful therapeutics. It was founded in 2001 by Robert Raulli.
Amulet Pharmaceuticals has developed a therapeutic technology, NORTECH(TM) for the treatment of gastrointestinal diseases. The company has also developed a safe method to deliver the nitric oxide topically to the affected tissues in the stomach and GI tract. Its nitric oxide delivery technology, NORTECH(TM) and AMU-301 delivers nitric oxide through a carbon-based (C-based) NONOate (Diazeniumdiolate) group in response to neutral and acidic pH. The company's primary area of focus is in the area of gastrointestinal disorders including: Gastroparesis, Obesity, Enteral feeding in critical care patients, Irritable bowel syndrome, Functional dyspepsia, Wounds, Diabetes therapeutics, Pain therapeutics and Glaucoma.
Amulet's compound, AMU-301, has a microporous hydrophobic polymer backbone where the acid-sensitive NONate groups sit deep in the polymer and are protected from the acidity of the stomach. AMU-301 can be used to treat other gastrointestinal conditions such as obesity, enteral feeding in critical care patients, irritable bowel syndrome, functional dyspepsia. AMU-301 delivers targeted nitric oxide throughout the GI tract. The polymer scaffold of AMU-301 is identical to the scaffold of the approved drug Cholestyramine USP which has a long history of safe clinical use. The same polymer scaffold is also used as a GRAS (generally regarded as safe by FDA) food additive.
Amulet has collaboration with several government and academic laboratories to identify novel IP to in-license as well as maintain access to the latest science and technology. It also has a collaboration agreement with NCI and share materials and data. The company has a collaboration agreement and a sub-contract with Georgetown University Medical Center to conduct research and animal studies in gastroparesis and agreements with several other leading universities.
Ascend Therapeutics, Inc. is a biopharmaceutical company that focuses on the research, development and use of transdermal drug delivery technology to overcome therapeutic barriers, thereby raising the standard of care for previously unmet chronic health conditions. It was founded in 2002 with a mission to develop and commercialize pharmaceuticals that have either greater efficacy, an improved safety profile or increased patient compliance, by leveraging its proprietary Enhanced Hydroalcoholic Gel technology.
Ascend uses its proprietary percutaneous hydroalcoholic gel technology, EHG(TM), to deliver therapy in instances where oral delivery is impossible or undesirable. Its EHG(TM) delivery mechanism allows the company to develop new, more effective therapies for unmet chronic health conditions, such as breast pain, gynecomastia and late-onset hypogonadism.
Ascend's technology allows for transdermal absorption of drugs through this barrier, using a proprietary combination of alcohol, water and a user-friendly permeation enhancer to temporarily loosen the intra-cellular bonds of the stratum corneum. This creates a channel through which the drug can enter the skin. Once the gel dries, the cell bonds tighten again, reforming the barrier membrane and trapping the drug in the skin. Its EHG(TM) Technology creates an 'invisible patch,' by enhancing the penetration of the active ingredient into the skin and allowing the skin itself to become the reservoir of drug release.
Ascend's product afimoxifene gel, an antiestrogen being evaluated for the treatment of cyclic breast pain and other estrogen dependent disorders in premenopausal women. The company's products include: Migranal for the treatment of the acute attack of migraine headaches; Suprax for the treatment of bacterial infections; Andrin for the treatment of late onset hypogonadism; Estrogel for the treatment of menopausal symptoms; Prochieve for the treatment of secondary amenorrhea and TamoGel for the treatment of cyclic breast pain.
Ascend's partners include: Lupin Ltd, Valeant Pharmaceuticals International, Columbia Laboratories Inc, Cornerstone Therapeutics, Inc. (formerly Cornerstone BioPharma, Inc.), PDI Inc and Besins International.
Bacilligen Inc is a biotechnology company engaged in developing vaccines for infectious diseases and technology for biological manufacturing. The company was founded in 2006.
Bacilligen's technologies include: BVS (Bacilligen Vector System/Vaccines) and rMB - Recombinant Mycobacteria/Bladder Cancer. Although based upon bacteriophage (viruses that infect bacteria), the BVS capsids can enter human/mammalian cells where their double-stranded RNA cargo is delivered and expressed to produce proteins (or therapeutic RNA). The company's BVS possesses the utility of mammalian-derived and generated vectors such as adeno-associated virus or adenovirus since it can enter human cells. Its proprietary rMB technology equips the Mycobacteria to more fight cancer cells, and resist interfering (pre-existing) immunity. The company has created rMB product candidates based on the proprietary genetic manipulations it has introduced into strains of Mycobacteria.
Bacilligen entered into a collaborative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to develop a single BVS vaccine against anthrax and plague. The company is funded via two NIH grants to develop BVS-based vaccines for HIV and flu.
Best Cyclotron Systems, Inc. (BCSI) has been established for the design and production of commercial cyclotrons. Its mission is to create technology to provide healthcare options for various needs around the world. The company is a subsidiary of Best Medical International.
BCSI offers radioisotopes and production capabilities for nuclear medicine and radiotherapy with its range of cyclotron systems. Its product list includes BCSI 14p - 14 MeV proton cyclotron; BCSI 25p - 25 MeV proton cyclotron; BCSI 35p - 35 MeV proton cyclotron; BCSI 70p - 70 MeV proton cyclotron, etc. The company provides solutions for PET-CT and molecular imaging radiopharmaceuticals.
BHR Pharma, LLC. is a pharmaceutical research & development company committed to bringing to market products using non-oral delivery systems with an emphasis on unmet and underserved medical needs. The company was founded in January 2008 with a mission to develop a robust pipeline of specialty drugs focusing on unmet medical needs. It's a wholly-owned subsidiary of Besins Healthcare.
BHR Pharma's, Enhanced Hydroalcoholic Gel (EHGÂ®) technology is transdermal delivery system that avoids the gut and first-pass liver metabolism, increasing bioavailability in many instances and avoiding the generation of potentially toxic metabolites. The company's development pipeline focuses on products that use the EHGÂ® technology and other parenteral formulations.
BHR Pharma's product pipeline includes: BHR-100 (i.v. progesterone infusion) in treating severe Traumatic Brain Injury patients; BHR-200 (transdermal estradiol gel) for the palliative treatment of advanced androgen-sensitive carcinoma of the prostate and for the treatment of the vasomotor side effects in men undergoing androgen deprivation therapy (ADT) for prostate cancer; and Afimoxifene gel for women with ductal carcinoma in situ (DCIS) of the breast and also as a treatment for gynecomastia, the overdevelopment of breast tissue in males, and associated breast pain. It's a topical gel with most active metabolites of tamoxifen, using Enhanced Hydroalcoholic Gel Technology (EHG(TM)). The gel is directly applied to the breast for transdermal delivery to the breast tissue.
BHR Pharma is an affiliate of Ascend Therapeutics, Inc.
Capricorn Pharma, Inc. is a specialty pharmaceutical, technology driven company, engaged in development, commercialization and manufacturing of pharmaceutical products - Orally Disintegrating Dosage (O.D.D) forms, Kortabs - modified release dosage forms, and Micro-encapsulations with multiple processes. It was founded by S. Rao Cherukuri, with a mission to increase shareholders value - solid revenue base from development and manufacturing with good profit margins and sustainable growth.
Capricorn Pharma has three business segments which include: specialty pharmaceuticals, consumer health care products and micro encapsulated ingredients. The company's technology platforms and products offer several compelling value propositions to specialty and generic pharmaceutical firms, including superior product performance, claims, convenience, patient compliance and profitability with its state-of-art development center. Its technologies include: Kortabs Modified Release Delivery System (M.R.D) - to optimize drug effectiveness; Orally Disintegrating Dosage Forms (O.D.D); Micro Encapsulations - for taste masking, stability improvement, and region specific drug delivery and for reduction of incompatibility; Enhanced Bioavailability (EAB) for poorly soluble drugs for enhanced drug release and absorption; and Medicated Gums.
Capricorn Pharma has developed five distinct orally disintegrating dosage (O.D.D) forms which include: Rapid Dispersible Tablet (RDT), Rapid Melt Beads (RMB), Disperse Beads (DAB), D-Zolv (DZ) and Healthee Chew (HC). The company has expertise in medicated chewing gums (gum bases, gums and coatings), delivery of drugs, flavors and taste masking.
Capricorn Pharma's OTC product categories include: analgesics, cough, cold and allergies, anti-emetic, gastri-intestinal tract and custom products. Its dietary supplements are categorized into diabetic friendly, sugar free supplements for fiber, weight reduction, stimulants and custom products. Its Oral care products include: breath freshening, plaque reduction/teeth whitening and custom products.
Capricorn Pharma has agreements with International Specialty Products and Teva Pharmaceuticals USA.
Celsion Corp is an oncology drug development company focused on improving treatment for those suffering with highly difficult forms of cancer. The company was founded in 1982 with a vision of using heat to kill cancer and treat other diseases.
Celsion's technology targets localized cancers with high concentrations on chemotherapeutics through the use of its heat activated lipid technology. It develops a liposomal formulation of docetaxel and a number of other liposomal formulations for existing chemotherapeutic cancer drugs. It intends to use various available focused-heat technologies, such as radio frequency ablation ("RFA"), microwave energy and high intensity focused ultrasound, to activate the release of drugs from its novel heat sensitive liposomes. The company has evaluated the liposomal docetaxel formulation in animal studies that demonstrated a statistically significant tumor inhibition effect when compared both to free Docetaxel and a non-heat sensitive formulation. In addition, the company is evaluating in animal studies its heat activated liposomal technology in combination with a peptide ligand that has an affinity for EGF receptors to provide targeted cancer treatments.
Celsion develops a product pipeline of cancer drugs that employ its heat activated liposomal technology. Its products include: ThermoDox plus for the treatment of liver cancer; ThermoDoxÂ® for the treatment of recurrent chest wall (RCW) breast cancer; Liposomal carboplatin for the treatment of cancer; and Temperature sensitive liposome with Docetaxel for the treatment of lung cancer.
Celsion's partners include: American Medical Systems Holdings Inc, Boston Scientific Corporation, Duke University, Fast Track Systems, Inc, Koninklijke Philips Electronics N.V, Medidata Solutions, Inc, National Institutes of Health, The U.S. Department of Health and Human Services, Valentis, Yakult Honsha Co., Ltd and so on.
Chikujee Therapeutics is a biotech company focused on the development of therapeutic targeted nanobindis to capitalize on the enormous opportunity to dramatically improve on marketed drugs or enable the delivery of novel classes of therapeutics and imaging contrast agents. It was founded in 2008 with a mission to bring together the full range of resources for launching a new product lines that make a difference in people's lives.
Chikujee has developed a revolutionary new technology of creating multifunctional nanoparticles that are suitable for in vivo delivery. The technology NanoBindi, offers the ability to convert insoluble or poorly soluble drugs into delivery vehicles allowing them to become soluble and easier to deliver. Its technology also provides a broad variety of routes of administration including intravenous, intra-arterial, inhalational, topical, and oral. The multifunctional NanoBindis are ideal for detection, monitoring of tumors and delivering drugs to the target site. It's Drugs on Target(TM) technology can be used to deliver a broad range of payloads including emerging therapeutic modalities such as RNAi, allowing it to address multiple therapeutic areas and indications. It is developing ultra sensitive detection probes through its Nidan(TM) platform utilizing its multifunctional nanobindi technology.
Chikujee's key priority is to leverage and exploit the potential for its NanoBindi(TM) based Surface Engineered Nano Probes (SENP) or Target Specific Delivery Vehicles (TSDV) technology, while continuing the discovery and development of new products. It has developed proprietary bionanotechnology based product engine that has broad applications in life-sciences, primarily in biotechnology, biopharmaceutical, and medical devices. The company has developed new Biomolecular Oligomeric Silica hybrid (BOSH) molecules and the TSDV drug delivery platform, a versatile system that addresses the diverse requirements for advanced target specific drug delivery.
Chikujee develops a full spectrum of products used primarily in oncology, cardiovascular diseases and critical care. It has created and developed its first oncology product for the treatment of metastatic breast cancer, using its proprietary nanobindi technology. The company's product pipeline includes: NB-PTXL-DTXL, contains docetaxel indicated for the treatment of prostate cancer, breast cancer, head and neck cancer etc; NB-BCNT and NB-METX, a boron neutron capture therapy product indicated for the treatment of brain tumour; NB-ACS-DTXL and NB-ACS-PTXL indicated for the treatment of cardiovascular diseases etc. It is developing an extensive pipeline of disease specific-contrasting agents for MRI imaging which includes further investigation with paramagnetic particles as well as several other promising iron oxide candidates.
Chikujee has an agreement with Alfagene Biosciences, Inc. to utilize its NanoBindi technology in certain research projects.
CytImmune Sciences, Inc. is a nano-medicine company focused on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. It was established in 1988 by Lawrence Tamarkin and Giulio F. Paciotti with a goal to mitigate the risks of drug development and build from these core technologies families of first-in-class therapeutics with accelerated clinical timelines, new commercialization value, and ultimately achieving greater patient benefits.
CytImmune's tumor-targeting technology platform offers the potential to enable and/or expand the clinical benefit of a variety of toxic agents (such as tumor necrosis factor alpha (TNF), interleukins and interferons, monoclonal antibodies, chemotherapeutic agents, etc) which may be used to treat multiple types of solid tumors -- either as monotherapies or in combination with existing standards of care. Colloidal Gold masks the Polyethylene glycol (PEG) masks particles from immune recognition preventing uptake by liver and spleen and the nanoparticles exit circulatory system only at the tumor neovasculature due to leakiness of blood vessels. The TNF targeting molecule on particle's surface binds to receptors causing vascular disruption in and around tumor sites. Its tumor-targeted delivery can be ascribed to the size and composition of the nanoparticles regardless of tumor type.
CytImmune has developed a method to generate fully human monoclonal antibodies (mAbs) using lymphocytes from normal donors. The technology uses the properties of gold nanoparticles to create an "antigen presentation" system, which loosely mimics the natural presentation of antigens by cells. Its human drug candidates include: CYT-6091, (Aurimune) Pegylated Colloidal Gold bound TNF; CYT-21001, (AuriTol) Pegylated Colloidal Gold bound TNF with Paclitaxel; CYT-31000, (AuriCin) Pegylated Colloidal Gold bound TNF with Doxorubicin; CYT-41000, Pegylated Colloidal Gold bound TNF with Interleukin-12; etc.
CytImmune has partnerships with University of Maryland Biotechnology Institute, Boehringer Ingelheim, EntreMed Inc, National Institutes of Health, The US Department of Health & Human Services and OctoPlus N.V.
Genetic Immunity, LLC is a biopharmaceutical company focused on the discovery, development and commercialization of a new class of immunotherapeutic biologics ("Immune Therapies" or "Therapeutic Vaccines") for the treatment of chronic viral infections, cancer and allergy.
Genetic Immunity's proprietary Immune Therapy Platform Technology includes the plasmid DNA-based antigen design, nanomedicine formulation and topical administration targeting antigens to dendritic cells. There are four principal components that comprise its comprehensive Immune Therapy platform technology which are designed to work in conjunction to treat and/or control chronic infectious diseases, cancer and allergy, as follows: Active Pharmaceutical Ingredients (API), Nanomedicine, DermaPrep, and IT - Applied information technology.
Genetic Immunity's lead product candidate DermaVir is used for the treatment of HIV/AIDS, it is a therapeutic HIV vaccine effective in boosting immune responses that kill HIV-infected cells.
Genetic Immunity has collaboration with Aldevron, LLC.
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines.
GenVec's proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Its lead program, TNFerade(TM) represents a novel approach to treating cancer in combination with radiation and/or chemotherapy by introducing tumor necrosis factor-alpha (TNF-alpha). The company is developing TNFerade(TM) Biologic for use in combination with radiation and/or chemotherapy for the treatment of various cancers.
GenVec's TherAtoh Atonal therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. The ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function.
GenVec has collaborations with National Institutes of Health, Cobra Biomanufacturing Plc, Naval Medical Research Center, U.S. Department of Homeland Security etc.
Lentigen Corporation is a biologics company focused on the development and commercialization of breakthrough treatments for human disease. It was founded by Boro Dropulic, with a mission to advance biomedicine and improve human health by the development of biotherapeutics, vaccines, protein therapeutics and tools for discovery research.
Lentigen's Lentiviral vectors (LV) technology platform is widely recognized as the most efficient method for delivery of genetic sequence information into cells to reprogram their function. The ability to efficiently and stably reprogram mammalian cells has numerous uses in biotechnology and biomedicine, including drug discovery, target validation, biologics manufacturing and cellular therapies.
Lentigen is focused on the development of novel biotherapeutics for the treatment of serious diseases with unmet need. Its therapeutic pipeline includes somatic cell therapies, stem cell therapies, vaccines, protein therapeutics. The company is engaged in the development of several vaccine candidates including VLP vaccines for pandemic influenza and Hepatitis C virus infection. Its vaccines are - LG611, a virus-like particle (VLP) vaccine for pandemic flu; LG811, a therapeutic vaccine for seasonal influenza; LG912, a vaccine for Hepatitis C virus infection; LG912, a vaccine for HIV/AIDS. The company's product pipeline includes: LG690, a T cell therapy indicated for the treatment of Graft versus Host Disease; LG631, a stem cell therapy indicated for the treatment of Glioblastoma Multiforme; LG889, a cell therapy consisting of CD34+ hematopoietic stem cells indicated for the treatment of Hemophilia A; etc.
Lentigen Corporation has partnerships with International AIDS Vaccine Initiative (IAVI), PATH (Program for Appropriate Technology in Health), University of Pennsylvania, Case Western Reserve University, University of Toronto, University of Wisconsin, Medical University of South Carolina, Invitrogen, etc.
MaxCyte, Inc is specialized in cell modification technologies to enable the discovery, development, manufacturing, and delivery of therapeutic products. It was founded in 1999 to commercialize flow electroporation technology.
MaxCyte offers its platform technology in two scalable transfection systems, the MaxCyte STX and the MaxCyte GT. Both instruments use its proprietary flow electroporation technology to transfect up to 1010 cells in less than 30 minutes in a computer-controlled, sterile environment. The MaxCyteÂ® STX(TM) leads the way in high performance, high throughput transfection, enabling pre-clinical protein production and awidearray of cost and time effective cell-based assays. The MaxCyteÂ® GT(TM) enables the development of enhanced gene therapy and cell therapeutics by providing unparalleled consistency, scalability, and cell loading transfection efficiencies while avoiding the inherent drawbacks and safety concerns of alternative methods.
MaxCyte's transfection systems are based on a proprietary, fully-scalable electroporation technology. Its electroporation has the unique ability to perform both small- and large-scale transfection of primary cells, stem cells, and cell lines with any molecule(s) of interest including plasmids, mRNA, siRNA, proteins, and cell lysates.
MaxCyte has partnerships with BINEX Co., Ltd, MEDINET Co., Ltd, Sangamo BioSciences Inc, Geron Corporation, Cognate BioServices, Inc. (formerly Cognate Therapeutics, Inc.), Northern Therapeutics Inc., etc.
Meridian Medical Technologies Inc is engaged in the development and manufacture of auto-injector drug delivery systems for the emergency treatment of casualties. The company was founded in 1960 and is a wholly-owned subsidiary of King Pharmaceuticals, Inc.
Meridian Medical Technologies' auto-injectors are designed for emergency medical treatment of chemical nerve agent poisoning. The company's innovative Drug Delivery Technologies include: BinaJect(TM), SoluJect(TM) and TruJect(TM).
Meridian Medical Technologies has developed DuoDote(TM) Auto-Injector, a prefilled auto-injector that delivers atropine and pralidoxime chloride in 1 intramuscular injection. The company's Auto-Injector includes one AtroPenÂ® 2 mg (atropine injection) Auto-Injector, one Pralidoxime Chloride 600 mg (pralidoxime chloride injection) Auto-Injector which allows immediate and portable treatment with two antidotes.
Meridian Medical Technologies' partners include Merck France, Merck KGaA and Merck Sante s.a.s.
Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. Its approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system.
Northwest Biotherapeutics has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company's technology platform, DCVaxÂ®, uses a patient's own dendritic cells, the starter engine of the immune system, which is loaded with tumor proteins or antigens. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. It combines a patient's own dendritic cells (DC) with cancer related proteins, or antigens, to induce immune responses against a patient's cancer cells.
Northwest Biotherapeutics' ProstaView(TM) is a monoclonal antibody-based technology for the in vivo diagnostic imaging of metastatic prostate cancer. ProstaView(TM) antibodies bind to a protein called Prostate Specific Membrane Antigen (PSMA) located on the outside of live prostate cancer cells. The company's three product candidates include: DCVaxÂ®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer; DCVaxÂ®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme and monoclonal antibodies to CXCR4 for the treatment of cancer. DCVaxÂ®-Prostate and DCVaxÂ®-Brain has the ability to significantly delay disease progression, in addition to prolonging patient survival, while maintaining an excellent quality of life. CXCR4 is a monoclonal antibody therapy that targets the functional chemokine receptor.
Northwest Biotherapeutics has alliances with Cognate BioServices, Inc. (formerly Cognate Therapeutics, Inc.), Dako Denmark A/S (formerly DakoCytomation A/S), Inc, Medarex Inc, National Institutes of Health, Protein Sciences Corporation, Synteract, Inc., The National Cancer Institute and The US Department of Health and Human Services.
Novavax, Inc. is a biotechnology company creating vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The company's goal is to rapidly deliver a customized vaccine in the midst of a pandemic.
Novavax' research & development is focused on creating highly potent recombinant vaccines produced via cell culture. The company's proprietary technology platforms include: Virus-Like Particles and NovasomeÂ® paucilamellar vesicles. Its proprietary virus-like particle (VLP) technology builds a structure similar to a virus except for the genetic material required for viral replication. Once injected into the body, VLPs attach to cells and trigger an immune response sufficient enough to protect a person, if they are exposed to the virus.
Novavax targets its research efforts initially on various strains of viral influenza which include: H1N1 influenza referred to as swine flu, H5N1 pandemic influenza, often referred as bird flu, and seasonal influenza. It has created a VLP-based vaccine to protect against human immunodeficiency virus (HIV), the virus that causes AIDS.
Novavax' partners include: Acacia Research Corporatio, Biomedical Advanced Research and Development Authority, Cardinal Health Inc, Division of Microbiology and Infectious Diseases, Esprit Pharma, Inc, Ferndale Pharma Group, Inc, GlaxoSmithKline plc, IntelGenx Technologies Corp, King Pharmaceuticals, Inc, LG Life Sciences Ltd, National Institutes of Health, Organogenesis Inc, Pharmelle, Ranbaxy Laboratories Ltd, SmithKline Beecham Plc, Takeda America Holdings, Inc, United States Department of Health and Human Services, Vivalis, Wave Biotech LLC, Xcellerex, Inc and so on.
NuVue Therapeutics, Inc. (NVT) (formerly Critical Care Innovations, Inc.) is a biotechnology-driven medical device company focused on the development and commercialization of an integrated technology platform for the comprehensive management of soft tissue cancers. Its vision is to always believe in the ability to survive the odds through innovative products dedicated to the continued creation of long-term survival rates. It was incorporated in 1999 as Critical Care Innovations, Inc. and in 2008 its name has been changed to NuVue Therapeutics, Inc.
NVT developed, and brings to market, a totally new and innovative image-guided, site-specific, drug and cryothermally mediated, regimen of cancer therapy for soft tissue tumors. Its platform technologies include: enhanced ultrasound guided visualization, advanced microcapsulated technology and cryotherapeutics technology. Its enhanced ultrasound guided visualization platform technology consists of patented methods and devices for making minimally invasive medical instruments show up brightly under use of Doppler Ultrasound with the ability to be visualized in real-time during any soft tissue medical procedure. Advanced microcapsulated technology consists of patented methods for making miniaturized polymeric microencapsulated capsules with inherently robust biologics capable of delivering diagnostic and therapeutic agents in the body.
NVT's cryotherapeutics technology consists of patented and proprietary methods of using cryotherapeutics - the cooling of tissues for therapeutic purposes. The company has combined its technologies into a novel and proprietary disruptive format of cancer therapy, NuVue's Site-Specific Regimen of Cancer Therapy(TM). It has developed three product lines from its technology platform to fulfill existing unmet clinical needs: 1) NuVue ColorMark(TM) biopsy needles; 2) NuVue BrightMark(TM) tissue site markers; and 3) NuVue CryoChemoAblation(TM) system of soft-tissue cancer therapeutics.
OncoImmunin, Inc. is a biotechnology company that has designed, synthesized, validated and patented a new class of molecules that can serve as fluorogenic protease substrates for enzymatic activity determinations in live cells as well as in serum, in vivo delivery vehicles for oligonucleotides. It was founded in 1994 by Akira Komoriya and Beverly Packard.
OncoImmunin's fluorogenic protease substrate design allows determination of intracellular enzymatic activity using a fluorescence microscope. Determination of activity in buffer solution as well as in human serum can be accomplished using a standard fluorometer, or for large sample throughput, a proprietary high-throughput screening (HTS) system is available.
OncoImmunin's new class of cell permeable fluorogenic protease substrates are PhiPhiLuxÂ® is a novel and unique class of fluorogenic apoptosis assay substrates for the detection and measurement of caspase 3 and caspase 3-like activities in living cells, CyToxiLuxÂ®, PanToxiLux(TM) and GranToxiLuxÂ® is useful to measure cell death exclusively in target cell populations by flow cytometry or fluorescence microscopy, etc.
OncoImmunin has been issued three U.S. patents and one Australian patent on its proprietary design for protease inhibitors and fluorogenic substrates.
Profectus BioSciences, Inc. is a research and development company engaged in advancing the treatment and prevention of chronic infectious diseases. It was established in 2003 with a vision to reduce morbidity and mortality by advancing technologies and developing products that can be used to treat and prevent viral diseases. The company's mission is to "do well by doing good" for humankind and deliver superior returns to its shareholders.
Profectus' discovery and development programs include Therapeutic vaccination and Immunotherapeutics. Its therapeutic vaccination program focused on Hepatitis C Virus (HCV), Human Papilloma Virus (HPV), Herpes Simplex Virus type 2 (HSV-2), and Human Immunodeficiency Virus (HIV).
Profectus has designed multi-pronged approaches to identify inhibitors of NF-kB a focus on inhibiting the p65, a key regulator of immune activated genes. The company has in-licensed two powerful vaccine delivery platforms that can be used either alone or in combination to improve therapeutic outcomes. Its vaccine products include pDNA Vaccines, Vesicular stomatitis virus (rVSV) Vectored Vaccines, Transition-State Vaccines, Genetic Adjuvants and Thermal Stabilizers.
Profectus BioSciences has received 2009 best of baltimore award and 2006 technology transfer company of the Year. The company's partners include: Ichor Medical Systems, Inc, National Institute of Allergy and Infectious Diseases, National Institutes of Health, PATH (Program for Appropriate Technology in Health), PATH Malaria Vaccine Initiative, The National Cancer Institute, The U.S. Department of Health and Human Services, Wyeth (formerly American Home Products Corporation) and Wyeth Pharmaceuticals.
ProSpect Pharma Inc develops, markets and uses advanced technologies and products for the Life Science industries, particularly those related to drug design, vaccine development and metabolic studies.
ProSpect's technologies enable the visualization of molecules of the human body with a much higher resolution than competing techniques. Its core technologies are based on biological materials, principally proteins, amino acids and nucleic acids, which are "labeled" in specific locations with the stable isotopes such as carbon 13, nitrogen 15 and deuterium, and then analyzed by proprietary Nuclear Magnetic Resonance (NMR) methods.
ProSpect's technologies used either by, or in collaboration with, third parties or with investment for in-house drug design programs. The main programs active are in the fields of GPCRs, visualisation of key parts of the HIV-1 genome and analysis of materials for biodefense.
ReGenX Biosciences, LLC (RGNX) is a biopharmaceutical company developing novel therapeutics and research tools based on adeno-associated viral vectors, or AAV vectors. Its mission is to be an innovator in the development of novel therapeutics using AAV vectors to treat diseases with unmet medical needs; to create a platform of novel products and services using AAV vectors to enable pioneering basic pharmaceutical drug discovery and research and to become the leader in the production of high quality AAV vectors for all applications. The company was formed in 2009 as a partnership between Dr. Wilson, the University of Pennsylvania, and GlaxoSmithKline, to develop and commercialize therapeutics and life science research products utilizing Dr. Wilson's proprietary, novel AAV vectors for delivery of genetic material and related technologies.
ReGenX's technology and capabilities can enhance existing products or create entirely new products in a broad range of areas including: Cell therapy (including stem cells), Gene therapy, Gene modulation (e.g., RNAi and microRNA), Genetic vaccines and Protein therapy (e.g., monoclonal antibodies, cytokines). Its AAV vector technology enables the efficient, rapid, safe and specific delivery of genetic material into cells. Once delivered into a cell, the genetic material can use the existing cellular machinery to produce specific proteins encoded by the genetic material. This process may be used to treat disease by initiating normal protein production or gene regulation in cells that may have defects in their endogenous function. Delivery of genetic material may also enable cells to produce more of a certain protein or different proteins than they would normally produce, thereby treating a disease state.
ReGenX is engaged in reagent services, consulting services and research licenses. Its AAV vector applications include: Molecular Therapy, Target Validation, Creating Disease Models, GWAS etc. The company's AAV7 is targeted against Ocular diseases including: Age-Related Macular Degeneration and Leber Congenital Amaurosis; AAV8 is targeted against Metabolic disorders including: Familial Hypercholesteremia, Hurler Syndrome (MPS I), Maroteaux-Lamy Syndrome (MPS VI), Gaucher's disease and Retinitis Pigmentosa - an Ocular disease and AAV9 is targeted against Neurodegenerative disorders including: Amyotrophic Lateral Sclerosis, Parkinson's disease and Alzheimer's disease.
Sirnaomics, Inc. is a biopharmaceutical company specialized in discovering and developing targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology. It was established in 2007 by Patrick Y. Lu, David M. Evans, George J. Ji and Harry H. Yang, with a mission to advance RNAi technology using multi-targeted design of small interfering RNA (siRNA) and nanoparticle-enhanced delivery.
Sirnaomics uses its R4D approach to develop siRNA based therapeutics for significant markets in healthcare. R4D stands for Rapid Design, Discovery, Delivery and Development (of siRNAs for therapeutic development). Using a proprietary algorithm for siRNA sequence prediction against gene target of interest, it can rapidly identify siRNA sequences with Seven characteristics including (1) optimal thermodynamics, (2) enhanced RISC binding, (3) eliminated (or added) immune stimulating motifs, (4) minimized "Off-Target" potential, (5) having homology between human and mouse sequences (to facilitate ease of development), (6) patent searched and (7) no interaction when multiple sequences mixed in the cocktail.
Sirnaomics' delivery technologies allow selection of the best approach to ensure efficient and safe delivery of siRNAs to their target tissues. Its therapeutic programs are categorized into two stages: the programs in development and the programs in discovery. The company's therapeutics areas of interests include: siRNA therapeutics for skin scarless wound healing, respiratory influenza infection and ocular neovascularization diseases. Its pipeline products include: STP702 (FluQuitÂ®), STP601 for AMD and Retinopathy, STP705 (CutasilÂ®) for Skin Scarless Wound Healing (SSWH), STP503 for Breast Cancer, STP801 for Non-Small Cell Lung Cancer (NSCLC), and STP523 for Glioblastoma Multiforme (GBM).
Sirnaomics has collaboration agreements with National Institute of Allergy and Infectious Diseases, The National Cancer Institute, University of Maryland, General Research Laboratory, Inc., etc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company engaged in focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Its vision is to be a leading specialty pharmaceutical company focused on treating CNS disorders. The company wasÂ founded in December 2005 by Jack A. Khattar.
Supernus is leveraging 6 proprietary technology platforms and additional in-licensed technologies that allows the company to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. The company's technologies include: MicrotrolÂ®, SolutrolÂ®, etc. Its technologies are designed to meet specific clinical efficacy needs, permit more convenient and less frequent dosing, enhance patient compliance and improve tolerability in specific applications.
Supernus' product pipeline portfolio includes: Neurology Portfolio and Psychiatry Portfolio. The company's Neurology Portfolio includes: SPN-538 - a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy; and EpligaÂ® - a novel, oral, once-daily, extended-release formulation of oxcarbazepine for the treatment of epilepsy. Its Psychiatry Portfolio includes: SPN-810 - a novel treatment for impulsive aggression in patients with ADHD; SPN-812 - a novel nonstimulant treatment for ADHD; and SPN-809 - a novel once-daily norepinephrine reuptake inhibitor for the treatment of depression.
Supernus has collaborations with Daewoong Pharmaceutical Co Ltd, Depomed Inc, United Therapeutics Corp and Endo Pharmaceuticals Solutions Inc (formerly Indevus Pharmaceuticals Inc; Interneuron Pharmaceuticals Inc).
TissueGene, Inc. is a biopharmaceutical company focused on regenerative medicine therapeutics. It was founded in 1997 by Kwan H. Lee and Woong Yeul Lee, with a mission to improve patient well-being and quality of life. The company aims to combine business savvy, medicine, research and information technology to effectively become one of the leaders in providing novel therapeutics to the health care industry.
TissueGene has developed a proprietary cell technology with applications in the treatment and regeneration of damaged tissues such as cartilage and bones. The company uses a form of cell mediated therapy to deliver therapeutic proteins to damaged tissue, which initiates rapid and permanent repair of injured tissue without the need for surgery. The technology consists of a novel method for inserting a therapeutic growth-factor gene into cells, culturing and stabilizing the genetically modified cells and then injecting the modified cells into damaged tissue via a hypodermic needle. The modified cells then secrete therapeutic growth-factor proteins directly into the injured site, acting like living protein factories, and induce tissue regeneration and repair. This cell technology can be applied in the treatment and regeneration of damaged tissues such as cartilage and bones.
TissueGene has a broad patent base portfolio covering the areas of regenerative orthopedic medicine. Its product TissueGene-C (TG-C), contains transforming growth factor (TGF-beta 1) gene indicated for the treatment of severe osteoarthritis of the knee.
TissueGene has research collaborations with Spine Institute, Columbia University, University of Pittsburgh, and Inha University. It also has agreements with PharmaVigilant, RheoGene, Inc., Kolon Life Science, Inc, AT-GC BioPharm, etc.
VIRxSYS Corporation is a biotechnology company focused on the use of proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The company was founded in 1998 with a mission to become the recognized leader in RNA based medicines and vaccines to treat serious human diseases.
VIRxSYS Corporation's technology platforms include: SMaRT(TM) RNA Platform, Lentiviral vector platform. Its Spliceosome-Mediated RNA Trans-splicing (SMaRT(TM) RNA) is a novel, fully-patented, and versatile RNA technology used for multiple disease indications. This proprietary technology is capable of repairing and re-programming genes at the RNA level to produce a totally different protein of therapeutic interest, such as diverting plasma albumin production in the liver toward apolipoprotein A-I (apoA-I), factor VIII, or even small antibody fragments. Its SMaRT(TM) RNA Platform can also be used for second generation antibody production (in vivo antibody manufacturing), real-time molecular imaging, genomics and molecular evolution, and induced pluripotent stem cells (iPS cells) generation.
VIRxSYS Corporation has developed lentiviral vector technology platform for RNA molecule delivery. This vector platform is based on the lentivirus (LV) class of virus which has remarkable properties for safe, efficient, predictable, and sustained delivery of payloads into cells. The company's vector delivery platform is used in therapies against viral infections, genetic disorders, cardiovascular diseases and others. Its product pipeline includes: VRX496(TM) indicated for the treatment against HIV, VRX1243 indicated for the treatment of cardiovascular disease, VRX1273 indicated as a vaccine against HIV, etc.
VIRxSYS Corporation has collaborations with Duke University Medical Center, Johns Hopkins University, Harvard Medical School, National Cancer Institute, Stanford University, University of Barcelona, University of Iowa, University of Pennsylvania, etc.
GrayBug™ is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company’s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye. These technologies were co-developed by the lead founder of Graybug, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at Johns Hopkins University with joint appointments in four other Hopkins departments including Biomedical Engineering, in collaboration with top ophthalmology clinician-scientists from the Wilmer Eye Institute, Dr. Peter Campochiaro and Dr. Peter J. McDonnell.
Analytical Services (CRO); Research Services & Supplies; Testing Services
BIOQUAL, Inc. is committed to providing quality research, development and consulting services to Government and commercial contract clients. The company was founded by John C. Landon in 1981.
BIOQUAL laboratory offers services used to evaluate immunologic, virologic and molecular biologic parameters in animal models and support the development of vaccines and therapeutics for infectious diseases in humans. Its laboratories are actively involved in the evaluation of vaccines, vaccine therapeutics, microbicides and drug therapies in animal models including non-human primate models of infectious diseases in humans. Biological evaluation in these models may be performed by a variety of methods, including quantitative PCR, virus-cultivation assays, antigen and antibody ELISA detection assays, lymphocyte proliferation, intracellular cytokines, GLP Studies and flow cytometry.
BIOQUAL's in vitro laboratory services include: Culturing of permanent cell lines, Isolation of primary cells from blood and tissues, T lymphocyte proliferation assays, Antigen capture assays, ELISAs and Western blots, Cytokine quantitation, Challenge stock development, 6-color flow cytometry services, Immunophenotyping (CD markers), Intracellular cytokine assays, Tetramer/pentamer staining, CFSE labeling, Quantitative real-time PCR for RNA and DNA using the TAQMAN system, Plasmid DNA purification/characterization, Genomic DNA/RNA isolation, Recombinant virus constructions, Transformations/transductions and Antiviral assays for testing of therapeutics.
BIOQUAL's partners include: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Mach One Corp., The Johns Hopkins University, The US Department of Health and Human Services, Uniformed Services University, and ZooQuest Technologies, Ltd.
Clongen Laboratories LLC offers a broad range of specialty molecular testing procedures for clinicians, hospitals, clinical laboratories and researchers. It was founded in 1999 by Ahmed Kilani with a mission to improve health by providing clinical laboratory testing services in the areas of microbiology and molecular diagnostics of more than 95 human pathogens. The company's goal is to provide its clients with timely, accurate and dependable test results and support services.
Clongen's services include: 1) Bio Warfare Testing - bacteria testing, virus testing, parasite testing, yeast testing and fungi testing; 2) Biotceh-Biopharm Services - sterility assurance testing, mycoplasma testing, in vitro studies, LAL - endotoxin testing and microbiology services; 3) Molecular Diagnostics Services -sexually transmitted diseases tests, bloodborne pathogens tests, pulmonary disease tests and chronic fatigue syndrome tests, etc; 4) Custom Services- genotyping, western blotting, DNA services, DNA sequencing, protein expression services and research & development. Its test kits include: MycoFind Kits, TrichFind Kits, LymeFind Kits, Pjiroveci Kits, Urealyt Kits, BlastoFind Kits and Custom Kits.
Clongen uses rapid detection methods such as PCR, Real Time PCR and DNA sequencing for identification of human and animal pathogens. It offers more than 75 PCR assays for the detection of common pathogens (bacteria, viruses, fungi, and parasites). The company also offers Microbiology services (microbial identification), Genotyping of mouse tails, custom molecular and cell biology services such as custom cloning, protein expression and purification, western blotting, quantitative real time PCR, cDNA library construction and screening.
Penniman & Browne, Inc. is a civil engineering and environmental professional services and laboratory testing firm. The company was founded in the year 1896. Its mission is to provide its clients with accurate, reliable data in a timely, cost-efficient manner.
Penniman & Browne provides its clients with complete inspection, consulting, and analysis. The company offers a comprehensive line of services which include: civil engineering, geotechnical field and laboratory services, construction inspection, environmental analysis, fuel analysis, pharmaceutical analysis, and industrial hygiene. Its in-house capabilities deliver a combined approach to environmental, industrial hygiene, and engineering services.
Penniman & Browne's engineering services include: civil engineering assessments, on-site construction materials testing, laboratory construction materials testing and analysis, etc. its geotechnical services include: soil drilling, rock coring, test pitting, pump tests, etc. The company's field and laboratory services include: on-site construction material testing and laboratory analysis of construction materials. Its fuel analysis services include: jet/turbine fuels, diesel fuels, fuel oil, etc. Its pharmaceutical analysis services include: complete analytical services - GC, GCMS, HPLC, method development, material validation and quality control, etc. Its industrial hygiene services include: lead, asbestos and indoor air quality/mold identification.
The Bode Technology Group, Inc. provides forensic DNA analysis, advanced and proprietary DNA collection products, research services to law enforcement agencies, federal and state governments, crime laboratories, and disaster management organizations. Its mission is to make a positive contribution to society by using science responsibly and ethically to help create a safer and more secure world and to advance the cause of justice through the use of technologically advanced products and services.
The Bode's technologies include: DNA Typing, Touch DNA, Serology/Screening, and Quantitation. It processes the samples using the following technologies: STR DNA Analysis, Y-STR DNA Analysis, Mini-STR DNA Analysis, Touch DNA, Mitochondrial DNA Analysis, and Serology/Screening. Its Touch DNA analysis include: swabbing method, cutting method, Scraping, Tape Liftmethods. The company offers several Screening methods for the presence of biological fluids such as blood, semen, or saliva. Its quantitation procedure allows quantification of small quantities of human DNA using fluorescent detection methods.
The Bode holds accreditations from Forensic Quality Services-International, the American Society of Crime Laboratory Directors (ASCLD), and is certified by the New York State (NYS) Department of Health (DOH).
http://www.xceleron.com Pioneer of Acceleratory Mass Spectrometry For Drug Development Xceleron was founded in 1997 in York, UK and has since expanded its operations with a US facility in Maryland, providing bioanalytical accelerator mass spectrometry (AMS) services for accelerated early drug development.
The company pioneered human microdose and microtracer techniques using ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It has been providing drug development services for more than 10 years and has conducted more GLP and GCP studies than any other CRO of its type, with unmatched robust analytical processes and knowledge of experimental design.
Accelovance Inc. is a contract research organization (CRO) that provides clinical CRO and market commercialization services in compliance with international standards. The company was established in 2005 with a mission to improve the quality and predictability in clinical research.
Accelovance operate three core service divisions - Full-Service CRO, Accelovance Clinical Sites and Patient Recruitment that positively impact the productivity, quality and control of clinical research. The company has broad?based experience in a range of therapeutic areas: biodefense, vaccines, prophylactic, general health, infectious disease, cell and gene therapy, immunology, obesity, oncology, women and men's health and nutritional. Its services include: project management, monitoring, data management, biostatistics & analysis, pharmacovigilance, regulatory affairs & IND services, and medical writing.
Accelovance has signed a clinical trial service agreement with DelSite Biotechnologies for H5N1 influenza vaccine. The company has affiliations with BioCom, CHPA, Tech Council of Maryland, DIA CSO Directory, CenterWatch, Contract Pharma, Pharma Voice, etc.
AVANZA Laboratories is a preclinical contract research organization (CRO) that provides high quality regulatory-compliant drug development services. It was formed in December 2009 with a mission to continue advancing cures through drug development services.
AVANZA's services include: General toxicology, Safety pharmacology, Developmental and Reproductive Toxicology (DART), Vaccine safety, Product development and consulting service. The company's general toxicology services include the design, execution and analysis of research and regulatory studies that assess the safety profile of small molecules, vaccines, biologics, veterinary drugs, nutraceuticals, chemicals, and intermediates. Its pharmacology studies are designed to investigate the potential for adverse pharmacological events. Primary evaluations include cardiovascular, respiratory, and central nervous system assessment. Supplemental evaluations of renal/urinary, gastrointestinal, and immune functions may also be performed.
AVANZA's comprehensive Product Development and Consulting Services include: Project Planning, Agency Submissions & Representation, Remote or On-Site Staffing Services and IACUC and Animal Program Compliance. It conducts DART studies on small animals which include: Neurotoxicity studies, Neonatal dosing studies, Multigenerational studies, Prenatal and postnatal development, including maternal function - Segment III, etc.
BioReliance Corporation provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies that span the product cycle from early pre-clinical development to licensed production. The company's goal is to advance the development and delivery of healthcare and consumer products by providing the highest quality testing, development and manufacturing services in partnership with clients worldwide. It was founded in 1947 as Microbiological Associates. The company has been acquired by Sigma-Aldrich on Jan 31, 2012.
BioReliance's testing and manufacturing programs can be applied to an extensive range of therapeutic products including: Gene Therapies, Vaccines, Cell Therapies, Monoclonal Antibodies, Recombinant Proteins, Plasma/Blood Products etc. The company's custom services include: new assay development, method transfer, validation and qualification and assay optimization.
BioReliance has acquired CynerGene LLC, a privately held provider of pharmacogenomic testing services on April 8, 2010. The company's partners include: Provecs Medical GmbH, Gentronix Limited, Avid Bioservices, Inc., MedImmune, Inc. (formerly Cambridge Antibody Technology) and so on.
Bridge Laboratories (formerly Bridge Global Pharmaceutical Services, Inc) is a contract research organization (CRO) that provides US-level regulatory-compliant drug development services. The company is specialized in toxicology, including vaccines, developmental and reproductive toxicology (DART), and safety pharmacology.
Bridge Laboratories helps and conduct safety assessment studies to assist compound development programs involving small molecules, biologics, nutraceuticals, vaccines, chemicals and intermediates. The company conducts short and long-term in vivo studies, from acute to carcinogenicity protocols like general toxicology, developmental and reproductive toxicology (DART), safety pharmacology (CV, CNS, respiratory), vaccine development, pathology services, bioanalytical services and DMPK.
Bridge Laboratories has agreements with The National Institute on Drug Abuse (NIDA), SRI International, National Foundation for Cancer Research (NFCR), Anesiva, Inc, Industrial Technology Research Institute and Development Center For Biotechnology, etc.
EPL Inc is recognized nationally and internationally for its ability to meet the demands of the scientific community and the challenges of safety testing and toxicologic pathology. It was founded in 1971. Its mission is to provide the highest quality service in the fields of pathology and related scientific services to our clients, create a positive work environment for employees, and generate growth and a reasonable return for its shareholders.
EPL's services are delivered by experienced scientific and technical personnel, either at its own state-of-the-art facilities or at the client's site. The company offers services in the departments of: 1) Toxicologic Pathology services which include: Necropsy; Mammalian, Avian and Aquatic Histology; Mammalian Pathology; and Avian and Aquatic Pathology; 2) Pathology consultation services include: Pathology Peer Review, Pathology Working Groups (PWG), Scientific Advisory Panels, Regulatory Consultation and Training Seminars; 3) Special Pathology services include: Digital Image Quantification and Morphometry, Immunohistochemistry, Neuropathology, Medical Devices, Developmental and Reproductive Pathology and Electron Microscopy; 4) Toxicology services include: Study Monitoring and Data Auditing, Toxicology Study Design and management, Report Preparation and Review. Its Pathology consultation provides toxicologic pathology support and interpretation of regulatory toxicology study data, as well as the more complex and demanding expertise required for Pathology Peer Review and management of Pathology Working Group panels.
EPL has developed several systems to meet client needs and their tightest deadlines. Its approaches include: checks and balances system for histopathology data handling and workflow, a data and tissue tracking system; Pathology Peer Review System; and the option of client-site services.
EPL has formed strategic alliance with Flagship Biosciences LLC to Provide Preclinical Pathology and Quantitative Services.
SNBL Clinical Pharmacology Center Inc (SNBL CPC) is a contract research organization focused on phase I/IIa complex clinical pharmacology research. The company's mission is to facilitate and accelerate drug and medical device development through collaboration and high quality research. It is a wholly owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. Â SNBL Clinical Pharmacology Center has expertise in a broad spectrum of therapeutic areas, including: CNS, women's health, infectious disease, immunology, cardiovascular, metabolic disease, ophthalmology, urology, nephrology, etc. Its clinical trial services include: first-in-human studies, dose escalation, bioavailability / bioequivalence, pharmacokinetic / pharmacodynamic (PK/PD), drug-drug interaction, food effect studies, vaccine development, novel delivery systems, radio labeling / mass balance, challenge studies, receptor occupancy, etc. The company is specialized in providing capacity available guarantee(TM), rapid set-up program, flexible reporting formats and real-time tracking, expedited sample turnaround, flexible trial protocol and configuration, etc.
SNBL Clinical Pharmacology Center has partnerships with UPM Pharmaceuticals, Inc. and University Medicines International, LLC.
ACell Inc., is focused on next generation medicines through the development and commercialization of unique extracellular matrix devices to repair and remodel damaged tissues and organs in a broad range of surgical procedure. The company was founded by Alan R.Spievack.
ACell's MatriStemÂ® technology is a naturally occurring, non-crosslinked, completely resorbable, acellular material. Its MatriStem devices are unique from other scaffold technologies in that they fundamentally change healing by triggering abundant new blood vessel formation and recruiting numerous cell types to the site of injury. It appears that these cells, including progenitor cells, have the potential to differentiate into numerous types of site specific tissues. This proprietary UBM scaffold technology can be used in a broad range of medical applications such as wound care, general surgery, gastrointestinal surgery, urology and plastic and reconstructive surgery.
ACell has developed a proprietary line of plastic surgery and wound care devices utilizing an advanced regeneration methodology. Its Plastic Surgery Matrix is intended for implantation to reinforce soft tissue where weakness exists including tissue and body wall repair. The company's MatriStem devices are intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears), and draining wounds. It has also developed MatristemÂ® Hernia Matrix, a proprietary line of general surgery devices utilizing an advanced regenerative medicine technology.
ACell has an agreement with Medline Industries, Inc. for MatriStem wound care matrix.
Artecel inc. is a provider of adipose-derived stem cell (ASC) banking services and therapeutic products derived from ASCs. It is focused on autologous applications in cosmetic surgery and hematopoietic support. The company was founded in 2000 as Artecel Sciences and later in April, 2003 Capital Corp. has acquired the assets of Artecel Sciences and changed its name to Artecel.
Artecel develops products and services in two major lines of business: cell banking of ASCs and therapeutic products made from ASCs for orthopaedic and dental applications, and soft tissue and cosmetic applications. The company also develops certain applications of ASCs in high-value drug discovery and research tools to be used in liver toxicity testing. It applies its products in four clinical applications: (1) soft tissue cosmesis, (2) hematopoietic support during bone marrow transplantation, (3) repair of bone, and (4) repair of cartilage.
Artecel's Cell banking is an emerging treatment strategy premised on the ready availability of an individual's viable, multi-lineage, autologous cells for the repair of diseased or injured tissues. The company's first generation ASC products are autologous (i.e., made from an individual patient's own cells, with minimal manipulation). Its second generation products are allogeneic (i.e., made with cells obtained from a donor, grown to large numbers in cell culture and stored in inventory, and delivered to other patients).
Artecel has alliances with The National Institutes of Health, and United States Department of Health and Human Services.
BioSET, Inc (Biosurface Engineering Technologies) is engaged in developing synthetic peptide growth factor mimetics for advanced tissue repair. It was founded by Tom Roueche and Paul Zamora in 2001, with a goal to pair the most appropriate signaling molecule with tissue-specific scaffolds for advanced tissue regeneration in bone and soft tissue repair. Â BioSET is specialized in developing orthobiologic devices-medical technologies that combine the mechanical benefits of medical devices with bioactive treatments to improve device performance. It has developed a library of signaling compounds, targeting specific mechanisms of action. The company's technology is based on pairing of custom-designed bioactive treatments with tissue-specific scaffolds. These scaffolds provide the necessary biomaterial for new cell integration and the bioactive compounds guide the healing process.
BioSET's lead product Amplex is an implantable combination device used in spine fusion surgery. Its product Amplex combines a bioresorbable ceramic scaffold in granule form with its patented B2AÂ® peptide indicated for enhancing bone healing. The company is also focused on the development of products for sports medicine applications based on patented F2A(TM) peptide. It is engaged in evaluating appropriate peptide signaling molecules and various scaffold biomaterials used in musculoskeletal applications such as trauma, fracture repair and additional soft tissue treatments. The company's product F2A(TM) peptide is a biomimetic of basic fibroblast growth factor (bFGF) that plays a role in soft tissue regeneration and in increasing tissue vascularity.
BioSET's investors include: The Vertical Group, EDF Ventures, MB Venture Partners, PTV Sciences and Heron Capital. The company has agreements with Tornier, Inc. and Biomet, Inc.
Bonegrafix Inc is a medical device and biomaterials company engaged in the development and commercialization of innovative synthetic bone products that replace missing or diseased bone and promote rapid healing and remodeling of bone tissue. The company intends to develop products using its proprietary technology to produce unique, cost-effective bone replacement devices with regenerative autograft/allograft properties and no complications.
Bonegrafix employs its proprietary manufacturing process to create standardized bone blocks or a custom bone replacement based on patient-specific CT information that can be refined (as required) by the surgeon through CAD software. The company's manufacturing process is a technology that can incorporate and selectively place biologic and non-biologic substances into the block during the manufacturing process.
Bonegrafix' product line is being developed utilizing the company's proprietary drug, formulation, delivery and manufacturing processes. Its products contain bioactive substances to achieve ideal graft attributes. The company's products fall into two categories: (1) solid bone blocks for bone replacement and (2) small powdered or granular substances (with and without inclusion of a cement) for filling defects or holes in bone or holding bone together during healing.
Cytomedix Inc is a biotechnology company that develops, sells and licenses biologically active regenerative therapies for wound care, angiogenesis, and inflammation. The company's primary focus is the utilization of platelets and platelet derivatives to manage wound healing. Its vision is to achieve a leadership position in the field of advanced tissue regeneration technologies.
Cytomedix's AutoloGel(TM) System is indicated for use in certain chronic wounds. The AutoloGel(TM) System utilizes a unique technology that enables rapid isolation and activation of platelet rich plasma (PRP) from a patient's own blood. The PRP is subsequently processed to produce a gel for application to the wound bed, re-establishing a balance needed for natural healing to occur. AutoloGel contains growth factors, cytokines and chemokines that are essential for exuding wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and for the management of mechanically or surgically-debrided wounds. Some of these cytokines and growth factors have been shown to mobilize white blood cells and stem cells, enhance cell proliferation, and/or reduce inflammation.
Cytomedix's product pipeline comprises of CT-112, an octapeptide sequence with demonstrated anti-inflammatory activity when administered either orally or parenterally. CT-112 may be particularly useful for therapeutic intervention into inflammatory mediated disease such as, but not limited to, autoimmune diseases, graft versus host disease, COPD, reperfusion injury and artherosclerosis.
Cytomedix has agreements with Sorin S.p.A., Millennia Holdings Inc, CellMedix Inc, National Wound Therapies, LLC, SafeBlood Technologies, Inc., Perfusion Partners and Associates, Inc., DePuy Spine, Inc. (Formerly DePuy AcroMed, Inc.), etc.
ILSbio, LLC (Integrated Laboratory Services - Biotech) is a biomedical services company dedicated to providing high quality research materials and support to academic and commercial biotechnology organizations.
ILSbio a wide range of specimen types, including matched sets of normal and diseased tissue, FFPE, blood, and serum, focusing primarily on cancer. The company's products include: Snap Frozen Tissue, FFPE Tissue Blocks, Tumor Tissue with Normal Adjacent Tissue, Surgical Normal Tissue, Post Mortem Tissue etc.
ILSbio offers a wide range of custom services which include: Custom Collections, Tissue Extractions, Tissue Microarrays, Slide Sectioning and Specimen Testing.
RegeneRx Biopharmaceuticals Inc is a clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. It was founded in 1982 with a mission to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.
RegeneRx is developing products based on Thymosin beta 4 (T Beta 4). T Beta 4 is a naturally occurring peptide. It is found in high concentrations in blood platelets, wound fluid and other tissues in the body. T Beta 4 has been found to play an important role in protection, regeneration and remodeling of injured or damaged tissues. Its T Beta 4 involved in a wide variety of biological activities includes regulation of actin, epithelialization, angiogenesis, apoptosis and anti-inflammation.
RegeneRx's products include: RGN352 for the treatment of Acute Myocardial Infarction; RGN137, a topical gel formulation of the peptide Tbeta4, as a novel treatment to accelerate dermal wound healing; RGN-259, a Tbeta4-based sterile eye drop, as a novel treatment for corneal healing; and RGN-457 as a novel inhaled (via nebulization) treatment for cystic fibrosis and bronchiectasis.
RegeneRx research and development efforts are primarily focused on collaborating with major research institutions to expand its technology platform for manufacturing and formulation of its products, and the sponsorship of human clinical trials. The company has collaborations with National Heart, Lung, and Blood Institute (NHLBI), University of Maryland, National Institutes of Health, The US Department of Health and Human Services, Defiante Farmaceutica L.d.a., etc.
Royer Biomedical Inc is engaged in developing novel products utilizing its proprietary drug delivery matrices. The company was founded in 1997 by Garfield Royer as Buford Biomedical, Inc and changed its name to Royer Biomedical Inc in December 2000. Its wholly owned subsidiary is Royer Animal Health LLC.
Royer Biomedical's R-Gel, and Matrix III are distinct technology platforms, each being bio-resorbable, and with the ability to provide a localized, controlled release of drugs over a broad range of time spans. Localized drug delivery provides increased drug concentration to the targeted site versus systemic delivery, and consequently enhanced efficacy, while minimizing or eliminating systemic side effects. Its Matrix III is an inorganic-biopolymer composite. In each product application, the inorganic components are mixed with an aqueous biopolymer solution containing the medicinal. The resulting slurry solidifies and entraps the medicinal. Its R-Gel is supplied in a two-syringe system. One syringe contains oxidized dextran and the other syringe contains powders of active ingredients, excipients, and the cross-linking reagent, which is adipic acid dihydrazide. The company has three priority products in human health- R-Gel Antibiotic, R-Gel 5-FU, and R-Gel Bupivacaine.
Royer Biomedical has collaborations with several corporate partners and institutions which include: Hospital for Special Surgery (NYC), Johns Hopkins / NIH / Brain Tumor Consortium, Ohio State University Marion duPont Scott Medical Ctr. (Univ. of MD/VA Tech) etc.
BioInformatics Services (BIS) is a biotechnology consulting firm that specializes in applying the power of computational biology to build solutions to complex biological and data analysis problems faced by scientists in public and private research institutes, biotechnology companies, and universities. The company is operated by Robert D. Phair.
BIS also provides service to clients that includes education and training necessary to establish integrative bioinformatics and advanced modeling techniques among their laboratory's core competencies. It supports the entire spectrum from hands-on partnering to outsourcing entire projects.
Calibrant Biosystems Inc offers a wide range of analytical services for global proteomic profiling, from standard multidimensional liquid chromatography to targeted analysis using the Geminiâ„¢ discovery engine.
Calibrant's Geminiâ„¢ discovery engine enables comprehensive and quantitative protein profiling of isolated and homogeneous cell populations from both fresh and archival formalin-fixed tissues. Geminiâ„¢ analysis begins by isolating specific cells of interest from solid tissue specimens using laser capture microdissection (LCM). Using this approach, biological relevance of the resulting proteomic data can be greatly enhanced, while larger numbers of disease-relevant proteins may be identified through the significant reduction in protein dynamic range afforded by the rejection of unwanted cell types.
Calibrant offers a wide range of analytical services for global proteomic profiling, from standard multidimensional liquid chromatography to targeted analysis using the Geminiâ„¢ discovery engine. Its services include: sample preparation, laser capture microdissection, bioinformatics, drug mechanism of action & predictive toxicology, characterization of protein product and protein contaminants, PTM analysis including phosphorylation and glycocylation, etc.
Calibrant's partners include: Armed Forces Institute of Pathology, Yale University and Cleveland Clinic.
Celadon Laboratories Inc is a developer of web-based software products for the design of nucleic acid primers and probes. It was founded in 1999 by Raymond J. Peterson. The company's goal is to cure disease through the design of more effective research and therapeutic oligonucleotides.
Celadon ProbeITy(TM) is web-based software for multi-method, oligonucleotide design for assay and other molecular biology techniques. Its GenoTyper(TM) is web-based multiplex analysis software for research and clinical genotyping. Easily configurable for any genotyping kit or platform, it implements a wide variety of features for allele and genotype calling, assay optimization, clinical interpretation and other data handling, with assay protocols derived from package inserts or researcher origination. The company's Immuno-Fit(TM) automates analysis of immunoassay assays from instrument to electronic health record.
Celadon seeks to improve oligonucleotide technology in order to make genomic methods simpler, faster, more efficient, and more accurate. It has conducted original research on Locked Nucleic Acids (LNA) with the goal of better designing primers and probes, especially for high-throughput and multiplexing applications which is supported by the U.S. National Cancer Institute and by the State of Maryland. The company's ProbeITy software applies modified nucleic acid technology to one or all of the oligonucleotides in the assay. It has licensed its software to vendors of proprietary genomic analysis methods, to provide fast, easy-to-use, web-based software that facilitates customers' assay design and purchasing process.
Celadon's partners include: Capital Genomix, Inc, LabVantage Solutions, Inc, National Institutes of Health, Proligo LLC, Sigma-Aldrich Corporation and The U.S. Department of Health and Human Services.
Correlogic Systems Inc is engaged in the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. Its mission is to advance the early identification of various cancers and other diseases, and to accelerate the new drug discovery process by applying its proprietary software to the development of proteomic and other biomarkers. The company was incorporated in 2000 by Peter J. Levine and Ben A. Hitt.Â
Correlogic's core technology is its proprietary pattern recognition and pattern discovery software, the Knowledge Discovery EngineÂ® (KDE). The KDE combines a simulation of neo-Darwinistic evolution with competitive, adaptive pattern mapping algorithms, and a method of determining cluster homogeneity. Proteome Quest is research application software derived from the KDE. It is designed specifically for the creation of computational biological state models. Its technology is developed specifically for the analysis of complex biological data sets containing thousands to millions of independent data points - such as those created by mass spectrometry, NMR, gene arrays, and highly multiplexed immunoassays. The company's technology can be used to combine the analysis of genomic and proteomic data streams to create a more comprehensive picture of a biological state or condition.
Correlogic's research areas include: Colorectal Cancer, Breast Cancer, Prostate Cancer and Other Diseases. The company's products include: ProstaCheckÂ® for prostate cancer; MammoCheckÂ®, a blood test for detection of breast cancer; and colorectal cancer, a blood test for detection of colon cancer and potentially for colon adenomas (precancerous polyps). The company provides research and development tools and support services to the pharmaceutical, research and diagnostic communities. Â Correlogic's partners include:Â Vermillion,Â Mitsui & Company, Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc, Jeol Ltd, Uniformed Services University, Advion Biosciences Inc, etc. The company's investors include: Quest Diagnostics, Inc., Mitsui & Co. Ltd, MASA Life Science Ventures and Ahn-Gook Pharmaceutical Co., Ltd.
CYNCA Laboratories Inc. is a biotech company with a mission of developing drugs against infectious and inflammatory diseases as well as a protein chip-based diagnosis and research tool. It was founded in 2004 with a goal of becoming a powerhouse of discovery and innovation on diagnosis and therapeutics.
CYNCA has developed a "two-step binding" technology for protein chip design. The technology can be used for the large-scale multiplex protein assay with high specificity and sensitivity. The technology provides the basis for design of various chip-based products for diagnosis and proteomic research applications. The company has also developed an in-vitro cell-based model for identification of disease-relevant small nucleotide polymorphism (SNP). This model combines in-vitro cell-based functional analysis from individual donors and identification of differential SNPs.
CYNCA's product pipeline includes: 1) CC301, a HIV-1 blocker to prevent HIV-1 infection; 2) CC401, a nature compound-derived drug for HIV-1/AIDS; 3) CC501, a protein chip for profiling secretory proteins; 4) CC502, a protein chip for profiling salivary proteins; and 5) CC601, a SNP assay for predicting individual response to sepsis.
EdgeBio is a research reagents company that provides nucleic acid purification products to the scientific research community. It was founded in 1989.
EdgeBio is committed to provide research products and services that give the competitive edge. The company's R&D continues to develop some of the most innovative products on the marketplace. Its products are manufactured under rigorously controlled conditions, using raw materials from specially qualified suppliers.
EdgeBio offers products for Dye Terminator Removal, PCR Purification, Sample Preparation and Bacterial Competent Cells. Its product line consists of: PERFORMAÂ® DTR (Dye Terminator Removal Systems), MagDTRâ„¢ Dye Terminator Removal Resin, sequencing buffers, QuickStepâ„¢ 2 PCR Purification Systems, PERFORMAÂ® Spin Columns, PurEluteâ„¢ Bacterial Genomic Kit and Acellaâ„¢ Competent Cells for Cloning and Protein Expression, Adhesive Plate Sealers, etc. The company's sampling projects include: Whole Transcriptome Analysis, Targeted Resequencing and Exome Sequencing, Small RNA Analysis, Methylation Analysis and Chromatin Immunoprecipitation sequencing (ChIP-Seq) & Analysis, etc. It provides sequencing via six NextGen sequencers and has a fully automated QC, LIMS and bioinformatics pipeline.
EdgeBio has an agreement with Caliper Life Sciences, Inc.
Electric Genetics Corporation is specialized in the field of computational genomics and provides genomic data analysis systems and validated drug targets for the pharmaceutical, biotechnology and genomics market. The company was established in 1997.
Electric Genetics has developed technologies in following areas - accurate and rapid analysis of genomic data, genomic comparisons, relating genotypic behavior to phenotypic characteristics and identifying and validating critical genes in infections diseases. Its products and services include: 1) stackPACK(TM) - a transcript reconstruction and management tool; 2) STACKdb(TM) - a reconstructed human gene index; 3) eVoke(TM) - an expression ontology toolkit and 4) ADAPT(TM) - a revolutionary in-silico technology for the rapid identification of medically important or otherwise specialized genes in any organism.
Electric Genetics provides the ability to clearly relate the relationships between genome, gene expression data and phenotype, through a core of transcriptomic data offerings. These products provide a novel and powerful means to integrate information from clinical genetics, genomics, expression studies and proteomics to link genotypes to humans' physical characteristics and pathologic states and thus boost the discovery process. The company provides specialized services aimed to increase the utility and effectiveness of open source bioinformatics tools through value-added activities such as documentation, validation, packaging, integration and training.
Electric Genetics is entering the drug discovery market by: Developing a portfolio of proprietary drug targets for major pathogens, including: Helicobacter pylori, Streptococcus pneumonia, Staphylococcus aureus, Mycobacterium tuberculosis and the malaria parasite, Plasmodium to be licensed. Establising target discovery collaborations with biotechnology/pharmaceutical companies to leverage the ADAPT(TM) system.
Electric Genetics' partners include: The South African National Bioinformatics Institute (SANBI), Imperial College of Science, Technology and Medicine, Lion Bioscience, Ensembl Project - Sanger Institute, Sygnis Pharma AG, Affymetrix Inc etc.
Expression Pathology Inc. (EPI) is a biotechnology company specializing in the development of innovative tissue protein analysis methods for research and diagnostic applications.
Expression's research and product development is based on two proprietary technologies; tissue dissection using our DIRECTOR laser microdissection slides, and the ability to solubilize FFPE tissue using the patent pending Liquid Tissue MS Protein Prep protocol so the sample can be analyzed using a range of different mass spectroscopy applications. The company offers high level collaborative research and fee-for-service development of tissue protein biomarker assays and comprehensive biomarker discovery and validation. Its services include Tissue Sourcing, DIRECTORÂ® Slide Laser Microdissection, Liquid TissueÂ® Sample Processing, Mass Spectrometry Analysis and Bioinformatics Analysis.
Expression has developed internal expertise and proprietary methods that make possible accurate and detailed mass spectrometry analysis of proteins in formalin-fixed paraffin-embedded (FFPE) tissue. Protein analysis in FFPE tissue relies on decades-old immunohistochemistry (IHC). EPI has assembled a patented platform of technologies that work together to enable protein biomarker discovery and accurate measurement of individual proteins and protein pathways in patient tissue that is routinely collected, preserved and stored in medical research and treatment facilities.
Expression Pathology's products include 1) Liquid TissueÂ® MS Protein Prep Kit - for quantitation and discovery of protein biomarkers in FFPE tissue; 2) DIRECTORÂ® Laser Microdissection Slides-Direct non-contact microdissection without plastic film or sticky caps; 3) ProteoSOL(TM) Tissue Extraction System.
Expression Pathology has collaboration with The Children's Oncology Group, Roche Holding, Ltd., NextGen Sciences, Inc., Thermo Fisher Scientific Inc., ORIDIS Biomed GmbH, Tom Baker Cancer Centre, Digene Corporation, KPL, Inc. etc.
Expression Pathology Inc. (EPI) is a biotechnology company specializing in the development of innovative tissue protein analysis methods for research and diagnostic applications.
Expression's research and product development is based on two proprietary technologies; tissue dissection using our DIRECTOR laser microdissection slides, and the ability to solubilize FFPE tissue using the patent pending Liquid Tissue MS Protein Prep protocol so the sample can be analyzed using a range of different mass spectroscopy applications. The company offers high level collaborative research and fee-for-service development of tissue protein biomarker assays and comprehensive biomarker discovery and validation. Its services include Tissue Sourcing, DIRECTORÂ® Slide Laser Microdissection, Liquid TissueÂ® Sample Processing, Mass Spectrometry Analysis and Bioinformatics Analysis.
Expression has developed internal expertise and proprietary methods that make possible accurate and detailed mass spectrometry analysis of proteins in formalin-fixed paraffin-embedded (FFPE) tissue. Protein analysis in FFPE tissue relies on decades-old immunohistochemistry (IHC). EPI has assembled a patented platform of technologies that work together to enable protein biomarker discovery and accurate measurement of individual proteins and protein pathways in patient tissue that is routinely collected, preserved and stored in medical research and treatment facilities.
Expression Pathology's products include 1) Liquid TissueÂ® MS Protein Prep Kit - for quantitation and discovery of protein biomarkers in FFPE tissue; 2) DIRECTORÂ® Laser Microdissection Slides-Direct non-contact microdissection without plastic film or sticky caps; 3) ProteoSOL(TM) Tissue Extraction System.
Expression Pathology has collaboration with The Children's Oncology Group, Roche Holding, Ltd., NextGen Sciences, Inc., Thermo Fisher Scientific Inc., ORIDIS Biomed GmbH, Tom Baker Cancer Centre, Digene Corporation, KPL, Inc. etc.
GeneCopoeia, Inc. is a manufacturer and provider of genomics and proteomics products and services for academic and governmental research institutes, pharmaceutical and biotechnology industry. The company was founded in 1999, with a mission to be the premier provider of technologies, products, unique tools and services for research discoveries and product development in the areas of biological and biomedical research.
GeneCopoeia is involved in manufacture and distribution of genomics and proteomics based biological research reagent products of the highest possible quality, which include nucleic acid, protein and antibody based research reagent products and services. The company offers a wide range of technologies that include: The GatewayÂ® Cloning technology is based on the site specific recombination reaction of phage lambda, an efficient biochemical process that conserves genetic information; AviTag(TM) technology is based on biotinylation of AviTag by Biotin ligase in vitro or in vivo and on the specific and reverse binding of avidin or streptavidin to biotin for immobilizing, purifying and visualizing proteins; HaloTagÂ® technology is a multi-functional protein tag that binds covalently and specifically to a variety of synthetic ligands, which enables tagged proteins to be labeled with fluorophores for both in vitro and in vivo imaging or with affinity agents for purification; SNAP-tag (TM) technology cleaves para-substituted benzyl guanines by transferring the substituted benzyl group to its active thiol and releasing free guanine; Yeast Two Hybrid technology is used for high throughput studying protein-protein interaction etc.
MetaMorphix Inc is a life science company that uses DNA, to improve the global food supply and human health. It was founded in 1994. The company's wholly owned subsidiary MMI Genomics, Inc develops innovative life science technologies to introduce environmentally friendly solutions that improve food and human and animal well being.
MetaMorphix is focused on the development of products based on two foundation technologies that include: Growth Factor technology based on Myostatin, which is encoded by the GDF-8 gene; and Genomics used to discover gene-based therapeutic and disease prevention strategies for livestock production and animal health. Its technology platforms have the potential to effect dramatic improvements in livestock production and animal and human health.
MetaMorphix is developing a pipeline of products addressing all major livestock sectors including cattle, swine, poultry and aquaculture as well as developing products that enhance the health of companion animals. Its product portfolio includes: Tru-Marbling(TM), a DNA-based genetic test that contains a panel of 128 unique DNA markers, each one highly associated with the expression for marbling score and quality grade and validated in both commercial cross-bred feeder cattle populations and in Angus cattle; Tru-Tenderness(TM), a DNA-based genetic test that contains a panel of 11 unique DNA markers, each one highly associated with expression for tender meat; MMIG Parentage and Identification; Tru-CoatColor(TM), a test that enables animal breeders to determine the genetics of coat color for the tested animal; Canine DNA Parentage Test, used to determine parents of dogs; etc.
MetaMorphix has partnerships with Sequenom Inc, Genetic Technologies Limited, Monsanto Company, Willmar Poultry Company etc.
MetaMorphix on February 4, 2011 the company announced its intention to sell all, or substantially all, of its assets as part of its reorganization under a sale in Chapter 11 pursuant to section 363 of the Bankruptcy Code. It has also announced that American MedTech Advisors has been retained to assist in the sale of the company.
Mirari Biosciences, Inc is a biotechnology company that invents, develops and markets proprietary platform biotechnologies to enhance healthcare. The company is dedicated to improve healthcare by accelerating protein & gene discovery and detection. The company was founded in 2000 by Mark T. Martin. Â Mirari's technologies include: Microwave-Accelerated Surface Chemistry(TM) (MASCTM) allows acceleration of biochemical reactions without harming the relatively fragile biomolecules, Microwave Fluidics(TM) allows fluids to be moved through channels or tubes using only the energy of microwaves, and Direct Protein Amplification (Peplica(TM)) allows proteins to be amplified. Its MASCTM can streamline many applications where biomolecules are analyzed, including; pharmaceutical discovery and development, medical diagnostics, veterinary diagnostics, food testing (such as routine testing of meat, poultry, and vegetables), water testing, agricultural testing (such as for contaminant genetically modified plants on farms), and bio/chemical warfare agent testing.
Mirari has collaborations with National Institutes of Health and United States Department of Health and Human Services.
OriGene Technologies, Inc. focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The company's vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. It was founded in 1997.
OriGene uses high-throughput gene cloning and gene expression profiling to develop commercially available products for pharmaceutical, biotechnology, and academic research and discovery applications. Its product areas include: Full-length cDNA Clones, RNAi with HuSH-29 and Exact-shRNA, Gene Expression, Lysates and proteins, Antibodies, Tissues and other products.
OriGene's Full-length cDNA Clones products include: TrueORF cDNA Clones, TrueClone Human TrueClone Mouse Collection, ExactORF Cloning Service, GFC Transfection Arrays and Transfection Reagents. Its Gene Expression products include: TissueScan qPCR Arrays, qPCR Primers, qPCR Template Standards, First Strand cDNA and Rapid Scan cDNA Panel. Its Lysates and proteins products include: Tagged Over expression Lysates and Purified Proteins. The company's Antibodies products include: Primary Antibodies, Antitag Antibodies and Western Reagents. Its Tissues products include: TissueFocus Blocks, TissueFocus Sections and TissueFocus RNA Products.
OriGene's other products include: Transfection Reagents, PolyA+ and Total RNAs, Sure Race cDNA 5 End Discovery Panels, Rapid Screen Arrayed cDNA Libraries, DupLEX A and cDNA Libraries and Molecular Tools.
OriGene's partners include: Bayer Ag, Cytomyx LLC, Essen BioScience, Inc. (formerly Essen Instruments, Inc.), Genentech, Inc, Millipore Corporation, Novasite Pharmaceuticals, Inc, ProteinOne, Roche Holding, Ltd, Serologicals Corp, Tanox, Inc, Xantos AG and so on.
Rafagen Inc is focused on the development and commercialization of next generation gene expression systems, with applications in molecular therapeutics. It was founded by Sung Ho Hahm, Ja Shin Koo and Oltac Unsal with a goal to become a leader of novel molecular therapeutics development.
Rafagen's technologies include: Synthetic Gene Promotor Technology, Gene Expression Vector Technologies, and Cell Line Selection Technologies. Its synthetic gene promotor technology enables high throughput production of synthetic gene promoters for patient treatment and for the use in maximizing protein/antibody drug production levels, respectively. The company is developing gene elements that can mimic the activities of chromosome insulators, a matrix attachment region, or other chromatin structure opening elements. These elements will be used in preventing positional effects and inactivation processes of the stably incorporated genes, resulting in a marked and sustained expression of the recombinant genes. It possesses proprietary FACS-aided and non-antibody-based technology for a rapid selection of highly expressing cell lines.
Rafagen's products include: Super Promoters, which are tailor made according to the need of a specific cell type or growth conditions; and Targeting Promoters (TPs) that allow cell type-specific gene expression at an unprecedented level of precision and efficiency. Its services include: cell line development for protein and monoclonal antibody drug production. The company also has expertise in the following areas: Gene Cloning, Codon Optimization, Library construction, Sequencing, DNA microarray, Gene Synthesis, Cell culture optimization, and Flow Cytometry.
Rafagen's partners include: Goodwin Biotechnology, Inc, UMBI - University of Maryland Biotechnology Institute, American Gene Technology International, Inc. (AGTII), Johns Hopkins University, National Institutes of Health, University of Maryland, Korea Research Institute of Bioscience and Biotechnology, and Korea Advanced Institute of Science and Technology (KAIST).
Theranostics Health is engaged in the development and commercialization of proprietary, proteomic-based services and discoveries that are intended for the treatment of patients with diseases such as cancer. It was established in 2006.
Theranostics' core technology includes: Reverse Phase Protein Microarray (RPMA) and Laser Capture Microdissection (LCM). Its technology measures the activity of a large number of biomarkers, enabling pharmaceutical companies to accurately profile their drug candidates to facilitate efficient and effective drug development. Its uses Laser Capture Microdissection (LCM) to isolate a specific cellular population from cellular components normally existing in a clinical biopsy, which is essential to generate correct pathway activation portraits in specific cellular samples.
Theranostics also uses Reverse Phase Protein Microarray (RPMA) which enables sensitive, non-subjective, quantitative, calibrated, multiplexed analysis of cellular proteins from a limited amount of starting sample, such as clinical specimens. Its services provide specific solutions which include: proprietary molecular fixation, analysis of various sample types, isolation of specific cells of interest through Laser Capture Microdissection (LCM) etc.
Theranostics Health has collaborations with Duke University and National Institutes of Health.
TriStar Technology Group, LLC is engaged in the commercialization of very high-density tissue arrays for truly large-scale analysis of gene/protein expression in human normal and cancer tissues. It was founded in 2003.
TriStar's repository of formalin fixed and frozen human tissues & tissue arrays cover the following therapeutic areas: Cancer - Solid Tumors and Hematological Malignancies; Neurodegenerative diseases - Alzheimer's disease, Parkinson's disease, Stroke and Vascular dementia; Inflammatory diseases - Rheumatoid Arthritis, Psoriasis Arthritis, Detritus Synovialitis / CPPD etc. The following types of biological materials can be provided for academic / commercial research: Tissue micro array slides & blocks, Large sections, Tissue blocks (paraffin embedded), Tissue blocks (OCT embedded), Snap-frozen tissue and RNA/DNA.
TriStar's products & services include Normal Tissue Array 96 , Multi Tumor Tissue Array 880 , Human Cancer Stem Cell (CSC) cytoinclusion array with matched CSC generated xenografts, Breast cancers primary & paired distant metastases, Triple negative breast cancer with follow up information, Breast cancers with trastuzumab treatment data, Breast cancer prognosis array 600, Colon cancer Stage IV with KRAS data, Colon cancer with bevacizumab treatment information, Prostate cancer progression array 370, Prostate cancer prognosis array, Pancreatic cancer primary & matched mets etc. Its contract research services include Large scale multi-tumor (>3500 donor samples) & normal human tissue (>600 donor samples) analysis, Large scale tumor prognosis analysis and GLP tissue cross reactivity studies.
Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It was founded in 2003 by Mihales Polymeropoulos. The company is developing new medicines to improve the lives of patients.
Vanda Pharmaceuticals' uses new technologies, including genetics and genomics, to inform drug discovery, clinical trials and commercial positioning of its compounds. It is working to advance the science of developing new medicines and novel approaches to deliver these new medicines to patients.
Vanda Pharmaceuticals' products include: Fanapt(TM) (iloperidone), belongs to a class of medications for schizophrenia known as atypical antipsychotics; and Tasimelteon (VEC-162) for the treatment of circadian rhythm sleep disorders, to include the transient insomnia of jet lag.
Vanda Pharmaceuticals has collaboration with Clinilabs, Inc., Laboratory Corp Of America Holdings, Novartis AG and Bristol-Myers Squibb Company.
Omic Biosystems creates and provides state-of-the-art technological solutions for the studies of omics biosciences.
The field of Omics Science and Technology is huge and rapidly changing, with many new discoveries, emerging tools and solutions. Omic Biosystems will work together with its customers, partners and collaborators, take good experimental strategies, and discover useful biomarkers timely and within budget.
Specialties biomarker discovery and validation, quantitative omics analysis, sample preparation and analysis, bioinformatics and data analysis
OpGen’s Whole Genome Mapping technology, formerly “Optical” Mapping technology, provides innovative tools for genomic sequence assembly and finishing, microbial strain comparison and species characterization. Our mission is to positively influence individual healthcare outcomes, advance scientific research, and enhance public health by delivering precise, actionable information and results to customers in the life science and healthcare communities. Our customers are focused on DNA sequencing, epidemiology, outbreak identification, microbial forensics, biodefense and pharmaceutical discovery.
Abraxis NeoDiagnostix Inc, a subsidiary of Abraxis Bioscience is a cancer diagnostics company with an emphasis in women's health. Its mission is to improve the quality of life for the patient and optimize the use of healthcare resources. The company is a wholly-owned subsidiary of Celgene Corporation.
Abraxis NeoDiagnostix is dedicated to provide physicians with more accurate and timely information that will lead to better patient care decisions. Its product Cervical DNA DtexÂ® test uses florescent in-situ hybridization (FISH) technology to identify the irreversible DNA damage to cervical cells as defined by multiple copies of 3q26 and 5p15. The Cervical DNA Dtex is used in conjunction with Pap and HPV testing to assist physicians in identifying which LSIL and ASCUS HPV+ patients are at risk of progressing to severe dysplasia. Its The Cervical DNA Dtex test utilizes standard liquid-based cytology.
Akonni Biosystems is a molecular diagnostics (MDx) company that develops, manufactures and markets integrated molecular diagnostic systems. It was established in 2003, with a mission to improve the human condition by enabling the personalized medicine revolution by providing faster, approachable and affordable molecular diagnostic tools.
Akonni's TruDiagnosisÂ® system enables rapid and highly affordable testing for infectious and other human diseases on a gel drop array platform by incorporating standardized operating procedures and automating multiple manual laboratory processes. Its system integrates a number of complicated and time intensive steps, including sample preparation, nucleic acid amplification, detection and reporting, enabling the multiplexed analyses of complex biological samples within a single assay and delivering results in as little as two hours.
Akonni's product portfolio includes: 1) MDx Tests - TruArray MDR-TB Test, TruArray HE Test, TruArray MRSA Test, TruArray BTA Test, TruArray BER Test and Custom TruArray Microarrays; 2) Nucleic Acid Extraction Kits - TruTip DNA Kits, TruTip DNA/RNA Blood Kits, TruTip gDNA Blood & Semen Kits, TruTip gDNA Saliva Kits and TruTip DNA Kits for MTB and so on; and 3) Instruments and Software - TruSentry(TM) System, TruDiagnosis System, TruDx 1000 Reader, TruCycler Satellite Thermal Cycler etc.
Akonni has alliances with Argonne National Laboratory (Chicago, IL), CUBRC, Inc, Columbia University, Los Alamos National Lab, and Wadsworth Center. It has agreements with Eppendorf AG and National Institutes of Health.
BioMarker Strategies is a tissue-based cancer diagnostics company that is focused on the development of the SnapPath(TM) ex vivo biomarker platform to improve the treatment of cancer. The company was founded in 2006 by Scott Allocco and Douglas P. Clark.
BioMarker's SnapPath(TM) biomarker testing system is an automated live tumor cell processing platform that enables next-generation predictive tests known as Functional Signaling Profiles (FSPs) to guide targeted drug therapy selection for individual cancer patients. Its SnapPath (TM) platform uniquely enables the ex vivo induction of functional biomarkers to show the response of patient's live tumor cells to pathway stimulants (such as growth factors) and inhibitors (targeted drugs).
BioMarker has an agreement with the National Cancer Institute (NCI).
BioSciCon, Inc is a biotech company focused on the development of a proprietary platform MarkPapÂ® technology for improving Pap test and a more accurate early detection of cervical cancer and precancerosis. It was incorporated in 1996 with a mission to bring the new MarkPapÂ® Technology products to public benefit and save women's lives around the world.
BioSciCon is a R&D component of a consortium with three more companies: MarkPap LLC, MarkPap Pacific LLC and The Global Academy for Women's Health, Inc. It designs and develops patented Pap test related products and services under the brand name MarkPapÂ®. The company sponsors the development of MarkPapÂ® System, a proprietary biomarker-based technology with potentials for development of multiple medical devices for in vitro diagnostics of women's health status. The MarkPapÂ® System is an assembly of invitro diagnostic devices and procedures that may have practical application in cervical cancer screening for the improvement of Pap test. It is also a research tool to study cervical acid phosphatase in relation to the development of cervical pre-cancerous lesions and their transformation into cancer. In addition, MarkPap test could be used for determination of acid phosphatase in other epithelial tumors (oral, breast, lung, laryngeal, thyroid, colon, prostate) where this enzyme has been related to the tumor biology and has been considered as a target for new chemotherapies.
BioSciCon's MarkPapÂ® products and laboratory services available for commercialization are: MarkPapÂ® Test (method, assay, procedure), MarkPapÂ® Research Kit and MarkPapÂ® Accessories: MarkPapÂ® Solution. Its MarkPapÂ® Cytopreservative Solution is an accessory to the MarkPapÂ® Research Kit. The solution is made for the preservation of enzyme marker activity and cell morphology during an extended period of time. The company's MarkPap Digital concept allows evaluation of cytological specimens at distance (telecytopathology), using digital images sent from a remote laboratory sites.
Brachytherapy Services, Inc. (BSI) is engaged in providing devices for localized delivery of radiation to treat cancer with minimal disruption to patients' lives. The company's mission is to uphold its reputation for excellence in the healthcare field by developing, manufacturing and delivering cost-effective, high quality products to benefit patients around the world. It has its roots in North American Scientific, Inc., an industrial radioactive sources manufacturing company. The company is a member of TeamBest.
Brachytherapy Services develops and improves radiation treatments to treat patients more safely, effectively, and quickly. Its products treat prostate and eye cancer, two of the most prevalent types of cancer. The company's products ProsperaÂ® I-125 and Pd-103 seeds are used in low-dose-rate brachytherapy treatment for prostate cancer. ProsperaÂ® brachytherapy seed is superior in its design and engineering that delivers a highly efficient radiation profile. Its seed strands enable the stable placement of radiation sources outside the borders of the prostate, giving more options of minimally invasive brachytherapy treatment. The company's product portfolio includes: BrachyPak(TM) Surgery Kit, ProsperaÂ® I-125 and Pd-103, ProsperaÂ® Strands etc.
Canon U.S. Life Sciences is engaged to extend canon core technologies to the field of life sciences and to the introduction and marketing of vital, new-platform products in the critical area of molecular diagnostics. It was established in 2002, with a focus not only on research and development, but on the concrete introduction and marketing of vital products in the area of molecular diagnostics.
Canon identifies and develops life sciences solutions with potential applications in diagnostics and medical instrumentation. The company conducts research and development in the area of nano-liter (droplet size), continuous-flow, DNA analysis instruments. Its eventual aim is a complete 'sample-to-answer' solution for molecular diagnostics, with a platform that fully integrates clinical-sample preparation into the process. The company's core technologies are also applied to automation, environmental benefits, miniaturization and low instrument cost.
Canon has collaboration with Caliper Life Sciences Inc. It is an ISO14001 certified company.
DioGenix Inc (DGx) is a molecular diagnostics company focusing on the rapid development and commercialization of novel non-invasive diagnostic, prognostic and treatment response monitoring tests. It was acquired by Nerveda, Inc. in September 2008.
DGxÂ is focusedÂ on developing highly accurate diagnostic tests based on the use of gene signatures. The company uses state-of-the-art genomics technologies and sophisticated biostatistics to quickly identify and validate gene signatures that form the groundwork for the development of critically needed molecular diagnostic assays and improve patient management for difficult-to-manage diseases like multiple sclerosis. DGx's lead program is focused on improving the information available to neurologists when Multiple Sclerosis (MS) is suspected.
GlobaleMed LLC provides a comprehensive solution for medical diagnostic test products and laboratory needs by offering advanced technology, flexible purchasing, rapid delivery and superior technical support through its GlobaleMED system. The company develops its own line of rapid immunodiagnostic products, enabling GlobaleMed to provide its customers with a range of highly cost effective products for quantitative and point-of-care testing of human medical conditions and infectious diseases.
GlobaleMed products incorporate modern technology in open flexible formats that utilize genetically engineered techniques to diagnose infectious diseases such as Cholera, Hepatitis, Tuberculosis, and various sexually transmitted diseases, and are also used in the areas of reproductive health, viral and bacterial infectious diseases, gastrointestinal, hormones, cancer, cardiac, autoimmune disorders and for therapeutic drug treatment and drug abuse testing.
GlobaleMed's products include Infectious Disease Tests - Smart Check(TM) HIV Test, Smart Check(TM) Anti-HCV, Smart Check(TM) HBsAg Test; Tropical Disease Tests - Smart Check(TM) Dengue IgG/IgM 3, Smart Check Malaria(TM) Pf, Smart Check(TM) Strip VL; Sexually Transmitted Disease Tests - Smart Check(TM) Syphilis test, Smart Check(TM) Chlamydia Test, Smart Check(TM) Gonorrhea Test etc; Women Health - Smart Check(TM) hCG Test, Smart Check(TM) LH (Ovulation) Test, The Smart Check(TM) FSH Test etc; Gastrointestinal Test; Cardiac Marker Tests - Smart Check(TM) Myoglobin Test and Smart Check(TM) Troponin I test; Cancer Markers Tests - Smart Check(TM) PSA Test and Smart Check / Strip PSA Test; Drugs Of Abuse Tests - Smart Check(TM) alcohol strips and Smart Check(TM) Device/Cup/Strip/Panel Drugs.
GlobaleMed has collaborations with Caldon Biotech Inc., Joint Purchasing Corporation etc.
Kappametrics Inc. is a medical technology company specialized in the development of innovative solutions to the problems of data acquisition in functional MRI environments. It was established in 2004 as a spin-out company from Unilever. The company's goal is to create an EEG imaging technology that can be used in conjunction with fMRI for better clinical diagnosis and treatment of patients suffering from chronic neurologic disease.
Kappametrics has developed a revolutionary technology which is able to capture electroencephalography (EEG) data concurrently with functional magnetic resonance imaging (fMRI). The f-EEG(TM) technology is based on the concept of 'reference loops', a breakthrough concept that enables EEG data to be collected simultaneously with functional MRI. The 'reference loop' technology provides 'direct noise cancellation' to remove noise at the source, and acquire an EEG signal that is largely unaffected by the interference induced by functional MRI scanner and enables the real-time collection of physiologic EEG data during fMRI scans.
Kappametrics has partnership with Cortech Solutions, Inc.
LKC Technologies is a provider of high technology visual electrophysiology equipment to diagnose ophthalmic conditions. The company was founded in 1975 by Jerome Leight, Sigmund Krassowsky and Frank Chen. The company's goal is to help research and medical professionals preserve and enhance sight using LKC visual diagnostic systems.
LKC Technologies' products include: Mini-Ganzfeld Stimulators, Compliance Pack Software, EPIC-4000-a visual electrodiagnostic testing system, Multi-focal ERG, SG 2002- a standalone ganzfield, SST-1- whole field scotopic sensitivity tester, UBA-4204- Universal Biomedical amplifier, UTAS Visual Diagnostic Systems, electrodes etc. Its products are used to diagnose a large number of ophthalmic conditions by measuring evoked potentials, including ERG active electrodes, EOG active electrodes, VEP active electrodes, dark adaptometry etc.
LKC strives to be the preferred designer and manufacturer of state-of-the-art visual function testing equipment. Its clients include eye clinics, universities and major teaching hospitals in the United States.
Principio is a biotechnology company that develops and manufactures novel, proprietary molecular imaging agents and therapeutic radiopharmaceuticals for the treatment of cancer. It was founded by Joe Hernandez.
Principio is mainly focused on: 1) Molecular Imaging Radiopharmaceuticals - radioactive drugs that target specific proteins or biochemical processes that permit the visualization of disease using PET or SPECT scanners; 2) Therapeutic Radiopharmaceuticals - radioactive drugs that selectively target cancer cells to deliver lethal cellular radiation for therapeutic benefit; and 3) Near Infrared (NIR) Molecular Imaging Agents - NIR molecules target cancer tissue and provide a real-time image of the tumors during surgery using NIR cameras for precise tumor extraction.
Principio's product pipeline includes: Visinol(TM) - for the imaging of EBV associated cancer which include most lymphomas, stomach cancer, nasopharyngeal cancer and AIDS related lymphomas; Prostavis(TM) - for the imaging of prostate cancer via a prostate cancer specific receptor; Curinol(TM) - for the molecular radiotherapy of EBV associated cancers; Prostara(TM) - for the molecular radiotherapy of prostate cancer via the via a prostate cancer specific receptor; and Nirlux(TM) - for real-time guided surgery of prostate cancer using NIR.
Principio has an agreement with Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Ravgen, Inc. specializes in the scientific expertise of prenatal diagnostic testing. It was founded in 2000 by Ravinder Dhallan, with a mission to provide state of the art genetic testing that will enrich the lives of its patients.
Ravgen is focused on developing safe, noninvasive, pre-birth testing alternatives for expectant mothers. The company's core technology is based on its ability to increase the percentage of fetal DNA that is found in the mother's blood. Through its research with free floating fetal DNA, the company has developed and patented a variety of noninvasive prenatal tests that simply require a safe blood draw from the mother. Its core technology is focused on testing for single gene disorders, such as cystic fibrosis, sickle cell anemia, and the Jewish panel, as well as paternity testing disease.
Ravgen's patented, core technology the Ravgen Method is developed to diagnose disease using the unique genetic signature carried by each individual. Its Ravgen Method is developed by combining three important concepts that include: (1) using formaldehyde to enrich fetal DNA, which is present in maternal blood during pregnancy, (2) using SNPs to distinguish maternal DNA from fetal DNA and (3) calculating a ratio at heterozygous SNPs to determine chromosome copy number.
Systems Pathology Company, LLC (SPC) develops automated digital imaging software tools for use in toxicologic pathology and pathology-related analyses. It was formally established in January 2006 to target, acquire, develop, validate and commercialize software technologies to augment traditional toxicological pathology methods.
Systems Pathology's CAPS(TM) development strategy systematically builds comprehensive analytic applications for toxicological pathology. Each application was developed to provide validated software that easily integrates into traditional toxicological pathology workflows.
Systems Pathology's CAPS(TM) partially automates three key functions of toxicological pathology: HistoQC(TM): this software conducts quality control screening of H & E histologic sections prior to pathologist evaluation and/or automated analysis; HistoPATH(TM) is adaptive software, its sensitivity and specificity increases as it is used by a particular client and a solid database of historically accepted, normal control tissues is established; and HistoPATHDx(TM): this software separates normal from non-normal tissues and provides specific tissue change/lesion identification and quantification for an expanding list of tissue changes and organs.
Systems Pathology's partner is Aperio Technologies Inc.
Therataxis, LLC is a biomedical company focused on the development and optimization of new delivery devices through simulation of tissue physiology. It was founded in 2004 by Raghu Raghavan and Martin Brady, with a mission to improve direct delivery of therapeutics into brain and other solid tissue by predicting the distribution of therapies (both particulate and energetic) for specific individuals.
Therataxis' research and development is focused on planning, executing, and monitoring the targeted delivery of therapies into the brain. Its core technologies center on the modeling and simulation of brain response to therapy. The company is focused on predicting the distribution of agents delivered directly into tissue and to develop simulation-based delivery-device designs. It has developed fast stochastic simulation algorithms for transport in a strongly anisotropic, inhomogenous medium, implemented in a comprehensive C++ library designed for efficient prototyping of different mathematical models. The company designs and evaluates devices for direct delivery of therapies to the brain. It is also focused on the development of new methods of using MRI and CT to measure, infer, and estimate three-dimensional maps of important physiological parameters.
Therataxis' modeling, simulation and support technologies include: brain cancer treatments, Parkinson's disease treatments, systemic drug delivery, brain edema, acoustic focusing, catheter device development and testing. It develops computational models, image analysis methods, and device designs to support the direct delivery of therapies into brain tissue. The company has focused its research expertise in physiological modeling, simulation, and medical image processing. It services include: evaluation of packaging of existing devices, designing and construction of prototypes of new devices, quantitative analysis of imaging results, quantitative assessment of indvidual's physiology from radiological imaging, quantitative tracking of surrogate tracers, etc.
TrimGen Corporation is a diagnostic company with a business focus on nucleic acid-based molecular diagnosis. It was founded in 1999, with a mission to provide advanced genetic tests to transform traditional medicine into personalized medicine.
TrimGen provides over 100 molecular tests and test products for leukemia, cancer and infectious diseases. The company's products are developed based on proprietary technologies and have superior accuracy and sensitivity.
TrimGen's products include: KRAS mutation kits, Colorimetric mutation detection, Multiplex mutation detection, Paraffin sample DNA extraction, Paraffin sample RNA extraction, Paraffin-PCR combo kit, Buccal cell collection and Buccal DNA extraction.
TrimGen has collaboration with Life Technologies Corporation and Spartan Bioscience Inc.
VIDAR Systems Corporation is an optical imaging technology manufacturing company, specialized in the medical and life sciences imaging markets. It was founded in 1984, with a vision to be recognized as a leader in medical and dental imaging markets. The company is a part of the Contex Group.
VIDAR provides high-quality medical film digitizers for a variety of applications, including PACS, mammography CAD, teleradiology, oncology, and orthopedic surgery. Its dental film digitizer is specifically designed for scanning analog dental film. The company has leveraged its experience and technological expertise in medical imaging and has developed new products in life science research including REVOLUTIONÂ® 4200 and 4550 Microarray Scanner. Its product portfolio includes: DiagnosticPROÂ® Advantage, CAD PROÂ® Advantage, SIERRA Advantage, DosimetryPROÂ® Advantage (Red), Dental Film Digitizer, ClinicalExpressÂ® DICOM Software, etc.
VIDAR has collaboration with IDX Systems Corporation. The company's international distribution partners include ATX Medical Solutions, ModernTech Computer & Peripheral Ltd., View Tec (goupe Qualimedis), Cynaptix Technologies Pvt. Ltd., Nihon Binary Co., Ltd., Eye-2-Eye Communications Pte Ltd, ITRIS Trading AG, Meditel Limited etc. It is an ISO 9001:2000 certified company.
www.metabiomics.com Metabiomics® is an early stage molecular diagnostics company that is developing products and services based on advances in human microbiome metagenomic sciences. We have developed and implemented patent-pending and proprietary technology for biomarker discovery and molecular diagnostics that integrates advances in next-generation sequencing, computational biology, bioinformatics, microbial ecology, and systems biology. Demonstrating the effectiveness of our patent-pending MultiTag™ Sequencing (MTS™) analysis platform, we have developed non-invasive molecular diagnostic methods for several gastrointestinal diseases, including but not limited to colon polyps, colorectal cancer, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and hepatic encephalopathy in chronic liver disease (patents-pending). Our metagenomic diagnostic methods are based on multi-functional biomarkers associated with the molecular pathways of GI dysbiosis and autoimmune diseases that provide the earliest possible detection, unprecedented sensitivity and accuracy, and lower costs as compared to traditional tests.
An innovative Israeli company has just launched a new office in the Shady Grove Innovation Center in Montgomery County, with ties to the University of Maryland Department of Microbiology & Immunology. The company, OptiCul Diagnostics, a medical diagnostic device company established in early 2008, employs innovative spectroscopic methods to quickly and accurately identify bacteria in body samples in a point-of-care setting. The goal of their being in the States – to conduct clinical trials and get FDA approval for their first product, StrepSense, a rapid test for detecting Streptococcus A in patients suffering from a sore throat, and to complete work on a second product, a quick test to determine if patients entering a hospital are carrying Methicillin-Resistant Staphylococcus Aureus (MRSA).
20/20 GeneSystems Inc is a diagnostic company engaged in the development and commercialization of proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. The company was founded in May 2000.
20/20's novel patented multiplex immunohistochemistry platform (L-IHC) is an innovative service available to drug developers and other researchers. L-IHC allows simultaneous detection of 10+ biomarkers in a single tissue section and is vital to any study in which information content is paramount and tissue supply is limiting. The platform augments investigations in biomarker discovery and development including whole pathway profiling.
20/20's products include: mTOR PredicTORâ„¢ drug response test, PAULAsâ„¢ Test for early detection of lung cancer and BioCheckÂ®, Suspicious powder screening test.
20/20 has partnerships with Smiths Detection Group Limited, Ortho-Clinical Diagnostics, Celgene, Wako Pure Chemical Industries, Ltd etc.
Adlyfe Inc. is a biotechnology company, focused on bringing innovative diagnostic products to the market for neurodegenerative diseases. It was founded in 2003 to develop novel technologies for blood testing for early targets of amyloid diseases. The company is developing a novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain diseases.
Adlyfe's novel technology is based on the synthesis of small peptide, or Pronucleon(TM) ligands, that are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes (structural changes in shape) associated with amyloid formation.
Adlyfe is developing novel tests for the detection of human neurodegenerative diseases including: 1) Sporadic & variant Creutzfeldt - Jakob disease (sCJD, vCJD) for screening for the presence of misfolded prion proteins (PrPsc); 2) Animal TSE Diseases test - to detect prion misfolded protein (PrPsc) in of animals confirmed by matching brain tissue and Western Blot analysis with matching plasma samples; and 3) Alzheimer's Disease test for a-beta amyloid protein.
Adlyfe has signed an agreement with Wyeth Pharmaceuticals for the development of a biomarker assays designed to measure levels of beta amyloid in the human brain.
Allied Biotech Inc (ABI) is a biotechnology company engaged in developing commercial and research applications upon its proprietary technologies in molecular biology, animal surveillance and integrated protein microarray system. Its mission is to build bioassay tools for post-genomic life sciences and to become a leading supplier of molecular diagnostic tests and multiplexed screening system for drug discovery.
Allied BioTech's research and development programs discover and patent platform technologies and methods to better identify and understand the principles of protein interaction. Its vaccine research program incorporates the advances in immunology and infectious disease to develop and deliver vaccines. Its protein microarray technology can be applied to Allergy Research, Animal Surveillance, Antibody / Serum Profiling, Biomarker Profiling, Cancer Research, Cytokine Detection, Infectious Disease Research, Protein - Protein Interactions, Signal Transduction and Whole Proteome Studies. Its Real-time PCR technology monitors the fluorescence emitted during the reaction as an indicator of amplicon production during each PCR cycle (i.e., in real time) as opposed to the endpoint detection by conventional quantitative PCR methods.
ABI's product line includes: Telomerase Detection Kits - Quantitative Telomerase Detection Kit (QTD), which is specifically designed for quantitative detecting telomerase activity; Protein Microarrays - Human Cytokine Microarray, Mouse Cytokine Microarray, Mouse Surveillance Microarray, Rat Surveillance Microarray, Reagents, Human Cardiovascular Array and Human Angiogenesis Array; Instruments and Software - VisionSpot Colorimetric Microarray Scanner, which offers an inexpensive and throughput image-capturing tool for any colorimetric microarray (DNA, cDNA, protein, etc.) users; Antibiotics - Geldanamycin, a benzoquinone ansamycin antibiotic produced by Streptomyces hygroscopicus. This antibiotic exhibits a potent antitumor activity; Western Blotting Reagents - ECL kit, Protein Markers, Protein Stain Solution, One-hour-One-Step Western Blotting Kit, and Stripping Reagent; and Immunohistochemistry and Immunocytochemistry - UniversalTM One-step IHC, which are suitable for most primary antibodies and no need of secondary antibody. The company offers following services: Telomerase activity detection and quantification service, Cytokine detection and quantification service, Human Cardiovascular detection and quantification service and Human Angiogenesis detection and quantification service.
Avanti Therapeutics is a biopharmaceutical company that applies its innovative drug development & commercialization platform to generate a pipeline of personalized medicine candidates to treat cancer and other difficult-to-treat diseases. Its vision is to provide powerful, immersive and innovative technology platform that bring simplicity, elegance, versatility and consistent quality to drug development.
Avanti's Aayush platform includes a complementary portfolio of personalized diagnostics, targeted therapeutics and reporters of efficacy to create novel disease-specific personalized medicine candidates. Its multifunctional nanoparticle based Aayush platform provides multiple patient friendly advantages to the innovative drugs developed through this technology, especially in terms of ease of use and cost. Its technology can be used to deliver a broad range of payloads including emerging therapeutic modalities such as antibodies, recombinant proteins, RNAi allowing the company to address multiple therapeutic areas and indications.
Avanti has developed a revolutionary new technology of creating multifunctional nanoparticles that are suitable for in vivo delivery of a potentially broad range of imaging agents, biomarkers and therapeutic drugs. Its nanobindi technology offers the ability to covert insoluble or poorly soluble drugs into delivery vehicles allowing them to become soluble and easier to deliver. Â Avanti's product pipeline includes diagnostics, targeted therapeutics, reporters of therapeutic efficacy and biomarker monitoring. Using the proprietary platform, the company develops products for treatment areas â€“ such as cancer, and cardiovascular diseases and central nervous system disorders. The company has completed number of proof of concept studies in major disease areas, including oncology, cardiovascular diseases, infectious diseases, CNS and regenerative medicine. Its products include: CT-K-124 for ovarian cancer, CT-PC-348 for pancreatic cancer, AT-AS-123 for atherosclerosis, AT-APD-617 for anti platelet drug, AT-ND-146 and AT-ND- 273 for neurodegenerative, AT-ML-147 for malaria, AT-IF-326 for influenza, AT-BR-279 for bone regeneration, etc.
BD Diagnostics - Diagnostic Systems is engaged in manufacturing products and instruments used for diagnosing infectious diseases.
BD Diagnostics - Diagnostic Systems' products are used in the clinical market to screen for microbial presence, grow and identify organisms, and test for antibiotic susceptibility. In the industrial market, the company's products are used for the testing of sterile and non-sterile pharmaceuticals and medical devices, for environmental monitoring and to detect food pathogens.
BD Diagnostics - Diagnostic Systems' products categories include: Collection and Transport - BD(TM) Universal Viral Transport System (UVT), BD Falcon(TM) SWUBE(TM) Collection and Transport System, etc; Dehydrated Culture Media; Prepared Media - BD BBL(TM) Prepared Plated Media, BD Sterile Pack Bottles, Prepared Slide Media, etc; Environmental Systems - BD GasPak(TM) Products and Accessories; Direct Testing/Serology - BD Directigen(TM) Influenza Test Kits, BD Directigen(TM) RSV Test Kits, BD Directigen(TM) Meningitis Test System, etc; Stains and Reagents; Identification/Susceptibility - BBL(TM) Crystal(TM) Identification Systems, BBL(TM) Sensi-Disc(TM) Susceptibility Test Discs; Blood Culture - BD BACTEC(TM) Instrumented Blood Culture Systems; Molecular Diagnostics - BD Viper(TM) with XTR(TM) Technology and BD ProbeTec(TM) ET System; Equipment and Supplies - BD Lactinex(TM); etc.
BD Diagnostics - Diagnostic Systems' is an ISO 9001 and ISO 13485 certified company. Its partners include: Becton, Dickinson and Company, Bruker Daltonics Inc, Eurogentec S.A, HandyLab, Inc, Bruker Daltonics Inc, Lonza Group Ltd, Diagenode s.a. and MODA Technology Partners, Inc etc.
BRT Laboratories Inc. is a biotech company that specializes in offering a full range of clinical research and DNA testing services.
BRT Laboratories' Immigration DNA Testing service provides reliable results, quick turnaround and an easy DNA sample collection process. It also offers DNA Paternity Testing service that compares the DNA patterns of a child and alleged father to determine if there is any biological relationship. The company offers two levels of paternity testing that includes: testing for legal purposes and testing for personal knowledge. It also provides personal DNA testing, Family/Relationship DNA Testing for siblings, half-siblings, grandparents and grandchildren. The company's clinical testing offers Chimerism test that monitors and predicts the success of marrow transplant.
BRT Laboratories holds the following accreditations that include: American Association of Blood Banks (AABB), Clinical Laboratory Improvement Amendments (CLIA), and Better Business Bureau (BBB). The company is licensed by the New York State Department of Health (NYSDOH) and by the State of Maryland Department of Health & Mental Hygiene. It has an agreement with MDxHealth SA (formerly OncoMethylome Sciences S.A.).
Ceres Nanosciences, LLLP is engaged in development of diagnostic products and research platforms using its proprietary Nanotrap(TM) capture particle technology. Its mission is to introduce innovative Nanotechnology products, through the patented NanotrapÂ® technology, to commercial and government consumers, creating products and research applications that will benefit humanity.
Ceres Nanosciences' Nanotrap particles are smart particles that can be engineered to selectively collect and concentrate a diverse range of compounds (analytes) from complex solutions, such as serum and urine. Nanotrap particles enhance purification and diagnostic methods, including the harvesting of biomarkers. The company's Cancer diagnostic product is used for specific cancer focus TBD.
Ceres Nanosciences has collaborations with George Mason University, Shimadzu Scientific Instruments, SAIC-Frederick and United States Anti-Doping Agency (USADA).
Creatv MicroTech, Inc. is founded by Dr. Cha-Mei Tang, which is involved in microfabrication and biodetection. The company is involved in cutting-edge research and development that leverages in the sciences and engineering related to high-aspect-ratio microfabrication and ultra-sensitive biodetection. The company's fabrication of micro-metal and composite microstructures is unmatched and biodetection instruments are very sensitive, yet compact and easy to use. The mission of the company is to become a major supplier of diagnostic and analytical tools, reagents and services for the water, food, environmental, pharmaceutical and medical industries.
Creatv's micro and nanofabrication techniques make metal, composite and polymeric micro and nanostructures. Its research collaborators include Argonne and Los Alamos National Laboratories. FabricationMaterials include: Copper, Nickel, Lead, Gold, Ceramic, Metal powder composites, Low melt alloys, SU-8 for molds, Polyester, polyimid, polycarbonate PMMA Solid, layers or combinations. Some of the examples of applications include: Imaging - X-ray anti-scatter grids, Nuclear collimators and Medical, Medical implants - Medical tools, Micropores/Microfilter, Nanopores/Nanofilter, Microfluidic chips and Industrial - MM-wave structures, Molds for replication.
Creatv has developed proprietary methods to fabricate high-aspect-ratio metal and tungsten composite grids and collimators. Its grids improve the clarity, resolution and contrast of x-ray images. Solid copper waveguides with copper substrates are fabricated with straight walls, precision flatness and height. Precision gold x-ray masks are fabricated in various geometries and thicknesses. Custom Fabrication Services include: SU-8 Molds for Microfluidics, Tungsten Composite Collimator and Copper Grid on Nanocrystalline Diamond. It supplies analytical tools for the medical, food, water, environmental, pharmaceutical and agricultural industries. Its research collaborators include USDA, NIH, and numerous universities. Tools include: CTC microfilters and test kits, Spectrofluorometer: Signalyte(TM)-II, Conjugated Glass Products, E. coli O157 Test Kits, Assay Development Services and Custom Detection Systems. Precision, high porosity microfilters for enrichment of circulating tumor cells. The enrichment takes only minutes, does not depend on antibody capture, and works with both living and fixed cells. Signalyte(TM)-II is an ultra-sensitive spectrofluorometer that is up to 1000 times more sensitive than a fluorescent plate reader. Glass slides, conjugated glass beads, capillary tubes and glass fibers for DNA, RNA, protein & cell capture, immunoassays, enzymatic assays, chromatography and more. Test kits for detection of pathogenic E. coli in water, food and environmental samples. The E. coli kits can be used with Signalyte(TM)-II and fluorescent plate readers. Creatv develops custom assays and reagents for PCR detection, as well as immunoassay and quantitation of proteins, bacteria, viruses, disease markers, toxins, spores and other biomarkers. The company develops custom flow-through in-line continuous pathogen detection instruments for process control, manufacturing and monitoring. Personalized Cancer Therapy and Disease Monitoring "Liquid biopsy" using circulating tumor cells (CTCs) is a minimally invasive alternative to traditional tissue biopsy to determine cancer therapy. Enumeration of CTCs is used to indicate prognosis and to monitor treatment. Isolation of CTCs by size exclusion is a widely researched technique to collect CTCs from patient peripheral blood. Its precision fabrication method produces microfilters, CellSieve(TM) with dense, uniform pores. Starter CellSieve(TM) kit: Test its microfilters. No instrument except a fluorescent microscope is required.
Cylex Inc is a life science company focused on the development, manufacture and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine. It was founded in 1992.
Cylex has developed patented technology that provides an innovative platform to simply and reproducibly assess immune cell function, thus providing crucial insight for individualized transplant patient management. Its ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. The company's technology is used to help and identify kidney, liver, lung and heart transplant patients with low immune response - having the potential to lead to infection.
Cylex has alliances with Dynal Biotech, Life Technologies Corporation, and Medical & Biological Laboratories Co., Ltd. (MBL). The company's investors include: Canaan Partners, Channel Medical Partners, First Analysis and Siemens Venture Capital (SVC). It is an ISO 13485:2003 and 9001:2000 certified company.
Dexall Biomedical Labs Inc is engaged in the development and manufacture of immunodiagnostic products for physicians, clinical laboratories and hospitals. It manufactures diagnostic devices and operates under the Good Manufacturing Practice (GMP) Guidelines. The company was founded in 1978 by Thomas T. Hubscher.
Dexall's technology expands its diagnostic product line into the areas of infectious diseases, autoimmune diseases and malignancies. The company's products are based on its patented ActiTipÂ® technology. Its ActiTip enzyme immunoassays are fast, accurate and reliable and can be performed easier and with less hands-on time than competitive products.
Dexall's ActiTipÂ® product lines include: allergy, immunity, autoimmunity and infectious diseases. The Allergy Diagnostic test line is the first and best known of its patented Acti TipÂ® product lines. The allergy products include: Allerg E reg;, Allerg EnsÂ®, Rapid EnsÂ®, Allerg GnsÂ® and EnzyDexÂ®. Its Allergy-Visual EnsÂ® is a rapid visual screening test for the detection of allergen specific IgE antibodies in human serum. The company has also developed instruments which include: System 7074 Plus, a computer controlled, robotic, automated, Acti Tip enzyme immuno assay system; RoboDex-312, a robotic solid phase Acti Tip sample processor and washer; PipetDex, a single probe robotic pipettor; LumiDex, an electronic light box that aids in setting up the Acti Tips; LabDex APR, a one-plate, 96 well microplate reader; etc. Its MaestroDex is a PC-based powerful, proprietary, multi task software package operating under Windows 3.1, Windows 95 and Windows 98.
UMB Research Park, Building One,
800 W. Baltimore St., Suite 150
Baltimore, MD, 21201 USA
FASgen, Inc. is a drug development company that focused on development and commercialization of small molecule therapeutics and diagnostics using fatty acid biosynthesis targets. It was formed in 2000 by James D. Dick, Frank P. Kuhajda, Albert H. Owens and Craig A. Townsend.
FASgen has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. Its product pipeline is focused on the therapeutic areas of cancer, tuberculosis, obesity and diabetes. The company's product portfolio includes: FAS-detect(TM) IHC, a monoclonal antibody with specificity for Fatty Acid Synthase indicated for the treatment of a variety of common human carcinomas; and FAS-detect(TM) ELISA, an enzyme-linked immunosorbent assay used to detect soluble FAS in human serum.
FASgen has agreements with Centocor, Inc., The National Cancer Institute, The National Institutes of Health, etc.
Gene Logic is a genomics company that provides integrated genomic and biorepository services for pharmaceutical companies. The company's vision is to become the leader of genomics outsourcing in the world. It is a part of Ocimum Biosolutions.
Gene Logic expertise in drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. Its therapeutic areas include: oncologic, inflammatory, cardiovascular, central nervous system and metabolic disorders. The company's toxicogenomic product and service offering utilizes gene expression profiles of rat tissues and primary cells from toxicology studies that include time-course, dose, and clinical pathology information following in vivo and in vitro treatment with well characterized pharmaceuticals and chemicals.
Gene Logic's services include: Gene, Exon & miRNA Expression, Genotyping & Copy Number, Bioinformatic Analysis, Biorepository and Biobanking, Nucleic Acid Isolation , Laser Capture Microdissection (LCM), Study Design & Methods Development and Platform Specific Services. It's Genomics and Toxicogenomics products and services include: ToxExpressÂ® Program, that enables pharmaceutical and biotechnology companies to add toxicogenomic analysis to their evaluation of candidate and lead drug compounds; BioExpressÂ® System, that provides a comprehensive collection of Affymetrix GeneChipÂ® array data; ASCENTAÂ® System, that provides microarray gene expression profiles; Genomics Data Generation & Analysis Services. The company's Genesis Enterprise SystemÂ® Software provides the computational platform for enterprise wide, rigorous, open-ended data mining and analysis for the BioExpressÂ® System and ToxExpressÂ® System.
Gene Logic has alliances with Abbott Laboratories, Eli Lilly & Co, U.S. Environmental Protection Agency, Solvay S.A., H. Lundbeck A/S, Selventa (formerly Genstruct, Inc.), etc.
GeneDx, Inc. is specialized in genetic testing for rare hereditary disorders. It was founded by Sherri Bale and John Compton, with a mission to make clinical testing available to people with rare genetic conditions and their families. The company was acquired by Bio-Reference Laboratories, Inc. on September 28, 2006. Â GeneDx's tests include full gene analysis by DNA sequencing, the gold standard of genetic testing. It offers a wide range of tests which include: diagnostic tests, molecular cytogenetic tests, prenatal diagnosis, mutation specific/carrier tests, cardiology genetics, etc. The company offers tests for the following genes: AAAS, ABCA12, ABHD5 (CGI-58) Chanarin-Dorfman syndrome (Neutral lipid storage disease with ichthyosis, NLSD), ATP2C1 Hailey-Hailey disease (HHD; familial benign chronic pemphigus), etc. It offers full-service molecular cytogenetic testing, including a custom-designed whole-genome array CGH test. Â GeneDx's CGH test is available to rule out 65 common or novel genomic disorders as well as terminal and pericentromeric chromosomal rearrangements. The company has also developed FISH service that can be requested as a stand-alone test for genomic disorders or specific segmental aneuploidies, or as a follow-up test for parents of a proband with a positive array CGH result. It offers cardiology genetic testing services for Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Long QT syndrome, Brugada Syndrome, Arrhythmogenic Right Ventricular Cardiomyopathy, etc.
Hemagen Diagnostics, Inc. is a biotechnology company that develops, manufactures, and markets more than 150 FDA-cleared proprietary medical diagnostic test kits used to aid in the diagnosis of certain autoimmune and infectious diseases. It was founded in 1985, with a mission to offer high quality diagnostic test kits in user friendly formats.
Hemagen's product categories include:1) Chemistry - Supplies, Equipment, & Accessories; 2) Hematology - Equipment; 3) Electrolyte- Electrodes, Supplies, and Equipment. Its Human Diagnostics' products include: 1) Autoimmune - Tissue Section and Antiphospholipid Assays; 2) Infectious; 3) Universal IFA Components; 4) Specialty Assays - Chagas, Acute Phase Proteins and Cytokines; 5) Chemistry - Supplies, Controls & Calibrators, Accessories and H-Rotors; and 6) Electrolyte- Electrodes, Supplies, and Equipment.
Hemagen's products include: HemagenÂ® DNA Kit for the qualitative and semi-quantitative determination of circulating antibodies to double-stranded deoxyribonucleic acid (nDNA or dsDNA) in human serum; VIRGOÂ® AMA IgG for the detection and titration of antimitochondrial IgG antibodies in human sera; VET Flex; Calibrator; HemagenÂ® ChagasÂ® Kit for the detection of circulating antibodies to Trypanosoma cruzi, the causative agent of Chagas' disease; VIRGOÂ® C-Reactive Protein Kit is designed for the semi-quantitative measurement of C-reactive protein (CRP) in human serum and plasma; etc.
Hemagen's partners include: Adeona Pharmaceuticals, Inc, Boston University, Meda AB, MedPointe, Inc and Roche Holding, Ltd.
New Horizons Diagnostics Corp is a manufacturer and developer of products for the medical, diagnostic, environmental and food testing markets. It specializes in manufacturing tests for the rapid detection of bacteria and toxins in human, environmental, surface, food and water samples for use by municipal and corporate customers.
New Horizons' products are categorized into Medical, Diagnostic kits, Collection kits, Environmental, Food testing and Bacteriophage. The company's products include: Cholera and Bengal SMART(TM), colorimetric tests specific for Vibrio cholerae-O1 and Vibrio cholerae-O139; GonoGen(TM), a monoclonal antibody based colorimetric test intended for the confirmatory identification of Neisseria gonorrhoeae; SMART(TM) Group A Strep, a colorimetric test specific for group A streptococcal polysaccharide; SMART(TM)-II Rapid Salmonella strip test, a rapid, non-culture diagnostic assay that detects the presence of the organism from a food sample pre-enriched in a selective medium; SMART(TM) Cholera O1; SWIPE(TM)-1 large surface sample collection kit; SWIPE(TM)-4 Air sampler sample collection kit; SMART(TM) Tularemia; etc.
New Horizons' partners include: Power 3 Medical Products Inc, Advanced Biotherapy Inc and Pacific Northwest Research Institute (PNRI).
Panacea Pharmaceuticals, Inc. discovers, develops and commercializes therapeutic and diagnostic products for cancer and diseases of the central nervous system. The company was founded in 1999 by Hossein A. Ghanbari. The company's division is Panacea Laboratories.
Panacea's core technologies exploit changes in disease-relevant proteins by altered expression, post-translational modification, and functional variation. The company has active programs in cancer, stroke/ischemia, Alzheimer's disease, and Parkinson's disease. The company's products include: PAN-22, a fully human anit-HAAH monoclonal antibody for the treatment of hepatocellular carcinoma, PAN-622 - Toxin Conjugate for the treatment of carcinoma of the bile duct and PAN-811 for treatment of Ischemic Stroke.
Panacea has collaborations with National Institutes of Health, United States Department of Health and Human Services, National Institute on Aging, US Army, SRL, Inc., JSR Corporation, Massachusetts General Hospital, The Harvard University, etc.
Quickpath Technologies, Inc is specialized in the areas of microbiology, ecotoxicology and glycobiology.
Quickpath is developing a range of technologies for both environmental diagnostic as well as medical use in the field of pathogen detection and remediation. It targets active pathogens and toxins using the science of glycomics (targeting the sugar receptors). The company's products include: Quickpath Field, a filter technology for point or continuous field sampling; and Quickpath Lab, a reagent for rapid concentration of toxin samples in the lab.
Roveko, Ltd. is specialized in the Research & Development of several in-vitro diagnostic (IVD) kits. It was founded in December 1984 with a mission to create the best possible diagnostic reagents and kits.
Roveko's service areas include: Protein/Antibody Purification, Protein Characterization, Enzyme/Ligand-Antibody Conjugation, Immunogold, Polyclonal Antibody Products, Assay Development, Antibody Fragmentation, Contract Manufacturing and SV40 Polyoma Virus ELISA. The company's Contract Manufacturing services include: Lyophilization, Dispensing & Vialing, Microtiter Plate Coating, Solution Preparation, Custom Vialing, Lateral Flow Strip Production, Labeling etc. Its Antibody Fragmentation services include: Papain Cleavage, Pepsin Cleavage, F(ab')2 and Fc, etc.
Roveko's clients include IVD kit manufacturers, private and government research institutions and pharmaceutical industry laboratories.
SAIC-Frederick, Inc. is engaged in speeding the delivery of new technologies and treatments to patients with cancer and AIDS. It was created as a wholly owned subsidiary of SAIC in 1995 to fulfill the operations and technical support contract for the National Cancer Institute at Frederick.
SAIC-Frederick provides proteomics technologies to identify and characterize the protein signatures of human cancer cells and tissues. Its imaging technologies include: clinical-grade magnetic resonance imager, optical scanners including fluorescence and bioluminescence, positron emission tomography scanner, single photon emission computed tomography scanner, an X-ray computed tomography scanner, and ultrasound. The company's nanotechnology is involved in the characterization of nanoparticles by physical attributes, in vitro biological properties, and in vivo compatibility, using animal models. It also operates the Mouse Models of Human Cancers Consortium (MMHCC) Repository, an NCI-funded resource for mouse cancer models and associated strains.
SAIC-Frederick offers various genetics & genomics services including genotyping, array technologies, DNA sequencing, gene expression, and miRNA (microRNA) analysis. It also operates the Mouse Models of Human Cancers Consortium (MMHCC) Repository, an NCI-funded resource for mouse cancer models and associated strains. The repository makes strains available to all members of the scientific community (academic, nonprofit, and commercial). MMHCC Repository strains are maintained as live colonies or cryoarchived as frozen embryos, depending on demand. The company's biopharmaceutical production services include: development of monoclonal antibodies, recombinant proteins, peptide and DNA vaccines, virus vaccines and oncolytic virus, gene therapy products, and other biological agents.
SAIC-Frederick has partnerships with Fluidigm Corporation, INDIVUMED GmbH, Applied Research & Photonics, Inc, GenVec Inc, Protein Chemistry Laboratory, Roche Applied Science, Roche Diagnostics Corp etc.
TessArae LLC is a diagnostics company developing microarray-based tools and services for the simultaneous detection and definitive identification of hundreds of natural and emergent viral and bacterial pathogens, for medical and scientific research, and clinical diagnostics. It was founded by Clark Tibbetts in 2005 to develop and commercialize comprehensive differential diagnostic technology for the detection of infectious disease agents.
TessArae's TessArrayÂ® RPM (Resequencing Pathogen Microarray) technology detects and identifies numerous pathogens from clinical and environmental samples, enabling characterization of multiple co-infecting pathogens and elucidation of novel sequence variants. Its RPM technology is unique in that direct nucleotide sequence is generated from pathogen-specific targets or loci present in the sample.
TessArae's TessArrayÂ® RPM products are high density, high performance microarrays based on the AffymetrixÂ® CustomSeqÂ® resequencing microarray platform. The company's TessArray Products include: The TessArray RPM-Flu Array - provides comprehensive coverage of Influenza, including avian influenza, providing genus-, species, serotype- and strain-level information; The TessArray RPM-TEI Array - provides comprehensive detection of CDC Category A, B, and C threat agents; and The TessArray RPM-HFV Array - provides complete genome resequencing of numerous hemorrhagic fever viruses to strain level identification of known and unknown isolates. It has created several custom designs for microbial detection and identification based on RPM assay technology, including: Agriculture Applications: agriculture public health and food safety, Human Health: public health and personalized medicine; and Pharma: microbial analysis for GMP. It has created several custom genetic testing designs to detect specific mutations in human genes, including SNP's (missense and nonsense mutations), insertions and deletions, which are linked to genetic disease pathology.
TessArae has an agreement with Galil Genetic Analysis, Ltd.
Tetracore Inc is a biotechnology research and development organization that develops diagnostic reagents and assays for infectious diseases and biological warfare (BW) threat agents. Its mission is to create and develop highly diagnostic reagents, assays, and instruments for the detection of infectious diseases and bio-terrorism threat agents. The company focuses on veterinary, domestic preparedness, clinical, antibody and ELISA products.
Tetracore offers highly-specific, rapid, antibody-based test kits and antibody reagents for the detection of BW infectious agents and toxins; real-time, probe hydrolysis Polymerase Chain Reaction (PCR) test kits for sensitive and specific detection of animal pathogens.
Tetracore's products include: RedLine Alert â„¢ - an antibody-based test kit for use as an aid in the clinical laboratory identification of Bacillus anthracis colonies; BioThreat AlertÂ® - antibody-based test kits for the detection of biological terrorism-related infectious agents and toxins in suspicious samples, including tests for anthrax, plague, tularemia, botulinum toxin, ricin toxin, and SEB toxin; VetAlertâ„¢ - real-time PCR and rt-PCR kits for use in detection of bacterial and viral pathogens of animals, including tests for Foot-and-mouth disease virus, West Nile virus, and Classical Swine Fever virus; TetracoreÂ® Real-Time PCR reagents and portable PCR thermocycler â€“ to analyze potential threats for the rapid confirmatory analysis of potential BW agents and high-impact veterinary diseases; etc.
Tetracore has alliances with FASgen Diagnostics LLC and FASgen Inc.
Trinity Laboratories, Inc is specialized in design, manufacturing and marketing of medical devices for the health care industry. The company's mission is to provide quality cost-effective products and service to the customers.
Trinity's product categories include: Bulb Syringes, Dressing Change/Wound Management Trays, Hydrogel Dressings, I.V. Start Kits, Instrument Trays, Instruments (Bulk Non-Sterile), Instruments(Sterile Single-Use), Laceration Trays, Mucous Specimen Traps, Skin Staple Removers, Suction Catheter Kits, Suture Removal Kits, Towels/Drapes(Bulk Non-Sterile), Tracheostomy Care Sets, Wound Care Supplies (Bulk Sterile), Wound Management Trays, and Yankauer Suction Instruments. Its other products include: Biopsy Trays, Catheterization Insertion Packs, Circumcision Trays, Eye Trays, Irrigation Trays, O.R. Prep Scrub Trays and Standard Foley System Packs.
US Biomax, Inc. is a provider of human tissue microarray products and related services.
US Biomax' services include: Immunohistochemistry staining (IHC), In Situ Hybridization (ISH) and Histology Services. The company's histology services include: Paraffin tissue processing, embedding, sectioning and staining and frozen tissue sectioning.
US Biomax' products include: tissue arrays, antibody arrays, tissue bank, paraffin tissue section, frozen tissue section, antibodies, antigens and telomerase kit. Its Tissue array (tissue microarray or so called tissue-chip) slides contain protein, RNA, or DNA molecules, thus provides high-throughput platforms for the rapid analysis of molecular markers associated with disease diagnosis, prognosis and therapeutics in patients.
Alexandria Medical Arts Pharmacy & Compounding Lab is a pharmacy focused on the improvement of patient care through the art and science of compounding.
Alexandria Medical specializes in Bio-identical Hormone Replacement Therapy, Pain Management, Veterinary Medications, Nutritional Supplements, Homeopathy, Home Medical Equipment & Supplies and Compression Stockings. It produces a wide variety of unique medications for both human and veterinary clients such as preparations: sterile injections, troches, capsules, creams (both topical and vaginal), suppositories (both rectal and vaginal), gels, ophthalmic drops, ear puffers, solutions and suspensions. Its dosage forms include: Sterile Product, Transdermal Gels, Troches, Creams and Ointments, Suppositories/Rectal Rockets, Solutions and Suspensions, Lollipops, Time release Capsules, Flavorings and Sildenafil citrate liquid.
Alexandria Medical's veterinary prescriptions include: Apomorphine tablet triturates, Metronidazole liquid, Prednisolone liquid, DES capsules, Cyclosporin ophthalmic solution, Liquid enrofloxacin, Liquid methimazole, Ursodiol capsules (actigal), Potassium bromide liquid and capsules, Diazepam suppositories, Diltiazem long acting capsules and Sildenafil citrate liquid. The company provides custom prescription compounding for: Natural Hormone Replacement, (click here to view the BHRT pdf document), Tailored Pain Management, Kid-Friendly Changes for Difficult to Take Medicines, Veterinary Compounding & Medications, and Special Formulations to Meet Individual Needs.
Ameritox is specialized in pain medication monitoring solutions that offers specialized laboratory testing and proprietary methods of analysis backed by unparalleled service and comprehensive clinical support. The company was founded in 1996 as Universal Toxicology Laboratories (UTL).
Ameritox's specialized laboratory technology delivers the highest degrees of accuracy, specificity and sensitivity. It offers the comprehensive pain medication monitoring solutions(SM) need to provide the highest quality chronic pain care. The company's premier lab services and proprietary methods of analysis deliver a level of reporting not available anywhere else. Its expert support and comprehensive practice management tools help transform the data into the best possible outcomes for patients and practice.
Ameritox's Rx Guardian(SM) process identifies and quantifies the specific drug or metabolite for a broad range of controlled medications. Its Rx Guardian results report indicates the amount of prescribed pain medication or metabolite detected. The company's Rx Guardian results report provides further information by normalizing detected pain medications and comparing those values to an expected range for some of the most common prescribed medications.
Ameritox offers a wide range of tools and resources to give greater control of chronic pain patient care including Ameritox Online Services(SM), Rx Guardian AutoReminder(SM) automatically and randomly selects patients for monitoring based on a protocol select, eliminating guesswork and bias, Ameritox Virtual ToxicologistSM (V-Tox), A comprehensive array of reports track patient and practice progress for more effective risk management programs, etc.
Anceta, LLC is a subsidiary of American Medical Group Association (AMGA) to enhance the context and delivery of healthcare through the transformation of comprehensive healthcare information into actionable knowledge and accountable, evidenced-based practice.
Anceta Collaborative Data Warehouse illuminates the relationships between care process, patient outcomes, and cost - all the elements of the value equation. The company engages physicians and other clinicians in exploratory data analysis and motivates participation in collaborative improvement initiatives. Its intuitive analytics platform is designed to get clinicians engaged with the data, encouraging them to formulate and explore hypotheses.
Anceta's business operations are guided by its founding partners, AMGA, Sanofi-Aventis U.S., and Accenture.
BroadReach Healthcare is a global healthcare solutions company that provides consulting, implementation, and program management services. Its mission is to improve the lives of people around the world using new, innovative approaches to healthcare that combines the best of the private sector and public health.
BroadReach Healthcare's service include: 1) Distribution networks/product value chain - conduct studies of countries and regions to ascertain the viability of entering new or expanding markets, develop and implement sustainable business plans and financial models for entry into or expansion of a product in new and existing markets, develop, implement and manage a scalable/ ROI-positive LMD solution at the point of care, etc; 2) health systems strengthening (HSS) - training, operational re-engineering, and clinical outcomes and disease management; 3) patient education and community mobilization - enhance healthcare provider efficiency and effectiveness, educate providers and communities and increase treatment literacy and adherence, improve treatment and psychosocial support offerings, etc; 4) public-private partnerships (PPP) - identify program goals and objectives up front, create rigorous business, operational and relationship management plans to ensure success in implementation and sustainability, etc; and 5) strategic consulting.
BroadReach Healthcare works with a wide range of partners and clients, including national government, civil society, international donor agencies, pharmaceutical companies, biomedical device companies, local NGO partners, and other private-sector companies. Its partners and clients include: Acumen Fund, Merck & Co Inc, Harvard University, Bill & Melinda Gates Foundation, Pfizer Inc, World Health Organization, Pricewaterhouse Coopers, Centers for Disease Control and Prevention, etc. The company worked with the following consulting firms: McKinsey & Company, Deloitte Consulting, CSC (Computer Sciences Corporation), Boston Consulting Group, ZS Associates, etc.
Chindex International Inc. is a healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the community. It was founded in 1981 by Roberta Lipson and Elyse Beth Silverberg.
Chindex International operates two healthcare businesses that include: United Family Healthcare (UFH) - includes a network of hospitals that offer premium health care services, and Chindex Medical Limited (CML) - delivers marketing, distribution and service of medical capital equipment and instrumentation. Its business Chindex Medical Limited (CML) offers a unique full-service distribution platform to manufacturers of medical devices, from product registration to marketing and sales. CML owns and manufactures several patented technologies, including proprietary blood banking and transfusion equipment, wound closure products, and general surgery theater instruments. Its CML offers distribution services in the following therapeutic areas: imaging, women's health, surgery, dermatology, and dental. The company's business United Family Healthcare (UFH) provides comprehensive, integrated healthcare services in a uniquely warm and caring patient and family service-oriented environment.
Chindex International has agreements with Shanghai Fosun Pharmaceutical Group Co., Ltd., Biotest AG, Cutera Inc, Polichem S.A., etc.
Clinical Care Options is involved in the development of interactive medical education programs for healthcare professionals, creates and publishes original CME and information resources that translate the latest developments in science and medicine to clinically useful information. The company was founded by Jeffrey L. Drezner.
Clinical Care is specialized in the development, distribution and analysis of next-generation CME-certified programs. The company's expertise in CME, technology solutions, and clinical knowledge allows it to rapidly deliver the content simultaneously online, in print, and at live meetings, in the service of improving patient care. Its medical education programs are designed specifically for healthcare providers in the areas of hepatitis, HIV, oncology, neurology, transplantation, urology, and other specialties.
Comsort Inc was founded in the year 1991 and became a wholly owned subsidiary of Merck & Co., Inc. in December 2003.
Comsort is committed to impact the state of healthcare delivery locally by developing state-of-the art technologies that empower providers, organizations, and the pharmaceutical industry to support their customers and constituents. The company produced quality continuing medical education materials focusing on the patient-provider experience.
Coventry Health Care, Inc. (Coventry) is a diversified national managed health care company operating health plans, insurance companies, network rental service companies, and workers' compensation service companies. It provides a full range of risk and fee-based managed care products and services to a broad cross section of individuals, employer and government-funded groups, government agencies, and other insurance carriers and administrators. It was incorporated on November 21, 1986.
Coventry provides a full range of products and services, including group and individual health insurance, Medicare and Medicaid programs, and coverage for specialty services such as workers' compensation and behavioral health care. Its Workers' Comp Services offers a suite of client solutions designed to help drive industry-leading medical outcomes and identify appropriate cost savings at every step of an injured worker's recovery. The company offers variety of dental services which include: Insured plans for all size groups, Full-Service dental third-party administrator specializing in private-label programs and Full suite of discount products.
Coventry has entered into a strategic relationship with Rite Aid Corporation.
GetWellNetwork Inc is a provider of interactive patient care solutions serving hospitals and healthcare organizations. The company was founded by Michael B. O'Neil, Jr. in 1999 with a mission to transform the care process into an interactive patient care environment that drives an optimal quality care experience.
GetWellNetwork's Interactive Patient Care Solution offers a patient-centered approach that improves both the outcomes for patients and the hospital. It offers the industry's interactive patient care platform - PatientLife SystemÂ® that empowers patients with direct, on-demand access to a patient education video library and medications database, hospital stay and visitor information, movies and games, non-clinical service request menus, meal ordering, surveys and real-time feedback features, Internet and email access, music and more. Its Patient Pathways(TM) appears on the patient's monitor to proactively invite each patient, at the appropriate time, to learn more about his/her care, condition, and safety as well as other important aspects of their hospital visit. The company's solution includes: all the necessary hardware to support a complete interactive patient care experience.
GetWellNetwork provides several levels of Integration services in order to offer a high degree of personalization and customization of the patient experience. It was also recognized by KLASÂ® as the leader in the new Interactive Patient Systems category and exclusively endorsed by the American Hospital Association. Â GetWellNetwork's investors include: Valhalla Partners, Grosvenor Funds, Village Ventures, Point Judith Capital Partners, Long River Ventures, Tall Oaks Capital, and FreshTracks Capital. The company has entered into alliances with American Society of Health-System Pharmacists (ASHP), Blausen Medical Communication, Injoy Videos, Inc, KidsHealth, Milner-Fenwick, Wired.md etc.
IgG America is a specialty pharmacy company that is focused on providing immunoglobulin therapy and clinical management through pharmacy and nursing services. The company was founded 1999, with a mission to provide outstanding clinical services to patients who require immunoglobulin (IgG) therapy. It is a subsidiary of Amerisourcebergen Corp.
IgG America specializes in immunoglobulin services and do not provide any other types of services (such as antibiotics, parenteral nutrition, or pain management). The company has been accredited as a provider of pharmacy, specialty pharmacy and infusion nursing services. Depending on specific needs, the company provides both pharmacy and nursing services. This is an important requirement in providing immunoglobulin therapies, since clinical management is often complex, challenging and costly.
IgG America's division FactorSource America joins several other pharmaceutical services companies to form AmerisourceBergen Specialty Group, an integral part of AmerisourceBergen Corporation.
Magellan Health Services, Inc. is a specialty health care management company, specializing in behavioral health, diagnostic imaging and specialty pharmaceutical services. Its wholly owned subsidiaries include: ICORE Healthcare and National Imaging Associates (NIA).
Magellan Health Services' Specialty Pharmacy services are offered through its affiliate company, ICORE Healthcare which works with health plan customers to manage specialty drug use through clinically based formulary management, pharmacy distribution and strategic consulting. Behavioral Health Management Services are designed to improve lives through better insight and impact programs. Radiology Benefits Management services are offered through its affiliate National Imaging Associates by delivering innovative solutions that improves patient care through clinically appropriate, cost effective diagnostic imaging. The company's Medicaid Administration provides integrated clinical management, superior operational administration, leading information technology solutions and world-class service.
Magellan Health has acquired National Imaging Associates, Inc. (NIA) in 2006.
OneNet PPO LLC (OneNet) is a healthcare company specialized in providing a network of ancillary and healthcare services.
OneNet's services include: MAPSI (Behavioral Health Network), MultiPlanÂ®, Utilization Management and Dental Services. The company provides services to Third Party Administrators Insurance Carriers, Union Health and Welfare funds, Federal Employees Health and so on.
Otsuka America Pharmaceutical Inc (OAPI) is a healthcare company, with a strong focus and commitment to neuroscience, oncology and hospital therapies. It was established in 1989. The company is part of the Otsuka Group ("Otsuka").
Otsuka America has commercialized a diversified portfolio of products for use in the following therapeutic categories: Schizophrenia, Bipolar Disorder, Adjunctive Therapy for Major Depressive Disorder, Conditioning agent prior to allogeneic hematopoietic stem cell transplantation in CML, Clinically Significant Hypervolemic and Euvolemic Hyponatremia, Intermittent Claudication, and Detection of H. Pylori. Its product portfolio includes: ABILIFYÂ® (aripiprazole) Tablets, SAMSCAÂ® (tolvaptan), IV BUSULFEXÂ® (busulfan) Injection, BreathTekÂ®, Urea BreathÂ® Test (UBT) for H.pylori Kits, PLETALÂ® (cilostazol) Tablets, etc. The company's product portfolio is focused primarily in the areas of neuroscience, oncology, and hospital therapies.
Otsuka America has agreements with Xceleron Ltd, Sacred Heart Medical Center & Children's Hospital, Summit Corporate Services, Inc., Prasco Laboratories, etc.
PinnacleCare is a provider of health advisory and personalized healthcare services. It was founded by John Hutchins, with a mission to ensure that all members realize their highest expectations for their health. Its vision is to revolutionize the delivery of personalized healthcare to reflect freedom of choice and the authority of the patient.
PinnacleCare provides its members with electronic health records that enables secure and private access to updated health records twenty-four hours a day, anywhere in the world. Its medical records are collected, updated, reviewed by physicians and securely stored electronically.
PinnacleCare has an agreement with Champions Biotechnology, Inc.
QuadraMed Corp develops and provides information technology solutions to healthcare organizations to leverage quality care into positive financial outcomes. It was founded in 1993 with the goal of assisting healthcare providers to improve productivity, ensure regulatory and legal compliance, and enhance the quality of patient care and safety.
QuadraMed provides following solutions - 1) QuadraMed Access Management: through this solutions, patients and resources are identified accurately at every entry point to a healthcare enterprise; 2) QuadraMed Smart Identity Management: provides a comprehensive identity management program; 3) QuadraMed Care Management: Its Electronic Health Record (EHR) provides integrated, workflow-driven solutions to enable clinicians to organize and manage patient care activities, access patient information and document the care they provide; 4) QuadraMed Health Information Management: The Health Information Management (HIM) solutions enable healthcare organizations to efficiently manage information critical to all processes within their facility and 5) QuadraMed Patient Revenue Management: are designed to facilitate timely, accurate and complete billing.
QuadraMed's products include - 1) Patient Access: QuadraMed Enterprise Scheduling, Access Management Web solutions, MediKiosk, EDI, Precise ID etc.; 2) Identity Management: SmartScan, MPIspy, SmartMerge, SmartID, MPI Professional Services, Affinity Precise ID etc.; 3) HIM: Electronic Document Management, Abstracting, Inpatient Compliance, Outpatient Compliance, Facility Coding, Correspondence Management, Encoder Product Suite and VIP Compliance suite, etc.; 4) Care Management: The company's Computerized Patient Record (CPR) is a key component of QuadraMed's Care-Based Revenue Cycle(TM) solutions. It provides clinical decision support tools, patient data reporting modules, and secure access to patient clinical information and 5) Patient Revenue: Patient Revenue Management solutions are designed to facilitate timely, accurate and complete billing which include Workflow suite, Contract Management, Central Business Office, InSight etc.
QuadraMed has collaborations with Inova Health System, Medcath Corp, Baylor Health Care System, U.S. Department of Veterans Affairs, Brecon Pharmaceuticals Ltd, AmerisourceBergen Corp etc.
The Spine & Joint Center is a comprehensive practice that focuses on the management of spine and joint problems. Its goal is to give patients with chronic and acute spine and joint conditions access to all the services they need for the best possible healing and recovery.
The Spine & Joint Center's comprehensive services include: Spine care, joint replacement, non-operative management of arthritis, on-site neuroradiology & pain management services, physical medicine & rehabilitation, fracture care, hand surgery and sports medicine. Its Spine Care services are management of Back and neck pain, Sciatica, Spinal Stenosis, Neurogenic Claudication, and Minimally invasive surgery for herniated discs.
The Spine & Joint Center has affiliated with the following hospitals: Bowie Health Center, Laurel Regional Medical Center, Prince Georges Hospital Center and Doctors Community Hospital.
U.S NeuroSurgical, Inc. is a medical services company that partners with hospitals and physicians to own and operate facilities utilizing state-of-the-art and technologies in medical treatment and diagnosis. The company was founded in July 1993 by Alan Gold as a wholly-owned subsidiary of GHS, Inc.
U.S NeuroSurgical's Leksell Gamma Knife is a unique stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery. Its Gamma Knife delivers a single, high dose of ionizing radiation emanating from 201 cobalt-60 sources positioned about a hemispherical, precision machined cavity, and the lesion is first targeted with precision accuracy using advanced imaging and three dimensional treatment planning techniques such as CT Scans or MR Scans.
U.S NeuroSurgical's services include: IMRT (Intensity Modulated Radiation Therapy) to treat tumors to a higher dose, retreat irradiated cancers and safely treat tumors located close to vital organ areas; tomotherapy, a fully integrated state-of-the-art radiation therapy delivery system to target conformal radiation treatment to the patient's tumor while helping to limit damage to surrounding tissues; Computerized Tomography (CT), scanners produce a series of successive images; Magnetic Resonance Imaging (MRI) that measures the change in the field's energy as patients are exposed to various radio frequencies; Positron Emission Tomography (PET) that provides a color-coded image of the body's function, metabolism and structure; and Magnetic-Encephalography (MEG) that allows scientists to study the brain in real time.
U.S NeuroSurgical's partners include: Nyu Medical Center, The Midwest Gamma Knife Center And Southern California Regional Gamma Knife Center At San Antonio Community Hospital.
Voxiva Inc. is engaged in delivering interactive mobile health services. The company was founded in 2001.
Voxiva provides a novel approach to engage patients through its mobile-based solutions. It works with companies to incorporate its solutions into adherence programs in sectors which include: Health Plans, Employers, Public Health and Life Sciences. The company's core technology platform was designed to support the rapid development and deployment of interactive health information services. The platform supports a broad range of functionality including: Interactive Communication, Real-Time Data Collection, Data Management and Analysis.
Voxiva offers solutions in areas which include: Maternal Health: text4baby(SM); Smoking Cessation: Text2Quit(SM), a novel mobile health service designed to help smokers through the quitting process; and Diabetes: Care4life(SM), a personalized interactive mobile health service designed to help diabetics manage their condition by leveraging the ubiquity of mobile phones to educate, interact, and engage the patient. The company also provides Custom Solutions with its HealthConnect platform to design and support a customer's end-user engagement programs. HealthConnect combines a multi-channel approach with robust data analytics to improve adherence and enhance outcomes.
Voxiva has partnerships with Alberta Health Services, CDC, Alere, Aetna, Wellpoint, pfizer, CareFirst, CTIA The Wireless Foundation, at&t, telcel, Verizon wireless, Syniverse, PositiveID Corporation etc.
Clonexpress, Inc. offers a variety of stem cell lines and products for related research. The company strives to be a provider of all human CNS cells to research community and develops human CNS cells for therapeutic applications.
Clonexpress has developed a cell separation technology to identify and isolate specific cell types from various tissues and development of growth media for such specific cell types. These cells are used as primary cells for various applications or immortalized to obtain a continuous source of cells for drug discovery, high throughput screening (HTS), drug metabolism, toxicology, and cell therapy applications. The immortalized cell lines are isolated to ensure retention of almost all of the biochemical properties of corresponding cognate primary cell types.
Clonexpress works on various areas of development of cell systems for research and therapeutical applications which include: Expansion of Human Neuronal Precursor Cells (HNPC) and Development of Human Neuronal Cell Lines; Human Neuronal Precursor Cell Line (HNPCL); Microglial cells and cell lines (MG), Astrocytes and astrocyte cell lines; Matched pair of human neuronal precursor, astrocyte, and microglial cell lines; Human Dopaminergic Neurons (DAN); Neuronal precursor cells and cell lines from Down's syndrome; and Human hepatocyte, pancreatic beta cell lines.
Clonexpress' services include: custom development of cell lines and gene transfer. The custom development of cell lines includes the optimization of growth conditions for the cell type and development of several clones of immortalized cell lines. The company can isolate and characterize clones for expression of exogeneously introduced genes using procedures provided by the client.
GlobalStem, Inc. is a provider of high-quality standardized tools and reagents for use in stem cell research and reliable services to ensure the identity, stability and integrity of stem cell lines. The company was founded in March 2006, with a mission to advance stem cell discovery by supplying research scientists with the necessary tools and reagents needed to work more efficiently and obtain reliable results faster.
GlobalStem's products are categorized into Human Embryonal Carcinoma Cells, Mouse Feeder Cells, Human Feeder Cells, ES Cell Culture Media and FBS, Kits and Stem Cells. It provides authentication services for newly derived embryonic stem cell lines. The company's services include: Stem Cell Banking, Authentication/Characterization, Cell Storage and Distribution, DNA-fingerprinting, GlobalStem Expert Cell Storage and Distribution Services, human pathogen screening, mouse pathogen screening, HLA testing I, etc.
GlobalStem has agreements with CHDI Foundation, Inc., BI BIOTECH INDIA Pvt. Ltd. and Mediatech, Inc. The company has been awarded two Phase 1 SBIR grants by the U.S. National Institutes of Health (NIH).
Hemacell Perfusion, Inc. provides the scientific community with a variety of products derived from proprietary stem cell purification technologies. Its vision is to provide researchers with convenient access to essential material and with the tools required to facilitate technological breakthroughs in molecular biology, developmental biology, hematology, oncology, endocrinology, cardiology, neurology and other fundamental areas of therapeutic research.
Hemacell Perfusion's products include: term amniotic tissue, umbilical cord stem cells, umbilical cord blood, and stem cell derivation. The company has developed a novel human, mesenchymal stromal cell line from term amniotic tissue membrane. The cell line has been characterized as being CD 44+ and CD117- (c-kit), and also display cell markers for both fibroblasts (beta subunit of prolyl 4-hydroxylase) and Nestin.
Hemacell Perfusion provides consulting, subcontract, and training services. It offers consulting services on quality and process efficiency attributes of cell culture facilities, writing SOPs for cGMP compliance and lean manufacturing techniques.
Lifeline Cell Technology is specialized in the development and manufacture of purified primary human cells and optimized reagents for cell culture. The company is a wholly owned subsidiary of International Stem Cell Corporation.
Lifeline is focused on treating retinal degeneration, diabetes and liver diseases. The company's products include: Advanced skin test products - AST 2000, EST 1000, etc; Cryopreservation Solutions - KryoLife Cryopreservation Solution; Endothelial cell systems- VascuLifeÂ® EnGS Cell Culture Medium, VascuLifeÂ® VEGF Cell Culture Medium, etc; Fibroblast systems / stem cell products - FibroLifeÂ® S2 Cell Culture Medium, FibroLifeÂ® Serum Free Cell Culture Medium and so on; Keratinocyte systems - DermaLifeÂ® K Cell Culture Medium and DermaLife Calcium-Free Basal Medium, etc; Melanocyte cell systems - Normal Human Epidermal Melanocytes, DermaLifeÂ® M Melanocyte Culture Medium, etc; Prostate cell systems - Normal Human Prostate Epithelial Cells and ProstaLife Prostate Epithelial Cell Culture Medium; Stem Cell Systems, Human - Human Mesenchymal Stem Cells, StemLife MSC Culture Medium, etc.
Lifeline has collaborations with Sristi Biosciences Private Limited, VERITAS Corporation, DiscoveryBioMed, Inc., Advanced Cell Technology Inc, BioTime, Inc., Cytori Therapeutics Inc, NeuroNascent, Inc., etc. Its distributors include: Aurora Biotech, BST Scientific, KDR Biotech, KURABO Bio-Medical department, etc.
Molecular Transfer Inc discovers, develops and commercializes technologies and products for gene delivery and stem cell based research. The company was established in 2002, with a vision to provide superior products in the area of transformation and transfection reagents. Its division GlobalStem is focused on supplying research scientists with the necessary tools and reagents needed to work more efficiently and obtain reliable results faster. Â Molecular Transfer's product categories include: stem cell reagents, transformation reagents, and transfection reagents. The company provides high-quality standardized tools and reagents for use in stem cell research and contract services to ensure the identity, stability and integrity of stem cell lines. The whole range of stem cell reagents and services is sold through its GlobalStem division. Its transfection products are sold exclusively through its OEM partners. The company's transformation reagents are sold through its Globalstem division under the Transformation Bioscience (TFB) brand. Its transformation reagents include: TFB 5alpha(TM), TFB Blue(TM), TFB 10B(TM), etc.Â
Molecular Transfer has acquired GlobalStem, a provider of stem cell reagents and services on April 19, 2010.
Neuralstem Inc. is a biotherapeutics company with a mission to apply stem cell research and its patented human neural stem cell technology to treat diseases of the central nervous system including ischemic paraplegia, traumatic spinal cord injury, ALS (Amyotrophic Lateral Sclerosis) and Parkinson's disease. It was founded in 1996 by Karl Johe, I. Richard Garr and Merrill Solomon.
Neuralstem utilizes its patented Human Neural Stem Cell technology to create cures for diseases of the CNS (central nervous system). The company's technology allows for the isolation of CNS stem cells from tissue; the expansion in vitro of each cell up to a billion billion times (60 doublings), and the controlled differentiation of the cells into mature, physiologically relevant human neurons and glia which can be used to treat CNS diseases and conditions, and which provide a unique window for traditional drug discovery and genomic applications.
Neuralstem has collaborations with China Medical University, Cleveland Clinic, University of Pennsylvania, University of California, University of Michigan, Biomedical Research Models, Inc., etc.
Osiris Therapeutics Inc is a stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. It was founded in 1992 by Peter Friedli.
Osiris Therapeutics' platform technology uses stem cells which possess anti-inflammatory properties, prevents scar tissue formation and regenerates specific tissue structures, making them potentially useful in a wide range of conditions. The company has developed a first-in-field manufacturing process for the expansion of human mesenchymal stem cells (MSCs). In the manufacturing process, human MSCs are derived from bone marrow aspirate obtained from qualified healthy adult donors. The company is committed to develop its proprietary adult stem cell technology in order to provide physicians with next-generation tools for the treatment and functional restoration of damaged or diseased tissues.
Osiris Therapeutics' stem cell product candidates possess multi-potential character that provides the basis for a cell therapy platform and represents a virtually limitless number of indications. Its product portfolio includes: ProchymalÂ®, a formulation of mesenchymal stem cells (human) indicated for the treatment of several diseases including Acute Graft Versus Host Disease (GvHD), Crohn's Disease, Acute Myocardial Infarction, Acute Radiation Syndrome, etc; and Chondrogen(TM), contains adult human mesenchymal stem cells (hMSCs) indicated for the treatment of osteoarthritis in the knee. The company's biosurgery division harnesses the ability of cells and novel constructs to promote the body's natural healing. Its wound healing products are - GrafixÂ®, a living skin substitute allograft comprised of a biologic membrane with native mesenchymal stem cells used as a covering to promote healing and tissue repair in chronic wounds, limb salvage procedures, tendon repair and burns; and Ovation, an allograft product that provides the necessary elements for tissue repair in an easy-to-use formulation.
Osiris Therapeutics has agreements with Allosource, Genzyme Corporation, Boston Scientific Corporation, Lonza Group Ltd, NuVasive Inc, JCR Pharmaceuticals Co., Ltd, etc.
Stem Cell Medicine, LLC develops biological tools for basic science, drug screening and therapeutic development. It has been established by Tsuneo Kido on November 9, 2004. Their mission is to provide new therapies using stem cell technologies for patients with diseases lacking any effective treatment or cure.
Stem Cell Medicine invented a new type of human neural stem cells, which can differentiate into oligodendrocytes which are important for neuronal function. The company is developing a new cell-based therapy for patients with spinal cord injury and congenital demyelinating diseases.
Stem Cell Medicine, based on their human neural stem cell technology, is developing drug-screening systems for neurological disorders or mental disorders. The target diseases for drug-screening systems are: Multiple Sclerosis, Depression and Alzheimer disease. The company also prepares commercial products of human, mouse, and rat oligodendrocyte related cells for basic research.
Theradigm, Inc. is engaged in developing cell-based therapies for the treatment of the central nervous system (CNS) disorders.
Theradigm's technology platform is based on Bone Marrow Stromal Cells (BMSC) and Neural Stem Cells (NSCs). It uses BMSCs for treatment of neurological diseases such as cerebral ischemia and spinal cord injury. The company's activities are focused on the establishment of new human NSC lines and development of methods to improve the growth rate and expansion potential of these cells to obtain clinically relevant numbers of these NSCs.
Theradigm's programs address large unmet medical needs in CNS disease, such as stroke, spinal cord injury, ALS (Lou Gehrig's disease) and others. Preclinical data have shown recovery from stroke and traumatic brain injury upon IV infusion of BMSC cells and early preclinical reports with NSCs have demonstrated potential repair in an ALS model as well as homing to brain tumors. Development is underway for an 'off-the-shelf' product for immediate delivery after injury.
Vesta Therapeutics is developer of cell therapeutics for liver repair and regeneration.
Vesta's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation. The company is also working on isolating populations of stem and progenitor cells, immature cells that are committed to the liver lineage, but do not yet express most mature liver cell functions. The stem or progenitor cells are much more proliferative compared to mature hepatocytes and are expanding the use of a single donor organ to treat hundreds or even thousands of patients.
Vesta has alliances with Clinical Data Inc, Cytonet GmbH & Co. KG, Icoria, Inc, National Institutes of Health, The U.S. Department of Health and Human Services and National Institute of Diabetes and Digestive and Kidney Diseases.
FOSS NIRSystems, Inc. is engaged in supplying laboratory, at-line and process Near-Infrared (NIR) solutions for use in the pharmaceutical, chemical, petrochemical, and related industries. The company is a unit of FOSS A/S. It is committed to providing the most accurate and precise rapid test and measurement products to meet its customer's needs.
FOSS NIRSystems' FOSSÂ® instrumentation measures virtually any chemical form, including clear to turbid liquids, solids, powders, flakes, gels, pastes, and slurries. Its solutions enable customers to control the quality of materials from incoming raw materials, through production to final product delivery. The company's instrumentation and software packages allow users to operate within the confines of strict regulatory compliance guidelines. Its applications include: Biotechnology, Chemicals, Nutraceuticals, Petrochemicals, Pharmaceuticals, Polymers & Plastics, Pulp & Paper, Research & Development, Textiles and Others.
FOSS NIRSystems product categories include: Laboratory and At-Line Analyzers, Process Analyzers and Software, etc. A patented monochromator and modular sampling accessories make its instruments uniquely capable of analyzing powders, granules, solids, slurries, gels, pastes, and turbid or clear liquids. It offers a variety of dedicated laboratory and at-line analyzers including: XDS Rapid Content Analyzer (RCA), XDS MultiVial Analyzer, XDS MasterLab, XDS SmartProbe Analzer, XDS Rapid Liquid Analyzer (RLA), etc. The company's Process AnalyticsÂ® analyzers are setting the standard for real-time process analysis. Designed for seamless integration into process control strategies, these NIR (near-infrared) analyzers provide outstanding measurement stability and performance. It offers a variety of dedicated process analyzers including: XDS Process Analytics MicroBundle Analyzers, XDS Process Analytics Single Fiber Analyzers and Non-Contact Process Analyzers. The company's VisionÂ® software features a user-friendly environment for instrument operation and method development.
Since our creation in 2001, we have presented nationally and internationally to over 35,000 individuals from more than 900 companies and have sold over 40,000 Primer booklets.
Having built relationships with many of the largest biotechnology and pharmaceutical companies, we have been an invited to present for the past seven years at the annual Biotechnology Industry Organization (BIO) International Convention, and have forged strong partnerships with many leading associations including AdvaMed, AusBiotech, BayBio, BIOCOM, and PABio. BioTech Primer is committed to providing quality classes, services and products to help educate the non-science professional in the basics of biotechnology, pharmaceuticals and medical devices. However, not all classes are specific to the non-scientist; drug development is applicable to all who need a better understanding of the regulatory and business choices that go into bringing a drug to market.
Forward-thinking, professionals, whose products or services are tied to the industry, recognize the importance of improving their skills and competencies by increasing their knowledge of scientific concepts. BioTech Primer builds on its extensive experience to facilitate learning in a quick, easy-to-understand manner.
Root3 Labs was founded by Chad Schneider, a mechanical designer with 15 years of engineering and product design experience, to design electromechanical prototypes and products. Previously, he had worked as a product development consultant, designing complex devices for the highly-regulated medical device industry at an ISO13485-certified engineering and product development firm. Mr. Schneider grew up in Maryland and was educated locally, with a BS in mechanical engineering from the University of Maryland, College Park and a Master’s (M.S.E.) in Haptics and Medical Robotics from the Johns Hopkins University. At home and at work, Chad enjoys digging into challenging technical problems, whether that means designing a microfluidic pump from scratch to cut costs from the Bill of Materials or breathing new life into a neglected bicycle (or computer, or motorcycle, or house, etc.). Prior to founding Root3 Labs, he worked as a project manager and/or senior engineer on the development of numerous products.
Tech USA Scientific
Gaithersburg, MD, US
http://www.techusa.net/scientific.html Tech USA, Scientific Solutions is a comprehensive provider of staffing and recruiting solutions throughout the Scientific Industry. The nation's leading institutions rely on Tech USA to provide them with the best and brightest talent. We support a variety of industries, including Pharmaceutical, Biotechnology, Biodefense, Clinical Research, Health Care, Universities, Federal Agencies and Environmental, Chemical and Food Sciences.
America’s biopharmaceutical sector helps to research, manufacture, distribute and promote innovative therapies that make a critical difference in the lives of millions of people. In the last ten years, scientists have discovered and developed more than 300 completely new medicines, vaccines and biologics approved by FDA.
The value of this sector, however, extends beyond life-enhancing advancements in medicine and includes great contributions to United States economy. As vital economic partners, biopharmaceutical companies generate tax revenue, create high-paying jobs and provide growth opportunities for related industries and domestic labor. In fact:
Biopharmaceutical companies supported a total of 3.1 million jobs in the U.S. in 2008 – 655,025 directly in the sector and 2,439,928 in other sectors. Direct biopharmaceutical wages in the U.S. were estimated to be $114.6 billion in 2008, approximately three and a half times the average GDP contribution per sector in the rest of the U.S. economy. In 2010, U.S. scientists and researchers were conducting 15,134 studies to develop medicines targeting cancers, rare diseases, and other important conditions. In 2008, biopharmaceutical companies invested $63.7 billion in research and development of new medicines, of which about $51 billion was for research conducted in the U.S. In addition, many biopharmaceutical companies provide philanthropic assistance in their local communities through support of access to affordable products, education, social services, arts and other community needs.
To learn more, download the fact sheet (PDF): The Biopharmaceutical Sector’s Impact on the Economy of the U.S.
Athena Environmental Sciences Inc is a biotechnology company specialized in the development and commercialization of advanced biotechnology-based products and provides life cycle contract R&D and manufacturing services for development of innovative ideas from conceptualization to production of product. It was founded in 1994, with a mission to provide quality service and products through dedication and expertise.
Athena Environmental's division is Athena Enzyme Systems(TM). It provides products and services aimed at helping researchers and manufacturers improve the production and recovery of recombinant proteins. Its division manufactures and sells products which include: a proprietary line of bacteriological media specifically designed to increase the expression of recombinant proteins; a line of serum-free medium for the culture of human cell lines along with accessory products for cell culture; the PDQ Protease Assay(TM), a broad-spectrum, one step protease assay; specialty enzymes such as the AFM reference protein I27O(TM) as well as bacterial esterases and other proteins; and a line of reagents for the refolding of denatured proteins.
Athena Environmental's product areas include: Expression Media, Cell Culture Products, Custom Culture Media, Specialty Proteins, Protein Refolding Reagents, Enzyme Assays, GenieÂ® Family of Products, Reference Standards and Promotional products. Its cell culture products include: SFM Screening Kit, BRFF-BMZERO(TM), BRFF-EPM2(TM), BRFF-HPC1(TM), BRFF-P4-8F(TM), DMEM/F12, IMDM SFM, PET(TM), etc. Its proprietary serum-free media (SFM) is used for a wide range of research purposes including drug discovery, physiological, and gene expression studies. Â Athena Environmental has collaboration with TEC Edmonton.
Certis USA is involved in the development of biological pesticides and is a manufacturer and distributor of biopesticides. The company specializes in: Biological product development, from screening to formulation to field development, manufacturing: fermentation and formulation, Global registrations for biological products and Global sales channels. The company traces its roots to some of the early leaders in the development of biological and botanical pesticides, beginning with the formation of Thermo Trilogy in 1996 and the acquisition of neem technologies from W.R. Grace. In 2001, Mitsui & Co., acquired Thermo Trilogy and renamed it Certis USA LLC. Within Mitsui's AgriScience Division, Certis USA is positioned as the global competence center for biological control technologies.
Certis USA's core technologies include: Neem extracts (azadirachtin and clarified hydrophobic extract of neem oil), Bacillus thuringiensis bioinsecticides, Baculovirus technologies, Pathogenic and pesticidal fungi technologies.
Certis USA's markets include: Agriculture, Turf, Nursery and Greenhouse, Home and Garden. The company through marketing agreements, shares its sales and technical team with key companies to supply and distribute their products. CYD-XÂ® insecticidal virus is used to control codling moth on apples and controls the pest in walnuts. SoilGardÂ® microbial fungicide keeps nursery soils disease free and growers use it to clean post-harvest soils before planting a second crop. The company has grown by identifying and acquiring products that complement its product line. These include baculovirus products acquired from Biosys in 1997 and Bt bioinsecticide products acquired from Novartis in 1997 and Ecogen in 2002. the company's product brands include its granulovirus products CYD-XÂ® codling moth virus, GemstarÂ® corn earworm virus, and Spod-XÂ® beet armyworm virus; as well as AgreeÂ®, CrymaxÂ®, DeliverÂ® and JavelinÂ® Bt bioinsecticides; AzatinÂ®, NeemazadÂ® and NeemixÂ® botanical insect growth regulators; TrilogyÂ® botanical fungicide/miticide; SoilGardÂ® microbial fungicide; MeloConÂ® bionematicide; BasamidÂ® granular soil fumigant; SCREEN Duo(TM) Heat Stress Management for Plants; DES-X(TM) insecticidal soap concentrate; Cueva(TM) liquid copper fungicide concentrate; Seduce(TM) insecticidal bait; SluggoÂ® slug and snail bait (Eastern markets only); and Final-San(TM)-O herbicidal concentrate.
Meadows Corporate Park I, 12510 Prosperity Dr., Suite #310
Silver Spring, MD, USA
Knock-Out Technologies Ltd is engaged in the development of environmentally safe products and also continues to research and develop holistic products for health and cleanliness. The company has acquired MedElite, Inc. which distributes clinically proven products to physicians who then prescribe the products for their patients. It is a wholly owned subsidiary of Nuvilex, Inc.
Knock-Out Technologies developed sporocidal product that eradicates anthrax and a germicidal product that can eradicate the bacteria like E-colli, Listeria, Pseudomonas, Salmonella, Staphylococcus and Streptococcus. The company targets the market areas such as hospitals, nursing homes, clinics, doctor's offices, medical instruments, emergency equipment, restaurants and industrial/commercial public areas.
Knock-Out Technologies developed germicidal spray called Knock-Outs Big 6 Plus which has been found effective during testing by independent laboratories like AOAC laboratory against 5 major infection-causing organisms such as Staph aureus, Salmonella choleraesuis, Strep, e.Coli, Listeria, Pseudomonas aeruginosa, and Avian Influenza. Its sporocidal products include: Trimycin, Auromoxin, Occusyn, OraPhyte, Immune Booster Bar and Cinnecholâ„¢ which are developed to completely eradicate the EPA organism for anthrax.
Knock-Out Technologies has partnership with United States Department of Agriculture. It is the exclusive U.S. distributor of the Talsynâ„¢ product line that has been clinically proven to facilitate and improve the appearance, redness and strength of scars.
Nutramax Laboratories, Inc. researches, develops, and markets products to support the lifestyles of people and animals. The corporate entity has two business divisions: Consumer Products and Veterinary Science. The mission of the company is to serve the Lord and glorify him using the gifts he has given its employees to research, develop, manufacture, and market products that improve the quality of life for people and their pets. It was founded in1992.
Nutramax includes consumer, agricultural, veterinary and pet product lines. Nutramax Agriculture, Inc. markets environmentally safe biofertilizers for the turf industry. Nutramax Manufacturing, Inc. manufactures Nutramax Laboratories, Inc. products following production standards similar to the pharmaceutical industry.
Nutramax Laboratories supports laboratory research and clinical studies on its products. The company's products include: CosaminÂ®ASU, CosaminÂ®DS, OmegaMint(TM), DASuquinÂ®, ConsilÂ®, QuelantÂ®, etc.
BUGSS is a Maryland non-profit corporation started in the summer of 2012 to provide a place for people interested in biotechnology to learn, practice and hang-out with others fascinated by the world-changing potential of synthetic biology and biotechnology.
Come check out our space-2700 square feet of wet and dry labs convieniently located in east Baltimore.
BUGSS members enjoy lab access, credits for lab supplies to work on your own projects, participation in group projects, discounts on courses and being part of the coolest science project around.
Cellphire, Inc. is a biotechnology R&D company focusing on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets. It was established in 2006 as a spinout of Adlyfe, Inc. Its efforts and product development are aimed towards stabilized platelets for advanced wound care, transfusion and reagent products for clinical and research diagnostics. The company's strategic focus is on neurodegenerative diagnostics development.
Cellphire has developed a proprietary method for the stabilization of blood in dry state. The company is developing freeze-dried stabilized platelets for hemostasis and wound-healing therapies, and as a control reagent for platelet function diagnostics. It is stabilizing and modifying platelets into a product that can be stored well beyond the limit of 5-7 days. Platelets are often in short supply because of this extremely short shelf life which then causes problems in the treatment of cancer patients and actively bleeding surgical or trauma patients.
Cellphire's first platelet stabilization product is Thrombogent(TM), an easily rehydrated platelet product for use as a control reagent for hematology and clinical diagnostic analysis and drug development. The company's second product is Thromboderm(TM), an advanced freeze-dried, platelet based topical hemostatic agent that enables clotting, sealing and wound healing in the same application. Its Thromboderm(TM) can be incorporated with a variety of healing materials such as collagen and/or different types of polymers and applied through a dry bandage. Its Thrombosomes(TM) are freeze-dried, fully functional platelet transfusion hemostatic agents targeted for cardiopulmonary bypass and emergency trauma and in indications that require costly coagulation therapies and be packaged in a dry powder ready for immediate use or for long term stockpiling.
ChemPacific Corporation is engaged in producing fine and custom chemicals for the pharmaceutical and chemical manufacturing industries. It is focused on research and development and small scale manufacturing. Its mission is to provide active pharmaceutical ingredients (APIs) and intermediates to meet each pharmaceutical, biotechnology and fine chemical customer's requirements for speed, safety, reliability, quality and value. The company's vision is to continually strive to be the best full service producer of fine and custom chemicals. It was founded in 1995 by Rebecca Chiu, Tony Liang and Chen Zhou.
ChemPacific manufactures bulk active pharmaceutical ingredients (APIs) and advanced synthetic intermediates to support clinical trial studies in various stages of product development research, including Phase I through Phase III clinical trials. The company's product portfolio includes: Norepinephrine bitartrate, (3R)-3-Pyrrolidinol, (3S)-3-Pyrrolidinamine, 2, 4-Difluorophenyl derivatives and 2, 3-Difluorophenyl derivatives. Its reaction capacities include: acetoacetylations, polymerizations, hydrogenations, imidizations, oxidations, sulfonations, saponifications, suspension polymerizations, reductions, aldol condensations, etc.
ChemPacific offers the following services that include: cGMP custom manufacturing services, contract research services, custom chemicals, process development and API manufacturing services. Its custom manufacturing business is a key supplier of custom and fine chemicals with extensive experience in the manufacturing of complex organic molecules. It has extensive resources in chemical analysis to develop, test and prove efficient new processes. The company's special capabilities include: cGMP manufacturing of APIs and intermediates for clinical trial supplies (at all phases) and commercial products; Process development, scale-up and optimization; Full process safety and hazard assessment; and Bulk handling of hazardous materials.
W.R. Grace & Co. is a specialty chemicals and materials company that provides value-added products and services to customers in a wide range of industries. It was founded in 1854 by William Russell Grace.
W. R. Grace's operating segments include: Grace Davison and Grace Construction Products. Its Davison segment provides specialty chemicals, materials and formulation technologies. The company's Construction Products produces specialty construction materials, systems and services that strengthen enhance and protect structures.
W. R. Grace's technologies include: BioFuel Technologies, Refining Technologies, Advanced Refining Technologies, Materials & Packaging Technologies, Specialty Catalysts & Process Technologies, Discovery Sciences etc. Its BioFuel Technologies group is a manufacturer and marketer of specialty materials and analytical tools for enhanced biodiesel and bioethanol production. The company also develops and manufactures fluid catalytic cracking catalysts and additives that enable petroleum refiners to improve yields and product quality.
Group Dental Service of Maryland Inc is a provider of dental benefit products, networks and administrative solutions. It was founded in the year 1965 by two dentists. It was acquired by Coventry Health Care in the year 2008.
Group Dental Service offers services like dental provider networks and service, dental claims processing, clinical review, dental product development, sales and marketing strategy, etc. The company specializes in offering services on a private label basis to clients such as health plans, insurance companies and third party administrators.
OraTec Corporation is a comprehensive source for products and information for anti-infective periodontics and dental home care. It was established in 1986 as a source for in-office microbial assessment with 6 different BioScan Video Microscopy Systems and the BANA Enzymatic Test.
Oratec's professional products range from state-of-the-art microbial tests for periodontal risk to subgingival irrigation systems and professional strength antimicrobial agents. The company produces several professional strength antimicrobial agents (TheraSol, OraChlor and other natural products), heated and non-heated professional office irrigators (Viajet) and offers a wide range of texts related to anti-infective periodontal therapy.
OraTec offers an extensive selection of home care products including a wide variety of powered and hand held irrigation systems, irrigating solutions and other oral hygiene aids. The company carries a number of hand held, deep pocket irrigators like the Pocket Care or Perioflex and natural mouthwashes and toothpastes, including PerioClear, PerioScript and PerioPaste.
Bioderm Sciences, Inc. is specialized in the development and commercialization of dermatological products for wound healing, sports medicine and first aid. Its core focus is to develop and commercialize wound and muscle injury management products which optimize, enhance and accelerate the body's natural healing processes.
Bioderm Sciences' therapeutic approach is based on providing moisture and nutrients directly to the wound or injury site while maintaining a low pH in an optimal healing environment to improve patient outcomes and recovery times. Its therapeutic approach addresses three major problems of traditional wound management therapies: (1) lack of moisture; (2) insufficient trace elements; and (3) sub-optimal pH levels. The company's product portfolio includes: Wound Solution, Wound Dressing, Wound Spray and Wound Cream.
Glycotex, Inc. is a biopharmaceutical company focused on the discovery and development of drugs intended to accelerate human wound healing and tissue repair in acute and chronic wounds. It is a part of Novogen Limited.
Glycotex's proprietary technology is based on the extraction of yeast cells containing the carbohydrate (1-3)(1-6)-Beta-glucan in a specific configuration and size. The company has developed significant expertise with respect to engineering, characterizing and producing the optimal forms of this molecule for use in wound healing. A key component of its proprietary technology is an understanding of the structure-function relationship of the (1-3)(1-6)-beta-glucan molecule and its interaction with target cells in the wound.
Glycotex's lead product GLYC-101 is indicated for the treatment of burn wounds, post surgical wounds, diabetic ulcers and chronic venous ulcers. The active pharmaceutical ingredient in GLYC-101 is a glucoprime. Glucoprime has a unique mechanism of action that stimulates the action of macrophages by binding to the Dectin-1 receptor expressed on the critical cells involved in the wound healing process.
Glycotex has an agreement with Advanced Medical Solutions Group plc (AMS).
Mattioli Engineering Corporation is a medical device company that provides state of the art technology to the medical community specifically in the field of dermatology, cosmetic and general surgery. The company was established in1991.
Mattioli Engineering's DermoelectroporationÂ® technology utilizes the skin's water based channels to allow ionic drug solutions to penetrate due to controlled current pulsed delivered to the patient. TransdermÂ® Ionto system uses DermoelectroporationÂ® Technology to deliver Ionic drug solution into the body and when connected to UltrapeelÂ® microdermabrader allows a very efficient transdermal delivery of products.
Mattioli Engineering introduced UltrapeelÂ® Microdermabrasion Systems are completed by the introduction of the new proprietary DermoelectroporationÂ® technology thru TransdermÂ® Ionto powered drug delivery system indicated for the local administration of Ionic drug solution into the body for medical purposes. Its product folio includes: Needles Free Injection SystemÂ®, UltrapeelÂ® II Microdermabrasion Systems, Dermoelectroporation TransdermÂ® Ionto System, UltrapeelÂ® Microdermabrasion Systems, Aesthipeel Microdermabrasion Systems, Surgical CO2 laser system, etc.
Apollo is a healthcare IT software development company that provides application that enables clinicians and healthcare institutions to capture, manage, access, and share clinical multimedia content across a diverse array of medical specialties. It was founded in 1993. Its open-system solutions optimize clinician workflow and efficiency, enabling institutions to make the most of legacy systems and turning multimedia into a strategic healthcare enterprise resource.
Apollo's products and solutions include: Apollo Enterprise Patient Media Manager (Apollo EPMM(TM)), a multi-tiered, open-system software solution that helps healthcare institutions improve patient care and operational efficiency by enabling simple and secure management of, and access to, distributed clinical multimedia and data; Apollo PathPACSÂ® an open-system software solution that brings PACS features and functionality to the Pathology department; and PathPACSÂ® Web; ASAP ImagingÂ® an integral component of an Apollo EPMM or PathPACSÂ® system. It offers a broad range of professional services to customers that include: consulting, configuration, implementation, training, customization and support services.
Apollo has partnerships with National Digital Medical Archive, Inc, DMetrix, Inc, Digital Pathology Association and MicroBrightField, Inc.
astre Corporation provides services to industry and small business. It was split into several business teams: Water Treatment and Reuse, Medical & Pharmaceutical Products, IT and Technical Services, High Technology Business Consulting and Finance and Accounting.
astre Corporation's Medical & Pharmaceutical Products services have spanned a variety of specialties, including hemodialysis, catheter design, fermentation processes, sterilization, respiratory care, transdermal delivery, medical informations systems, ultrafiltration, 510(k) and NDA submissions, clinical trials, and Good Manufacturing Processes. Its water efforts are geared to the development and optimization of physicochemical and microbial processes. The company's software and I.T services group develops solutions to Hardware and Networking Issues that includes: Cabling and Wireless connections with security, Broadband connections and optimization, PDA, Tablets, and Desktop solutions to maximize staff productivity, etc and software systems and training that includes: Microsoft Office System, Document Assembly and XML Solutions, Accounting Software (Quicken, Quickbooks, Microsoft, Acccountmate), etc.
BME Systems Inc is engaged in creating systems for biotechnology, pharmaceutical and medical research companies that facilitate, integrate, streamline and automate using informatic, mechanical and electronic engineering tools and products. It was incorporated in 1987 by former employees and students of Johns Hopkins University to provide assistance to researchers in academia who could not afford a full-time engineering staff.
BME Systems creates instrumentation and software used in biomedical research. Its products include: Six Channel Valve Controller provides six independent and automatically timed channels of solenoid control for the precise administration of drugs and solutions to patch clamp and other neuropharmacological preparations; and Vibratactile Stimulator, a linear motor for delivering precise, single-point vibratory stimuli.
BME Systems uses engineering principles to combine commercially available tools and products that integrate, facilitate and automate laboratory experiments and processes in biological research and production. It has expertise in the areas of: Process Monitoring and Control, Laboratory Automation and Medical Equipment Prototyping.
Civilized Software Inc is a developer of software for the pharmaceutical and biological industries. The company is the developer of MLAB (Modeling LABoratory), an advanced mathematical and statistical modeling system. It is especially designed to handle differential equation models.
Civilized Software offers various Data Analysis and Modeling Services. The company offers various versions of MLAB including: MLAB for PC (DOS, Windows3.1, Windows95/98/NT/2000/XP, Linux), Macintosh PPC(OS 8.x, OS 9, OS X-classic mode, OS X-native mode), older Motorola Macintosh systems, SGI, and NeXT (Motorola, Intel, and HP) platforms.
Civilized Software's MLAB helps the customers to perform various computations including: algebraic models, autoregression models, boundary-value problems, cluster analysis, contour maps, curve-fitting, data manipulation, deconvolution, definite integrals, delay terms, descriptive statistics, differential equations, differential equation-defined models, distribution function estimation, eigenvalues, eigenvectors, equation-solving, Fourier transforms, etc.
CTIS Inc is a health informatics company focused in the areas of Clinical Trial Research and Management (CTRM) and Health Information Exchange (HIE) solutions. The company is committed to delivering solutions which improve healthcare initiatives by providing information outreach, information analysis, decision support, business intelligence services, research information management services and infrastructure services. Its mission is to harness the power of information technology to help advance international medical research and improve patient well-being. The company's primary focus areas include Chronic Diseases such as cancer, heart, diabetes, neurology and kidney; Individualized Healthcare and; Health Disparities.
CTIS offers innovative software solutions across a number of technology platforms. The company's services include: Program management services, software development services, IT infrastructure services, Technical and Clinical Services, best practices services. It also offers mobile platforms that provide real-time access to patient outcome data at the point-of-care allowing providers to make informed decisions efficiently and accurately, resulting in improved patient care and treatment outcomes. Its core solution and application offerings include: Clinical Trial Research Management (CTRM) Solutions, health information exchange (HIE) solutions, global health solutions, data warehousing & data mining applications, process re-engineering & systems integration (SI), prevention & epidemiology application, thought leadership and subject matter expertise (SME).
CTIS' products include: iMHealtheâ„¢ a cutting edge healthcare application specifically designed to serve as a Personal Health Record (PHR) for chronically ill patients; Electronic Research Information and Compliance (eRIC) is a paperless, electronic system designed to automate the submission, tracking, and reviewing of scientific regulatory and compliance information that is required for the safe conduct of human subjects research.; Safety Profiler, event management software using mobile and wireless technologies to assist with the needs of Clinical Trials professionals.
CTIS' partners include: Georgetown University, National Institute of Allergy and Infectious Diseases, National Institutes of Health, OmniComm Systems Inc, The Johns Hopkins University and The U.S. Department of Health and Human Services.
EMINENT Services Corporation is specialized in providing investigational drug management and information technology services to the pharmaceutical & biotechnology industries and research organizations. The company was founded in 1997 by K. Paul Thadikonda.
EMINENT offers various pharmaceutical services including Regulatory Consulting, Pharmaceutical Research, Clinical Manufacturing, Packaging and Labeling, Drug Repository, Biological Repository, Direct-To-Patient(Rx), Clinical Distribution, Clinical Randomization and Technology Services. The company's information technology services include: Integration Solutions, Application Development and Management Services, Testing Solutions and Web Development Services. It is involved in developing the formulations for oral, parenteral and nasal routes of drug delivery. The company's packaging capabilities include bottling, blister packing, and custom kit configurations.
EMINENT's certifications are: FDA Registered Drug Establishment, NDC Labeler Code, MD State Pharmacy Distributor License, DEA Manufacturing / Distribution / Research / Pharmacy Registration, Frederick County Alarm Permit, EPA Regulated Waste ID, etc.
EPL Archives, Inc provides GXP-compliant biorepository services and solutions. The company is focused on serving the global biorepository needs of clients in the discovery; pre-clinical research; clinical research, and manufacturing phases of biopharmaceutical development. . It was founded in 1978 by William Busey and John Ferrell. Its mission is to maximize the quality and extend the life of its clients' global biomaterials assets, research data and related manufactured goods through innovative, managed biorepository services and solutions.
EPL utilizes validated, 21CFR Part 11 compliant telemetry monitoring technology to monitor and manage environmental conditions throughout its facilities. The company's client biomaterials information is recorded in OracleÂ®-based GXP-compliant LabTrak(TM) materials management systems. The company also has extensive experience in bar-code programming, OracleÂ® database development, MicrosoftÂ® AccessÂ® development, documentation tools, and validation in regulated environments.
EPL provides biorepository services for physical and digital biomaterial assets in all required environmental conditions - from controlled room temperature (CRT) to cryogenic storage environments; specialized storage conditions and GXP compliant procedures for specialized media, radioactive, and hazardous biomaterials, etc. The company has extensive expertise in biobanking, biostorage and biomaterials archiving services and also provides extensive training to all employees including: GXP training; laboratory safety; chemical hygiene; blood-borne pathogens; radiation safety; and hazardous materials handling and shipping.
EPL's biorepository solutions include Best practices consulting - policies and procedures, retention scheduling, indexing and access, etc; Special Projects - facility design, shutdown & relocation, etc; Independent Audits - vendor assessments, inspection checklists, self assessments, etc; Biomaterial Escrow & Litigation Support.
Harris Healthcare Solution provides enterprise intelligence solutions and services for commercial and government customers, including interoperability, imaging, managed services infrastructure, systems and cyber integration, and informatics. Its mission is to improve health outcomes through optimal enterprise intelligence by ensuring that critical medical information is delivered with security and privacy to the right person, on the right device, at the point of care. The company is a business unit of Harris Corporation.
Harris Healthcare's products and services include: 1) Imaging Solutions - enterprise intelligence for healthcare, remote digital pathology, global image management, etc 2) Informatics Solutions - enterprise intelligence, registries, clinical services 3) Integration Solutions - InfoCasterâ„¢ digital signage solutions for healthcare enterprises, nationwide health information network, privacy and security program offerings for healthcare, state health information exchange (hie) solutions, etc 4) Infrastructure Solutions - enterprise intelligence for healthcare, privacy and security program offerings for healthcare, InfoCasterâ„¢ digital signage solutions for healthcare enterprises 5) Interoperability Solutions - enterprise intelligence for healthcare, CONNECT support services pocket reference, state health information exchange (HIE) solutions, nationwide health information networkâ€”integration and support services, etc.
Harris Healthcare's customers include: U.S. Army Dental Global IT Services, Department of Defense (DoD), Emergency Response Communications, Greek Healthcare Sector, Department of Veterans Affairs, Military Health System (MHS), Social Security Administration, U.S. Air Force Medical Information Technology Transition (MITT) Last Mile Architecture (LMA), etc. The company's partner list includes Cancer Treatment Services International (CTSI), First Genesis Mobius and The Virtual Computing Company (VCE).
HealthCare IT, Inc delivers biomedical research software, healthcare managed hosting services, and professional services to the biomedical research, clinical research, and health care sectors. The company was initially established as Ardais, later changed its name to GulfStream Bioinformatics and finally changed its name to HealthCare IT, Inc. Its mission is to provide critical information technology solutions at the intersection of biomedical science and medicine in support of those who are advancing the state of medical research and healthcare delivery.
HealthCare provides critical information technology solutions at the intersection of biomedical research and medical science. It offers BIGRÂ® a software suite for biospecimen and biorepository management along with disease-centric data collection and analysis systems with models for over 75 distinct diseases. Its co-managed hosting solution is designed for healthcare organizations that do not want to own and manage physical infrastructure but who have substantial in-house application and database skills.
HealthCare offers services in the fields of: Architectural Services, System Design, SW Engineering, System & Application Integration, Website Content Development, Health Information Exchange (HIE) Technology Services, Clinical Trial Management System Consulting, and Biorepository Technology Consulting. The company supports caBIGÂ® Program as an Enterprise Services Provider offering rapid access to caBIGÂ® applications through its caBIG.Â
HealthCare has agreements with RemedyMD Inc., CytomX Holdings PLC, University of Arkansas, Geisinger Health System, and American Type Culture Collection.
Media Cybernetics, Inc. is a scientific image analysis software provider engaged in developing digital image processing software to extract and mine knowledge from images. It was founded in 1981 and is a subsidiary of Roper Industries, Inc. The company supports rapidly growing scientific and industrial imaging community with Image-ProÂ® Plus its flagship image analysis software.
Media Cybernetics technology is based on Image-Pro Plus which is a powerful 2D and 3D image processing, enhancement, and analysis software with extensive measurement and customization features and IQbase which is an enterprise image database software helps to store, manage and extract knowledge from images and associated data and provides a full range of image management tools that allow effectively to archive, search, review, export, report, and share images and related data. The image analysis solutions are used in a number of industries and applications such as Cell biology, failure analysis, forensics, genomics/proteomics, materials analysis, microscopy, neuroscience, pathology, pharmaceutical, semiconductor inspection, quality assurance, etc.
Media Cybernetics' products include: Image analysis software like Image-Pro Family, AutoQuant X Deconvolution Software, IQbase Image Database, IQmaterials, Gel-Pro Analyzer and Array-Pro Analyzer; and Other Acquisiton Devices - Evolution(TM) Cameras, Infinity 1 Digital Kit, Spectrim Kits, Pro-Series Turboscan, Pro-Series OASIS, Pro-Series Controller Kits and IO-Pro.
Media Cybernetics corporate partners include: Life Technologies Corporation, inforMax, Applied Maths, Applied Scientific Instrumentation, Inc., IBM Life Sciences, Objective Imaging Ltd, Optical Imaging Association, OriginLab, Photometrics, Photon Technology International, Inc., Princeton Instruments, Inc. /Acton, Prior Scientific Inc., Purdue University Cytometry Laboratories, Purdue University Cytometry Laboratories, Qioptiq Imaging Solutions and so on.
Acuity Medical, Inc is a medical sales and marketing organization. It is committed to delivering quality products, personalized customer service, detailed clinical support and a storng overall value propostion to its customers. The company was founded in 1987. It is a member of IMDA, HIRA, and MANA.
Acuity Medical product lines include capital equipment and disposable products. It has developed a Partner Focus Program (PFP) that is a custom business plan for each sales partner. The company's PFP program includes: Training Schedule, both initial and ongoing, Co-travel with manufacturer, Channel management, Sales contests, Clinical review and support, Marketing programs, SWOT Analysis and Competitive matrix. Its medical programs include: Independent Manufacturer Sales Representatives, Specialty Distribution, Medical Product Business Development Consulting and Clinical Support.
Parabon NanoLabs (PNL) is a nano-pharmaceutical company that develops novel therapeutics using its proprietary Essemblix(TM) Drug Design Platform, a powerful combination of computer-aided design (CAD) software for designing macromolecules and nanoscale fabrication technology for their production. It was founded by Steven Armentrout, Michael Norton, and Christopher Dwyer. The company is a subsidiary of Parabon Computation, Inc.
Parabon has developed a CAD (computer-aided design) application, called inSequio(TM), which facilitates the design and sequencing of therapeutic nanostructures using grid-scale supercomputing capacity. Utilizing this revolutionary technology, the company has developed proprietary macromolecules for several domain areas including: Nano-sensors for bioweapons defense, Nano-arrays for DNA biometrics and Nano-additives for consumer products. The company also provides custom nano-design and nano-manufacturing services.
Parabon's partners include: Parabon Computation and National Science Foundation. The company also provides custom nano-design and nano-fabrication services.
NanoRods, LLC is a nanotechnology company based in the state of Maryland. Our mission is to meet the current demands of the industry and academia and speed up the development of gold nanorod-based products. We produce gold nanorods and offer nanotechnologies with applications in sensing, biotechnology and energy efficient platforms.